Pharmacological aspects of the inhibition of mammalian respiratory complex I by Serreli, Riccardo
Pharmacological aspects of the inhibition of 


































Forgiveness is about them and God.  
It’s my job to arrange the meeting. 














This dissertation, entitled “Pharmacological aspects of the inhibition of mammalian 
respiratory complex I”, is the result of my own work and includes nothing which is 
the outcome of work done in collaboration except as declared in the Preface and 
specified in the text. 
It is not substantially the same as any that I have submitted, or, is being concurrently 
submitted for a degree or diploma or other qualification at the University of 
Cambridge or any other University or similar institution except as declared in the 
Preface and specified in the text. I further state that no substantial part of my 
dissertation has already been submitted, or, is being concurrently submitted for any 
such degree, diploma or other qualification at the University of Cambridge or any 
other University or similar institution except as declared in the Preface and specified 
in the text. 
It does not exceed the prescribed word limit for the relevant Degree Committee. 
This work was carried out between October 2013 and September 2017, under the 
supervision of Dr Judy Hirst. Information and data derived from other sources has 















I would like to thank all the people that are responsible, in so many different ways, to 
the person I am today and that are (at least partially) responsible for my being able to 
obtain a PhD at the University of Cambridge. In chronological order… 
Edi Spiazzi. You have faced enormous challenges and emerged stronger than before, 
always. You could have achieved anything in life and sacrificed your dreams for your 
family. You are the example I will always follow. I am honoured to have spent a part 
of my life with you. Thank you mum. 
Piercarlo Serreli. You taught me how to play baseball, poker, chess, basketball, and 
another million things. Most importantly, you taught me the power of reason and 
logic above all else, something that I will cherish forever. If fitness is a paramount 
part of my life (thanks to which I will live much longer and better), I owe that 
exclusively to you. Thank you dad. 
Stefano Serreli. My childhood would not have been the same without you. I am so 
glad that, no matter what, we can always laugh together. Thank you brother. 
All the people who beat me up on a regular basis from 3 until 13 years of age 
(and their parents that were evidently not aware of the damage they would have 
inflicted to society with their rotten produce). I wish I could make you aware of 
which kind of despicable human beings you are but, given your extremely limited 
intelligence, you would not be able to understand. After all, you have given me the 
drive to be as different from you as I possibly can. Hopefully, life has given you what 
you deserve. If not, when I meet you in hell, I will.   
Alessandro “Alexubinik” Obinu, Paolo “Cane Pazzo Tannen” Ticcò and Alberto 
“Generale Cadorna” Camerotto, the best neighbours the world has ever seen. You 
cannot begin to comprehend how happy I am every time I see you and spend time 
with you. I am so proud to be able to call you my friends.  
Matteo “Scott Henderson” Gasparin and Sebastiano “Billy Sheehan” Pozzobon, 
the best musicians I have had the honour to play with. We literally rocked the world, 
even though most of it did not know it. Most importantly, you rocked my world, and 
 iv 
 
that’s what matters here. Who would have thought that drumming would have made 
me discover what true friendship is? 
Alessandro “Keystone” Bertoni. You’ve been in hell for the first part of your life but 
managed, against all odds, to end up in heaven. You are my brother. 
Davide “Daniel Heiman” Artusato and Francesco “John Petrucci” Artusato (a.k.a. 
the Artusato Brothers). Your musical prowess expanded my drumming horizons in 
ways I would have never been able to accomplish on my own. It was an honour to 
play with you.  
Dario “Sinnerevolution” Bizzotto. A world-class artist I am so proud to call my 
friend. The lab coats you painted for me are a true reflection of astonishing grandeur.  
Francesco Novara. Thanks for introducing me to 50 girls in 2 months back in 
2001…you probably snogged them all anyway, but it was always great to spend time 
with you, something I have always looked forward to. 
Prof. Guido Mantovani. Did you enjoy laughing at me every time I would bring you 
the drafts of my economics BSc thesis? Of course you did! I bet the condescending 
smirks you gave me (and surely many other students) were (and still are) the highlight 
of your day. Why was I even surprised, after all that agreed very well with what many 
of your colleagues used to say about you behind your back. I should have just listened 
to them and get a decent supervisor instead.  
Prof. Giuseppe Tattara. You didn’t even bother reading the drafts of my economics 
MSc thesis, and as a result I’ve lost a summa cum laude because of you. Now I know 
why everyone at the department dreaded to have you as a supervisor, no wonder. The 
only reason why I won’t be telling you these things in your face is just because the 
way you talk makes most people plunge into a deep coma from which no one, in 
recorded history, has ever come back from. 
Prof. Dave Adams. You are the best supervisor an undergraduate student could wish 
for. Master of organic chemistry, master of biotechnology and master of the universe, 
without your guidance I would have been lost in the recondite maze of 2,4-
dichloropyrimidines. It was an honour to work with you. 
 v 
 
Dr. Judy Hirst. You accepted a person like me in your brilliant group, something I 
will always be grateful for. You brought so much value to my thesis and elevated it to 
a standard I would have never reached on my own, ever. Your invaluable scientific 
guidance taught me the priceless value of intellectual rigour. 
Dr. Hannah “Maynard James Keenan” Bridges. Your help with cellular assays and 
with the sublime Seahorse XF 96 analyser was unbeatable.  
Dr. Andy “almost the Almighty” Jones. Wonderful colleague, scientist 
extraordinaire, exceptional team member, humble and exemplar human being. Your 
succinate:O2 assay deserved at least a Nature paper. 
Dr. Justin “Jordan -The wizard- Rudess” Fedor. While the AOX nightmare was 
upon me, a hand appeared to save me. Thanks to you, those dark reflections mutated 
into a glowing rainbow and never will I fear again to venture into blackness. Let the 
spirit of Jordan Rudess (who is still alive at the time of writing this thesis, by the way) 
guide you, and allow the majestic Korg Kronos to enter your life forever: a future as a 
world-leading progressive metal keyboard player is waiting for you, even though you 
may not know it yet. 
The guy who does the cleaning at night during weekdays (I don’t know what his 
name is). Seeing you on a daily basis mopping the floor and replacing the bins at 4am 
during my AOX dark ages was a much needed grip on reality. 
Noor “Dwayne -The Equalizer- Johnson” Agip. Simply the best. Thank you so much 
for our very interesting conversations about anything under the sun and for keeping 
me in the loop with the “internal affairs” in the group. You really need to write a book 
about your friends and people you hang out with, the things that happened to you with 
them would definitely make a whole TV series worth watching. And, above all, thank 
you for letting me in on your human experience: many would have lost their moral 
compass, you never did. 
Dr. Febin “DA MAN” Varghese, for always being there even when you weren’t. 
Dr. Roger “2.5L of coffee a day” Springett, for never being there even when you 
were. 
No thanks to AOX, the most annoying enzyme on the planet. 
 vi 
 
Erica “the Speech-Ninja” Falconbury. I would have never imagined to meet 
someone like you, let alone this person becoming the most important relationship I’ve 
ever had. You didn’t just dismiss me as an unattractive bald stammering weirdo. You 











































Mitochondrial complex I, a large respiratory enzyme located in the inner 
mitochondrial membrane, catalyses electron transfer from NADH to ubiquinone while 
concomitantly translocating protons across the membrane to sustain ATP synthesis. A 
crucial aspect of the pharmacology of complex I is drug-induced mitochondrial 
dysfunction, particularly its role in liver toxicity. Complex I inhibition causes an 
energy deficit and can lead to adverse changes in the status of the mitochondrial 
[NADH]/[NAD+] pool and increased reactive oxygen species production, causing 
widespread damage. 
A library of molecules that are known candidates for causing complex I-driven drug-
induced mitochondrial dysfunction was compiled using database and literature 
searches and then tested with assays on isolated mammalian complex I, mitochondrial 
membranes and cultured mammalian cells. The results extend the knowledge of 
complex I-linked drug toxicity and define a proof-of-principle methodology for the 
investigation of further unknown candidate molecules. Using this methodology, the 
Screen-Well V2 library from Enzo Life Sciences, containing 786 FDA-approved 
drugs, was used to investigate the role of complex I-linked drug toxicity on a wider 
scale. The results show that complex I is targeted by many structurally unrelated 
pharmacological compounds, but whether catalysis is inhibited in vivo requires drug 
transport into the mitochondrion, limiting the adverse physiological consequences in 
most cases tested. 
Furthermore, three structure-activity relationship studies were carried out on specific 
classes of complex I inhibitors: rotenoid natural product compounds, a family of 
pyrazole-based compounds under investigation as anticancer drugs, and variants on 
the drug Mubritinib. These studies identified structural determinants of binding to 









In addition to the abbreviations reported below, standard chemical symbols and SI 





ΔµH+ Proton electrochemical potential 
Δψ Membrane potential 
Δp Proton motive force 
ΔpH pH difference across the membrane 
A/D Active/deactive state 
AAT Aspartate amino-transferase 
Acetyl-CoA Acyl-coenzyme A 
ACS Acetyl-CoA synthetase 
ADP Adenosine diphosphate 
ALA Aminolevulinic acid 
AML Acute myeloid leukaemia 
AMP  Adenosine monophosphate 
ANT Adenine nucleotide translocator 
AOX Alternative oxidase 
ATP Adenosine triphosphate 
APAD+ 3-acetylpyridine adenine dinucleotide 
APADH Reduced 3-acetylpyridine adenine dinucleotide 
B. taurus Bos taurus 
BCA Bicinchronic acid 
BSA Bovine serum albumin 
CPT-1 Carnitine palmitoyltransferase I 
Cat Catalase 




Complex I NADH:ubiquinone oxidoreductase 
Complex II Succinate:ubiquinone oxidoreductase 
Complex III Ubiquinol:cytochrome c oxidoreductase 
Complex IV Cytochrome c oxidase 
Complex V ATP synthase 
CPT Carnitine palmitoyltransferase 
CYP Cytochrome P450 
Cyt c Cytochrome c 
DCPIP 2,6-dichlorophenolindophenol 
DDM n-dodecyl-ß-D-maltopyranoside 




ECAR Extracellular acidification rate 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethyleneglycoltetraacetic acid 
ETC Electron transport chain 
ETF Electron transferring flavoprotein 
FAD Flavin adenine dinucleotide 
FeCN Potassium hexacyanoferrate 
FeS Iron-sulphur 
FMN Flavin mononucleotide 
FumC Fumarate hydratase 
GPDH Glycerol 3-phosphate dehydrogenase 
GPx Glutathione peroxidase 
GR Glutathione reductase 
H2O2 Hydrogen peroxide 
HAR Hexaammineruthenium(III) chloride 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HiPIP High potential iron-sulphur protein 
HRP Horseradish peroxidase 
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HPLC High pressure liquid chromatography 
IMM Inner mitochondrial membrane 
IMS Inter-membrane space 
INT 2-(4-iodo-phenyl)-3-(4-nitrophenyl)-5-phenyl tetrazolium chloride 
IPTG Isopropyl ß-D-1-thiogalactopyranoside 
KCN Potassium cyanide 
LCFA Long chain fatty acid 
MaeB Oxaloacetate decarboxylating malic dehydrogenase 
MAO Monoamine oxidase 
MDH Malate dehydrogenase 
MRC Mitochondrial respiratory chain 
MPT Mitochondrial permeability transition 
mtDNA Mitochondrial DNA 
NaCN Sodium cyanide 
NAD+ Oxidised nicotinamide adenine dinucleotide 
NADH  Reduced nicotinamide adenine dinucleotide 
NADP+ Oxidised nicotinamide adenine dinucleotide phosphate 
NADPH Reduced nicotinamide adenine dinucleotide phosphate 
NAPQI N-acetyl-p-benzoquinone imine 
NDH Alternative NADH-ubiquinone oxidoreductase 
NOX NADPH oxidase 
NRTI Nucleoside reverse transcriptase inhibitors 
OCR Oxygen consumption rate 
OD600 Optical density at 600 nm 
OG Octyl-glucoside 
OMM Outer mitochondrial membrane 
OXPHOS Oxidative phosphorylation 
PC Phosphatidylcholine 
P. denitrificans Paracoccus denitrificans 
PE Phosphatidylethanolamine 
Pi Inorganic phosphate 




Q10 Coenzyme Q10 
Q10H2 Reduced coenzyme Q10 
R Gas constant 
RET Reverse electron transport 
ROS Reactive oxygen species 
SAR Structure-activity relationship 
SOD Superoxide dismutase 
SMP Sub-mitochondrial particle 
T. thermophilus Thermus thermophilus 
Tris Tris(hydroxymethyl)aminomethane 
Trx Thioredoxin 
VDAC Voltage-dependent anion channel 
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1.1 Chemiosmotic Theory 
Living organisms are capable of incorporating energy into chemically usable forms so 
that they can power energetically unfavourable reactions necessary to sustain life. A 
prominent example of such a molecule is ATP. In eukaryotic cells, mitochondria 
channel the energy derived from nutrients into the endergonic synthesis of ATP from 
ADP and inorganic phosphate via the process of oxidative phosphorylation 
(OXPHOS). An electron transport chain delivers electrons through a series of 
membrane-bound redox enzymes and electron carriers from redox centres with more 
negative midpoint potential to redox centres with more positive midpoint potential 
(from NADH/FADH2 to O2). The energy from cellular respiration is stored across the 
inner mitochondrial membrane (IMM) in the form of an electrochemical proton 
gradient (∆µH+) which is then used by ATP synthase (complex V) to synthesise 
ATP1. ∆µH+ is expressed in units of voltage of the protonmotive force (PMF or ∆p, 
the energy required to transfer protons across the IMM against the gradient) according 
to the equation below (F is the Faraday constant, R is the gas constant and T is the 








The PMF comprises an electrical term or charge gradient, ∆Ψ, and a chemical 
gradient of protons, ∆pH, both expressed in terms of difference between the P-phase 
compartment (intermembrane space or IMS) and N-phase compartment (matrix): in 
respiring mitochondria, ∆p is about 180-220 mV, with the major contributor being ∆Ψ 
with about 150-180 mV2. At the heart of the chemiosmotic theory, originally 
proposed by Peter Mitchell, lies the proton translocation capabilities of respiratory 
complexes in mitochondria: this allows energy from substrate oxidation to be 
converted and stored in a proton gradient. The four postulates of Mitchell’s theory can 
be summarised as follows3 
1) The PMF is the result of enzymes in the respiratory chain that couple the sequential 
electron fluxes to proton movement across the IMM. Reducing equivalents NADH, 
 2 
 
FADH2, Q10H2 and reduced cytochrome c transfer electrons across the respiratory 
chain while complexes I, III and IV eject protons into the IMS (see section 1.3). 
2) Complex V (a proton-translocating ATPase) couples the redox-generated PMF to 
ATP synthesis. It can also work in reverse by ejecting protons from the matrix into 
the IMS with the energy generated by ATP hydrolysis. 
3) The potential across the IMM promotes accumulation of cations in the matrix and 
hinders anions from entering it. Exchange carriers in the IMM satisfy the 
physiological need to prevent membrane potential-driven cation accumulation in the 
matrix (which would lead to osmotic swelling) and to ensure transport of substrates 
and metabolites across the IMM whilst maintaining the membrane potential (e.g. 
transporters that transfer Ca2+ in and out of the IMM are the mitochondrial calcium 
uniporter and mitochondrial H+/Ca2+ and Na+/Ca2+ exchangers, respectively)4. 
4) The IMM is very impermeable to ions, especially protons (ion leaks would 
otherwise dissipate ∆p by short-circuiting the IMM). However, proton leak does 
happen and is physiologically relevant. Unregulated or basal proton leak through the 
IMM only accounts for about 5% of the overall proton leak, the rest is catalysed by 
uncoupling proteins (UCPs), mainly for thermogenesis and regulation of ROS5. 
Figure 1.1 illustrates the concept of an energy transducing membrane in mitochondria. 
 
Figure 1.1. Generation of ATP by the proton gradient across the IMM. Protons are 
pumped in the IMS from the matrix, generating a proton gradient. Complex V generates ATP 
by transferring protons back to the matrix. Picture taken from Campbell and Farrell6. 
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are a feature of the structure of ATP synthase. Protons flow back into the matrix 
through ion channels in the ATP synthase; the F0 part of the protein is the proton 
channel. The flow of protons is accompanied by formation of ATP, which takes 
place in he F1 unit (Figure 20.18). The unique feature of chemios otic oupling 
is the direct linkage of the proton gradient to the phosphorylation reaction. The 
details of the way in which phosphorylation takes place as a result of the linkage to 
the proton gradient are not explicitly specified in this mechanism.
A reasonable mode of action for uncouplers can be proposed in light of the 
existence of a proton gradient. Dinitrophenol is an acid; its conjugate base, 
dinitrophenolate anion, is the actual uncoupler because it can react with 
protons in the intermembrane space, reducing the difference in proton 
concentration between the two sides of the inner mitochondrial membrane.
The antibiotic uncouplers, such as gramicidin A and valinomycin, are 
ionophores, creating a channel through which ions such as H1, K1, and Na1 can 
pass through the membrane. The proton gradient is overcome, resulting in the 
uncoupling of oxidation and phosphorylation. BIOCHEMICAL CONNECTIONS 20.1 
discusses a natural uncoupler.
ionophores substances that create 
channels for ions to pass through the inner 
mitochondrial membrane














Figure 20.17 ATP can be produced by closed 
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Mitochondria are thought to have originated from aerobic bacteria that were engulfed 
by an ancestral anaerobic (proto)eukaryote. The acquisition of an aerobic symbiont 
meant that a more efficient metabolism was available for the host: the resulting 
symbiotic system (along with the transfer of bacterial genes to the nucleus at a later 
stage) eventually became the eukaryotic cell7. It is still debated whether mitochondria 
were acquired early during eukaryotic evolution or when much of the development of 
eukaryotic cells was already accomplished8.  
Mitochondria possess a double membrane structure, the outer mitochondrial 
membrane (OMM) and IMM with the IMS in between. The OMM is recognised as a 
platform for apoptosis execution and its predominant protein component is the 
voltage-dependent anion channel (VDAC), a weakly selective channel for anions that 
transports all water-soluble mitochondrial substrates and metabolites9. The IMM is 
much more extended than the OMM and it can be further divided into the inner 
boundary membrane, closer to the OMM, and cristae membranes, invaginations of the 
IMM that begin with narrow openings (crista junctions) and are very rich in OXPHOS 
enzymes10. Figure 1.2 shows how mitochondria are internally structured.  
Mitochondria are a highly dynamic organelle and form an integrated network in the 
cell: depending on the metabolic inputs their morphology can alter from a more 
hyperfused state (e.g. during nutrient withdrawal) to a more fragmented state (e.g. 
during severe stress, nutrient excess or impaired OXPHOS system) 11 . The 
remodelling of mitochondria within the network is performed by different families of 
proteins that control the processes of fusion, primarily mitofusin 1, 2 (Mfn) and optic 
atrophy 1 (OPA1), and fission, primarily dynamin-related protein 1 (Drp1): these 
events are also vital for mitochondrial quality control, so that fission can segregate 
damaged mitochondria and fusion can allow exchange of material between viable 
mitochondria12. 
An important aspect of mitochondrial morphology is mitochondria-associated 
membranes (MAMs), contact sites between mitochondria and a specialised 
subdomain of the endoplasmic reticulum that allow faster and direct signalling 
between these two organelles: key functions of MAMs include regulation of lipid 





Figure 1.2. Membrane compartments in mitochondria. Top. Three-dimensional volume 
(A) and tomographic slice (B) of mouse heart mitochondrion determined by cryo-ET. Picture 
from Kühlbrandt14. Bottom. The OMM, IMS and IMM are shown along with typical 
mitochondrial membrane proteins. The respiratory chain complexes (I, II, III, IV and dimers 
of V) will be explained in more detail later. MICOS, mitochondrial contact site and cristae 
organizing system; TIM, translocase of the inner membrane; TOM, translocase of the outer 
membrane; OXA, oxidase assembly; PAM, presequence translocase-associated motor; MIM, 
mitochondrial import complex of the outer membrane; MIA, mitochondrial intermembrane 




Mitochondria serve or contribute to a plethora of functions in cells: amino acid 
metabolism and urea cycle15, regulation of apoptosis16, heat generation via UCP-
proteins5, regulation of immune defense, epigenetics and stem cell development17, β-
oxidation of fatty acids 18 , Krebs cycle 19 , ketone body generation 20 , heme 
biosynthesis21, calcium storage and signalling22. Other functions of mitochondria such 
as ATP generation, oxidative phosphorylation, ROS formation and signalling, 
mitochondrial permeability transition and Fe-S cluster biogenesis will be explained in 
more detail later. 
1.3 Structure and functions of enzymes in the 
respiratory chain 
The respiratory chain in mitochondria is classically arranged as shown in Figure 1.3: 
plant mitochondria possess additional enzymes in their respiratory chain and the 
canonical enzymes generally have extra subunits than their animal counterparts23. 
Most of the subunits are encoded by the nuclear genome, while mitochondrial DNA 
encodes 7 subunits of complex I, 1 subunit of complex III, 3 subunits of complex IV 
and 2 subunits of complex V24. Complexes I, III and IV are also known to form multi-
enzyme assemblies of different stoichiometries known as supercomplexes25. 
 
Figure 1.3. Organisation of the respiratory chain. The inner mitochondrial membrane 
hosts complexes I to V of the respiratory chain and the protonmotive force is generated by the 
proton gradient via transport of protons across the membrane by complexes I, III, and IV. 
Endergonic synthesis of free ATP is, then, fuelled by the protonmotive force through complex 
V. Picture adapted from Kühlbrandt14. 
organelles, the high matrix density has the disadvantage
of obscuring internal detail.
The equivalent of the periplasm in the bacterial ances-
tors of mitochondria is the intermembrane space. This is
the ~20 nm gap between the outer membrane and the
part of the inner membrane that is known as the inner
boundary membrane. All matrix proteins imported into
the mitochondrion from the cytoplasm must pass
through the outer and inner membrane and therefore
also through the intermembrane space. Conventional
EM of thin plastic sections suggested sites of direct con-
tact between the lipid bilayers of the inner and outer
membrane [24, 25], but these seem to be artifacts of fix-
ation and dehydration. Protein translocases of the outer
(TOM) and inner (TIM) membrane form a supercom-
plex that has been visualized by cryo-ET [26]. The
TOM/TIM supercomplex spans the intermembrane
space and appears to be held together by the polypeptide
in transit. The inner boundary membrane must contain
large numbers of the carrier proteins that shuttle ions,
ATP, ADP and small metabolites between the cytoplasm
and the matrix. These small membrane proteins include
most notably the 33 kDa ATP/ADP carrier [27], as well
as numerous other related and unrelated membrane
transporters.
The inner membrane forms invaginations, called cris-
tae, that extend deeply into the matrix. The cristae de-
fine the third mitochondrial compartment, the crista
lumen. The crista membranes contain most, if not all, of
the fully assembled complexes of the electron transport
chain and the ATP synthase (Fig. 2). The crista lumen
contains large amounts of the small soluble electron car-
rier protein cytochrome c. The mitochondrial cristae are
thus the main site of biological energy conversion in all
non-photosynthetic eukaryotes.
The inner membrane cristae
Cristae were first discovered by electron microscopy
in thin sections of plastic-embedded cells and tissues
[28, 29]. They are disk-like lamellar, tubular or bag-like ex-
tensions of the inner boundary membrane, and are con-
tinuous with it at the crista junctions. Crista junctions in
mitochondria of post-mitotic hea t or liver cells are small
circular apertures of ~25 nm diameter [14, 30]. In cells
that divide frequently, such as yeasts, the crista junctions
tend to form 25 nm slits in the boundary membrane that
are up to a few 100 nm long [26, 30]. In mitochondria of
all organisms, the mitochondrial contact site and cristae
organizing (MICOS) system [31], an assembly of one sol-
uble and five me brane proteins, anchors the cristae to
the outer membrane. Cristae of yeast strains where
particular MICOS components have been knocked
out look like concentric onion rings and have few if
any junctions [32].
It is thought that the MICOS complex forms a diffusion
arr er within the inner membrane a the crista junctions
to account for the apparent lateral segregation of proteins














































Mitochondrial respiratory chain complexes
Fig. 2. Membrane protein complexes of the respiratory chain. Electron transport complexes I (NADH/ubiquinone oxidoreductase, blue), II
(succinate dehydrogenase, pink), III (cytochrome c reductase, orange), IV (cytochrome c oxidase, green) and the mitochondrial ATP synthase (also
known as complex V, tan) work together in oxidative phosphorylation to harness energy for the cell. Complexes I, III and IV pump protons across
the cristae membrane, creating the proton gradient that drives ATP synthesis. UQ ubiquinol. (Adapted from Davies KA, Daum B. Biochem. Soc.
Trans. 2013;41:1227–34.)
Kühlbrandt BMC Biology  (2015) 13:89 Page 3 of 11
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1.3.1 Complex I 
Mitochondrial complex I is located in the IMM, it is made up of 45 subunits (14 
conserved core subunits and 31 supernumerary subunits) and it catalyses the oxidation 
of NADH to NAD+ and the reduction of ubiquinone to ubiquinol while concomitantly 
pumping 4 protons from the matrix to the IMS26. 
Figure 1.4 shows the structure of complex I (including the 14 core subunits from the 
tip of the peripheral arm 51 kDa subunit to the end of the membrane arm ND5 
subunit) on the left and a schematic overview highlighting the main functional 




Figure 1.4. The structure of complex I. On the left, intact complex I from Bos taurus is 
shown, with the Fe-S clusters depicted outside the hydrophilic arm for clarity. Picture adapted 
from Vinothkumar, Zhu and Hirst27. On the right, the scheme shows the quinone binding site 
at the interface between the hydrophilic and membrane domains and the trail of charged 
residues possibly involved in the proton pumping mechanism, see text for details (picture 
from Brandt28). 
The 14 central subunits, common to both prokaryotic and eukaryotic complex I, fulfil 
the core bioenergetic function of the enzyme (discussed below); the supernumerary 
subunits in the mitochondrial enzyme are thought to play important roles in 





a chain of seven iron–sulfur clusters. The Q- and N-modules
form the peripheral arm of complex I that sits almost
perpendicular at one end of the 180 ! long membrane arm.
This P-module harbors the proton pumps and is subdivided
into a proximal and a distal domain each of which is known to
pump half of the protons.[6]
The crystal structure of the entire bacterial complex I
from Thermus thermophilus[7] at 3.3 ! resolution now pro-
vides a complete picture of all the components of this
remarkably large and complicated enzyme. It offers detailed
insights into the connection between the redox prosthetic
groups of the peripheral arm and the proton pumps of the
membrane arm. The roughly 300 ! long, continuous array of
functional elements encompasses all parts of the giant
multiprotein complex and reaches fr m he NADH oxidatio
site at the top of the peripheral arm all the way to the most
distal pump site at the end of the membrane arm (Figure 1).
In addition to the putative proton uptake and release
channels described previously within the three subunits
homologous to Mrp-type Na+/H+ antiporters,[3] a fourth set
of putative channels is now clearly described that runs
through the membrane right next to the docking region of
the peripheral arm and possibly even involving it in part.
Although the number of four pump sites suggested from the
structure fits the experimental pumping stoichiometry of
complex I of 4H+/e! , the functionality of all the putative
channels must still be tested experimentally.
Confirming earlier reports,[2, 4,8] the headgroups of the
substrate ubiquinone and the quinone-analogous inhibitor
piericidin A are shown to bind to a conserved tyrosine next to
the terminal iron–sulfur cluster N2 residing about 25–30 !
above the membrane surface in a large amphipathic pocket of
the Q-module.[7] This pocket extends as a narrow channel into
the P-module, thereby providing access to the membrane
domain. However, such a constrained path does not seem
compatible with efficient substrate exchange. This may be
overcome during turnover by the transient opening of the
ubiquinone pocket to some extent. On the other hand, the
formation of a well-shielded reaction chamber is well in line
with the proposal that tight control of the protonation of
anionic ubiquinone intermediates is critical for the energy-
converting mechanism of complex I.[9] In good agreement
with this idea and corroborating an earlier proposal that
energy transmission within complex I may occur through
electrostatic coupling,[10] the ubiquinone binding pocket now
appears as the starting point of a unique uninterrupted chain
of positively and negatively charged residues that for the most
part runs through the middle of the P-module and connects
the four putative proton-input and -output channels observed
in the structure of the membrane domain.[7] While it is
tempting to speculate that this unique feature of complex I
represents the key energy-transducing element driving the
proton pumps, to prove this, several pertinent questions need
to be answered both theoretically and experimentally. How
are the charges shielded securely from access by water and
ions to ensure tight coupling and prevent the uncontrolled
dissipation of energy? Does the mechanism proceed through
conformational changes at all, or does it operate exclusively
by electrostatically controlled changes in the apparent pKs of
the residues involved? How is the gating of proton access and
release ensured? Do all pumping elements operate in sync?
At any rate, the strikingly long lateral horizontal helix
bridging the distal and the proximal part of the P-module
seems to merely stabilize the structure of the membrane
domain together with a set of b-hairpin-helix elements on the
opposite side of the membrane rather than playing an active
part in the pumping mechanism as suggested earlier.[3, 4]
The structure of the entire bacterial complex I offers
a stunning inside view into a unique and fascinating molecular
machine.[7] We are only just starting to understand how
complex I might work as a redox-driven proton pump. Its
sheer size and complexity, a binding site for its hydrophobic
substrate in the hydrophilic domain and a peculiar long chain
of charge residues running through the middle of its
membrane domain pose major challenges for future structural
and functional studies.
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Figure 1. Schematic overview of the functional elements of complex I.
In the N-module, electrons from NADH enter a chain of seven iron–
sulfur clusters (orange dots). They are transferred from the terminal
cluster N2 of the chain onto a ubiquinone molecule (space-filling
model) bound in a pocket of the Q-module reaching into the
membrane domain. A long chain of charged residues passing through
the middle of the membrane integral P-module connects the Q-binding
pocket to four putative pump sites consisting of separate proton input
and output channels. The long lateral helix (HL) and a series of b-
hai pin-h lix elements (bH) bridge the proximal (Pp) and distal (PD)
domain of the P-module.
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The reaction catalysed by the enzyme is shown below30 
/01& +&' + 3 + 4&56789:
' → /01' + 3&< + 4&=>?
'  
In summary, the enzymatic process starts with the binding of the electron donor 
NADH to the 51 kDa subunit (at the top of the hydrophilic arm), in a juxtaposed 
configuration over the isoalloxazine system of the flavin mononucleotide (FMN) 
cofactor to facilitate hydride transfer from the former to the latter cofactor. Then, 
electrons are transferred through a chain of 7 iron-sulphur (Fe-S) clusters (the role of 
the additional [2Fe-2S] cluster next to the flavin is unclear) down the hydrophilic arm 
of the enzyme to the quinone chamber where formation of quinol ensues31. 
1.3.1.1 Substrates and cofactors: NADH and metabolic consequences of complex I 
inhibition 
NAD+ is obtained in humans by de novo synthesis from tryptophan and, more 
importantly, from salvage pathways from the niacins (nicotinic acid, nicotinamide and 
nicotinamide riboside)32. Figure 1.5 shows the structure of NADH, its standard 
reduction potential and the chemical change it undergoes upon reduction. While 
intracellular NAD+ levels are kept between 0.2 and 0.5 mM, in mitochondria they can 
be up to four times higher33. 
 
Figure 1.5. NADH structure and its redox states. NADH donates two electrons to complex 
I via hydride transfer from the nicotinamide ring. Reduction potential taken from Poian and 
Castanho34. 
Even though in mammals there are a mitochondrial and a nucleocytosolic 
[NADH/NAD+] pool (connected with each other by redox shuttles and compartmental 
NAD+ biosynthetic pathways)35, both are kept very oxidised in cells since many 
cellular processes use NAD+ as an oxidizing agent to function36: obvious examples 
are the TCA cycle and β-fatty acid oxidation in the mitochondrial matrix, glycolysis 
























NADH/NAD+ Eo' -320 mV
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produced in the cytosol is then transferred into the mitochondrial matrix via either the 
glycerol 3-phosphate shuttle (which bypasses complex I) or the malate aspartate 
shuttle (the predominant shuttle in most oxidative tissues37), unless it remains in the 
cytosol where it can be reoxidised by lactate dehydrogenase to form lactate from 
pyruvate38. 
Figure 1.6 displays major classes of metabolic pathways where NAD+ and NADH are 
involved in mammals. Even though NADH can still be oxidized by the nicotinamide 
nucleotide transhydrogenase in mitochondria (which keeps the NADPH pool reduced 
at the expense of NADH and proton motive force39), an inhibition of complex I causes 
the NADH/NAD+ ratio to rise, progressively hampering the above-mentioned 
processes as well as proton pumping that ultimately leads to decreased ATP 
production. Furthermore, Santidrian et al.40 reported that a higher NADH/NAD+ ratio 
elicited by complex I inhibition (obtained by knockdown of NDUFV1 which encodes 
the 51 kDa subunit) enhanced the metastatic potential of breast cancer cells (while 







Figure 1.6. Major metabolic pathways using NAD+ or NADH in mammals. Triacylglycerols (TAG, bue 
area) are split into fatty acids and glycerol: the former will be oxidised and ultimately converted to acetyl 
CoA towards the TCA cycle (yellow area) which can be redirected towards ketone body formation (light 
green area), the latter will enter the glycolytic/gluconeogenetic pathway (orange area). The end product of 
glycolysis, pyruvate, can either be reduced to lactate or converted to acetyl CoA. A side path leads to amino 
acids and purine biosynthesis (purple and grey areas respectively). Finally, ethanol metabolism requires two 
equivalent of NAD+ (dark green area). References: Lipids, TCA cycle and glycolysis/gluconeogenesis, 
McMurry41; Desaturase, Nakamura and Nara42; Citrate export in TCA cycle, Gnoni et al.43; Ketone bodies, 
Newman and Verdin44; Ethanol, Louvet and Mathurin45; Amino acids, Grant46, Kikuchi et al.47, Pemberton 




























































































































































































1.3.1.2 Substrates and cofactors: FMN 
Figure 1.7 shows the structure of FMN, its standard reduction potential and the 
different redox states it can assume. 
 
Figure 1.7. FMN structure and its redox states. FMN is capable of assuming different 
redox states to switch from a two-electrons donor (NADH) to one-electron acceptors (Fe-S 
clusters). Reduction potential taken from Kussmaul and Hirst50. 
FMN can undergo (just like ubiquinone) one- and two- electron transfer and therefore 
can serve as a redox switch between obligate two- and one- electron redox partners51. 
The precursor from FMN and FAD is riboflavin (or vitamin B2), which cannot be 
synthesised by animals and, therefore, it must be acquired from the diet52. In humans, 
riboflavin is converted first to FMN by riboflavin kinase and then FAD synthase 
adenylates FMN to obtain FAD and also delivers it to the client apo-flavoproteins as a 
molecular chaperone53. It is also noteworthy that transporters for FAD and riboflavin 
exist in mitochondria54  and that riboflavin supplementation can be an effective 
treatment in mitochondrial diseases due to NDUFV1 mutations55. 
1.3.1.3 Substrates and cofactors: Fe-S clusters and electron tunnelling 
Figure 1.8 shows the types of Fe-S clusters that can be found in the enzymes of the 
respiratory chain and the chain of clusters in complex I. Fe-S clusters are inorganic 
cofactors made up of iron centres and sulphide ions and typically bind to thiolate side 
chains of protein cysteine residues: they can efficiently shuttle single electrons since 
the overlap of transition metal orbitals of the iron centres with the orbitals of sulphur 
allows effective delocalisation across the clusters56. The biosynthesis of Fe-S clusters 
mainly depends on the activity of the cysteine desulfurase NSF1 that provides sulphur 
atoms by binding to its substrate cysteine and converting it to persulfide (with 
assistance by accessory protein ISD11 and frataxin): sulphur is then transferred to the 
scaffold protein ISCU where it will combine with iron57. Isoforms of the core 
components have also been identified in extramitochondrial millieux in humans: they 
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Figure 1.8. Fe-S clusters in the respiratory chain and in complex I. Top. From left to 
right, exemplifying structures of [2Fe-2S], [3Fe-4S] and [4Fe-4S] Fe-S clusters: the first and 
the last can be found in complex I, the first in complex III and complex II includes all three 
types. Colour code: S yellow, Fe green, C grey. Picture from Sharpe and Housecroft59. 
Bottom. FeS clusters in complex I from Bos taurus, edge-to-edge distances in Å. Adapted 
from Hirst31. 
Their role in facilitating electron transfer in proteins is already well-established, and 
other functions carried out by FeS proteins are molecular oxygen and nitric oxide 
biological sensing60 and, more recently discovered, their substantial role in DNA 
replication and repair61. The oxidation state of the iron centres is either (II) or  (III), 
with a high-spin configuration and a tetrahedral geometry: protein bound clusters 
generally adopt only a pair of overall charge states (for [4Fe-4S] and [2Fe-2S] 
ferredoxins usually +2/+1, or +3/+2 if they are high potential iron clusters) 62. Typical 
reduction potentials range from -700 to -100 mV for clusters that possess cysteine 
residues, and higher potentials (-100 to 400 mV) for clusters that also possess other 
ligands, especially histidine63 (see section 1.3.3 for Rieske protein in complex III). 
Electron transfer in complex I from the FMN through the Fe-S clusters (and, in 
general, electron transfers between redox centres in enzymes) occurs via electron 
tunnelling64, whereby, under certain conditions, an energetic barrier can be crossed 
without the energy needed to surmount it65. The rate of electronic tunnelling between 
donor and acceptor depends on four parameters: frequency at which both attain the 
transition state, difference in their standard potentials, reorganisation energy, both 
inner sphere (changes in metal-ligand bond lengths and metal centre geometrya), and 
                                               
a Electron transfer between Fe-S clusters is generally fast because of a very low inner-sphere reorganisation 
energy: upon reduction, the strong Fe-S bonds change very little and in both iron oxidation states (II) and (III) 
tetrahedral geometry is strongly favoured, as opposed to, for instance, four-coordinate Cu(II) and Cu(I) complexes, 
that favour square planar and tetrahedral geometry, respectively66. 
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outer-sphere (changes in solvent molecules orientation) and extent of overlap of their 
orbitals67. Within the protein matrix the latter term is the dominant factor and distance 
between redox centres is paramount: if this distance happens to be bigger than the 
threshold value of 14 Å the electron transfer is likely a physiologically unproductive 
and adverse reaction68.  
The transfer of electrons along the 7 Fe-S clusters in complex I is generally 
considered to be fast and not rate liming and the longest known distance between 
clusters (4th and 5th in the sequence, 14 Å in the bovine enzyme) is conserved in Bos 
taurus, Yarrowia lipolytica and Thermus thermophilus69. The potential energy profile 
for electron transfer in bovine complex I alternates high and low potential FeS 
clusters31. Biological redox chains can often exhibit such an alternating or “roller-
coaster” landscape in the energetics of electron transfer (e.g. the C-subunit in the 
photosynthetic reaction centre of purple photosynthetic bacteria Blastochloris viridis 
that facilitates electron transfer to the special pair70). Even though the reasons behind 
the selection pressure to conserve this pattern are not entirely clear, uphill tunnelling 
steps might play a regulatory role (electron transfer to the chain would accelerate only 
after a threshold supply of electrons has been accumulated71) or even to spatially 
separate high potential hemes with low potential ones in order to prevent electrostatic 
interaction from increasing the variability of the chain energy profile72. 
1.3.1.4 Substrate and cofactors: ubiquinone 
Figure 1.9 shows the general structure of ubiquinone, its standard reduction potential 
and the different redox states it can assume. Ubiquinone (or coenzyme Q) is a 
membrane-bound compound contained in the endomembranes of all animal cells. It 
consists of a hydrophobic isoprenoid tail that anchor the molecule in membrane lipid 
bilayers, and a hydrophilic head group that can interact with hydrophilic domains of 
proteins: it acts as a mobile electron and proton carrier in the respiratory chain (from 
complexes I and II to complex III, see later) but it has also a role in pro- and anti- 
oxidant processes73. Other enzymes that feed the Q-pool (i.e. ubiquinone is their 
electron acceptor) are electron-transferring flavoprotein ubiquinone oxidoreductase, 
glycerol 3-phosphate dehydrogenase, dihydroorotate dehydrogenase, choline 
dehydrogenase, proline dehydrogenase and sulfide:quinone oxidoreductase74. 
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Figure 1.9. Ubiquinone structure and redox states. Ubiquinone, just like FMN, can assume 
different redox states in order to switch from a two-electron acceptor (complex III) to a one-
electron donor (cytochrome c, see paragraph on complex III). Reduction potential taken from 
Vinogradov and Grivennikova75. 
The number of isoprenoid units in the tail varies among species: the predominant 
forms are Q10 in human and dog, Q9 in rodent and fly, Q8 in bacteria and Q6 in yeast76. 
The biosynthesis of ubiquinone has been studied extensively for yeast Saccharomyces 
cerevisiae and the enzymes involved seem to be well conserved in animals, apart 
from the enzyme that catalyses the committed step of the process (COQ1), the 
assembly and elongation of the isoprenoid tail. The next steps (attachment of the tail 
to either one of the 2 precursors, 4-hydroxybenzoic acid or 4-aminobenzoic acid, and 
ring modifications) are well characterised but the order of reactions in the mammalian 
system is still not clearly established77. In humans, Q10 is found at the highest 
concentrations in heart, kidney, liver and muscle, whereas lung and colon possess the 
lowest amounts 78 . Finally, the efficacy of Q10 supplementation for therapeutic 
purposes (e.g. metabolic control in diabetes 79  and prevention of cardiovascular 
diseases80) is still unclear. 
1.3.1.5 Coupling between proton translocation and electron transfer        
The exact mechanism of coupling between electron transfer and proton pumping is 
still unresolved, but it entails two possible major redox energy release points, quinone 
reduction and, less importantly, reduction of the last cluster N2. The midpoint redox 
potentials in complex I for FMN and most of the Fe-S clusters are within -370 to -240 
mV, hence very similar to the NADH/NAD+ couple. Only at the last Fe-S cluster of 



























depending on the species), and this large energy span (along with the one associated 
with electron transfter from N2 to ubiquinone) are often assumed to be the major 
driving force for proton translocation81. However, Zwicker et al. reported that when 
the residue responsible for the pH dependency of the redox potential of N2 was 
mutated (H226M in the 49-kDa subunit in Yarrowia lipolytica), the pH dependency 
was lost and the N2 potential shifted by -80 mV, leaving the proton pumping capacity 
of complex I unaltered82. This suggests that such redox centre is not involved with 
proton translocation and that the energy to drive this process is linked to redox 
chemistry of ubiquinone. N2 sequentially transfers two electrons from the FeS wire to 
ubiquinone (which assumes a semiubiquinone intermediate redox state in the 
process): notably, the ubiquinone binding site (a long and narrow cavity mostly 
provided by the PSST, 49- and 30-kDa subunits) is about 20 Å away from the 
hydrophobic membrane core, where most of the Q pool is located83. Once electron 
transfer from cluster N2 is complete, it is thought that electrostatic interactions would 
drive conformational changes in the E-channel (ND1 subunit in the corner of the 
enzyme). At this point, these changes would propagate throughout the membrane arm 
of the complex via a central axis of charged and polar residues, from ND1 all the way 
to the end of the membrane domain, ND5, causing proton ejections to the IMS at four 
sites (three antiporters and the E-channel) from Lys/Glu groups84. Whether complex I 
operates by translocating all four protons at once (one-stroke model) or in two stages 
(two-stroke model) is still unknown30. 
1.3.1.6 Active and inactive complex I 
An interesting feature of mitochondrial complex I is that it can exist in a catalytically 
active state (A-form) but also in an inactive or dormant state (D-form, sometimes 
referred to in the literature as “deactive” state). Experimentally, the D-form can be 
induced by exposing the enzyme to elevated physiological temperatures in the 
absence of substrate and it is characterised by a so-called temporary lag-phase, 
wherein NADH oxidation activity is much slower than in the active state: addition of 
substrate reverts the D-form population into the A-form85. Structurally, it has been 
proposed by Zhu et al. that the deactive state is characterised by a disordered loop 
between transmembrane helices 1 and 2 in ND3, which contributes to the ubiquinone-
binding site and, as such, could explain lack of catalytic activity86. Some areas of 
complex I are more exposed in the D-form, such as ND1, ND3 and the NDUFA9 
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accessory subunit, suggesting an important role for the junction between the 
hydrophilic and membrane domain of complex I in the conformational 
rearrangements from A- to D- form87. Physiologically, the D-state is manifest when 
respiration rate is severely decreased and, therefore, the respiratory chain tends to be 
in a highly reduced state and its activity very limited, especially in highly 
metabolising tissues such as brain and heart. Subsequent reperfusion (hence 
reintroduction of oxygen) would eventually restore the A-form status88. Crucially, the 
reactivation of complex I during reperfusion of ischemic tissue brings about oxidative 
damage and tissue necrosis. It was found that selective S-nitrosation of a key residue 
in the ND3 region (Cys39) that becomes exposed in the D-form protects from the 
damage following ischemia-reperfusion injury: the S-nitrosothiol cap is slowly 
removed by glutathione and thioredoxin, preventing an (unwanted) sudden 
reactivation of complex I which would cause excessive and damaging formation of 
ROS89. Finally, the D-form in the bovine enzyme has also been shown to possess 
Na+/H+ activity which is abolished when substrate is added and complex I is 
reactivated90.  
1.3.2 Complex II 
Mitochondrial complex II is different in many important aspects from the other 
enzymes in the respiratory chain: it does not pump protons, it also belongs to the TCA 
cycle and all of its subunits are encoded by nuclear DNA91. Complex II is also known 
as succinate dehydrogenase (SDH, oxidation of succinate to fumarate) or 
succinate:ubiquinone oxidoreductase (SQR, reduction of ubiquinone to ubiquinol): 
additionally, bacterial fumarate reductase (structurally and functionally similar to 
complex II) catalyses the reverse reaction92.  
The total reaction catalysed by mitochondrial complex II is, therefore, the following93 
@ABBCDEFG + 3 → (AHEIEFG + 3&< 
Complex II is actually a superfamily of enzymes, divided into subfamilies A to E 
(according to the number of membrane-spanning polypeptides and whether a b heme 
is present or not), but they all share a main structural scaffold, a large soluble domain 
(where oxidoreduction of succinate and fumarate occurs) with two polypeptide chains 
(SdhA, a flavoprotein, and SdhB, an iron-sulfur protein containing three Fe-S 
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clusters) and a smaller membrane domain (where oxidoreduction of ubiquinol and 
ubiquinone occurs), with other two chains (SdhC and SdhD)94. The electron transfer 
of the enzyme is similar to complex I, since electron transfer proceeds from FAD 
through a chain of three FeS clusters to ubiquinone. Figure 1.10 shows the structure 
of complex II on the left and the same structure with the cofactors highlighted on the 
right. 
 
Figure 1.10. The structure of complex II. Porcine succinate dehydrogenase exhibits features 
typical of the complex II superfamily, namely the four different subunits with FAD and Fe-S 
clusters in the soluble domain and a b heme in the membrane domain. Picture taken from Van 
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1.3.3 Complex III 
Cytochrome bc1 (or complex III) catalyses the oxidation of ubiquinol from the IMM 
Q-pool to ubiquinone and the reduction of two molecules of cytochrome c: the energy 
transfer is coupled to the release of four protons to the IMS, two of which originate 
from the matrix. The total reaction catalysed by complex III is, therefore, the 
following96. 
3&< + 2	BKF	BL: + 2&56789:
' → 3 + 2BKF	B8MN 	+ 4&=>?
'  
The homodimeric cytochrome bc1 complexes share the same catalytic core, a 
cytochrome transmembrane subunit containing two b-type heme groups (bL and bH on 
account of their low and high potential, respectively) and two soluble domains, a 
Rieske Fe-S proteinb called ISP and another cytochrome subunit with a c-type heme 
called cytochrome c197. Owing to the nature of electron acceptor and donor in this 
enzyme (ubiquinone carries two electrons whereas cytochrome c only carries one), a 
switch from a two-electron to a one-electron carrier is needed in the catalytic 
mechanism, the so-called Q cycle. The current level of understanding of the Q cycle 
involves, critically, a bifurcated electron transfer whereby one molecule of ubiquinol 
binds to the Qo site and is sequentially oxidised with one electron taking a high 
potential path (through the Rieske protein and cytochrome c1) that will ultimately 
reduce cytochrome c, and the other electron taking a low potential path (through the 
hemes bL and bH) that will ultimately reduce a second ubiquinone molecule (bound to 
another site, Qi) to semiubiquinone radical. Another repetition of the cycle will 
generate another reduced cytochrome c and will reduce semiubiquinone to ubiquinol 
in the Qi site98. Interestingly, movement of the ISP protein was shown to be required 
for electron transfer from the Q0 site to c199. Figure 1.11 shows the structure of 
complex III on the left and a cartoon illustrating the Q-cycle on the right. 
                                               
b While most FeS centres have negative reduction potentials, Rieske proteins are an exception: their reduction 
potentials are higher and usually positive because their [2Fe-2S] cluster has one Fe coordinated by two imidazole 
ligands rather than cysteine, and this stabilises the metal centre as Fe(II)59. 
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Figure 1.11. Structure of complex III and Q cycle. On the left, bc1 homodimer complex 
from bovine mitochondria is shown. The heme groups and FeS cluster are highlighted in 
black. Picture taken from Xia et al98. On the right, a schematic representation of the Q-cycle is 
depicted, with the high potential path (blue arrow), low potential path (red arrow) and 
movement of the Rieske protein (black double-headed arrow) highlighted. Picture taken from 
Cooley97.       
1.3.4 Complex IV 
The terminal enzyme of the respiratory chain in mitochondria is cytochrome c oxidase 
or complex IV. It catalyses the reduction of molecular oxygen to water by delivering 
4 “chemical” protons to the former and, at the same time, pumps 4 protons per 
electron in the IMS to contribute towards ∆p. The total reaction catalysed by complex 
IV is, therefore, the following100 
4BKF	B8MN + O< + 8&56789:
' → 4BKF	BL: + 2&<O + 4&=>?
'  
The eukaryotic enzyme contains an overall of 13 subunits but the three largest 
subunits include the catalytic core of the enzyme and are very similar to their bacterial 
counterparts. The prosthetic groups embedded in the main catalytic subunits are, in 
order of electron transfer sequence, a copper site (Cua, with two copper centres), a 
heme group (heme a) and a heme/copper centre (heme a3/Cub)101. The mechanism is 
not unanimously accepted but there is widespread agreement on the major key points: 
molecular oxygen binds the iron in heme a3/Cub when both metal centres are reduced 
and then one oxygen atom is transferred as OH- to Cub; further reduction and proton 
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transfer converts the other oxygen into OH- and then both hydroxyl ligands become 
protonated and exit the metal centre as H2O. Three possible proton-transfer pathways 
have been identified: K- and D- transfer protons for water formation at the O2 
reduction site, whereas H- is for pumping protons towards the transmembrane proton 
gradient102. Figure 1.12 shows the structure of complex IV on the left and a scheme 
illustrating the cofactors and the possible proton pathways on the right. 
  
Figure 1.12. Structure of complex IV. On the left. Complex IV from Rhodobacter 
sphaeroides highlighting the major subunits and cofactors. Picture taken from Nyquist et 
al.103. On the right, cartoon representing the three putative proton channels and the prosthetic 
groups in complex IV. Picture taken from Yoshikawa and Shimada102.  
1.3.5 Complex V 
The protons pumped from the matrix to the IMS by complexes I, III and IV generate a 
PMF that is used by ATP synthase (or complex V) to catalyse the conversion of ADP 
to ATP. The enzyme exists as a dimer in mitochondria, forming V-shaped rows along 
the cristae that contribute to the curvature of the IMM104.  The core subunits of 
bacterial complex V are located in the F0 membrane sector (a1, b2 and c10-15) and in 
the F1 hydrophilic sector (α3, β3, γ, δ and ε), and the mitochondrial enzyme contains 
more peripheral subunits to the core ones105. The rotational catalytic activity starts 
with the transport of protons at the interface between the a and c subunits where they 
are loaded into the membrane part of the rotor: this drives rotation of the rotor and the 
movement of its hydrophilic part (γ and ε subunits) induces conformational changes 
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in each β subunit (which can assume ADP-bound, ATP-bound and empty forms) 
leading to ATP release (complex V can also work in reverse leading to ATP 
hydrolysis)106. Figure 1.13 shows a model of the c-ring and the way proton motion 
drives its rotation. 
 
Figure 1.13. Rotation of the c-ring fuelled by protons. Each proton from the IMS binds to 
an acidic residue (Asp61 in E. coli) through a half-channel in the a subunit. Proton binding 
elicits successive rotations of the c-ring whereby a bound proton undergoes a full circle 
before entering the matrix via a second half-channel. Picture from Iwasa and Marshall107.  
It is actually the release of ATP from the β subunit that requires the PMF, not 
formation of the (enzyme-bound) ATP itself, and magnesium ion plays a key role in 
ATP synthesis, since it acts as a separate substrate with ADP and Pi and it is bound to 
ATP upon product release: the chemical reaction catalysed by complex V is, 
therefore, the following108 
01QRS +	Q9
<S 	+ TU<' +	&' → TU0.Q<S +	&<O 
Each 360˚ rotation of the rotor produces 3 ATP molecules and requires a number of 
protons equal to the number of the c subunits: the bovine enzyme (and most likely all 





space into the middle of the  a subunit, and the other leads from the 
middle of the  a subunit into the matrix. It is proposed that each pro-
ton moves from the intermembrane space through the half‐channel 
and binds to a negatively charged acidic residue situated at the sur-
face of the adjoining  c subunit. This acidic residue is apparently an 
aspartic acid in  E .  coli (Figure  5.29), but is a glutamic ci residue in 
animal mitochondria. Binding of the proton to the carboxyl group of 
that residue causes that subunit to rotate approximately 308 in a 
counterclockwise direction. The movement of the recently proto-
nated  c subunit brings the adjoining subunit in the ring (which was 
protonated at an earlier step) into alignment with the second half‐
channel of the  a subunit. Once there, the acidic residue releases its 
associated proton, which diffuses into the matrix. Following disso-
ciation of the proton, the  c subunit returns to its original conforma-
tion and is ready to accept another proton from the intermembrane 
space and repeat the cycle. 
 According to this model, the proton‐binding residue of each 
 c subunit acts like a revolving proton carrier. A proton hops onto the 
carrier at a selected pick‐up site and is then carried around a circle 
before being released at a selected drop‐off site. Movement of the ring 
is driven by the conformational changes associated with the sequential 
protonation and deprotonation of the acidic residue of each  c sub-
unit. Consequently, the number of protons translocated for each rota-
tion of the  c ring is generally considered to be equal to the number of 
subunits that make up the ring, although this is not always experi-
mentally validated. The  c ring has been shown to contain between 8 
and 15 subunits, depending on the source. For the sake of simplicity, 
we will describe a  c ring composed of 12 subunits, as illustrated in 
Figure  5.29 . In this case, the association/dissociation of four protons 
in the manner described would move the ring  120°. Movement of 
the  c ring  120° would drive a corresponding rotation of the attached 
 subunit  120°, which would lead to the release of one newly synthe-
sized molecule of ATP by the  F1 complex. According to this stoichi-
ometry, the translocation of 12 protons would lead to the full  360°
rotation of the  c ring and   subunit, and the synthesis and release of 
three molecules of ATP. If the  c ring were to contain greater or fewer 
than 12 subunits, the  H ATP/  ratio would change, but this can easily 
be accommodated within the basic model of proton‐driven rotation 
shown in Figure  5.29 . 
 Other Roles for the Proton‐Motive 
Force in Addition to  ATP Synthesis 
 Although the production of ATP may be the most important activity 
of mitochondria, these organelles are engaged in numerous other 
processes that require the input of energy. Unlike most organelles 
that rely primarily on ATP hydrolysis to power their activities, mito-
chondria rely on an alternate source of energy—the proton‐motive 
force. For example, the proton‐motive force drives the uptake of 
ADP and  Pi into the mitochondria in exchange for ATP and  H , 
respectively. Exchange of ATP for ADP across the membrane is 
accomplished by the  adenine nucleotide translocase (ANT), which 
makes the ATP produced within the mitochondria available to meet 
the en rgy needs of the remainder of the cell. These and other activi-
ties that take place during aerobic respiration are summarized in 
FIGURE  5.30 . In other examples, the proton‐motive force may be 
used as the source of energy to “pull” calcium ions into the mito-
chondrion; to drive the events of mitochondrial fusion; and to cause 
specifically targeted polypeptides to enter the mitochondrion from 
the matrix (Figure 8.47). 
 5.10  Peroxisomes 
 Peroxisomes are simple, membrane‐bound vesicles (Figure  5.31 a ) 
with a diameter of 0.1 to  10  μm that may contain a dense, crystalline 
core of oxidative enzymes. Peroxisomes are multifunctional orga-
nelles, containing more than 50 enzymes involved in such diverse 
activities as the oxidation of very‐long‐chain fatty acids (VLCFAs, 
ones whose chain typically contains 24 to 26 carbons) and the syn-












FIGURE 5.29   A model in which proton diffusion is coupled to the 
rotation of the  c ring of the F o complex.  As discussed in the text, the 
number of subunits in the  c  ring is variable. For the sake of simplicity, this 
c  ring consists of 12 subunits. It is proposed in this model that each proton 
from the intermembrane space enters a half‐channel within the  a subunit 
and then binds to an acidic residue (Asp61 in  E .  coli ) that is accessible on 
one of the  c  subunits. Proton binding induces a conformational change that 
causes the ring to move by approximately  30°. The bound proton is carried 
in a full circle by the rotation of the  c  ring and is then released into a 
second half‐channel that opens into the m trix. A succes ion of protons 
that engage in this activity causes the  c  ring to rotate in a counterclockwise 
direction as shown. 
 REVIEW 
1.  Describe a proposed mechanism whereby proton 
diffusion from the intermembrane space into the 
matrix drives the phosphorylation of ADP. 
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per ATP plus one proton that accounts for electrogenic exchange of ATP for ADP 
combined with non-electrogenic symport of Pi and a proton, totalling to 3.7109. The 
stoichiometry of the c-ring is constant within a species but the number of unit varies, 
from eukaryotic smaller c-rings (e.g. Saccharomyces cerevisiae, 10 units) to larger 
prokaryotic and chloroplast larger c-rings up to 15 subunits (e.g. Ilyobacter tartaricus, 
11 units, Spinacia oleracea, 14 units)110.  Figure 1.14 shows a scheme of complex V 
on the left and its structure from bovine mitochondria on the right. 
  
Figure 1.14. Structure of complex V. On the left, cartoon of the mitochondrial enzyme 
representing the major subunits. On the right, molecular structure from bovine mitochondria. 
Pictures taken from Walker109. 
1.4 The mitochondrial permeability transition pore 
An important topic of mitochondrial physiology, especially linked to drug-induced 
mitochondrial dysfunction, is the mitochondrial permeability transition (MPT). It is 
defined as the permeabilisation of the IMM to solutes up to 1.5 kDa (due to the 
formation of a protein pore) and facilitated by events such as Ca2+ overload and 
oxidative stress111. The consequences of MPT are very severe and commonly linked 
to mitochondrial dysfunction: as for long-lasting openings, these includes 
mitochondrial depolarisation, arrest of ATP synthesis, depletion of matrix substrates 
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and ultimately matrix swelling and release of proapoptotic proteins (in contrast to 
short-term openings that could be involved in physiological Ca2+ regulation and ROS 
homeostasis)112. The molecular identity of the protein pore has been (and still is) a 
matter of intense debate, with many different suggested formulations: genetic 
inactivation of putative components have disproved the need for once considered 
indispensable elements of the pore such as the adenine nucleotide translocator (ANT), 
voltage-dependent anion channel (VDAC), phosphate carrier (PiC) and translocator 
protein (TSPO). The role of the prolyl isomerase Cyclophilin D (and its inhibitor 
Cyclosporin A) in modulating the MPT by lowering the Ca2+ load required for pore 
opening is nowadays fully accepted 113. Crucially, progress in the determination of the 
molecular identity of the pore has led to the discovery of the possible role of Complex 
V in MPT: the two leading ideas about the mechanisms on how such enzyme may be 
involved (through the interface of its dimers or via the c-ring) have recently been 
proposed to act in a unified way114. The MPTP is pharmacologically important, 
inasmuch as it is a viable drug target (for instance, a very recent work highlighted 
how its pharmacological deactivation via a CypD inhibitor, JW47, can offer 
neuroprotection in multiple sclerosis in mice115; on the other hand, several drugs can 
trigger MPTP, such as Methapyrilene (via liver glutathione depletion116), Minocycline 
(mitochondrial swelling and cyt c release117), Betulin (CsA dependent and cholesterol-
enhanced cyt c and caspase activation118) and Tetrandrine (CsA dependent cyt c and 
caspase activation119). 
1.5 ROS 
Reactive oxygen species (or ROS) are reactive byproducts of aerobic metabolism 
formed within the cell: depending on their chemical nature, they can be divided into 
radicals (e.g. superoxide ion O2•−, hydroxyl OH•) and nonradicals (e.g. hydrogen 
peroxide H2O2) 120 . The main endogenous ROS-generating cellular systems are 
depicted in Figure 1.15. Even though O2 can be irreversibly reduced all the way to 
water (from a thermodynamic perspective), it is kinetically relatively inert because of 
spin restriction (it cannot accept two electrons with antiparallel spin at the same time): 
enzymes that use O2 as substrate, therefore, employ one-electron cofactors to prevent 
such electron transfer restriction121. The one-electron reduction of O2 to O2•− in 
mitochondria occurs by protein-bound electron carriers and depends not only on 
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substrate concentration but also on how much enzyme is capable of interacting with 
O2 to actually generate superoxide: the reduction is thermodynamically favourable, 
but it is kinetic factors that mostly control the reaction122. Superoxide can then be 
further reduced to H2O2 via a disproportionation reaction, which can occur 
spontaneously at physiological pH but, more importantly, via superoxide dismutase 
(SOD): while the CuZn isoform is found in the mitochondrial IMS, the Mn isoform is 
found in the mitochondrial matrix123. Hydrogen peroxide can generate the more 
reactive and toxic hydroxyl radical in a chemical fashion with an appropriate electron 
donor: depending on the identity of the latter, the Fenton reaction (reduced iron center 
such as Fe2+ or Cu+) or the Haber-Weiss reaction (superoxide ion) can take place124. 
 
Figure 1.15. The major cellular sources of ROS. Enzymes and chemical electron donors 
located in the cytoplasm and in several organelles contribute to ROS generation in cells. 
Particularly relevant to mitochondria are the electron transfer chain (ETC) in the inner 
mitochondrial membranes and monoamine oxidases (MAO) in the outer mitochondrial 
membrane. Picture taken from Bachi, Dalle-Donne and Scaloni120. NOX, NADPH oxidase; 
DUOX, dual oxidase; XO, xanthine oxidase; MPO, myeloperoxidase; EPO, eosinophil 
peroxidase; GPx, glutathione peroxidase; Prx, peroxyredoxin; mNOS, mitochondrial nitric 
oxide synthase; iNOS, inducible nitric oxide synthase; XDH, xanthine dehydrogenase; Ero1, 
ER oxidoreductin 1.  
Mitochondria are both important sources and sinks of ROS, but whether this organelle 
is the major cellular source or not is still debated125. ROS are key players in signalling 
pathways regulating immune response, autophagy, cell proliferation, angiogenesis and 
differentiation, but concentrations large enough to surpass local antioxidant 
Figure 2. Main endogenous cellular systems generating ROS and RNS. (A) Any electron-transferring protein or enzymatic system can result in the
formation of ROS or RNS as “byproducts” of electron transfer reactions. Mitochondrial electron transport chain (ETC) within the inner
mitochondrial membrane is a significant source of ROS, together with monoamine oxidase (MAO)-catalyzed production of H2O2 during oxidative
deamination of biogenic amines within the outer mitochondrial membrane. Plasma membrane is a major source of ROS through NADPH oxidases
(NOXs) located on either side. Enzymes of the same class displaying low activity are also present as free species within the cytoplasm. Smooth
endoplasmic reticulum (ER) contains enzymes, including cytochrome P-450 and b5 families, which catalyze a series of reactions to detoxify lipid-
soluble drugs and harmful metabolic products. It also contains NOXs and dual oxidases (DUOXs). Peroxisomes are an important source of total
cellular H2O2 production. They contain a number of H2O2-generating enzymes of the oxidase family. Peroxisomal catalase uses H2O2 produced by
these oxidases to modify a variety of other substrates through peroxidative reactions, particularly in liver and kidney cells, where peroxisomes detoxify
various noxious molecules entering the circulation. To contrast microbial infections, phagocytes produce toxic ROS and RNS in a process also
known as the respiratory burst, which is the result of the activity of phagocytic NOX releasing O2
•− as a primary product. In neutrophils, monocytes
and macrophages, myeloperoxidase (MPO) is released into the phagosome when lysosomes fuse with it, thus generating the phagolysosome, where
MPO forms highly reactive halide (particularly chloride)-derived oxidants in the presence of H2O2, such as HOCl and chloramines. In eosinophils,
the predominant component of their specific granules is eosinophil peroxidase (EPO) that, along with H2O2 produced by the highly active
eosinophil NOX system, oxidizes low abundant substrates such as Br−, NO2
−, and SCN− yielding HOBr, NO2
•, and HOSCN, respectively. In
addition, cytoplasmic soluble enzymes, such as xanthine oxidase (XO), aldehyde oxidase, flavoprotein dehydrogenase, and tryptophan dioxygenase,
can generate ROS during catalytic cycling. Autoxidation of small molecules, such as dopamine, epinephrine, flavins and hydroquinones, can also yield
intracellular ROS. In most cases, the product of such autoxidation reactions is O2
•−. Transition redox-active metals (Fe, Cu, Cr, and Co), due to their
capacity to lose electrons, have the potential to generate ROS and, therefore, oxidative damage. (B) The vast majority of cellular ROS (∼90%) in
eukaryotic, nonphagocytic cells is generated within mitochondria, which house within their inner membrane (IMM) the ETC transferring electrons
from NADH and FADH2 along a controlled redox path ending in the four-electron reduction of O2 to H2O during respiratory ATP synthesis.
However, O2 occasionally undergoes one- or two-electron reduction reactions to form ROS, particularly O2
•− and H2O2. Production of
mitochondrial O2
•− occurs primarily at complex I (NADH−ubiquinone oxidoreductase) and III (ubiquinol−cytochrome c oxidoreductase). Under
normal metabolic conditions, complex III is the main site of ROS production. O2
•− produced at complex I is thought to form only within the matrix,
whereas at complex III it is released both into the matrix and into the intermembrane space. Once generated, O2
•− is dismutated spontaneously or
enzymatically by Mn-SOD (SOD2) within the mitochondrial matrix and by Cu/Zn-SOD (SOD1) within the cytoplasm and, to a lesser extent, in the
mitochondrial intermembrane space. H2O2 formed is further catabolized by the action of enzymes such as glutathione peroxidase (GPx1) and
peroxiredoxins (Prxs). In addition to the respiratory chain, the flavoprotein MAO, localized on the outer mitochondrial membrane (OMM), is
another important mitochondrial source of H2O2.
Chemical Reviews Review
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capabilities can trigger oxidative stress, aging and cell death126,127. ROS signalling 
primary targets are cysteine residues, owing to their intrinsic rich chemistry: ROS-
mediated redox modifications include sulfenylation (-SOH), sulfinylation (-SO2H) 
and sulfonylation (-SO3H) and these modifications play a role in regulation of 
different protein functions such as ligand binding activity, protein-protein interactions 
and protein stability128. The ROS entity involved in cysteine signalling is H2O2 on 
account of its biochemical features: its steady-state intracellular concentration levels, 
nM to low µM range, are much higher than O2•− (due to the very large rate constants 
for both chemical and SOD-driven dismutation to H2O2 and water), it is a mild 
oxidant and it can easily cross membranes, directly or via aquaporin-mediated 
transfer 129 . H2O2 is primarily metabolised in cells by two enzyme families, 
peroxiredoxins (Prx) and glutathione peroxidase (GPx), and the enzymes responsible 
for recycling the enzymes back to their active state with NADPH are thioredoxin 
(Trx) and glutathione reductase (GR), respectively: the isoform Prx3 is more efficient 
at scavenging H2O2 than Prx5, while Gpx1 (matrix soluble) is more H2O2-specific 
than Gpx4 (which eliminates lipid hydroperoxides)130. Catalase, usually considered a 
peroxisomal H2O2 scavenger protein, is also present in mitochondria131. Figure 1.16 
shows the main ROS degradation pathways in mitochondria. 
Mitochondrial complex I can generate ROS while working in reverse (reverse 
electron transport or RET), where ubiquinol transfers electrons back to complex I 
while generating NADH via NAD+ reduction: this happens when FADH2-related 
substrates (e.g. succinate or fatty acids) are preferentially used leading to reduction of 
the ubiquinone pool and generating a membrane potential and favourable 
thermodynamic conditions for such an electron transfer to happen132. RET at complex 




Figure 1.16. O2•− and H2O2 metabolism in mitochondria. The ETC generates O2•− on both 
sides of the inner mitochondrial membrane and that is rapidly converted to H2O2: its 
metabolism can involve either Prx or Gpx pathways, and those are regenerated by Trx and 
GR, respectively, ultimately requiring NAPDH. Other ways of H2O2 sequestration involve 
lipoic acid and pyruvate. Picture taken from Mailloux, McBride and Harper130. Idh, isocitrate 
dehydrogenase; ME, malic enzyme; Elth, energy liberating transhydrogenase; G6pd, glucose-
6-phosphate dehydrogenase; GSH, glutathione; GSSG, glutathione disulphide. 
1.6 The cellular response to hypoxia and O2-sensing 
capabilities of mitochondria 
1.6.1 Mitochondrial ROS and hypoxia 
One of the roles of mitochondria is to trigger a response upon detection of hypoxia in 
cells: while the detailed mechanisms are not yet completely understood, the role of 
ROS production by complex III in hypoxia signalling seems to be critical134. ROS 
(particularly superoxide) are also produced by complexes I and II but they are 
directed towards the matrix and easily sequestered by MnSOD, as opposed to 
complex III-generated ROS that can be released to both sides of the inner membrane 
(especially superoxide that is formed within the inner membrane but ejected in the 
intermembrane space on account of the huge electrical field inside it) and, as such, 
exert a potentially more extended signalling power135. In order to indirectly modulate 
ROS degradation: mitochondrial antioxidant defense
O2 can only accept one electron at a time due to its unique
chemistry [18,19]. Reduction of O2 to H2O requires four
electrons and proceeds through a series of ROS intermedi-
ates, namely O2
!", H2O2, and hydroxyl radical (OH
!") [19].
All these intermediates differ in reactivity and behave as
either electron donors or acceptors. A hydroxyl radical has
a redox potential of #2 V and is thus the most reactive and
damaging of the group. Hydroxyl radicals can also be
produced from H2O2 through Fenton and Haber–Weiss
reactions [20,21].
The sites of mitochondrial O2
!" production have been
extensively reviewed (Box 1) [12,18,22,23]. Respiratory
chain complexes I and III re major sites of O2
!" produc-
tion. Complex I produces O2
!" on the matrix side of the
MIM, whereas complex III releases O2
!" into the matrix
and intermembrane space [24–26]. Complex II (succinate
dehydrogenase, SDH) has also been shown to produce both
O2
!" and H2O2 [27]. Other sources of mitochondrial ROS
include 2-oxoglutarate dehydrogenase (Odh), dihydrooro-
tate dehydrogenase, sn-glycerol-3-phosphate dehydroge-
nase (mGPDH), electron transfer flavoprotein:ubiquinol
oxidoreductase (ETF–QO), p66shc/Cytochrome C, and
Mia40p/Erv1p [28–33]. Whether O2
!" or H2O2, or both,
are generated depen s on experimental and cell physiology
conditions.
O2
!" is rapidly dismutated in mitochondria by SOD
(Figure 1). This is due to the high concentration
(#10 mM) and rapid kinetics (k $ 2 % 109 M!1 s!1) of
SOD. Given the normally greater concentration of O2
(#25 mM) relative to O2!" (10–200 pM), O2!" formation
is energetically favorable [18]. Dismutation of O2
!" is
carried out in the intermembrane space and matrix by
Cu/Zn–SOD and MnSOD, respectively (Figure 1). The
amount of O2
!" produced is affected by the metabolic state
of the mitochondria. A high PMF, blockage of the electron
transfer chain downstream of electron entry, high NADH/
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Figure 1. Mitochondrial superoxide (O2
!") and hydrogen peroxide (H2O2) degradation pathways. Mitochondrial oxidative processes liberate electrons that can univalently
reduce O2 to O2
!" in the matrix or intermembrane space. O2
!" is then rapidly dismutated by MnSOD in the matrix or Cu/ZnSOD in the intermembrane space. H2O2 is
degraded by multiple pathways in the matrix; of chief importance are peroxiredoxin-3 (Prx3) and glutathione (GSH)/glutathione peroxidase-1 (Gpx1) systems. Prx3 is a
homodimer and relies on a peroxidatic cyst ine (CysP) that is oxidized by H2O2 to a sulfenic acid (–SOH), which subsequently fo ms a isulfide bond with a resolving
cysteine (CysR) on a neighboring Prx3 monomer. The reductive power of thioredoxin-2 (Trx2) restores Prx3 catalytic activity. Trx2 is then reduced by thioredoxin reductase-2
(Trx 2). CysR can also be further oxidized to sulfinic (–SO2H), which is then reduced by sulfiredoxin (Srx). For glutathione, Gpx1 catalyzes the sequestration of H2O2 by two
GSH molecules generating GSSG. GSSG is then reduced by glutathione reductase (GR) regenerating 2GSH. Regeneration of both systems requires the reductive power of
NADPH produced by isocitrate dehydrogenase (Idh), malic enzyme (ME), energy liberating transhydrogenase (Elth), and glucose-6-phosphate dehydrogenase (G6pd). H2O2
can also be sequestered by lipoic acid and a-ketoacids such as pyruvate. H2O2 generated in the matrix can also diffuse into the intermembrane space where it is degraded by
similar systems or participates in signaling.
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ROS generation at complex III, then, electron flow through this enzyme could be 
blocked upstream at complex I: this strategy would firstly lead to increased generation 
of ROS at complex I and, more importantly, to an overall decrease in ATP production 
due to lower proton pumping by these two enzymes.  
A more selective strategy for the same target is to employ compounds that can inhibit 
ROS formation while keeping other aspects of mitochondrial physiology (proton 
pumping in particular) unaltered. One such molucule is Terpestacin, an anti-
angiogenic drug: its molecular target is Ubiquinol-cytochrome c reductase binding 
protein (UQCRB), a subunit of complex III which is involved in complex III-
mediated ROS generation during the hypoxia response136,137. Even more recently, a 
series of selective suppressors of superoxide generated at complex III that leave 
energy metabolism and membrane potential unimpaired (called “S3QELs”) was 
introduced138. 
1.6.2 The hypoxia-inducible transcription factor 
The reason why targeting mitochondrial ROS (especially originating from the ETC) 
could be an attractive strategy for cancer therapy is the hypoxia-inducible 
transcription factor (HIF-1). HIF-1 is a transcription factor that, during hypoxia, 
targets genes primarily responsible for either increasing O2 delivery such as 
erythropoietin (EPO, synthesis of red blood cells) and vascular endothelial growth 
factor (VEGF, angiogenesis)139 or decreasing O2 consumption: these are mainly 
proteins involved in glucose metabolism such as glucose transporters, glycolytic 
enzymes, lactate dehydrodenase A (LDHA) and pyruvate dehydrogenase kinase-1 




Figure 1.17. Cellular response to hypoxic stress and mitochondria as O2 sensors. 
Superoxide ion is produced at higher rates during hypoxia and quickly converted to hydrogen 
peroxide. In the cytosol, hydrogen peroxide inhibits the enzyme PHD2 which, in normoxic 
conditions, would otherwise direct HIF1-α towards degradation. Instead, the now active 
HIF1-α dimerises with HIF1-β and initiates the hypoxic response in the nucleus. EPO, 
erythropoietin; VEGF, vascular endothelial growth factor; GLUT, glucose transporters; 
LDHA, lactate dehydrogenase A. References are listed in this paragraph. 
1.6.2.1 Structure and activity of HIF-1 
HIF-1 is a heterodimer of an unstable, oxygen-sensitive α-unit and a stable, oxygen 
insensitive β-unit: these two are part of the HIF family of proteins that includes 5 
major isoforms141. Under normal oxygen cellular concentrations (normoxia), the 
hydroxylation of HIF1α by prolyl hydroxylase domain protein 2 (PHD2) and factor 
inhibiting HIF-1 (FIH-1) precede ubiquination by the von Hippel-Lindau protein 
(VHL) and the eventual proteasomal degradation. During hypoxia, though, the 
inhibition of hydroxylating enzymes causes stabilisation of HIF1α: dimerization with 
HIF1β follows, thus allowing the newly formed transcription factor dimer (along with 
the coactivator p300) to migrate to the nucleus and bind to target genes142. Molecular 
oxygen is a substrate for both PHD2 and FIH but the Km is much higher for FIH, 
rendering PHD2 (and, ultimately, HIF1α) very sensitive to O2 level variations143. 
1.6.2.2 The Warburg effect 
The HIF response fits with two major features of cancer cells: hypoxia and greater 
glucose uptake and metabolism. The growth of cancer cells tends to outpace the blood 
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environment is managed by invoking HIFs144. Most cancer cells exhibit a peculiar 
metabolic phenotype called the “Warburg effect” in which glucose uptake is much 
higher than in normal cells. Most of the glycolytic pathway of cancer cells is devoted 
to feeding biosynthetic pathways (particularly important is the pentose phosphate 
pathway for NADPH and nucleotide precursors synthesis) and what is left in the form 
of pyruvate is preferentially reduced to lactate rather than being oxidised to acetyl 
CoA and fed into the TCA cycle in mitochondria. Within this phenotype, 
mitochondrial ATP production still operates, but the TCA cycle is replenished by 
other fuels such as glutamine, effectively uncoupling glycolysis from OXPHOS145,146; 
in addition, the [NADH]/[NAD+] balance is kept low by lactate dehydrogenase 
(which contributes to acidification of the tumor microenvironment) and also by the 
plasma membrane electron transport (PMET)147.   
1.6.2.3 Mitochondria and ROS in cancer 
The hypoxia-response pathway is crucially dependent on mitochondrial ROS, since 
hypoxia increases mitochondrial ROS generation, especially superoxide from 
complex III, and this stabilises HIF-1α via inhibition of PHD2, even though the 
mechanism is still elusive: remarkably, tumour cells are capable of recruiting 
mitochondria to enhance ROS-derived HIF activation148. However, H2O2 can actually 
cross the IMM (either by diffusion of via aquaporins) 149 , thus the precise 
identification of its enzymatic source is not clear-cut (see chapter 6 for a discussion 
about the mode of action of the drug BAY-87-2243). A recent study by Lee et al. 
showed how PHD2 can be rendered inactive by disulphide bond-mediated 
dimerization caused by increased ROS levels in oncogenic signalling pathways150. 
More generally, it is now possible to appreciate why cancer cells exhibit very high 
rates of glycolysis combined with a fully (but different to normal cells) operating 
TCA cycle: rapidly proliferating cells need ATP to sustain growth, oxidative 
metabolism in cancer cells produces substantial amounts of ROS that are conveyed 
towards signalling pathways promoting tumorigenesis and, in order to prevent ROS 
damage, high levels of antioxidant activity in the form of NADPH are generated151. 
HIF-1α stabilization under hypoxia mediated by ROS from complex III is not a 
unanimously accepted model: some evidence, for instance, suggests that the increased 
cytosolic O2 levels due to reduced electron transport chain activity could be enough to 
fully stabilise PHDs, thus leading to normal HIF-1α degradation152. 
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1.6.2.4 Strategies for cancer therapy targeting the hypoxia response 
Given the prominent role of HIF-1 in tumour survival and growth, new possibilities 
for cancer therapy have emerged in the past 20 years. Inhibitors of HIF-1α can be 
distinguished according to their mechanism of action: chemical inhibitors include 
inhibitors of transcription or DNA binding (YC-1, PX-12, Pleurotin, Echinomycin, 
polyamides, Flavopiridol, Chetomin, Brotezomib), inhibitors of protein translation 
(Silibinin, 2-Methoxyestradiol, Phenethyl isothiocyanate) and promoters of protein 
degradation (Geldanamycin, Radicicol, Trichostatin A, Wondonin, Resveratrol). 
Given their common lack of specificity, more promising fields are monoclonal 
antibodies (Cetuximab, Herceptin), nucleic adic inhibitors (RX-0047) and heavy-
chain antibodies153. 
1.6.3 Mitochondria as drug targets 
 Mitochondria are promising targets for cancer therapy for a number of reasons: 
firstly, given the marked difference in the level of expression of genes and mutations 
across the landascape of tumours, it makes sense to target entities that are 
omnipresent within neoplastic pathologies; secondly, mitochondria are both energy 
generators and contain numerous apoptosis-promoting proteins. Anti-cancer agents 
that act via mitochondrial destabilization are called Mitocans and they are classified 
according to their site of action: specifically, drugs targeting complex I belong to the 
class of electron redox chain targeting drugs, examples of which are Tamoxifen, 
Adaphostin, 3-bromopyruvic acid, α-TOS and MitoVES154. 
Very important in this context is the role of specific and potent ETC inhibitors on 
ROS production and the subsequent (de)stabilisation of HIF-1 in cells: rotenone, 
myxothiazol and stigmatellin (the last 2 are complex III Q0 site inhibitors) lower 
mitochondrial ROS and destabilise HIF1, whereas antimycin A (a complex III Qi 
inhibitor) increases mitochondrial ROS and stabilises HIF1 155 . Another set of 
alkyliminophenylacetate compounds identified through a small library screening and 
structurally similar to strobilurins, known complex III inhibitors, was found to inhibit 
HIF-1 activity156. Finally (as it will be explained in detail in chapter 6), the selective 
complex I inhibitors BAY-87-2243 and 10759 possess antitumor activity that was 
found to be linked to complex I-driven HIF deactivation. 
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1.7 Aims of this thesis 
Mitochondrial complex I is a major metabolic hub whose dysfunction can potentially 
affect a myriad of cellular pathways. Since this enzyme could be the off-target of 
many drugs it is crucial to extensively characterise it from a pharmacological 
perspective in order to define, as much as possible, its role within drug-induced 
mitochondrial dysfunction. In addition, SAR studies are useful tools to elucidate 
molecular binding and pinpoint mechanisms of toxicity, hence they constitute a major 
part of this work. 
The goal of chapter 3 was to assemble a library of complex I specific inhibitors that 
are known to cause side effects linked to drug-induced mitochondrial dysfunction 
with a novel and simple methodology. The compounds were tested with several 
assays on different systems with the aim of elucidating their role in complex I-based 
mitochondrial toxicity. 
Chapter 4 extends the scope of chapter 3 by analysing a commercial library of FDA-
approved drugs and categorising them according to target specificity within OXPHOS 
and binding site on complex I. An assay with isolated mitochondria on specific 
complex I inhibitors added physiological relevance and the novel methodology 
presented to address target categorisation and binding site could be applied to similar 
enzymes within metabolic pathways similar to complex I. 
The work presented in chapter 5 is a SAR study on rotenoids to improve the 
understanding of rotenone binding to complex I. Hydroxylated species are particularly 
interesting for their potential therapeutic use as less toxic than lipophilic compounds. 
Finally, the work illustrated in chapter 6 consists of two SAR studies based on 
anticancer agents developed by The Anderson Cancer Centre and Takeda, 
respectively. Assessing target specificity to complex I and improving the 





2 Experimental Methods 
2.1 Sources of chemicals and reagents 
Estradiol and Doxorubicin were purchased from Cayman Chemical Co. (Ann Arbor, 
MI); Nefazodone HCl, Clozapine, Tamoxifen citrate, Amlodipine, Aripiprazole, 
Rosiglitazone maleate, Propafenone HCl, Duloxetine HCl, Iloperidone and Salmeterol 
were purchased from LKT Laboratories (St. Paul, MN, USA); Fenofibrate, 
Nisoldipine and decylubiquinone (dQ) were purchased from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA); all other chemicals were purchased from Sigma 
Aldrich (Sigma-Aldrich Company Ltd., Gillingham, Dorset, UK), and were all of 
purity always higher than 97%. The Screen-Well FDA-approved drug library V2, 
consisting of 786 compounds, was provided as 10 mM stock solutions in DMSO 
(BML-2843-0100, Enzo Life Sciences, Farmingdale, NY). Ultra-pure water was 
obtained from a Milli-Q purification system (Millipore, Watford, UK). Non-aqueous 
solvents were of HPLC grade. 
2.2 Preparation of bovine mitochondrial membranes, 
isolated complex I and SMPs 
2.2.1 Isolation of bovine heart mitochondria 
This preparation method was adapted from a protocol by Walker et al.157. The whole 
procedure was carried out at 4˚C. Muscle tissue from hearts of freshly slaughtered 
cows (Bos taurus) was separated from fat and connective tissue and mechanically 
minced. 1 kg portions of the resulting mince were mixed with 1.4 L of mitochondrial 
buffer (250 mM sucrose and 10 mM tris-SO4, pH 7.8 at room temperature or RT) and 
the solid matter filtered out with a single layer of muslin. Filtered batches were mixed 
with 1.6 L of mitochondrial buffer (+ 200 µM EDTA) and homogenised in a Waring 
blender for 30 seconds (“high” setting). The resulting homogenate was centrifuged at 
2,600 g for 15 minutes in a RC12-BP centrifuge and the supernatant filtered through a 
single layer of muslin and centrifuged again at 20,400 g for 27 minutes in a SLA 3000 
rotor. Finally, the supernatant was discarded and the pellets containing isolated 
mitochondria stored at -20 ˚C: usually two bovine hearts constitute a ~50 g pellet (wet 
weight). 
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2.2.2 Preparation of bovine mitochondrial membranes from 
isolated bovine heart mitochondria 
This preparation method was adapted from a protocol by Walker et al.157. The whole 
procedure was carried out at 4˚C. Isolated mitochondrial pellets from the equivalent 
of two bovine hearts were thawed overnight, resuspended in 2 L of Milli-Q water and 
homogenised with a Waring blender (2 minutes on “medium” setting). 150 mM 
(solid) KCl was added and homogenised with the Waring blender further (3 minutes 
on “medium” setting). The homogenate was centrifuged at 13,700 g for 40 minutes in 
a SLA-3000 rotor, the supernatant was discarded and the pellet resuspended in 250 
mL of buffer (10% glycerol, 20 mM tris-HCl, 1 mM EDTA, pH 7.55 at 4 ˚C). The 
resulting mitochondrial membrane suspension was stored at -80 ˚C (typical 
concentration of 10 mg mL-1). 
2.2.3 Complex I isolation from mitochondrial membranes 
This preparation method was adapted from a method by Sharpley et al.158. All the 
steps were carried out at 4 ˚C. 30 mL of mitochondrial membranes were thawed and 
PMSF (0.005%) was added. Solubilisation with 1% DDM (added dropwise from a 
10% stock) was followed by constant stirring for 30 minutes, then the suspension was 
centrifuged at 47,800 g for 30 minutes. The supernatant was filtered through a 0.22 
µm filter (Millipore) and loaded at 2 mL min-1 onto a Q-sepharose HP column (GE 
Healthcare), pre-equilibrated with buffer A (20 mM Tris-HCl, 10% ethylene glycol, 
0.2% DDM, 2 mM EDTA, 25 µg mL-1 cardiolipin, 25 µg mL-1 phosphatidylcholine, 
25 µg mL-1 phosphatidylethanolamine, pH 7.55 at RT). Lipids were purchased from 
Avanti. The column was transferred to an Äkta explorer FPLC system (GE 
Healthcare) and washed with buffer A at 3 mL min-1 until the absorbance at 280 nm 
baselined. At this point the components of the respiratory chain were eluted with a 
NaCl gradient with buffer B (buffer A + 1M NaCl): 25% buffer B eluted complex V 
and IV and 35% buffer B eluted complex I. The relevant fractions were pooled and 
concentrated to ~1 mL (100 kDa cut off filter). In order to separate complex I from 
any remaining complex IV the concentrated sample was split into two batches and 
both were run on a 24 mL Superose-6 Increase gel filtration column (GE Healthcare) 
pre-equilibrated in phospholipid-free buffer A. Complex I fractions were pooled and 
concentrated as before to ~300 µL, glycerol was added to 20 % and aliquots were 
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snap frozen to be stored at -80 ˚C. The final concentration was approximately 15 mg 
mL-1 of pure complex I. 
2.2.4 Preparation of submitochondrial particles from bovine 
heart mitochondria 
The preparation of submitochondrial particles (SMPs) was adapted from a method 
described in the literature159. All the steps were carried out at 4 ˚C. A pellet of bovine 
heart mitochondria (~10 g) was resuspended in 40 mL of SMP buffer and the 
resulting suspension was centrifuged for 12 minutes at 11,300 x g (Ti 45 tubes 
Beckman Coulter). The supernatants were discarded, the pellets homogenised in 30 
mL of buffer and the pH of the suspension was brought to 9 with 2 M Tris for 10 
minutes to dissociate endogenous ATPase inhibitor IF1 from ATPase. The suspension 
was further centrifuged once for 14 minutes at 37900 x g and then twice for 12 
minutes at 11300 x g (the supernatant was discarded each time). The resulting pellet 
was resuspended in 40 mL of SMP buffer, 15 mM of MgSO4 was added and the 
resulting mixture was sonicated 10 times in 15 seconds bursts each at 150 W, 1 
minute intervals. The mixture was centrifuged for 20 minutes at 24700 x g (MLA80 
tubes Beckman Coulter): the top 1.5 mL of the supernatant in each tube was collected 
and the pooled top fractions were centrifuged for 30 minutes at 74700 x g, rinsed with 
buffer and resuspended to ~10 mg mL-1. 
2.3 Microsomal incubations 
Human liver microsomes from 50 different individual donors were purchased from 
Gibco. Drugs were incubated in amber glass vials and the caps were pierced with a 
small needle to let oxygen through. Drug incubations were carried out in 800 µL of 
K-Pi buffer (20 mM, pH 7.5 at 37 ˚C) with 0.4 mg mL-1 microsomes, 1 U mL-1 of 
glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides (Sigma), 3 mM 
MgCl2, 1 mM EDTA, 70 U mL-1 superoxide dismutase from bovine erythrocytes 
(Sigma), 70 U mL-1 catalase from Corynebacterium glutamicum (Sigma). 
Microsomes were activated with 1 mM NADP+ and 10 mM of glucose-6-phosphate, 
incubations lasted 6 hours with constant shaking at 37 ˚C. Microsomal mixtures were 
then quenched with addition of 800 µL of dry ice-cooled Et2O and mixed up and 
down several times, placed at -20 ˚C for 3 hours and subsequently at 4 ˚C for 12 
hours. Et2O was then removed by placing the vials in a vacuum desiccator for 1 hour, 
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the microsomal proteins were pelleted out with centrifugation at 5000 x g for 10 
minutes and the supernatants were transferred in clean vials. 50 µL of each 
supernatant constituted a quarter of the 200 µL total well volume for a regular 
NADH:O2 oxidoreduction assay. 
2.4 Preparation of enzymes for the succinate:O2 
coupled assay 
The method described by Jones and Hirst160 was followed. 
2.4.1 Overexpression of FumC and MaeB 
The plasmids carrying the fumarase C (FumC) and decarboxylating malic enzyme 
(MaeB) genes were generously provided by Todd Weaver at University of Wisconsin-
La Crosse and María Drincovich at National University of Rosario, respectively.  
The procedure followed for FumC and MaeB over-expression was the same unless 
otherwise stated. Starter cultures of 50 mL LB supplemented with 50 µg mL-1 
ampicillin were inoculated and incubated at 37 ˚C whilst shaking overnight. The 
cultures were scaled up to 4x1 L flasks of LB supplemented with 50 µg mL-1 
ampicillin and incubated at 32 ˚C with shaking: expression of the protein was induced 
with 1 mM or 0.1 mM IPTG (FumC or MaeB respectively) when the optical density 
(OD) at A600 was 0.6. Cultures were incubated with shaking overnight at 20 ˚C. 
2.4.2 Harvesting and purification of FumC and MaeB 
All the steps were carried out at 4 ˚C. Cells were collected by centrifugation at 7000 x 
g for 15 minutes and resuspended in 120 mL of buffer A for FumC (50 mM 
potassium phosphate and 300 mM of NaCl, pH 7.8 at 4 ˚C) and buffer B for MaeB 
(100 mM NaCl, 25 mM imidazole, 20 mM Tris-SO4 and 10% glycerol, pH 7.4 at 4 
˚C), with three protease inhibitor tablets (Roche) added to each. A pre-cooled 
Constant cell disruption system was used to lyse cells with two passes at 30 psi. The 
lysates were then centrifuged at 150000 x g for 45 minutes, the pellets discarded and 
the supernatants filtered through a 0.2 µm pore filter. 
The lysates were loaded on to a 25 mL Ni-sepharose 6 Fast Flow column (GE 
Healthcare) with a peristaltic pump at 2 mL min-1, transferred to a Äkta Prime plus 
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FPLC and washed at 2 mL min-1 with buffer A (+ 60 mM imidazole) for FumC and 
buffer B for MaeB until the absorbance at 280 nm returned to baseline. Gradients 
spread over 40 mL with buffer A (+ 400 mM imidazole) for FumC or buffer B (+ 300 
mM imidazole) for MaeB were set up: the proteins were monitored at 280 nm and 
usually began to elute at 75-80% of the gradient. Pooled fractions were concentrated 
with 50-kDa centrifugal filters (Amicon) by about 10 (FumC) or 20 (MaeB) fold. 
Dialysis followed for FumC in buffer C (1 mM DTT, 5 mM EDTA and 10 mM Tris-
SO4, pH 7.0 at 4 ˚C) and for MaeB in buffer D (10% glycerol, 20 mM β-
mercaptoethanol and 60 mM Tris-SO4, pH 7.4 at 4 ˚C). Finally, the proteins were 
stored at -80 ˚C in 50% glycerol with typical yields of about 36 and 60 mg mL-1 for 
FumC and MaeB, respectively. 
2.5 Preparation of recombinant trypanosomal 
alternative oxidase (AOX) 
2.5.1 Expression of AOX in E. coli FN102 
This protocol was adapted from Jones, Blaza et al., 2016161. The E. coli strain 
FN102/pTbAO was used to over-express the alternative oxidase from Trypanosoma 
brucei brucei. The FN102 strain does not possess glutamyl-tRNA reductase (gene 
hemA), which produces 5-aminolevulinic acid (ALA, i.e. the strain is auxotrophic for 
it) in the first step of heme biosynthesis in E. coli, a pathway required for the 
synthesis of cytochrome bd quinol oxidase: addition of ALA in the media is therefore 
essential. FN102/pTbAO cells were added on LB plates supplemented with 100 mg 
mL-1 ampicillin, 100 mg mL-1 ALA (both from Sigma-Aldrich) and 50 mg mL-1 
kanamycin (Merck) and incubated for 18 hours at 37 ˚C. Large colonies were selected 
to inoculate 300 mL starter cultures in K-broth (0.74 g L-1 Na-citrate.2H2O, 2.5 g L-1 
(NH4)2SO4, 10.4 g L-1 K2HPO4, 3 g L-1 KH2PO4, 10 g L-1 tryptone, 5 g L-1 yeast 
extract, 5 g L-1 casamino acids and 0.2 % glucose) supplemented with 100 µg mL-1 
carbenicillin, 50 µg mL-1 kanamycin, 100 µg mL-1 ALA and 0.2 % glucose and 
incubated at 37 ˚C with shaking for ~3 hours until the OD at A600 was about 0.6. The 
cells were collected by centrifugation for 10 minutes at 3000 x g and the media 
exchanged (to remove ALA and introduce the iron needed for AOX over-expression) 
with 50 µg mL-1 MgSO4, 25 µg mL-1 FeSO4, 25 µg mL-1 FeCl3, 100 µg mL-1 
carbenicillin and 0.2 % glucose. The exchange of media was repeated and the second 
 36 
resuspension amounted to 10 mL of metal-supplemented K-broth concentrated 
inoculum. Then, 16 L of K-broth supplemented with 50 µg mL-1 kanamycin, 100 µg 
mL-1 carbenicillin, 50 µg mL-1 MgSO4, 25 µg mL-1 FeSO4, 25 µg mL-1 FeCl3 and 0.2 
% glucose were inoculated to ~0.01 OD with the concentrated inoculum and the 
resulting cultures were incubated with shaking at 30 ˚C (190 rpm) until the OD at A600 
reached ~0.6, at which point 25 µM of isopropyl ß-D-1-thiogalactopyranoside (IPTG) 
was added to induce AOX expression. Cultures were incubated overnight at 30 ˚C 
with shaking (190 rpm). 
2.5.2 Cell disruption and membrane harvesting 
Cells were harvested by centrifugation at 7000 x g for 15 minutes, the supernatant 
discarded and the pellet resuspended to 10 mL g-1 of cells in buffer at 4 ˚C (50 mM 
Tris-HCl, pH 7.5 at RT). 1 mM MgSO4, protease inhibitor tablets (Roche, 1 per 50 
mL) and ~5000 U of benzonase were added to the resuspension before being 
disrupted with a pre-cooled Constant cell disruption system (one pass at 15 kpsi and 
two passes at 30 kpsi). The lysate was centrifuged for 15 minutes at 8300 x g and the 
pellet discarded. The supernatant was then centrifuged for 80 minutes at 160,000 x g 
to reveal a two-layered pellet, a grey-bottom one and a yellowish-upper one. The 
upper layer of membranes was collected (making sure to leave the bottom layer 
undisturbed), resuspended to ~20 mL in buffer (50 mM Tris-HCl, pH 7.5 at RT), snap 
frozen in liquid nitrogen and stored at -80 ˚C. 
2.5.3 Purification of AOX 
The following steps were carried out at 4 ˚C. A ~20 mL membrane aliquot was 
thawed for one hour on ice and solubilised at 6 mg of protein mL-1 in solubilisation 
buffer (200 mM MgSO4, 20 % glycerol, 1.4 % octyl-glucoside and 25 mM tris-HCl, 
pH 7.5 at RT) for another hour (buffer was added dropwise with constant stirring. The 
sample was centrifuged for 30 minutes at 165,000 x g, the supernatant was filtered 
through a 0.2 µM filter (Sartorius Stedim) and mixed with TALON cobalt metal 
affinity resin (Clontech). The resin had been previously washed with 20 times its 
volume in binding buffer (100 mM MgSO4, 20 % glycerol, 1.4 % octyl-glucoside and 
50 mM tris-HCl, pH 7.3 at RT) and it was applied to the solubilised protein solution 
at a volume 5 times lower. The protein was left to bind to the resin for 45 minutes, the 
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mixture was centrifuged for 5 minutes at 1000 x g and the supernatant removed. The 
resin was washed three times in a row with washing buffer (20 % glycerol, 20 mM 
imidazole, 50 mM MgSO4, 0.042 % dodecyl-maltoside and 20 mM tris-HCl, pH 7.3 
at RT) and poured into a XK50 column casing (GE Healthcare) and allowed to settle. 
The column was then transferred to a Äkta Prime plus FPLC (GE Healthcare) at 3.5 
mL min-1 with washing buffer, when the absorbance at 280 nm reached baseline it 
was switched to 50% elution buffer (20 % glycerol, 250 mM imidazole, 50 mM 
MgSO4, 160 mM NaCl, 0.042 % dodecyl-maltoside and 20 mM tris-HCl, pH 7.3 at 
RT) and when it reached baseline again it was switched to 100% elution buffer. The 
fractions containing protein were collected, pooled and concentrated ten times with 30 
kDa molecular weight cut off filter (Amicon). The purified protein was dialysed 
against 2 L of dialysis buffer (50 mM MgSO4, 20 % glycerol, 160 mM NaCl, 0.042 % 
dodecyl-maltoside and 20 mM Tris-HCl, pH 7.3 at RT) for 5 hours to remove 
imidazole. The purified protein (with a concentration of ~1.3 mg mL-1, typically ~8 
mg overall) was snap frozen with liquid nitrogen and stored at -80 ˚C. 
2.6 Preparation of co-reconstituted complex 
I:AOX:Q10 liposomes 
This preparation was adapted from Jones, Blaza et al., 2016161. In general, 10 mg 
of phospholipids are required for every 1 mL of preparation. Bovine PC, CL and PE 
were homogenised together at a ratio of 8:1:1 respectively (lipids were added from a 
25 mg mL-1 chloroform stock by Avanti). Then, the required amount of Q10 dissolved 
in chloroform was added and the sample thoroughly mixed before evaporating the 
chloroform with a gentle stream of N2 followed by vacuum desiccation for 30 
minutes. Lipids were resuspended in 650 µL of PL buffer (10 mM Tris-SO4 and 50 
mM KCl, pH 7.5 at 4˚C). The exact amount of buffer was dictated by the volumes of 
protein (AOX and complex I) and detergent (OG) stocks needed in a later stage in 
order to maintain a 1 mL final volume. The suspended lipids were extruded nine times 
thorugh a 0.1 µM pore-tracked edge membrane (Watman) and homogenised again 
with 160 µL of octyl-glucoside (OG, 10% stock in MQ water) with a final OG 
concentration of 1.6%. The mixture was sonicated for 10 minutes, placed in a 2 mL 
Eppendorf and cooled on ice for 10 minutes. 
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The next steps were carried out at 4 ˚C. After cooling, 0.2 mg of AOX and 0.2 mg of 
complex I were added to the solubilised lipids and the mixture incubated for 10 
minutes. Then, 100 µL of prewashed (1 volume of methanol and at least 20 volumes 
of MQ water) damp SM-2 Biobeads (from Biorad) were added to remove the 
detergent. The mixture thus obtained was gently agitated for 4 hours, adding further 
100 µL of Biobeads every hour: absence of bubbles indicated the removal of 
detergent. The Biobeads were removed with spinning through a 1.5 mL coarse 
centrifugal filter (Bio-Rad). The liposome suspension was centrifuged at 57,500 x g 
for 45 minutes, the supernatant discarded, the surface of the pellet carefully washed 
with 300 µL of PL buffer and finally resuspended in 100 µL of PL buffer. A typical 
preparation yielded ~200 µL of material at ~1.5 mg mL-1 of total protein. The 
concentration of complex I was quantified using the NADH:APAD oxidoreduction 
reaction162, and the AOX concentration was assumed to be the difference between the 
total protein and complex I concentration. 
2.7 Reduction of dQ to dQH2 
This protocol was adapted from Kirby et al.163 and it does not require anaerobic 
conditions (the same procedure was applied for Q1 reduction to Q1H2). 200 µL of a 
~50 µM stock of dQ (in EtOH), 100 µL of MQ water and 10 µL of 1 M HCL were 
combined in a 10 mL glass bottle and ~5 mg of NaBH4 was added. Gentle stirring 
turned the solution from orange to colourless within seconds with concomitant 
formation of H2 gas. The excess NaBH4 was neutralised with successive additions of 
10 µL 1 M HCl until gas formation stopped. Then 500 µL of hexane and 500 µL of 
diethyl ether were added and the resulting 2-phase mixture well shaken. The upper 
organic phase was transferred to another small glass bottle and organic washing with 
hexane/diethyl ether repeated another two times. The collected organic layers were 
pooled, the same volume of 2 M NaCl added and the 2-phase mixture shaken well. 
The upper organic layer was then removed and evaporated with a gentle stream of N2. 
Finally, 300 µL of EtOH and 30 µL of 1 M HCl were added to re-dissolve the 
crystallised dQH2. The final concentration of dQH2 was obtained 
spectrophotometrically by measuring the absorbance at 289 nm assuming 4140 M-1 
cm-1 as extinction coefficient164. 
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2.8 Reduction of cytochrome c 
Cytochrome c was reduced according to a protocol by Spinazzi et al.165. 130 mg of 
Na-ascorbate were dissolved in 1 mL of 10 mM K-Pi buffer (pH 7.0 at 4 ˚C) and 100 
µL of it were added to 500 µL of 1.5 mM stock of cytochrome c and 800 µL of K-Pi 
buffer. A sudden change in colour from brown to pink-orange signalled the complete 
reduction of cytochrome c. This solution was left incubating with shaking at 4 ˚C for 
2 hours and 50 µL of the Na-ascorbate solution were finally added. The resulting 
mixture was dialysed against 0.5 L of K-Pi buffer for 24 hours at 4 ˚C, during which 
time the buffer was replaced 4 times. The A550/A565 ratio was over 10, indicating 
complete reduction of cytochrome c. The absorbance at 550 nm was always constant 
when monitored after addition of 100 mM FeCN (which immediately oxidises 
cytochrome c) indicating the absence of residual ascorbic acid (that would slowly 
reduce cytochrome c). 
2.9 Analytical methods 
2.9.1 Protein quantification by the bicinchonic acid (BCA) assay 
All protein concentrations were determined using the Pierce BCA protein assay kit by 
Life Technologies. The assay measures the increase in absorbance at 562 nm 
associated with Cu+ ion following chelation of Cu2+ to (and its reduction by) peptide 
bonds: this reaction took place via a 30 minutes incubation at 37 ˚C. Bovine serum 
albumin standards (ranging from 0 to 2 mg mL-1) were used to obtain a standard curve 
against which the protein samples (appropriately diluted) were compared. This 
method is hampered by chelators (e.g. EDTA), reducing agents (e.g. DTT) and some 
detergents (e.g. OG). 
2.9.2 Phospholipid quantification 
This method166 is based on the formation of phosphomolybdate at 820 nm with 
multiple sample dilutions compared with standards ranging from 0 to 500 µM 
KH2PO4. Samples or standards (100 µL in boiling tubes) were mixed with 50 µL of 
MeOH and 30 µL of ethanolic stock of 390 mM Mg(NO3)2. Tubes were heated with a 
blue flame making sure to avoid boiling/popping of the samples. When the residue in 
the tubes turned white heating was stopped and the samples left to cool for 5 minutes. 
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0.3 mL of 500 mM HCl were added and the tubes heated in a heat block at 99 ˚C for 
15 minutes (marbles were placed on top of them to prevent excessive evaporation). 
Once the tubes cooled down, 0.7 mL of 114 mM ascorbic acid, 2.72 mM 
((NH4)6Mo7)24 and 400 mM H2SO4 were added. New marbles were placed on top of 
the tubes and incubation at 37 ˚C for 1 hour followed. Finally, 200 µL from each tube 
was transferred into a quartz 96-well plate and absorbance at 820 nm measured. 
2.9.3 Q10 quantification 
The absorbance spectrum of the sample (225-475 nm) was recorded before and after 
addition of 2 mM KBH4 to completely reduce the sample. The change in absorbance 
at 275 nm using 14,020 M-1 cm-1 as extinction coefficient167 quantified Q10 in the 
sample. In order to make sure no scattering issues from the high lipid content of the 
samples were encountered, 1% SDS was first used to fully solubilise the lipids. 
2.10 Kinetic measurements 
Spectrophotometric absorbance measurements were carried out at 32 ˚C using a 
Spectra max 348 plus 96-well plate reader (Molecular Devices) with disposable 96-
well polystyrene Corning plates (or a Molecular Devices 96 well quartz plate when 
the absorbance to be monitored was in the UV region). As a standard practice, each 
well to be monitored was filled up with 160 µL of buffer containing the protein of 
interest and every reagent but the electron donor. Drugs/inhibitors were added at this 
stage too and left incubating for 5 minutes before initiating the reaction. Every 
reaction was started with addition of 40 µL of electron donor that made up 200 µL of 
well overall volume. Rates were calculated by linear regression of the maximal rate 
(at least 60 seconds were considered for the linear fit). Well pathlengths were also 
measured immediately after the end of the reaction measurements to calculate specific 
activities (expressed as moles per minute per mg of protein) via the water constant 
method: this is based on the difference in absorbance at 1000 and 900 nm of water 
whose value is stored in the plate reader factory settings. All the IC50 determination 
experiments (and most of the other assays unless otherwise stated) were performed in 
triplicates. Inhibitors/drugs were dissolved in either water, MeOH, EtOH or DMSO 
and the same amount of delivery solvent (5 µL of water or 1 µL of MeOH, EtOH or 
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DMSO) was added to the control (0 compound concentration) well. Monitored 
wavelengths and extinction coefficients are given in the table below. 
Reaction System λ (nm) ε M-1 cm-1 Chromophore 
NADH:O2 
Membranes 
340-380 4810168 NADH 
Succinate:O2 340-380 4810160 NADPH 
Succinate:dQ 276 18000169 dQ 
Succinate:ox. Cyt c 550-541 18000169 Cyt c 
NADH:ox. Cyt c 550-541 18000169 Cyt c 
Red. Cyt c:O2 550-541 18000169 Cyt c 




NADH:FeCN 420-500 1020170 Fe3+ 
NADH:HAR 340-380 4810170 NADH 
NADH:APAD 400-450 3160170 APAD 
ROS 557-620 51600170 Resorufin 
NADH:Q1 340-380 4810171 NADH 
 
Control assays in the absence of protein, with the highest concentration of inhibitor, 
were carried out to test for non-enzymatic reactions and for drug interference with 
assay enzymes (succinate:O2 and NADH:Q10 oxidoreductions and ROS assay). 
2.10.1 Kinetic measurements on membranes 
Assays were performed in 10 mM Tris SO4, pH 7.5, 250 mM sucrose (buffer K). The 
pH of this buffer remains the same upon addition of 100 µM HCl (checked using a pH 
meter). Concentrations for the assays were as follows: 
NADH:O2 oxidoreduction  
30 µg mL-1 membranes, 0.9 µM cytochrome c, 120 µM NADH (IC50 determinations 
were carried out with 50 µg mL-1 membranes and 1.5 µM cytochrome c). 
Succinate:O2 oxidoreduction 
The coupled enzyme assay by Jones and Hirst160 was chosen to measure complex II 
activity. The concentrations of reagents are the same as the ones indicated in the 
original paper: NADP+ (2 mM), succinate (5 mM), oxaloacetate decarboxylating 
malic enzyme (MaeB, 300 µg mL-1), fumarase C (Fum C, 60 µg mL-1), MgSO4 (2 
mM) and K2SO4 (1 mM). 500 nM of rotenone was also added to prevent the 
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involvement of complex I. 50 µM fumarate were used instead of membranes to test 
whether drugs inhibit the coupled enzyme system or not. The scheme below illustrates 
the reactions involved with the coupled assay. 
 
Reduced cytochrome c:O2 oxidoreduction  
6 µg mL-1 membranes, 1 µM antimycin, 60 µM reduced cytochrome c. 
dQH2:cytochrome c 
30 µg mL-1 membranes, 1 µM piericidin, 500 µM NaCN, 60 µM dQH2, 50 µM 
cytochrome c. 
Succinate:cytochrome c 
10 µg mL-1 membranes, 500 µM NaCN, 120 µM cytochrome c, 700 nM rotenone, 1 
mM succinate. 
NADH:cytochrome c 
10 µg mL-1 membranes, 500 µM NaCN, 120 µM cytochrome c, 500 nM atpenin, 150 
µM NADH. 
Succinate:dQ 
30 µg mL-1 membranes (incubated with 1% DDM for 30 minutes before use), 100 µM 
dQ, 1 mM NaCN, 2 mM succinate. 
2.10.2 Kinetic measurements on isolated complex I  
All assays were performed at 32 ˚C in 20 mM Tris-Cl, pH 7.5. 
NADH:dQ oxidoreduction  
0.5 µg mL-1 complex I, 100 µM NADH, 0.075% soy bean asolectin (Avanti Polar 
Lipids), 0.075% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 




Complex II FumC MaeB
(NADP+)
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followed by buffer and enzyme. IC50 determinations were carried out with 2 µg mL-1 
complex I. 
NADH:FeCN oxidoreduction 
0.3 µg mL-1 complex I, 1 mM Fe(CN)63- (FeCN), 100 µM NADH. 
NADH:HAR oxidoreduction 
0.6 µg mL-1 complex I, 3.5 mM Ru(NH3)63+ (HAR), 100 µM NADH. HAR stocks 
were freshly prepared in MQ water and used the day of preparation.  
NADH:APAD oxidoreduction 
0.8 µg mL-1 complex I, 1 mM APAD, 100 µM NADH. 
NADH:Q10 oxidoreduction 
The buffer was 100 mM Tris-Cl (pH 7.5 at 32 ˚C) and 50 mM KCl, with 0.5 µg mL-1 
complex I in AOX proteoliposomes (which commonly include 1.5 µg mL-1 AOX), 
200 µM NADH. When Q10 was not present, dQ was added instead (20 µM). Complex 
I-free runs (Q1H2:O2 assay) were performed to test whether a drug inhibits AOX or 
not: the buffer was 100 mM Tris-Cl (pH 7.5 at 32 ˚C), proteoliposomes were replaced 
by AOX enzyme (0.27 µg mL-1) and NADH was replaced by 100 µM Q1H2 (the 
extinction coefficient for Q1 was 13,700 M-1 cm-1 according to the literature172 but, 
rather than at 275 nm as reported, it was decided to follow the oxidation of Q1H2 at 
272 nm instead after the UV spectrum of Q1 was obtained). 
ROS assay 
H2O2 formation was followed in 30 µM NADH as the catalase-sensitive horseradish 
peroxidase-dependent oxidation of 10 µM Amplex Red to resorufin in 8 µg mL-1 
complex I, 10 U mL-1 peroxidase from horseradish (HRP, Sigma), 10 µM Amplex 
Red, 10 U mL-1 superoxide dismutase from bovine erythrocytes (SOD, Sigma), 5000 
U mL-1 catalase from Corynebacterium glutamicum (Sigma)50. Complex I-free runs 
were performed to test whether a drug inhibits horseradish peroxidase or not: complex 




4 µg mL-1 complex I, 100 µM Q1, 0.4 µg mL-1 asolectin, 2 µM rotenone, 100 µM 
NADH. 
2.11 OCR and ECAR measurements on cultured 
human cells 
Oxygen consumption rates (OCRs) and extracellular acidification rates (ECARs) on 
cultured human cells were measured using a Seahorse extracellular flux analyser 
XF96 at 32 °C.  
HeLa (cervical cancer) cells were grown on DMEM supplemented with 10% FBS and 
100 units mL-1 penicillin, 100  g mL-1 streptomycin at 37 °C in 5% CO2. 3 x 104 
cells per well were plated into Seahorse XF96 plates and incubated overnight at 37 °C 
in 5% CO2. The medium was exchanged for assay buffer containing DMEM, 4.5 g L-1 
glucose, 1 mM pyruvate, 32 mM NaCl, 2 mM GlutaMAX, 15 mg L-1 phenol red, and 
20 mM HEPES (pH 7.4) and the cells placed in a CO2-free incubator at 37 °C for 60 
min. 1 µM rotenone was used to inhibit complex I. To calculate the normalised, 
rotenone-sensitive OCR rates, the rotenone-insensitive rates (determined at the end of 
the experiment) were subtracted, and the traces normalised to 100% before drug 
addition. ECAR data were normalised to 100% before drug addition. The drugs were 
added 55 minutes after the start of the run and rotenone was added after 300 minutes. 
When a port injection failed the data from the corresponding well were excluded from 
the analyses169. 
2.12 OCR and ECAR measurements on isolated 
mitochondria 
Wistar rat liver mitochondria were plated at 18 µg per well in 70 mM sucrose, 220 
mM mannitol, 5 mM MgCl2, 10 mM KH2PO4, 1 mM EGTA, 0.2 % fatty acid-free 
BSA, and 2 mM HEPES (pH 7.4 at 37 °C) with 10 mM malate and 10 mM glutamate. 
They were subsequently adhered by centrifugation at 2000 g for 20 min at 4 °C. The 
medium was supplemented with a further 5 mM glutamate and 5 mM malate and the 
mitochondria incubated for 14 min. Three baseline readings were taken before the 
drugs were added after the beginning of the run. Drugs were left accumulating with 
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mitochondria for 30 minutes (6 readings) before 4 mM ADP was added. Finally, 2 
µM rotenone was added 3 minutes after ADP addition. Data from wells with failed 
port injections were excluded from the analyses173.   
2.13 Statistical methods 
IC50 values were determined by, first, measuring the enzymatic specific activity 
against selected compound concentrations and then translating these data into a plot 
of specific activity against logarithm 10 of compound concentration (the control well 
was the 100% activity point). The IC50 value was then estimated according to the 
following four-parameters dose-response curve (where Top is the uninhibited activity, 
Bottom is the compound insensitive rate, Hill slope is the steepness of the activity 
percentage plot): calculations for the fitting were performed with GraphPad Prism 6.0 





The concentration range for IC50 determination was chosen to obtain data points as 
evenly spread across the activity percentage plot as possible, with one data point 
between 100% and 90% residual activity and one data point for the lowest attainable 
residual activity. Other experimental values are reported as mean averages ± standard 
error of the mean (SEM). Statistics for OCR and ECAR comparisons were performed 
using an unpaired 2-tailed Student’s t test and the p-values symbols stand for P > 0.05 
(ns), 0.01<P<0.05 (*), 0.01<P<0.001 (**), 0.001<P<0.0001 (***) and P<0.0001 








3 First drug selection process and assessment of 
drug-induced mitochondrial dysfunction: a 
proof of principle study 
3.1 Introduction and aims 
The most relevant topic regarding the pharmacology of complex I (on account of its 
economic importance and clinical impact) is drug-induced liver injury (DILI), an 
adverse hepatic reaction to medication174. DILI is the most common reason for drug 
failure after approval and it is estimated that roughly 11% of acute liver failure cases 
are caused by it (this percentage does not include acetaminophen associated 
injury)175. Hepatotoxicity is known to be caused by over 1,000 drugs and even if the 
incidence of this condition is one in 10,000 to 100,000 cases, drug cessation in some 
patients does not result in improvement and there is no specific medical treatment 
available: the condition can subsequently lead to liver failure. The importance of DILI 
is well recognised by the scientific community, and this is demonstrated by the 
establishment in 2004 of the Drug-Induced Liver Injury Network (DILIN), a research 
network to collect and analyse cases of liver injury176. A more recent effort in 
fostering scientific research on DILI is LIVERTOX, a freely accessible website that 
includes records on the hepatotoxicity of over 1000 drugs177.  
3.1.1 Overview of DILI 
It makes sense that the liver is a major target of drug toxicity because it has a high 
capacity for xenobiotic metabolism (especially Phase I and II drug metabolism), it is 
the organ where orally administered drugs are transported before they reach the rest of 
the body (first-pass effect), it has an unique immune system and it has a significant 
blood supply from the portal vein178. DILI is very difficult to diagnose because there 
is no unique symptom to distinguish it from any other acute and chronic hepatic 
condition, it can in fact mimic all forms of liver diseases. Nonetheless, some critical 
factors have been identified as key determinants of DILI, such as exposure to toxic 
parent drugs or metabolites (as little as 50 mg), covalent binding of metabolites on 
cells or formation of glutathione adducts, and inhibition of mitochondrial function or 
bile salt export pump179. 
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Many drug classes can cause DILI, for example anti-tubercular drugs (e.g. Isoniazid), 
non-steroidal anti-inflammatory drugs (e.g. Acetaminophen and Ibuprofen), protease 
inhibitors (e.g. Indinavir), nucleoside analogues reverse transcriptase inhibitors (e.g. 
Stavudine), statins (e.g. Atorvastatin) and anesthetic agents (e.g. Halothane)180. 
Acetaminophen toxicity deserves a special mention: it is the most frequent cause of 
DILI in the Western World (accounting for 46% cases of acute liver failure in the US 
from 1998 to 2007) but it is also reproducible in animal models (as opposed to 
idiosyncratic DILI) and therefore can be considered a paradigm of hepatotoxicity181. 
Briefly, acetaminophen is normally sulfated or glucuronidated during Phase II of drug 
metabolism but Phase I of drug metabolism predominates at dosage higher than 4 g: 
acetaminophen is oxidized to N-acetyl-p-benzoquinone imine (NAPQI) which then 
leads to depletion of glutathione supply and NAPQI binding to cellular proteins, 
ultimately resulting in cell injury182. 
3.1.2 Mechanisms underlying drug hepatotoxicity: 
mitochondrial involvement in DILI 
Drugs damage the liver mainly because of mitochondrial dysfunction or formation of 
reactive metabolites: the latter can then lead to either direct toxicity or immune 
reactions183. Mitochondria are always involved in DILI, either directly or indirectly, 
because hepatic damage ultimately leads to the mitochondrial permeability 
transition184. Figure 3.1 illustrates the six main off-target drug toxicity locations in 
mitochondria along with their most common associated drugs185. 
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Figure 3.1. Main drug targets in mitochondria. Drugs can hit several molecular targets in 
mitochondria (1-6, explained in the text below), hence this organelle can be responsible for a 
wide range of drug-induced conditions: the focus of this work is on complex I in the 
respiratory chain (number 3). The picture was taken from Labbe, Pessayre and Fromenty186. 
LCFA, long chain fatty acid; CPT, carnitine palmitoyltransferase; ANT, adenine nucleotide 
translocator; ACS, acyl-CoA synthetase; VDAC, voltage-dependent anion channel; MRC, 
mitochondrial respiratory chain; MPT, mitochondrial permeability transition; NAPQI, N-
acetyl-p-benzoquinone imine; NRTI, nucleoside reverse transcriptase inhibitors. 
1) Some drugs may induce opening of the mitochondrial permeability transition 
pore, resulting in depolarization of the inner mitochondrial membrane, water 
influx into the matrix and, ultimately, cell death. 
2) mtDNA depletion leads to severe consequences, because the synthesis of 
mitochondrial dysfunction should be detected during the
course of preclinical saf ty studies.
In the present review, we first bri fly recall some key
features of mitochondria and the main molecular mech-
anisms whereby drugs can impair mitochondrial func-
tion and lead to liver injury. We then cite a few drugs,
the propensity of which to cause mitochondrial dysfunc-
tion and DILI has led to the premature termination of
clinical trials or to the withdrawal of the drug from the
market. We also indicate which in vitro and in vivo
investigations can be performed during preclinical safety
studies to detect DILI linked to mitochondrial dysfunc-
tion, or later in drug development to explain hepatotoxic
events in some individuals. Finally, we discuss the
possible means to improve the prediction of idiosyncratic
liver injury in the future, such as the use of animal
models with underlying mitochondrial and/or metabolic
ab ormalities. It is noteworthy that several excellent
reviews re available for those who wish to gain insight
into preclinical testing strategies independently of the
mechanism of DILI [9–11].
M I T O C H O N D R I A L F U N C T I O N S A N D
G E N O M E
The mitochondria: powerhouses of the cell and
crossroads of metabolic pathways
Mitochondria oxidizes many metabolites including fatty
acids, pyruvate (generated from glycolysis) and several
amino acids such as valine, leucine and methionine
336 G. Labbe et al.
ª 2008 The Authors Journal compilation ª 2008 Blackwell Publishing Ltd. Fundamental & Clinical Pharmacology 22 (2008) 335–353
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OXPHOS polypetides that are encoded by mtDNA can be impaired. 
3) Inhibition of respiratory chain enzymes decreases ATP formation and 
increases ROS formation but can also contribute to lactic acidosis and 
steatosis (abnormal accumulation of fat), on account of the higher 
[NADH]/[NAD+] ratio brought about by insufficient NADH reoxidation: less 
NAD+ means impaired ß-oxidation of fatty acids and lowered oxidation of 
pyruvate, more NADH means higher pyruvate conversion to lactate. This is 
the main focus of this work since complex I belongs to the respiratory chain.  
4) Some drugs are cationic amphiphiles: their lipophilic moiety combined with 
an amine functional group that tends to be protonated in the inner 
mitochondrial membrane allows them to be “electrophoretically pushed” into 
the mitochondrial matrix, dissipating ∆Y; depolarization can also be triggered 
by anionic uncouplers (e.g. many NSAIDs) that shuttle back and forth from 
the intermembrane space (as uncharged species that easily cross the inner 
membrane) to the matrix (as negatively charged species that are driven back 
by anion transporters). 
5) Inhibition of ß-fatty acid oxidation enzymes mainly causes steatosis, initially 
as small lipid vesicles in the liver that coalesce into bigger fat vacuoles; 
steatosis can also progress into steatohepatitis. 
6) Lastly, drugs can sequester fatty acid oxidation cofactors such as CoA, 
therefore limiting catabolism of fatty acids. 
The aims of the work in this chapter are to  
• test a methodology that combines a side effects-based drug database search 
with known inhibitors of complex I to obtain a library of compounds that are 
expected to cause complex I-driven drug-induced mitochondrial dysfunction  
• test the drugs that make up the library with an array of routine assays that 
focus on isolated complex I, on the whole respiratory chain and on cells: 
consequently, the drugs will be fully characterized according to their effect on 
complex I and classified accordingly in terms of potency and specificity 
• based on the experimental findings from the two points above, a proof of 
principle will be established and applied to a bigger library of approved drugs 
(see chapter 4). 
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3.2 Drug selection process for first drug library 
The initial library of drugs to conduct experiments on for this proof of principle study 
was prepared by identifying elements in common to the following two lists: 
1) Drugs with side effects (hepatic and extrahepatic) that might be associated 
with mitochondrial damage. 
2) Complex I inhibitors described in the literature. 
3.2.1 Side effects list 
The FDA provides a freely accessible database of about 95,000 drugs that can be 
queried according to side effects that the drug causes, the FDALabel. Other databases 
were initially interrogated, such as Drug Bank and Toxnet, but with FDALabel it is 
possible to directly and easily query side effects. Two lists of drugs were created 
according to the two different classes of side effects included in the database search as 
followsc.  
Liver side effects 
Hepatitis, steatosis, hepatic steatosis, microvesicular steatosis, macrovesicular 
steatosis, steatohepatitis185; acute liver failure187,188; autoimmune hepatitis189; liver 
necrosis, hepatocellular necrosis, hepatic necrosis, toxic hepatitis, liver steatosis, liver 
jaundice, hepatocellular jaundice, cholestatic jaundice, cholestasis, acute hepatitis, 
obstructive jaundice, chronic hepatitis, hepatomegaly, phospholipidosis, hepatic 
(liver) fibrosis, biliary sclerosis, hepatic vein thrombosis, peliosis hepatis, 
hepatoportal sclerosis, granulomatous hepatitis190; cirrhosis, nodular regenerative 
hyperplasia, hepatic adenoma191. 
Extraliver side effects 
Optic neuropathy, pancreatitis 192 ; cardiomyopathy 193 ; peripheral neuropathy194 ; 
hyperlactatemia, lactic acidosis195; rhabdomyolysis196; myopathy197; lipoatrophy198. 
The information comprised in the database includes the name of the drug, National 
Drug Code (NDC) and Unique Ingredient Identifier code (UNII). While the former 
identifies the drug itself, the latter identifies the active ingredient(s) that make up the 
                                               
c The FDALabel database was accessed on 24th January 2014. 
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drug: since the active ingredient of the drug is most important for this study, both 
drug and inhibitor lists were based on UNII codes. 
There were many redundancies in the database results and those were removed: drugs 
with the same name and drugs with different names but with the same active 
ingredients were deleted from the list. Also, very often drugs are sold in different 
versions (e.g. slow, fast and extended release), in different amounts of active 
ingredient or in different forms (e.g. chewable, injection, drops, crystals). At the end 
of the process no two active ingredients (UNII codes) were repeated in either list: the 
liver list comprises 806 hits (shown in appendix 3.7.3) and the extra-liver list 663 hits 
(shown in appendix 3.7.4), with 1016 drugs that belong uniquely to either one set or 
another. 
3.2.2 Complex I inhibitors list 
The main source for the complex I inhibitors list (i.e. compounds that have been 
reported to inhibit complex I) was the Scripps Institute Webpage on complex Id: all of 
the articles from 1997 onwards were screened and the ones about inhibition of 
complex I were added to the inhibitors list. In addition, other articles in the literature 
were used to expand on the original Scripps list. Particularly important was a review 
by Degli Esposti, where the author also proposed a classification of complex I 
inhibitors based on both an extensive literature search and original research: type A 
(antagonists of ubiquinone), type B (they displace ubisemiquinone) and type C 
(antagonists of ubiquinol)199. A UNII code was assigned, where possible, for all of the 
possible variants (e.g. normal, HCl, hydrate, Na+ salt…), most drugs, however, are 
available in “normal” and HCl forms. 22 inhibitors that did not have a UNII code 
were found to have a CAS code instead. 42 inhibitors were species synthesized in 
medicinal chemistry papers that are not commercially available (they mostly belonged 
to the family of annonaceous acetogenins)e. The final inhibitor list contains 151 
complex I inhibitors and their associated UNII codes (shown in appendix 3.7.2). 
                                               
d http://www.scripps.edu/yagi/ci/publications.html, last checked 10th April 2014. 
e The UNII list that was used to check against the inhibitors and the drugs dates back to 18th November 2013. A 
more recent list was uploaded (19th April 2014), and even though it contained 30,000 more UNII codes, no further 
hits were identified. 
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3.2.3 Intersection of the two lists and generation of the first 
compound library 
When the two lists were compared to find common active ingredients (complex I 
inhibitors against liver side effects and complex I inhibitors against extraliver side 
effects), 44 liver and 40 extraliver matches were obtained: 12 drugs exclusive to liver 
side effects and 8 exclusive to extraliver side effects, the remaining 32 were in 
common between the two lists (these drugs are reported in appendix 3.7.1). 
From the overall 52 hits, the list was then narrowed down to 29 by discarding some 
drugs for the following reasons: 
1) They were structurally similar to each other (e.g. imipramine is similar to 
desipramine and only the latter was purchased) 
2) Their IC50 in the literature was deemed too high (higher than 1 mM, e.g. 
valproate exhibited an IC50 higher than 5 mM with respect to complex I 
activity)200 
3) They were very expensive (e.g. mirtazapine) 
4) They required governmental authorisations (meperidine HCl) 
5) They were already the subject of ongoing research in the lab (e.g. metformin 
HCl) 
Preliminary NADH:O2 IC50 measurements (see section 3.3.2 for details about this 
assay) ruled out some of the selected compounds from the proof of principle list 
because their IC50 values are too high to be relevant. It was decided to set the 
threshold for IC50 to 500 µM and not to proceed to further analysis with 
Acetaminophen (~8 mM), Aspirin (>5 mM), Tetracycline (>2 mM), Na-Ibuprofen 
(~2.6 mM), Indomethacin (~1.2 mM), Piroxicam (~1 mM) or Ciprofloxacin (~500 
µM). Lastly, Simvastatin was ruled out because it did not dissolve to any appreciable 
degree in several solvents (water, DMSO, EtOH, MeOH, DCM). In the literature the 
inactive lactone form is usually hydrolysed with aqueous NaOH to the 
pharmacologically active acidic form to improve solubility201, but no substantial 
improvement in solubility could be achieved by this method. 
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Figure 3.2. Structures of the compounds tested in this chapter. 21 FDA-approved drugs were identified by combining the results from the side effect 





















































































































3.3 Overview of assays and systems 
3.3.1 Features of mitochondrial membranes 
Mitochondrial membranes from Bos taurus (bovine) heart mitochondria (membranes 
for short) are the main experimental system adopted in this thesis to assess ETC-based 
drug-induced mitochondrial dysfunction: they are an intermediate step in the isolation 
of complex I prepared according to Walker et al.157. In these almost completely 
unsealed inner mitochondrial membrane fragments (they do retain a small amount of 
coupling) the active sites of the relevant complexes are accessible to exogenous 
substrates202.  
Cytochrome c was added to assays of membranes (since it is lost during the 
preparation) and the optimum amount was found to be 1.5 µM for every 50 µg mL-1 
of protein  (the fact that exogenous cytochrome c stimulates NADH oxidase activity 
in mitochondrial preparations treated with KCl has been known for a long time203). 
Figure 3.3 shows how membrane activity responds to cytochrome c concentration, 
both for the NADH:O2 and succinate:O2 oxidoreduction assays (see section 3.3.2 for 
details about these assays).  
 
Figure 3.3. Substrate saturation curves for cytochrome c in different membrane 
concentrations. NADH:O2 and succinate:O2 sensitivities towards cytochrome c were 
performed at membrane concentrations used in this thesis to determine its optimal 
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The biochemical properties of the membrane system, combined with ease of 
preparation, make it a convenient platform to test drugs on OXPHOS enzymes for 
inhibition before expanding to more focused experiments with isolated enzymes. The 
main advantage of membranes over submitochondrial particles (SMPs, inside-out 
vesicles of the IMM obtained by sonication) is that they are naturally and almost 
completely uncoupled, so assays do not require addition of an uncoupler that could 
partially disrupt the lipid membrane and a further injection vehicle. 
3.3.2 Assays in membranes and isolated enzymes 
The first assay conducted on the selected drugs was NADH:O2 oxidoreduction in 
membranes: the data from inhibitor titrations were arranged to display the catalytic 
activity against the amount of inhibitor used and, as such, they express the sensitivity 
of the system towards the inhibitor. This assay is the simplest and most general way 
of testing the potency of a compound against the complex I-IV pathway. It does not 
indicate which (and in what measure) specific enzymes are inhibited but it lays the 
foundations of a more thorough investigation into the inhibitory power of selected 
drugs. The second assay was the NADH:dQ oxidoreduction on isolated complex I: 
this was performed in order to obtain a more clear-cut assessment of the inhibitory 
potency of the drugs with respect to the enzyme and therefore to remove any 
interference by the other enzymes of the respiratory chain. Comparing the results of 
these two assays with one another enabled a first assessment of how selective these 
drugs are in targeting complex I. Specificity was also, and more accurately, addressed 
with the coupled succinate:O2 assay that measures the activity of complexes II-IV160: 
it has many advantages over conventional assays for complex II that employ artificial 
electron acceptors such as DCPIP and INT, particularly because it includes the 
complete catalytic cycle of complex II and is stoichiometric. This experiment was 
performed to assess the effect of the drugs on the complex II-IV pathway. In order to 
detect artefacts that could lead to false positives in these assays, it was also confirmed 
that drug addition did not change the pH significantly and that the drugs did not react 
directly with NADH, cytochrome c or components of the succinate:O2 assay. Finally, 
other assays on isolated complex I (FeCN, HAR, APAD, Q1 and ROS assays) were 
conducted to assess the role of the flavin site in drug inhibition and whether ROS 
production was significantly altered by the compounds. 
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3.3.3 Cellular assays and microsomes 
The effects of the drugs on the liver were assessed with the aid of the XF96 Seahorse 
Extracellular Flux Analyzer on HeLa cells. This platform is instrumental to 
understand if and in which measure drugs are absorbed by cells and transported into 
mitochondria. It must be noted that, in HeLa cells, expression of cytochrome P450 
(CYP) drug-metabolising enzymes is low204, therefore the use of these cells in this 
work mainly addresses (parent) drug transport inside cells and their interaction with 
mitochondria, not necessarily the effect of drug metabolism. The role of drug 
metabolites will finally be addressed with drug incubations in human liver 
microsomes: they are microvesicles derived from fragments of the endoplasmic 
reticulum upon ultracentrifugation that are commonly used to study drug 
biotransformation in vitro205. 
3.4 Results 
3.4.1 Inhibition of complex I 
3.4.1.1 NADH:O2 and NADH:dQ oxidoreduction assays 
Table 3.1 reports the IC50 values (with confidence interval at 95%) measured for the 
drugs in the NADH:O2 assay. All the drugs exhibit either a single- or double-digit µM 
IC50 towards the complex I-IV pathway: the only two exceptions are Bupivacaine (the 
least potent, with 433 µM) and Nefazodone (the most potent, with 0.83 µM). 
Nadanaciva et al.206 reported an IC50 of 4 µM for Nefazodone and greater than 50 µM 
for Tamoxifen and Chlorpromazine (two of the most potent drugs in the library) but 
they used an immunocapture-based assay with solubilised bovine heart mitochondria. 
The discrepancies could be explained by differences in the total concentration of 
complex I in the two systems or Q1 used as electron acceptor (the latter could also be 
the main reason why Hroudová and Fišar200 detected an IC50 of 96 µM for 
Desipramine in brain crude mitochondrial fraction, almost 4x the NADH:O2 IC50 
measured in membranes using native Q10).  
Table 3.1 also reports the IC50 values (with confidence interval at 95%) measured for 
the drugs in the NADH:dQ assay. Similarly to the NADH:O2 assay, all the drugs 
exhibit either a single- or double-digit µM IC50 towards the isolated enzyme, but this 
time the average IC50 (66.2 µM) is almost twice as high as the average NADH:O2 IC50 
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value (38.6 µM). Also, Papaverine and Nefazodone are the most potent drugs (2.04 
and 2.28 µM IC50 respectively) and Bupivacaine the least potent (254 µM). 
3.4.1.2 Comparison between the NADH:O2 and NADH:dQ assays  
The comparison between IC50 values from these two assays can be useful to assess the 
response of the drugs to different Q acceptor species (endogenous Q10 in NADH:O2 
and dQ in NADH:dQ), to different aqueous environments (NADH:dQ is performed in 
the presence of 0.075% asolectin and CHAPS) and, more importantly, to several 
enzymes as opposed to isolated complex I. Chapter 4 includes a dedicated section on 
the differences between the NADH:O2, NADH:dQ and NADH:Q10 assays based on 
data from 150 drugs (not just the 21 in this section). Table 3.1 also reports Hill 
coefficients for both assays (with associated SEM). Hill coefficients measure the 
steepness of dose-response curves and an high coefficient can be diagnostic of 
important features of the inhibitor/drug, such as presence of multiple binding sites 
(i.e. cooperativity), physical phase transitions (e.g. colloid formation) or enzyme 
concentration greater than Kd207 (see chapter 5 for more information on the subject): 
comparison between NADH:O2 and NADH:dQ Hill coefficients can, thus, be 
informative as far as potential cooperativity is concerned (see section 3.4.2).  
Figure 3.4 shows an example of the dose-response curves for Fluphenazine (both the 
NADH:O2 and NADH:dQ assays), with IC50 values and Hill coefficients graphically 
highlighted. These plots display two common features of the drugs that emerged in 
the assays: when complex I is isolated, the drug IC50 rises (curve shifts towards right) 
and the Hill coefficient drops (the red slope is steeper than the blue slope). An 
interesting discovery is that the IC50 values in isolated complex I are almost always 
greater (several times more, on average) than the corresponding IC50 values in the 
NADH:O2 oxidoreduction assay: exceptions are Flutamide, Estradiol, Bupivacaine 
and Capsaicin, where the IC50 values for the isolated enzyme are lower (see Table 3.1 





 IC50 µM 
Confidence 
interval 95% Hill coefficient SEM IC50 µM 
Confidence 
interval 95% Hill coefficient SEM 
Chlorpromazine 11.1 10.0 12.3 2.08 0.15 52.7 48.3 57.5 1.46 0.08 
Desipramine 25.7 21.6 30.5 1.47 0.11 86.9 74.1 102 1.50 0.14 
Fluphenazine 17.6 15.6 19.9 2.24 0.20 102 86.9 119 1.74 0.2 
Flutamide 28 24.9 31.5 1.63 0.09 13.0 10.6 16.0 0.97 0.08 
Fenofibrate 3.6 3.17 4.17 1.60 0.10 17.1 15.5 18.8 1.2 0.06 
Estradiol 14.2 12.7 15.9 1.4 0.07 13.9 11.7 16.5 1.27 0.12 
Papaverine 1.7 1.57 1.88 1.07 0.03 2.04 1.88 2.22 1.04 0.04 
Bupivacaine 433 402 466 1.21 0.03 254 222 291 1.27 0.08 
Amiodarone 8.55 8.24 8.88 2.91 0.10 65.7 54.2 79.7 1.26 0.11 
Rosiglitazone 38.1 31.6 45.8 1.19 0.08 47.6 41.1 55.0 1.06 0.07 
Nefazodone 0.83 0.78 0.87 1.13 0.02 2.28 2.17 2.39 0.92 0.02 
Carvedilol 6.69 5.39 8.30 1.35 0.09 10.8 9.61 12.1 1.23 0.07 
Tamoxifen 5.3 4.67 6 2.52 0.26 168 90.5 310 1.05 0.11 
Clozapine 50.8 37.8 68.2 0.93 0.06 140 117 168 1.27 0.08 
Buspirone 18.3 16.4 20.4 1.07 0.04 40.4 36.3 45.0 0.77 0.02 
Haloperidol 2.37 2.24 2.52 1.42 0.04 8.27 7.50 9.12 1.07 0.05 
Sunitinib 9 8.28 9.77 1.48 0.06 29.4 25.7 33.6 1.03 0.04 
Trifluoperazine 13 12.0 14.2 2.29 0.15 213 131 346 1.39 0.17 
Capsaicin 25.8 22.7 29.2 1.56 0.09 24.7 22.6 27.1 1.3 0.06 
Doxorubicin 85.9 73.8 100 1.65 0.15 / / / / / 
Efavirenz 11.7 9.78 14.1 1.66 0.17 32.9 26.7 40.6 1.2 0.10 
Table 3.1. Assays with complex I in membranes (NADH:O2) or isolated (NADH:dQ). Data for the two assays are presented with confidence intervals at 
95% for IC50 values and Hill Coefficients with corresponding SEM of triplicates. It was not possible to assay Doxorubicin on NADH:dQ (the wells at 
midrange to high concentrations were too turbid for a reliable spectrophotometric reading). In general, IC50 values are lower and Hill coefficients are higher 
in the NADH:O2 than in the corresponding NADH:dQ assays. 
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Figure 3.4. Dose-response curves for fluphenazine. The main differences between 
NADH:O2 and NADH:dQ assays are highlighted: NADH:dQ exhibits a higher IC50 (the curve 
is shifted to the right) and a lower Hill coefficient (as indicated by the steepness of the curves, 
NADH:O2 indicated twice for comparison) than NADH:O2. Error bars are SEM of triplicates. 
 
Figure 3.5. Relationship between IC50 values for NADH:O2 and NADH:dQ. The majority 
of the drugs falls on the left of the 1:1 (red) line, indicating that their potency towards the I-IV 
pathway is higher than their corresponding potency towards the isolated enzyme (drugs for 
which the opposite is true are highlighted). Data shown in logarithmic form for better 
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3.4.2 Succinate:O2 oxidoreduction assays and OXPHOS 
specificity 
Table 3.2 reports the inhibition in the succinate:O2 assay, which indicates how 
specific to complex I a compound is: it was decided to only perform a one point 
inhibition for each drug at three times the IC50 value in their NADH:O2 assay. 11 
drugs inhibit the oxidoreduction to less than 5%, 6 of which cause no inhibition 
whatsoever. In order to classify drugs as specific complex I inhibitors, a threshold of 
15% on the succinate:O2 percentage inhibition was deemed enough: 7 drugs out of 21 
exhibit a value higher than this threshold. In order to investigate this aspect further, 
the ratio of the NADH:dQ and NADH:O2 IC50 values was calculated for each drug 
(see Table 3.2): the higher the ratio is, the more the drug inhibits the complex I-IV 
pathway than it inhibits isolated complex I, and this could be diagnostic of specific 
complex III and/or IV inhibition (in chapter 4 this indicator will be expanded upon in 
terms of number of drugs, strengths and limitations). All of the drugs that are above 
the threshold also exhibit high NADH:dQ to NADH:O2 ratios. Tamoxifen and 
Trifluoperazine, the drugs with the highest ratio, have been shown to be 
mitochondrial complex III inhibitors208,209 (but see also the role of Tamoxifen-based 
mitochondrial insult in drug-induced liver injury, section 3.5.1). Furthermore, of the 
three species with the highest inhibition towards the complex II-IV pathway, namely 
Amiodarone, Tamoxifen and Sunitinib (44, 36 and 49% inhibition respectively), the 
latter has the lowest IC50 ratio of the three: this could mean that this drug exerts mixed 
(or non-specific) OXPHOS inhibition, i.e. inhibition of complex I could be more 
important than in the other two species (in chapter 4 Sunitinib is indeed classified as a 
non-specific inhibitor of OXPHOS). Amiodarone, Trifluoperazine and Tamoxifen 
also exhibit a remarkable reduction (absolute value) in Hill coefficient from 
NADH:O2 oxidoreduction to NADH:dQ oxidoreduction (Table 3.1), and this can be 
indicative of multiple binding sites along the overall NADH:O2 chain (i.e. complexes 
III and IV). Indeed, almost all drugs experience this decrease, as a consequence of the 
removal of enzymes in the assay. Only three drugs show an increase in Hill 
coefficient (Desipramine, Bupivacaine and Clozapine), but this is not significant and 
it does not likely reflect a genuine underlying biochemical phenomenon. 
Based on these results, the 14 drugs that generate less than 15% inhibition in the II-IV 
pathway are complex I specific inhibitors (Rosiglitazone and Clozapine may still 
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deliver some degree of unspecific OXPHOS inhibition since they are the compounds 
with the highest values in this group). The other 7 drugs are specific inhibitors of 
other OXPHOS enzyme(s), even though this cannot be said about Doxorubicin 
because of lack of data for the NADH:dQ assay. Since its NADH:O2 IC50 value is the 
second highest (see Table 3.1) and its succinate:O2 percentage inhibition is the fifth 
highest in the whole library, Doxorubicin seems to inhibit less complex I than other 
OXPHOS enzymes. Indeed, Doxorubicin is known to inhibit several components of 
the respiratory chain, including complex IV and creatine kinase, as well as to undergo 
superoxide ion-based redox cycling on complex I210 (see also section 3.4.3.1 for ROS 
assay on Doxorubicin). 
Drugs Succinate:O2 Inhibition % SEM > 15% (NADH:dQ/NADH:O2) IC50 
Chlorpromazine 1.5 0.7  4.7 
Desipramine 2.8 1.9  3.4 
Fluphenazine 21.3 0.4 ✓ 5.8 
Flutamide -3.1 1.3  0.5 
Fenofibrate 28.2 1.4 ✓ 4.8 
Estradiol -2.3 2.9  1.0 
Papaverine 0.0 1.3  1.2 
Bupivacaine -0.2 2.7  0.6 
Amiodarone 44.3 0.1 ✓ 7.7 
Rosiglitazone 8.5 0.7  1.2 
Nefazodone 0.2 0.1  2.7 
Carvedilol 4.6 3.4  1.6 
Tamoxifen 36.1 0.4 ✓ 31.7 
Clozapine 14.6 0.5  2.8 
Buspirone 0.0 1.4  2.2 
Haloperidol 1.5 2.8  3.5 
Sunitinib 48.5 1.8 ✓ 3.3 
Trifluoperazine 18.4 2.5 ✓ 16.4 
Capsaicin 5.0 1.6  1.0 
Doxorubicin 25.3 1.6 ✓ / 
Efavirenz 3.6 4.2  2.8 
Table 3.2. Succinate:O2 percentage inhibition at three times IC50 for NADH:O2. Negative 
values indicate total lack of inhibition (i.e. higher than control within experimental error). 
SEM from triplicates. IC50 values from Table 3.1. 
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3.4.3 Flavin-site of complex I  
3.4.3.1 Initial assays 
The activity of complex I at the flavin site can be assessed by several assays 
depending on the electron acceptor: NADH:HAR (the electron acceptor is 
Ru(NH3)63+), NADH:FeCN (the electron acceptor is Fe(CN)63-), and ROS (catalase-
sensitive horseradish peroxidase-dependent oxidation of Amplex Red to resorufin via 
H2O2). Single point flavin-site experiments were carried out at three times the 
NADH:dQ IC50 for each of the above-mentioned assays, which are presented in 
Figure 3.6 (Trifluoperazine, Tamoxifen and Amiodarone were tested at 1.5x their 
NADH:dQ IC50 concentration because at higher concentrations they precipitated out 
of solution in the FeCN assay). 
 
Figure 3.6. Isolated complex I assays for the drugs in the library. All drugs were tested at 
three times their IC50 in the NADH:dQ assay except for the ones that precipitated out of 
solution at such a high concentration in the FeCN assay, Trifluoperazine, Tamoxifen and 
Amiodarone. Error bars are SEM. 
Often the measured rates did not reflect actual enzymatic inhibition or overactivation. 
This was particularly true for the FeCN assay (many issues in this assay were also 
experienced with the Enzo Library drugs, see chapter 4): Amiodarone, Fluphenazine 
and Trifluoperazine had solubility issues (the pathlengths exhibited were significantly 





























































































































































Doxorubicin exhibited a background rate over four times higher than the control rate; 
finally, the absorbance traces of Clozapine lasted for less than 20 seconds and then 
levelled off (the inhibition percentage shown in Figure 3.6 refers to such a short-timed 
rate). Of the drugs left, only a few exhibited either significant (± 20%) inhibition 
(Fenofibrate, Capsaicin, Efavirenz) or overactivation (Desipramine, Sunitibib) of the 
NADH:FeCN reaction. Interestingly, Wright and Kuhn211 reported that Capsaicin 
inhibited FeCN reductase activity of trans-plasma membrane electron transport in 
chick forebrain neurons. 
Similar issues were found in the NADH:HAR assay. Fenofibrate, Tamoxifen, 
Amiodarone, Fluphenazine and Efavirenz elicited a background rate over four times 
higher than the control; Trifluoperazine, Tamoxifen and Amiodarone had solubility 
issues (the pathlengths exhibited were significantly lower than the control). Of the 
drugs left, only Chlorpromazine exhibits a significant HAR inhibition (76% residual 
activity). 
As for the ROS assay, the pathlengths exhibited by Tamoxifen and Amiodarone were 
abnormally low (and this explains the measured overactivation) while Capsaicin 
inhibited horseradish peroxidase (HRP) enough to compromise the results. Every drug 
tested with the ROS assay was also tested with the same conditions in the presence of 
catalase (to remove H2O2 from the assay medium): the only compound that returned a 
significant H2O2-free rate was Doxorubicin (3.6x the control catalase rate and 70% 
the ROS, catalase-free, rate, where normal values for the other drugs were about ± 
1.2x and 20%, respectively). Doxorubicin ROS formation was also performed in a 
glovebox (O2-free environment) and Amplex red activity not generated by oxygen 
(i.e. artefactual production of ROS) was ruled out. The redox cycling capacity of 
Doxorubicin (mentioned in section 3.4.2), could explain why this drug was found to 





3.4.3.2 Structure-activity relationship on dibenzoheterocyclics 
In general, the drugs investigated were unreactive towards FeCN, HAR and ROS 
assays, implying a lack of reactivity at the flavin: for most of them the observed 
activity was within ± 20% of the control value. Furthermore, the majority of the drugs 
that induced greater changes appeared to be chemically incompatible with the 
reagents present in the assays, thus rendering these results dubious. Despite these 
limitations, a structural pattern emerged from the flavin-site assays data that was 
thought to reflect an underlying enzymatic phenomenon: four out of six compounds 
with a dibenzoheterocyclic core (Chlorpromazine, Desipramine, Trifluoperazine and 
Fluphenazine) exhibited significant overactivation of the NADH:FeCN activity and 
inhibition of the NADH:HAR activity. This trend, combined with the cheap 
commercial availability of structurally similar species, made it possible to develop a 
flavin-site structure-activity relationship (SAR) study to shed light on its underlying 
causes. Compound titrations over appropriate concentration ranges were conducted 
for 8 different species with 5 different assays according to the different electron 
acceptor interacting with the NADH-reduced flavin (FeCN, HAR, APAD, Q1 and O2 
in the ROS assay). Table 3.3 illustrates the overall findings, which are presented in a 
relatively descriptive way since the chemical characteristics of the compounds such as 
turbidity (as an indicator of poor solubility which can lead to artefactual light 
scattering) and background (i.e. complex I-free) rates varied and a proper IC50 
determination was, thus, unfeasible. The aim was to obtain a set of criteria as 
objective as possible. The general ascending (or descending) trends as compound 
concentration increases were described with 5 different labels, illustrated in Figure 3.7 
(top). Two representative traces are also shown in Figure 3.7 (bottom). The results are 
illustrated in Table 3.3 with different colour codes explained in the header row. The 
highest drug concentration in the titrations was set at 500 µM (or lower when the 








Figure 3.7. Criteria for trend labelling of flavin-site SAR study presented in Table 3.3 
and representative traces. Top. In order to present the data as objectively as possible, rates 
are classified according to which portion of the activity plot data points are within, at ½ the 
concentration range used in the titration. Colour codes will be illustrated in the header row of 
Table 3.3. Bottom. Data points related to NADH:FeCN assay with Promazine and 
NADH:HAR assay with Chlorpromazine are shown. Hashed lines are the same as in the plot 


















































Colour codes for data 
presentation 
Turbidity issues, either visible by eye or how smaller the pathlengths at the highest 
compound concentration is compared to control pathlength (if greater than 10%) 
Substantial complex I-free rates over complex I-driven rates along the titration (>10%) 
Trend labels aaaHigh ↑ aaaModerate ↑ aaaConstant aaaModerate ↓ aaaHigh ↓ (see Figure 3.7) 
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Table 3.3. Flavin site SAR on compounds sharing a TCA core. Five different complex I flavin-site assays were 
carried out on 8 structurally similar compounds. Data are presented in terms of turbidity (as a proxy for poor 



























The first three and last compounds in Table 3.3 are antipsychotic drugs, phenothiazine 
is used as a stabiliser and the second three are type II photoinitiators used in polymer 
generation processes, thioxanthone and two thioxanthone derivatives. 
There are some caveats to be aware of when analysing thioxanthone derivatives in a 
spectrophotometric assay. One of the major drawbacks related to the use of 
thioxanthone-based molecules can be the generation of radicals with reagents present 
in the assay mixture (primarily Tris buffer which is used in the isolated complex I 
assays) by absorption of light at the wavelengths involved in the assays (340, 380, 
400, 450, 577, 620 nm). Photoinitiators become excited in a triplet state upon 
absorption of light and then, when an appropriate coinitiator is present (tertiary amine, 
alcohol, thiol, ether,…) radicals are generated in a bimolecular process (the typical 
reaction scheme is depicted in Figure 3.8)212. 
 
Figure 3.8. General mechanism for type II photoinitiators in polymer formation. Light 
of appropriate frequency generates an excited triplet species (upon internal system crossing) 
which interacts with a coinitiator R-H (amines, alcohols, ethers, …) to generate two radicals: 
the polymerisation will be initiated by the radical coinitiator. 
If such radicals are generated (and this happens when the absorption bands and the 
light emission wavelength overlap) it means that the molecule being assayed is being 
degraded. Absorption maxima for thioxanthone derivatives are in the range between 
230-310 nm and 330-420 nm213 and tertiary amines are more reactive towards these 
species as coinitiators than alcohols or ethers214. The complex I-free rate should be 
enough to detect any radical-based mechanism: that is what might happen in the 
NADH:APAD assay with isopropyl thioxanthone (mixture of isomers) and 
Phenothiazine, where a significant negative background rate was found at compound 
concentrations higher than 50 µM (220 and 20% of the corresponding complex I-
driven rate at 80 µM in absolute value, respectively, where normally a 1% 
background rate across the whole titration is seen, see Table 3.3). Thioxanthone has 
also been tested as a monoamine oxidase (MAO) inhibitor (showing remarkable 
activity towards the isozyme MAO-A) by following absorbance at 315 and 360 nm215. 
Ar2C O Ar2C O
*hν 3
Ar2C OHAr2C O
*3 R H R
R + Monomer Polymer
+ +
 68 
Lastly, isopropyl thioxanthone is a mixture of two isomers (2- and 4-), so the response 
obtained with the assays is the combined effect of two species. 
The FeCN assay exhibits the most significant variations and also many chemical 
issues (turbidity and elevated background rates). Similarly, the NADH:Q1 reaction 
exhibited the most artefacts: the presence of asolectin in the assay could account for 
the formation of insoluble agglomerates at high drug concentration. The only 
molecule that interferes with the APAD reaction (without chemical interference) is 
chloro-propoxy thioxanthone, while the HAR reaction did not always follow the 
opposite trend of FeCN. The pattern exhibited by the ROS assay across the library 
suggests that ROS generation at the flavin site of complex I is affected by the central 
N atom in the dibenzoheterocyclic core; however, it was found that Phenothiazine 
inhibits HRP directly. The ROS assay performed with high NADH concentration (200 
µM as opposed to the regular 30 µM) on the compounds did not show a different 
pattern than the one seen with low concentration. Thioxanthone (the barest of the 
molecules when it comes to side chains and substituents, along with Phenothiazine) 
exhibited a constant rate for all of the flavin reactions: it appears that, in order to 
possess any complex I flavin activity, a dibenzoheterocycle-based molecule should 
have either a central N atom, a side Cl atom or an alkyl chain. 
In spite of the efforts undertaken to shed light on the relationship between the 
dibenzoheterocyclic core and flavin site activity at complex I, the conclusions are 
minor (a possible role for the central N atom of the core in flavin reactivity) and not 
entirely reliable at best (given the many chemical issues some assays are plagued 
with). In general, the flavin site of complex I seems relatively unreactive towards the 
drugs in the library (the same conclusion was drawn in chapter 4 and featured a much 
larger set of drugs).   
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3.4.4 Seahorse XF 96 cellular assays 
While the OCR is primarily a measure of mitochondrial respiration, ECAR is 
primarily a measure of lactic acid release, so a Seahorse experiment can be used to 
screen compounds for mitochondrial impairment and also to determine how well 
whole cells can invoke glycolysis to compensate for drug-induced mitochondrial 
dysfunction 216 . Figure 3.9 shows OCR and ECAR traces for five Seahorse 
experiments: the plots shown are indicative of common patterns of the tested drugs, 
which are explained in detail in Table 3.4. Table 3.5 reports OCR inhibition and 
residual ECAR rates from the Seahorse experiments, carried out at three times the 
IC50 value in the NADH:O2 assay (5-6 drugs were tested in different replicates within 
a single Seahorse 96 well plate at a time). The data point immediately before rotenone 
addition was considered, with associated p-values for the unpaired 2-tailed Student’s 
t-tests (t-tests and inhibition/residual percentages refer to the comparison with the 
control experiments). Furthermore, Table 3.5 includes a labelling system (presented in 
Table 3.4) to summarise the overall effects of the drugs on cells: the system was 
designed in order to be as objective as possible in assigning such labels and to include 
all of the data points in the trace rather than a single one. If the difference between 
every single control value and the corresponding OCR (or ECAR) value is greater 
than 20% in absolute value (and statistically significant with p ≤ 0.05) in the majority 
of data points between drug and rotenone injections it means that the (upward or 
downward) trend is significant, otherwise it is assumed to be constant. 
OCR ECAR LABEL Explanation 
  OXPHOS 
Inhibition of oxidative phosphorylation by the drug 
means that OCR is inhibited, the cell relies more on 
glycolysis and the ECAR trace subsequently rises 
(this trend is also common with TCA cycle217,218 or 
BCL-2219 inhibitors)  
  CELL DIES 
The drug exerts such a toxic effect on cells that ATP 
production from both glycolytic and mitochondrial 
sources is halted, leading to cell death  
 Constant FAO 
This is the signature of compounds like etomoxir, 
inhibitors of fatty acid oxidation through CPT-1, a 
carnitine transporter220 
Constant  ? This behaviour is unusual and cannot be explained 
Constant Constant NONE The drug does not have any detectable effect 
Table 3.4. Labels for Seahorse trends in Table 3.5. Trends were defined as whether the 
majority of the differences between every single control point with their corresponding OCR 
(or ECAR) points is over 20% (trend) or less (constant rate): five different patterns emerged 













Figure 3.9. Typical patterns of Seahorse experiments. Representative OCR and ECAR 
traces for the five Seahorse drug patterns illustrated in Table 3.4.  Drug and rotenone addition 




































































































































 SEAHORSE EXPERIMENT 
 MAJOR 
EFFECT 




SEM p-VALUE  SEM p-VALUE 
Chlorpromazine FAO 52.3 3.8 **** 98.3 6.4 ns 33.3 
Desipramine FAO 58.9 3.1 **** 116.1 5.9 ** 77.1 
Fluphenazine CELL DIES 60.4 2.2 **** 53.3 2.2 **** 52.8 
Flutamide OXPHOS 80.7 1.6 **** 185.9 5.7 **** 84.0 
Fenofibrate FAO 26.5 5.1 *** 105.5 4.9 ns 10.8 
Estradiol NONE 27.3 3.2 *** 106.4 3.6 ns 42.6 
Papaverine OXPHOS 74.8 3.2 **** 188.4 11.7 **** 5.10 
Bupivacaine ? 30.3 3.1 **** 151.1 5.4 **** 1299 
Amiodarone ? 32.1 2.5 **** 131.1 3.2 **** 25.7 
Rosiglitazone OXPHOS 97.4 2.5 **** 219.0 16.9 **** 114 
Nefazodone OXPHOS 31.0 1.7 **** 123.5 3.3 **** 2.49 
Carvedilol ? 29.7 2.5 **** 111.8 3.0 **** 20.1 
Tamoxifen OXPHOS 48.4 2.1 **** 127.7 4.1 **** 15.9 
Clozapine CELL DIES 61.5 2.8 **** 61.3 2.8 **** 152 
Buspirone OXPHOS 40.9 2.5 **** 121.7 3.2 **** 54.9 
Haloperidol NONE 10.7 1.9 *** 111.6 2.8 **** 7.11 
Sunitinib / / / / / / / 27.0 
Trifluoperazine CELL DIES 41.7 1.8 **** 66.5 14.5 ** 39.0 
Capsaicin OXPHOS 54.1 2.4 **** 145.7 11.2 **** 77.4 
Doxorubicin / / / / / / / 258 
Efavirenz OXPHOS 42.5 1.2 **** 111.0 5.5 ns 35.1 
Table 3.5. Results for the Seahorse experiments (both at three times IC50 for NADH:O2). 
OCR inhibition and residual ECAR values from the Seahorse experiment are presented with 
SEM (n≥23 for control, n≥6 for drugs) and p-values and they refer to the last data point prior 
to rotenone addition. Doxorubicin and Sunitinib Seahorse experiments were not successful 
due to their colouring of the assay buffer that, very likely, interfered with the fluorescence 
signals. Drug concentrations were three times their NADH:O2 IC50 values. The labels used to 
describe the major effects of the Seahorse experiment are explained in detail in Table 3.4. 
Statistical significance expressed as ****, p ≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 
0.05; ns, p ≥ 0.05. 
Indeed, considering the last data point prior to rotenone addition, all of the drugs in 
the library inhibit OCR to some extent, whereas the residual ECAR exhibits more 
varied trends (see Table 3.5). Considering the overall traces, recognisable patterns are 
inhibition of OXPHOS (substantial in Flutamide, Papaverine, Rosiglitazone and 
Capsaicin), inhibition of fatty acid oxidation (substantial for Chlorpromazine and 
Desipramine, borderline for Fenofibrate), cell death (substantial in Fluphenazine, 
Clozapine and Trifluoperazine) and lack of effects in cells (Estradiol and 
Haloperidol). The pattern followed by Bupivacaine, Amiodarone and (borderline) 
Carvedilol (constant OCR in tandem with increase of ECAR) does not have a clear 
explanation. As for the inhibition of fatty acid oxidation pattern, Pike et al.220 reported 
that inhibition of fatty acid transporter carnitine palmitoyltransferase I (CPT-1) only 
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generated a modest increase in glycolysis rate in SF188 (human glioblastoma) cells 
but a significant decrease in OCR. They ascribed the effect to endogenous fatty acid 
oxidation in cells playing further roles than just ATP synthesis and linked the former 
to NADPH generation and, therefore, to the antioxidant system of the cell. Since fatty 
acid oxidation generates one equivalent of NADH for each two-carbon unit oxidised, 
its inhibition would keep the NADH pool more oxidised, thus lightening the burden 
for complex I. This would be measured as a lower OCR, while the lack of 
compensatory glycolysis (constant ECAR) could reflect a negligible effect if fatty 
acid oxidation on the net cellular ATP demand. Furthermore, the ECAR trace does 
not reach the control levels after rotenone addition in the Seahorse fatty acid oxidation 
pattern (see Desipramine trace in Figure 3.9 and later in this section) and this could be 
indicative of cellular ROS damage due to the above-mentioned link between fatty 
acid oxidation inhibition and hampered the cellular antioxidant machinery.     
The only instances where the ECAR decreased significantly just before rotenone 
addition (Fluphenazine, Clozapine and Trifluoperazine, Table 3.5) experienced a 
decrease in OCR too: this means that the drugs have a detrimental effect on cells, 
disrupting both OXPHOS and glycolytic systems. It must be pointed out, however, 
that an inhibitor of hexokinase (the first enzyme of the glycolytic pathway), 2-
deoxyglucose, brought about the same response in HeLa cells than the compounds 
assumed to cause cell death in this work, namely lowering of both OCR and ECAR 
traces (even though the OCR decrease was minor compared to the ECAR one)221. The 
metabolic response of cancer cells to glycolysis inhibitors has been shown to be 
uniform in terms of ECAR (it diminishes), while in terms of OCR the response varies: 
in theory it should climb to reflect the higher mitochondrial respiration invoked to 
compensate for ATP depletion but inhibitors of different glycolytic enzymes 
exhibited various OCR trends222. Cell death is also reflected by the difference in 
ECAR (after rotenone addition) between control and drug traces: if they are roughly 
at the same level it means that glycolysis was not affected, whereas if the ECAR of 
the drug is significantly less than control it means that over the time course of the 
experiment glycolysis was severed (see final portion of the ECAR trace of Clozapine, 
Figure 3.9, lower panel, compared to the other ECAR traces). This last feature of the 
drugs, combined with a significant OCR decrease parallel to ECAR over time, were 
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the reasons why compounds that exhibited such metabolic signature were deemed 
toxic for cells, even though it is possible that their effect is glycolysis inhibition. 
In a study by Dyckens et al. 223 , Nefazodone and Buspirone were tested at 
concentrations similar to this work (6.25 and 25 µM respectively) in HepG2 cells, 
leading to the same pattern in oxygen consumption and ECAR. In another study, 
Funes et al.224 reported a significant (and concentration-dependent) decrease in basal 
respiration in human cell lines glioma U-251MG and neuroblastoma SH-SY5Y at 25 
µM. Different results were found by Nadanaciva et al.216, for Chlorpromazine, 
Clozapine and Rosiglitazone (tested at 300, 300 and 100 µM respectively): while 
Chlorpromazine increased both OCR and ECAR, Clozapine and Rosiglitazone had no 
effect on either. Flutamide, on the other hand (at 84 µM) generated an increase in 
ECAR and decrease in OCR in line with this work. It could be that the results 
obtained by Nadanaciva are due to the different expression of drug metabolising 
enzymes in the cell line they used, HepG2 (less than 1% of those found in normal 
human hepatocytes225) compared with the cell line used in this work, HeLa (whose 
expression of drug-metabolising enzymes is low as mentioned in section 3.3.3 but 
possibly not as low as in HepG2). Similarly, the results obtained by Dyckens and 
Funes could indicate that the toxicity observed by the drugs is not linked to formation 
of reactive metabolites (hence the similar findings to this work). One interesting 
feature of HepG2 cells that could be relevant in this context is that the expression of 
drug-transporting proteins is generally higher than in HeLa cells226.  
3.4.5 Drugs pKa and intracellular accumulation 
Literature therapeutic plasma concentration and pKa values are reported in Table 3.6 
in order to present physiologically relevant information on the drugs, along with the 
corresponding IC50 values for the NADH:O2 assay. It must be borne in mind that pKa 
values, as reported in the literature, often do not differentiate between protons from an 
acid and from the conjugate acid of a base, thus cannot specify whether a neutral 
molecule is an acid or a base (especially when the drug contains both acidic and basic 
groups)227: Table 3.6, therefore, includes the charge of the drugs at physiological pH. 
Also, calculated logP (clogP) values were obtained to find out whether a relationship 
between hydrophobicity of the drugs and their potency exists: as illustrated in Figure 
3.10, the correlation coefficient between NADH:O2 IC50 values and clogP is -0.025, 
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indicating lack of substantial correlation (when the IC50 is expressed in logarithmic 
terms, the correlation becomes -0.27). Interestingly, removing the drug with the 
highest NADH:O2 IC50 values (Bupivacaine, 433 nM) raises both correlation 
coefficients between clogP and IC50 in normal and logarithmic form (-0.53 and -0.40, 
respectively). As for the relationship between drug potency towards NADH:dQ and 
hydrophobicity, the correlation coefficients between IC50 values and clogP are 0.30 
and 0.28 (IC50 values in normal and logarithmic form, respectively); when 
Bupivacaine is removed from the set they become 0.32 and 0.27, respectively. 
However (and as it will be explained more thoroughly in chapter 4), the NADH:dQ 
assay is afflicted by experimental limitations, so the apparent positive correlation 
coefficient between potency and hydrophobicity may, in fact, be the result of 
artefacts. 
 Therapeutic 




IC50 µM clogP MW  
Chlorpromazine 0.5228 9.2229 P230 11.1 4.54 319 
Desipramine 1.9228 9.9231 P231 25.7 3.90 266 
Fluphenazine 0.01228 10.0229 P232 17.6 3.97 438 
Flutamide 0.4233 4.8234 N234 28 3.27 276 
Fenofibrate 13.9235 / Neutral 3.6 5.28 361 
Estradiol < 1nM236 10.7237 Neutral237 14.2 3.75 272 
Papaverine 3.00228 8.1238 P238 1.7 3.08 339 
Bupivacaine 5.2228 8.1239 P240 433 4.52 288 
Amiodarone 5.3228 9.4241 P242 8.55 7.64 645 
Rosiglitazone 0.8228 6.1243 Neutral243 38.1 3.08 357 
Nefazodone 4.0228 6.5244 Neutral244 0.83 4.65 470 
Carvedilol 0.4228 7.8245 P/Neutral246 6.69 3.51 405 
Tamoxifen 0.2247 10.8248 P248 5.3 6.35 372 
Clozapine 2.5228 7.6232 P/Neutral232 50.8 3.40 327 
Buspirone 0.01228 7.6249 P250 18.3 1.78 386 
Haloperidol 0.1228 8.65251 P252 2.37 3.66 376 
Sunitinib 0.1253 8.95253 P254 9 2.93 398 
Trifluoperazine 0.02255 8.97229 P256 13 4.66 408 
Capsaicin 8.1 nM257 10.1258 Neutral258 25.8 3.75 305 
Doxorubicin 0.2228 8.6259 P259 85.9 1.50 544 
Efavirenz 12.7260 10.2261 Neutral262 11.7 4.46 316 
Table 3.6. Literature values for therapeutic concentration and pKa. Literature values for 
therapeutic concentration and pKa are presented for the drugs tested in this chapter. IC50 
values for NADH:O2 are taken from Table 3.1. Green cells indicate which drug therapeutic 
concentration is higher than its corresponding NADH:O2 IC50 level. P, positive charge; N, 
negative charge. clogP values calculated using MarvinSketch Version 16.5.2.0 Consensus 
Model by ChemAxon. MW, molecular weight. 
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Figure 3.10. Relationship between hydrophobicity and inhibitory potency for the drugs 
featured in this chapter. Even though the correlation between the two variables is negative 
(as illustrated by the linear fit between them, black dashed line), it is not substantial. When 
the drug with the highest NADH:O2 IC50 value, Bupivacaine, is not considered, the 
correlation between potency and hydrophobicity becomes more significant. 
As for pKa values, if the charge of the drug at physiological pH is positive (i.e. the 
pKa of its conjugate acid is higher than 7.3-7.4), transport inside mitochondria could 
be enhanced (the matrix is more negatively charged than the intermembrane space), 
resulting in intramitochondrial accumulation of the drug: however, this would more 
likely occur with phenols than with amines because, once in the matrix, deprotonation 
could cause the (deprotonated) amine to cross the IMM back. It must be further 
pointed out that such transport depends on other factors as well (e.g. the structure of 
the drug) hence the pKa can be considered a necessary but not sufficient condition for 
electrophoretically-driven membrane crossing. Even though the pKa alone does not 
necessarily mean that the drug will be able to cross the inner mitochondrial 
membrane, several drugs with high pKa lower the OCR to a considerable degree (e.g. 
Chlorpromazine, Desipramine and Capsaicin, Table 3.5, only the latter being neutral 
at physiological pH, Table 3.6). Remarkably, some drugs with a pKa similar or lower 
than physiological pH decrease the OCR to an even lower level while promoting 
glycolysis (Flutamide, Papaverine and Rosiglitazone, Table 3.5), irrespective of 


















charge. Hence, it appears that the pKa values are not predictive of OCR inhibition, in 
fact some drugs possess the same pKa values and charge (Fluphenazine and 
Bupivacaine 8.1, Clozapine and Buspirone 7.6), and yet their penetration into 
mitochondria (as approximated by the OCR percentage inhibition) is different (in the 
former couple of drugs 60.4 and 30.3%, in the latter 61.5 and 40.9%, respectively): 
this means that pKa and charge are not enough to predict intramitochondrial 
accumulation of a drug.  
Only three drugs exhibit an IC50 for the NADH:O2 assay that is therapeutically 
relevant (green cells in Table 3.6), Fenofibrate, Nefazodone and Efavirenz (in chapter 
4 a dedicated section to this issue will be presented, in particular for the phenomenon 
of drug overdose that transcends the therapeutic boundary). These drugs are also 
neutral at physiological pH. 
3.4.6 Incorporation of drug metabolism in mitochondrial 
membrane assays 
3.4.6.1 Metabolism of xenobiotics: an introduction 
Drugs, and more in general xenobiotics, are substrates of a wide range of drug-
metabolising enzymes in our body: the actions of these enzymes are traditionally 
classified into a first transformation to a more polar metabolite (Phase I oxidations 
and reductions) commonly followed by a (Phase II) conjugation reaction where a 
polar handle is attached to the metabolite to make its excretion easier263. This is true 
in particular for orally ingested drugs: on its way to reaching systemic circulation, an 
oral dose is metabolised by different enzymes in the gut wall cells and primarily by 
the liver (through the portal vein), a process named the first-pass effect264. 
Phase I metabolising enzymes include peroxidases (the substrate is oxidised while 
hydrogen peroxide is reduced)265, flavin monooxygenase (FMOs, nucleophilic centres 
containing a lone pair are converted into the corresponding oxides and they act on a 
more restricted range of compounds than CYP450, see later) 266 , molybdenum 
hydroxylases (aldehyde oxidase and xanthine oxidoreductase, they catalyse oxidative 
hydroxylations of alkyl bonds), FAD-dependent amine oxidases (they catalyse the 
deamination of amines and oxidation of polyamines)267, aldo-keto reductases and the 
short-chain dehydrogenases/reductases (they catalyse the reduction of aldehydes and 
ketones to secondary alcohols)268,269. Phase II enzymes involve the addition of a polar 
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handle onto their substrate, commonly after the action of Phase I enzymes: UDP-
glycosyltransferases add sugars (especially glucuronic acids in mammals but also N-
acetylglucosamine, glucose and galactose)270, sulfotransferases add sulfonate to a 
hydroxyl or primary amine group271, N-acetyltransferases add acetyls onto a nitrogen 
in arlyamines, arylhydroxylamines and arylhydrazines272, and glutathione transferases 
add glutathione (via its sulfur atom)273.  
The dominant category of drug-metabolising enzymes is the cytochromes P450 
(CYP450): according to a very recent estimate, about 96% of all metabolic oxidation-
reduction of drugs are catalysed by this Phase I class, three-fourths of which are 
accounted for by only 5 isoforms, 1A2, 2C9, 2C19, 2D6 and 3A4 (27% just by 3A4 
on its own)274. There are 57 genes in humans encoding for isoforms of CYP450, 16 of 
which (based on a classification according to their major substrate class) act on 
xenobiotics, the others act on sterols, fatty acids, eicosanoids and vitamins (the 
substrates of 8 isoforms are still unknown)275. The range of reactions they catalyse 
and the diversity of substrates are truly astonishing: literally hundreds of different 
reactions such as hydroxylations, dealkylations, epoxidations are known276. The 
typical catalytic cycle of CYP-mediated metabolic transformation of compounds is 
depicted in Figure 3.11277. A general substrate R-H binds to the protein cavity (step 
2), NADPH provides electrons that are needed to reduce the iron metal centre (step 3) 
and to convert the peroxyl radical ligand to the peroxide (step 5). The electrons are 
not transferred directly but through P450 reductase, a protein embedded in the 
endoplasmic reticulum whose cofactors include a FAD and FMN group which are 
sequentially reduced during electron transfer278. After formation of a Fe(IV) oxide 




Figure 3.11. General catalytic cycle for CYP450-mediated oxidation of substrate RH. 
After substrate binding to the protein cavity (2), electrons are transferred from the P450 
reductase system to the Fe(III) centre (3) and to the dioxygen radical ligand (5). Water loss at 
this point (6) leaves an iron(IV)-oxo centre which delivers oxygen across the R-H bond of the 
substrate (8) to generate the corresponding product ROH. Scheme adapted from Olsen, 
Oostenbrink and Jørgensen277. 
Most of the CYP450s are localised in the endoplasmic reticulum, even though six 
isoforms are known to be present in mitochondria279: much of the enzymes, as well as 
P450 reductases, stick out of the ER membrane (to which they are attached by the 
amino terminus) into the cytosol280. Furthermore, several members of the CYP450 
class are bimodally targeted proteins, hence they can be present in multiple cellular 
































































3.4.6.2 Incorporation of drug metabolism in mitochondrial membrane assay 
In vitro drug metabolism assays often employ human liver microsomes, a well 
established and convenient way to mimic CYP-mediated metabolism, since they 
contain all CYP450 enzymes (as well as FMOs): homogenised liver samples are first 
centrifuged at lower force to obtain the S9 fraction, which contains a wide array of 
both Phase I and II enzymes; then, the S9 fraction is ultracentrifuged (commonly 
100,000g for at least one hour) to precipitate microsomes282.  
There are not many examples in the literature of “one-pot” assays that combine 
microsomal-driven metabolite formation with assessment of metabolism induced 
toxicity: these mostly take the form of gel-encapsulated microsomes on silica/quartz 
plates that are physically and directly connected to cytotoxicity assays283-286. Figure 
3.12 summarises the protocol to incorporate drug microsomal incubations in the 
NADH:O2 assay with mitochondrial membranes: drugs were incubated at a 
concentration that would give at least 50% inhibition in the assay (or the highest 
available concentration permitted by compound stocks concentration).  
 
Figure 3.12. Schematic procedure for incorporating microsomal metabolism into the 
NADH:O2 assay. The drug is incubated with a NADPH-regenerating system that also feeds a 
separate intraluminal NADP+ pool coupled to reductase enzymes. MgCl2 is added to support 
NADPH binding to P450 reductase, EDTA prevents lipid peroxidation and SOD/CAT stop 
ROS from building-up excessively. G6P, glucose 6-phosphate; δ-6-GPL, 6-phosphoglucono-






















Adapting a typical microsomal protocol so that the outcome (i.e. microsomal 
incubation of the drug) could be subsequently employed in a NADH:O2 assay to test 
metabolism-induced toxicity was challenging: many variables were taken into 
consideration in order to optimise the final procedure and whose main points are 
explained below. 
• Even though carbonate buffer would more appropriately reflect an in vivo 
environment, the experimental difficulties that would be encountered usually 
lead one to choose phosphate buffer (other buffers can affect CYP450 
activity)287. 
• Since NADPH is needed for CYP450 activity, it needs to be introduced in the 
microsomal incubation, either directly or via a NADPH-generating system with 
appropriate cofactors: isocitrate dehydrogenase with isocitrate or glucose 6-
phosphate dehydrogenase with glucose 6-phosphate (G6P). It was recently 
found that carbonyl reductase activity in microsomes (especially from the 
enzyme 11β-hydroxysteroid dehydrogenase type 1) is localised inside the 
lumen, to where NADPH and NADP+ do not have easy access: G6P can easily 
enter this milieu by a transporter protein and feed a separate intraluminal 
NADP+ pool coupled to reductase enzymes 288 . A G6P-driven NADPH-
generating system is, therefore, a better choice to feed CYP450 in microsomal 
incubations than just NADPH. Assays with activated microsomes always 
exhibited 30 to 50% higher absorbances at 340 nm than the assays with 
inactivated microsomes, indicating that NADPH (whose UV spectrum is 
identical to NADH) had been formed during the incubation.   
• EDTA was added to curtail NADPH- and iron-dependent lipid peroxidation 
which could degrade CYP450289. 
• A low microsomal protein concentration (0.4 mg mL-1, where the common 
range in the literature is 1-2 mg mL-1) was used to prevent the phenomenon of 
nonspecific binding, whereby (especially hydrophobic) compounds bind to the 
lipid-protein milieu of the microsomal membrane and are not metabolised290. 
• Drugs dissolved in organic solvents as stocks were added to the incubation 
making sure that the overall concentration of the solvent was less than 0.5%: a 
concentration higher than 1% can be severely detrimental to CYP450 
metabolism and activity291.  
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• Several organic solvents were trialled for quenching and even though lowering 
the temperature below water freezing point would be enough, rather than 
organic solvent addition 292, the latter is preferable because microsomal proteins 
denature and precipitate out of solution fully: this releases all of the substrates 
and products and removes a source of artefacts in the NADH:O2 assay (i.e. 
microsomes that are still active can oxidise NADPH and also, to a lower extent, 
NADH, leading to overestimation of rates). Diethyl ether was chosen because of 
its extremely limited chemical reactivity and ease of removal via evaporation. 
• Human liver microsomes are known to generate significant amounts of ROS in 
the presence of NADPH and NADH as reductant293, and this (combined with 
consumption of endogenous substrate) could explain the about 10 times higher 
NADPH-consumption rate than the actual drug-to-metabolite conversion rate294: 
superoxide dismutase and catalase were therefore added to avoid build-up of 
species with a potential for metabolite degradation295,296. 
• MgCl2 is added to support the binding of NADPH to P450 reductase297.  
• The incubations were all carried out in amber glass vials to prevent metabolite 
photodegradation and interaction with plastic298. 
• The literature describes many different centrifugation speeds to pellet the 
microsomal fraction out of the incubation mixture: 5000 x g was deemed 
enough to remove the vast majority of microsomes and not too much to degrade 
metabolites in the processf. 
• The drug incubation time with microsomes, 6 hours, was much longer than a 
typical microsomal protocol 299 : this was done to ensure that the 
biotransformation reactions went to completion and also to exhaust the above-
mentioned NADH oxidase activity of any microsomal protein that could survive 
the later stages of the process and that could, ultimately, affect the results of the 
NADH:O2 assay. 
The results for a test set of compounds are shown in Figure 3.13: microsomes were 
activated with G6P and NADP+ and the (drug-inhibited) NADH:O2 specific activity 
with inactivated microsomes signifies the amount of drug that has survived the 
incubation process. Rotenone was added for comparison and, interestingly, exhibited 
                                               
f During preliminary experiments, it was found that some drugs like Efavirenz, Capsaicin and Fenofibrate 
maintained their potency towards the NADH:O2 pathway after dilution in aqueous buffer but lost it almost 
completely after centrifugation at 10,000 x g for 10 minutes. 
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the highest deactivation (dihydro-rotenone and Deguelin were also detoxified to a 
similar extent). The only drugs in the library that after metabolism caused a 
significantly weaker inhibition than the corresponding parent compounds are 
Papaverine, Nefazodone, Capsaicin and Promazine. Chlorpromazine and Desipramine 
exhibited similar residual activity regardless of whether microsomes were activated or 
not. All of the other drugs exhibited no inhibition: evidently these compounds are not 
compatible with the microsome protocol, possibly due to aqueous degradation.  
 
Figure 3.13. Compounds that cause a lower inhibition of the NADH:O2 assay after 
microsomal metabolism. When microsomes are activated with NADPH, their catalytic 
activity transforms papaverine, nefazodone, capsaicin and rotenone to such an extent (greatest 
in rotenone) to contain their toxicity as captured by the NADH:O2 assay and as shown by the 
blue line for nefazodone. Statistical significance expressed as ****, p ≤ 0.0001; ***, p ≤ 
0.001; **, p ≤ 0.01; *, p ≤ 0.05. Error bars are SEM of triplicates. 
These results indicate that those compounds become less toxic (at least from an 
OXPHOS perspective) once CYP450 are involved. However, for some drugs, 
CYP450-mediated activity via the proposed protocol could be so slow that 
metabolites do not form in appreciable amounts during the incubation period and, 
therefore, what is mostly left is the parent drug; an alternative explanation is that 
metabolites are as damaging to the complex I-IV pathway as their corresponding 

























































































investigations at this point, but mass spectrometry could be used in order to discern 
how extensive the metabolism of compounds in these incubations is, and hence to be 
able to draw some conclusions on metabolite toxicity. The intensity of the parent drug 
peak in the incubation with inactivated microsomes would be compared to the 
intensity of the same peak in the incubation with activated microsomes and this 
should be enough to tell the extent of CYP450 mediated metabolism; additionally, the 
presence of peaks at +16 and +32 compared to the parent drug peak in the activated 
microsome product would be diagnostic of typical CYP450 metabolism (i.e. addition 
of one or two oxygens). 
3.5 Discussion 
3.5.1 Types of inhibition 
The data collected permit an evaluation of the type of inhibition the drugs elicit on the 
respiratory chain. Criteria were defined for potency (NADH:O2 IC50 less than 15 µM, 
see Table 3.1) and (lack of) specificity towards complex I (succinate:O2 inhibition 
greater than 15% and ratio of NADH:dQ over NADH:O2 IC50 values greater than 5, 
see Table 3.2). Potent and specific complex I inhibitors (7 drugs) tick off only the 
former indicator, whereas potent and specific inhibitors of the II-IV pathway (3 drugs) 
tick off all three of them. Furthermore, if a drug exhibits just potency and significant 
inhibition of succinate:O2 it is classified as an OXPHOS inhibitor (Fenofibrate and 
Sunitinib, the low NADH:dQ/NADH:O2 ratio indicates that complex I is involved 
too). Finally, lack of potency but presence of both specificity indicators defines a 
specific inhibitor of the II-IV pathway (Fluphenazine). This drug classification is 
presented in Table 3.7, along with data from Seahorse and molecular charge at 
physiological pH. 
Balijepalli et al.300 found that Haloperidol is indeed a specific and potent inhibitor of 
complex I in mouse brain mitochondria: also in line with this work, Chlorpromazine 
was found to be a specific inhibitor and Clozapine did not inhibit appreciably 
complex I (see Table 3.7). Fluphenazine, on the other hand, was found to be as potent 
an inhibitor of complex I as Chlorpromazine, perhaps an effect of Fluphenazine being 
more capable of inflicting oxidative damage to the enzyme in mouse brain, according 
to their proposed mechanism of inhibition.  
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Tamoxifen is the only drug that is classified as a potent and specific complex II-IV 
inhibitor and, at the same time, elicits its cellular effects via an OXPHOS type of 
inhibition (see Table 3.7). Indeed, Tamoxifen is a major contributor to drug-induced 
liver injury through several mechanisms of mitochondrial toxicity301 and was found to 
electrophoretically accumulate in mitochondria302,303. Theodossiou et al.304 recently 
reported that its mechanism of toxicity involves redox cycling of its oxidative 
metabolites around complex III: Fe centres may participate in such coupling, 
generating Fe2+ and, ultimately, hydroxyl radical OH· à la Fenton. This could mean 
that, given the cellular effects detected by Tamoxifen in this work, HeLa cells possess 
enough drug-metabolising enzymes to physiologically mimic some pharmacological 
events (see section 3.4.4). 
From the experimental findings presented here it can be concluded that the selected 
drugs indeed inhibit complex I to different extent and degree of specificity: the 
method applied for their selection was successful and the FDLabel is a reliable 
database for identifying culprits in OXPHOS-related drug-induced mitochondrial 
dysfunction. 
3.5.2 Chemical structures 
The drugs exhibit some common structural features that might play a role in their 
inhibitory potency. For instance, dibenzoheterocycles (a ring with at least an 
heteroatom flanked by two benzene rings) are included in Chlorpromazine, 
Fluphenazine, Trifluoperazine (first generation antipsychotics with phenothiazine 
moiety), Clozapine and Desipramine (second generation antipsychotic and a major 
metabolite of tricyclic antidepressant or TCA, respectively, both with a dibenzazepine 






 POTENCY (LACK OF) SPECIFICITY 
Type of inhibition Cellular effect Seahorse Charge  NADH:O2 IC50 < 15 µM 
Succinate:O2 
% inhibition > 15% 
(NADH:dQ/NADH:O2) 
IC50 >5 
Chlorpromazine ✓   Potent and specific CI FAO P 
Desipramine     FAO P 
Fluphenazine  ✓ ✓ Specific towards II-IV CELL DIES P 
Flutamide     OXPHOS N 
Fenofibrate ✓ ✓  OXPHOS FAO Neutral 
Estradiol ✓   Potent and specific CI NONE Neutral 
Papaverine ✓   Potent and specific CI OXPHOS P 
Bupivacaine     ? P 
Amiodarone ✓ ✓ ✓ Potent and specific II-IV ? P 
Rosiglitazone     OXPHOS Neutral 
Nefazodone ✓   Potent and specific CI OXPHOS Neutral 
Carvedilol ✓   Potent and specific CI ? P/Neutral 
Tamoxifen ✓ ✓ ✓ Potent and specific II-IV OXPHOS P 
Clozapine     CELL DIES P/Neutral 
Buspirone     OXPHOS P 
Haloperidol ✓   Potent and specific CI NONE P 
Sunitinib ✓ ✓  OXPHOS / P 
Trifluoperazine ✓ ✓ ✓ Potent and specific II-IV CELL DIES P 
Capsaicin     OXPHOS Neutral 
Doxorubicin  ✓ / / / P 
Efavirenz ✓   Potent and specific CI OXPHOS Neutral 
Table 3.7. Summary of relevant data for drugs featured in this work. By combining data for potency (Table 3.1) and specificity (Table 3.2), it is possible 
to determine the type of inhibiton pattern drugs exert in the respiratory chain. Cellular effects (Seahorse, Table 3.5) and charge at physiological pH (Table 
3.6) are also presented. Green cells indicate which drug therapeutic concentration is higher than its corresponding NADH:O2 IC50 level.
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Figure 3.14. Dibenzoheterocycles and o-dialkoxy containing molecules in the library. 
The compounds core is a ring with at least an heteroatom flanked by two benzene rings. 
Carvedilol, Capsaicin and Papaverine possesses a feature in common with rotenone, the o-
dialkoxy benzene ring (highlighted in red). 
All of these drugs except Carvedilol share some inhibitory trends: they possess fairly 
low IC50 values (both in NADH:O2 and NADH:dQ assays), inhibited the complex II 
pathway to different degrees (even though their benzoheterocycle moiety does not 
seem to correlate with the succinate:O2 assay) and exhibited a strong OCR inhibition. 
Carvedilol, instead, has the lowest IC50 among the drugs with a tricyclic moiety (but 
also the lowest OCR inhibition, which might indicate that it does not penetrate cells 
easily), and this can be ascribed to another common structural feature of some of the 
drugs, the A-ring rotenone-like o-dialkoxy benzene moiety, present in Capsaicin and 
Papaverine too (a benzene ring with 2 alkyl groups ortho to each other, see Figure 
3.14). The fact that only Papaverine possesses such a moiety (actually two) with the 
same alkyl substitution pattern as in rotenone (i.e. two methoxy groups) is reflected in 
its very low IC50 and high OCR inhibition compared to Capsaicin and Carvedilol. 
This dimethoxy substitution pattern in rotenone seems to be specific for complex I in 
bovine and not in other species, e.g. potato tuber and Escherichia coli306. See chapter 
4 for structural classification of FDA-approved drugs and chapter 5 for a SAR study 
on rotenone both based on this feature. 
3.5.3 Mitochondriotropics 
Drug accumulation in subcellular compartments is an important topic in 




















































the unwanted recipients. This is the case of weakly basic drugs that accumulate in 
acidic lysosomes on account of their being membrane-permeable when uncharged and 
membrane-impermeable when ionised: this phenomenon (referred as ion trapping or 
lysosomotropism) is one of the causes of anticancer multidrug resistance307. As for 
drug mitochondrial accumulation, mitochondriotropics were described as compounds 
with a delocalised positive charge that accumulate due to the electrochemical gradient 
across the IMM but their definition was extended to any agent that targets 
mitochondria irrespective of charge and accumulation308.  
A study by Horobin et al.309 challenged the traditional view of mitochondriotropics as 
mostly compounds with delocalised positive charge that target mitochondria and 
accumulate within them. They generated a dataset of 110 known mitochondriotropics 
from the literature and discovered that only about a third were lipophilic cations, as 
many compounds were acids. Amphiphilicity was not a molecular property for 
targeting mitochondria since 2/3 of the dataset was either weakly or not amphiphilic 
at all. A more recent cheminformatics structure-localisation relationship study was 
carried out by the Rosania group in order to identify unique physicochemical 
properties of compounds that would explain their subcellular accumulation 
patterns310. They stratified the compounds with known subcellular localisation into 
low (less than 500 Da) and high (more than 500 Da) molecular weight with the aim of 
better identifying such patterns: they concluded that mitochondrial accumulation 
exhibited opposite patterns in the two categories, increasing with molecular weight 
below the threshold and decreasing with molecular weight above the threshold. This 
could hint at an optimum drug molecular weight for mitochondrial accumulation close 
to 500 Da but also advise caution when fluorophores probes are attached to 
compounds for detecting their subcellular accumulation: probes (and more generally 
any chemical modification aimed at increasing mitochondriotropism) can alter 
physicochemical properties of the compound, hence influencing its organelle targeting 
paradigm which also depends on the cytoskeletal network, dissolved macromolecules 
and other dispersed organelles311. It is interesting to note that Fluphenazine and 
Trifluoperazine have both a molecular weight between 400 and 500 Da and they both 
cause cell death, but this is probably due to their very similar structure (see Figure 
3.14). Molecular weight does not seem to be a good predictor of mitochondrial 
targeting in the low range either, since the drugs with less than 300 Da (Desipramine, 
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Flutamide, Estradiol and Bupivacaine) all exhibit different cellular effects see (Table 
3.5 and Table 3.6). 
3.5.4 Known metabolism of drugs 
Rotenone and Deguelin are primarily metabolised by CYP3A4 and CYP2C19 in 
human microsomes and their major metabolites are Rotenolone and Tephrosin, 
respectively312: their IC50 in NADH:O2 membranes is 132 and 84 nM, much higher 
than their corresponding parent compounds, 8 and 12 nM respectively (see chapter 5) 
and this is reflected in the loss of inhibitory potency upon activation (see Figure 3.13). 
Figure 3.15 shows the main human metabolites of Capsaicin313, Papaverine314,315 and 
Nefazodone316 with parent compounds in black, metabolites in orange. Given their 
minor structural changes and loss of potency upon microsomal metabolism, it seems 
that significant binding interactions with complex I are found in the rotenone-like o-
dialkoxy moiety of Papaverine and in the isopropyl unit of Capsaicin. Nefazodone 
undergoes a drastic modification and likely the m-chloro benzene moiety is key to 
effective complex I binding. Interestingly, biotransformation of these compounds 
generates more hydrophilic metabolites, as expressed by their clogP values, see 
Figure 3.15, (the same happens during the biotransformation of Rotenone and 
Deguelin into their major metabolites, from 3.3 to 2.7 in terms of clogP for both, see 
chapter 5). This suggests that the binding sites for these compounds could be located 
in the membrane domain of complex I.   
 
Figure 3.15. Major products of human metabolism for Capsaicin, Papaverine and 
Nefazodone. Nefazodone undergoes a substantial excision while Capsaicin and Papaverine 
metabolic changes are minor. Parent compounds are shown in black, metabolites are shown in 
































































































The main experimental findings obtained in this work are summarised for each drug 
in Table 3.7. Most of the compounds chosen with the method proposed in this chapter 
turned out to be potent OXPHOS inhibitors with different degrees of specificity 
towards complex I: their characterisation was thorough, both in terms of biological 
systems and variety of assays performed. Ideally the methodology could be applied to 
any mitochondrial enzyme suspected to be the culprit of drug-induced mitochondrial 
dysfunction with the aim of identifying relevant toxicophores. In this regard, complex 
I inhibition does not seem to be restricted to a specific molecular scaffold (at least 
outside the flavin site), and this highlights the pharmacological relevance of this 
enzyme. Furthermore, the overall findings have been extremely useful to lay out a 
protocol of assays to be subsequently used to characterise a commercial library of 
approved drugs in chapter 4.  
Specificity of inhibition was tested by comparing the effects of the drugs to two 
different biochemical pathways, complex I-IV (with NADH:O2 oxidoreduction assay) 
and complex II-IV (with succinate:O2 oxidoreduction assay), and it was discovered 
that very few drugs (Amiodarone, Tamoxifen and Sunitinib) could target, to some 
extent, the second pathway: this proves that the FDALabel database, in tandem with 
an extensive literature search, is a reliable method for obtaining an appropriate library 
of drugs to assess complex I-driven drug-induced mitochondrial dysfunction.  
Flavin-site directed assays failed to detect any substantial patterns, indicating that the 
main target of the drugs lies somewhere else in complex I.  
The Seahorse experiment in HeLa cells showed that drugs exhibited diverse effects in 
cells, demonstrating that transport mechanisms (irrespective of pKa and charge) are 
important for drug toxicity. 
Finally, the role of drug metabolism was assessed with microsomes: for some drugs, it 
resulted in considerable decrease in potency towards the NADH:O2 pathway. Even 
though the results are encouraging, mass spectrometry is needed to confirm the 
viability of such a novel methodology. 
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3.7 Appendixes  
3.7.1 Compounds obtained by intersecting complex I inhibitors 
and FDALabel database search (liver and extraliver side 
effects) 
Drugs in common between the two side effects: Amiodarone, Amitriptyline, Aspirin, 
Citalopram, Clozapine, Ciprofloxacin, Desipramine, Divalproex, Doxorubicin, 
Efavirenz, Estradiol, Fenofibrate, Gemfibrozil, Ibuprofen, Ifosfamide, Indomethacin, 
Ketoconazole, Metformin, Mirtazapine, Nefazodone, Olanzapine, Paroxetine, 
Pioglitazone, Piroxicam, Propofol, Rosiglitazone, Sevoflurane, Simvastatin, 
Sorafenib, Tamoxifen, Tretinoin, Valproate. 
Drugs exclusive to liver side effects: Bupivacaine, Capsaicin, Carvedilol, 
Chlorpromazine, Fluphenazine, Flutamide, Halothane, Isoflurane, Meperidine, 
Papaverine, Probenecid, Ranolazine. 
Drugs exclusive to extraliver side effects: Buspirone, Haloperidol, Imipramine, 
Methamphetamine, Nitroglycerin, Risperidone, Sunitinib, Tetracycline. 
3.7.2 Complex I inhibitors obtained from the literature 
Alpha-Tocopherol Succinate, 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine, 2-
Methoxyestradiol, 2,4-Dinitrophenol, Acrolein, Alpidem, Amiodarone, Amitriptyline, 
Amobarbital, Ampicillin, Anandamide, Annonacin, Apigenin, Artemisinin, Aspirin, 
Aureothin, Bisphenol A Diglycidyl Ether, Basic Red 2, Benzamil, Benzimidazole, 
Berberine, Bezafibrate, Buformin, Bupivacaine, Buspirone, Laureth-8, Capsaicin, 
Carvedilol, Celastrol, Chlorpromazine, Ciprofloxacin, Citalopram, Clofibrate, 
Clofibric Acid, Clozapine, Chromone, Cianidanol, Ciglitazone, Cinnarizine, 
Ciprofibrate, Cubebin, Cyhalothrin, Deacetylketoconazole, Deguelin, Dequalinium 
Chloride, Desethylamiodarone, Desipramine, Dichlorvos, Diclofenac, 
Dicyclohexylcarbodiimide, Diospyrin, Diphenyleneiodonium, Doxorubicin, Ebselen, 
Efavirenz, Eipa, Epicatechin, Epicatechin Gallate, Epigallocatechin, Epigallocatechin 
Gallate, Estradiol, Farnesol, Fenazaquin, Fendiline Hydrochloride, Fenofibrate, 
Fenpyroximate, Flunarizine, Fluphenazine, Flutamide, Gallocatechin, Gemfibrozil, 
Gossypol, Haloperidol, Halothane, Ibuprofen, Idebenone, Ifosfamide, Imipramine, 
Indomethacin, Isoflurane, Isoproterenol, Kaempferol, Kanamycin, Ketamine, 
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Ketoconazole, Lauryl Sulfate, Malvidin Chloride, Mdma, Meperidine, Metformin, 
Methamphetamine, Methionine, Methoxychlor, Miconazole, Mirtazapine, Mucidin, 
N-Methyl-4-Phenylpyridinium, N-Methyl-L-Aspartic Acid, Nanafrocin, Naringenin, 
Nefazodone, Nitroglycerin, O-Phenanthroline, Olanzapine, Oxidopamine, Palmidrol, 
Papaverine, Paroxetine, Perhexiline, Phenethylamine, Phenformin, Pioglitazone, 
Piroxicam, Polymyxin B, Potassium Dichromate, Prasterone, Probenecid, Propofol, 
Pyridaben, Pyrimidifen, Ranolazine, Resveratrol, Rhein, Risperidone, Rosiglitazone, 
Pyriminil, Pyrocatechol, Pyrvinium Pamoate, Quercetin, Quinazoline, Sevoflurane, 
Simvastatin, Sodium Chromate, Sodium Palmitate, Sorafenib, Sunitinib, Tacrine, 
Tamoxifen, Tebufenpyrad, Tetracycline, Thioridazine, Thiothixene , Tolfenpyrad, 
Tretinoin, Trichloroethylene, Trifluoperazine, Troglitazone, Valproic Acid, 
Verticipyrone, Zinc Chromate. 
3.7.3 Drugs from FDALabel (liver side effects) 
Abacavir Sulfate, Abatacept, Acamprosate Calcium, Acarbose, Acetaminophen, 
Acetazolamide, Acetylcysteine, Acheta Domesticus, Acitretin, Acyclovir, 
Adalimumab, Adapalene, Adefovir Dipivoxil, Ado-Trastuzumab Emtansine, Agave 
Sisalana Fiber, Albendazole, Albumin Aggregated, Albumin Human, Aldesleukin, 
Aliskiren Hemifumarate, Allopurinol, Allopurinol Sodium, Alosetron Hydrochloride, 
Alpha 1-Proteinase Inhibitor Human, Alprazolam, Alprostadil, Ambrisentan, 
Ambrosia Artemisiifolia Pollen, Ambrosia Trifida Pollen, American Chestnut, 
Amiloride Hydrochloride, Aminocaproic Acid, Aminophylline, Aminosalicylic Acid, 
Amiodarone Hydrochloride, Amitriptyline Hydrochloride, Amlodipine Besylate, 
Amoxapine, Amoxicillin, Amoxicillin Sodium, Amphotericin B, Anastrozole, 
Anidulafungin, Antihemophilic Factor Human, Antithrombin Alfa, Antithrombin Iii 
Human, Aprotinin, Arabica Coffee Bean, Arginine, Aripiprazole, Armodafinil, 
Artemether, Artemisia Douglasiana Pollen, Ascorbic Acid, Aspirin, Atazanavir 
Sulfate, Atenolol, Atomoxetine Hydrochloride, Atorvastatin Calcium Trihydrate, 
Atovaquone, Atropine Sulfate, Auranofin, Azathioprine, Azithromycin Dihydrate, 
Azithromycin Monohydrate, Azithromycin, Unspecified Form, Aztreonam, Bacillus 
Calmette-Guerin Substrain Connaught Live Antigen, Bacillus Calmette-Guerin 
Substrain Tice Live Antigen, Balsalazide Disodium, Bedaquiline Fumarate, 
Belatacept, Benazepril Hydrochloride, Bendroflumethiazide, Benzalkonium Chloride, 
Betamethasone, Betamethasone Acetate, Betamethasone Sodium Phosphate, 
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Bicalutamide, Bisoprolol Fumarate, Bluefish, Boceprevir, Bortezomib, Bosentan, 
Bosutinib Monohydrate, Brimonidine Tartrate, Brinzolamide, Budesonide, 
Budesonide (11.Beta.,16.Alpha.(S)), Bumetanide, Bupivacaine Hydrochloride, 
Buprenorphine, Buprenorphine Hydrochloride, Bupropion Hydrobromide, Bupropion 
Hydrochloride, Busulfan, Butalbital, Caffeine, Calcitonin Salmon, Canakinumab, 
Candesartan Cilexetil, Capecitabine, Capreomycin Sulfate, Capsaicin, Captopril, 
Carbamazepine, Carbidopa, Carvedilol, Carvedilol Phosphate, Casein, Caspofungin 
Acetate, Cefaclor, Cefazolin Sodium, Cefdinir, Cefixime, Cefoperazone, Cefotaxime 
Sodium, Cefpodoxime Proxetil, Cefprozil, Ceftaroline Fosamil, Ceftriaxone Sodium, 
Cefuroxime Axetil, Celecoxib, Cephalexin, Cephalexin Anhydrous, Certolizumab 
Pegol, Cetirizine Hydrochloride, Cevimeline Hydrochloride, Chenodiol, Chloroquine 
Phosphate, Chlorothiazide, Chlorothiazide Sodium, Chlorpheniramine Maleate, 
Chlorpromazine Hydrochloride, Chlorpropamide, Chlorthalidone, Cholestyramine, 
Choline, Choline Fenofibrate, Choline Magnesium Trisalicylate, Cidofovir, Cilastatin 
Sodium, Cimetidine, Cimetidine Hydrochloride, Ciprofloxacin, Ciprofloxacin 
Hydrochloride, Citalopram Hydrobromide, Citric Acid Monohydrate, Clarithromycin, 
Clavulanate Potassium, Clavulanic Acid, Clindamycin, Clindamycin Hydrochloride, 
Clindamycin Palmitate Hydrochloride, Clindamycin Phosphate, Clomiphene Citrate, 
Clomipramine Hydrochloride, Clonazepam, Clonidine, Clonidine Hydrochloride, 
Clopidogrel Bisulfate, Clozapine, Coagulation Factor Ix Human, Coagulation Factor 
Vii Human, Coagulation Factor X Human, Cobicistat, Codeine Phosphate, Codeine 
Sulfate, Colchicine, Corcorus Capsularis Fiber, Corticotropin, Cortisone Acetate, 
Cotton Seed, Cow Milk, Cupric Chloride, Cupric Oxide, Cyanocobalamin, 
Cyclobenzaprine Hydrochloride, Cyclophosphamide, Cyclosporine, Cyproheptadine 
Hydrochloride, Dacarbazine, Dactinomycin, Dalfopristin, Danazol, Dantrolene 
Sodium, Dapsone, Darbepoetin Alfa, Darunavir Ethanolate, Dasatinib, Daunorubicin 
Citrate, Deferasirox, Deferiprone, Deferoxamine Mesylate, Delavirdine Mesylate, 
Demeclocycline Hydrochloride, Deracoxib, Dermatophagoides Farinae, 
Dermatophagoides Pteronyssinus, Desflurane, Desipramine Hydrochloride, 
Desirudin, Desloratadine, Desogestrel, Desvenlafaxine, Desvenlafaxine Succinate, 
Dexamethasone, Dexamethasone Phosphate, Dexamethasone Sodium Phosphate, 
Dexlansoprazole, Dextromethorphan Hydrobromide, Diatrizoate Sodium, Diazepam, 
Diclofenac Epolamine, Diclofenac Potassium, Diclofenac Sodium, Dicloxacillin 
Sodium, Didanosine, Diflunisal, Digoxin, Dihydrocodeine Bitartrate, Diltiazem 
 93 
Hydrochloride, Dimyristoylphosphatidylcholine, Dimyristoylphosphatidylglycerol, 
Diphenhydramine Citrate, Diphenhydramine Hydrochloride, Diphenoxylate 
Hydrochloride, Dipyridamole, Disopyramide Phosphate, Disulfiram, Divalproex 
Sodium, Docetaxel, Docetaxel Anhydrous, Docusate Sodium, Dolutegravir Sodium, 
Donepezil Hydrochloride, Dorzolamide Hydrochloride, Doxazosin Mesylate, 
Doxorubicin Hydrochloride, Doxycycline, Dronedarone, Drospirenone, Duloxetine 
Hydrochloride, Edetate Calcium Disodium, Efavirenz, Egg Phospholipids, Eletriptan 
Hydrobromide, Eltrombopag Olamine, Elvitegravir, Emtricitabine, Enalapril Maleate, 
Enalaprilat, Enflurane, Enfuvirtide, English Sole, Entacapone, Entecavir, Epirubicin 
Hydrochloride, Eprosartan Mesylate, Equine Thymocyte Immune Globulin, 
Erythromycin, Erythromycin Ethylsuccinate, Erythromycin Stearate, Erythropoietin, 
Escitalopram Oxalate, Esomeprazole Magnesium, Esomeprazole Sodium, 
Esomeprazole Strontium, Estradiol, Estradiol Acetate, Estradiol Cypionate, Estradiol 
Hemihydrate, Estradiol Valerate, Estrogens, Conjugated, Estrogens, Conjugated 
Synthetic A, Estrogens, Conjugated Synthetic B, Estrogens, Esterified, Estrone 
Sodium Sulfate, Estropipate, Eszopiclone, Etanercept, Ethacrynate Sodium, 
Ethacrynic Acid, Ethambutol Hydrochloride, Ethinyl Estradiol, Ethionamide, 
Etidronate Disodium, Etodolac, Etomidate, Etonogestrel, Etravirine, Everolimus, 
Exametazime, Exemestane, Ezetimibe, Factor Ix Complex, Factor Xiii Concentrate 
(Human), Famciclovir, Famotidine, Febuxostat, Felbamate, Felis Catus Dander, Felis 
Catus Hair, Felodipine, Fenofibrate, Fenofibric Acid, Fenoprofen Calcium, Fentanyl, 
Ferrous Gluconate, Ferumoxides Non-Stoichiometric Magnetite, Fibrinogen Human, 
Filgrastim, Flax Seed, Floxuridine, Fluconazole, Flucytosine, Fludrocortisone 
Acetate, Fluorometholone, Fluoxetine Hydrochloride, Fluoxymesterone, 
Fluphenazine Decanoate, Fluphenazine Hydrochloride, Flurbiprofen, Flutamide, 
Fluvastatin Sodium, Fluvoxamine Maleate, Folic Acid, Fosamprenavir Calcium, 
Fosfomycin Tromethamine, Fosinopril Sodium, Fosphenytoin Sodium, Fulvestrant, 
Furosemide, Gabapentin, Gabapentin Enacarbil, Gadoxetate Disodium, Galantamine 
Hydrobromide, Gamma-Aminobutyric Acid, Ganciclovir Sodium, Gemcitabine 
Hydrochloride, Gemfibrozil, Gemifloxacin Mesylate, Gemtuzumab Ozogamicin, 
Gentamicin Sulfate, Glatiramer Acetate, Glimepiride, Glipizide, Glucarpidase, 
Glyburide, Glycerin, Goat Milk, Gold Sodium Thiomalate, Golimumab, Grain Mill 
Dust, Griseofulvin, Guanidine Hydrochloride, Haemophilus Influenzae Type B 
Capsular Polysaccharide Meningococcal Outer Membrane Protein Conjugate Antigen, 
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Haemophilus Influenzae Type B Strain 20752 Capsular Polysaccharide Tetanus 
Toxoid Conjugate Antigen, Halothane, Hepatitis A Virus Strain Cr 326F Antigen 
(Formaldehyde Inactivated), Hepatitis A Virus Strain Hm175 Antigen (Formaldehyde 
Inactivated), Hepatitis B Virus Subtype Adw Hbsag Surface Protein Antigen, 
Hepatitis B Virus Subtype Adw2 Hbsag Surface Protein Antigen, Histamine, 
Histamine Phosphate, Histidine, House Dust, Human Botulinum Neurotoxin A/B 
Immune Globulin, Human C1-Esterase Inhibitor, Human Clostridium Tetani Toxoid 
Immune Globulin, Human Cord Blood Hematopoietic Progenitor Cell, Human 
Cytomegalovirus Immune Globulin, Human Hepatitis B Virus Immune Globulin, 
Human Immunoglobulin G, Human Papillomavirus Type 11 L1 Capsid Protein 
Antigen, Human Papillomavirus Type 16 L1 Capsid Protein Antigen, Human 
Papillomavirus Type 16 L1 Capsid Protein Residues 2-471 Antigen, Human 
Papillomavirus Type 18 L1 Capsid Protein Antigen, Human Papillomavirus Type 18 
L1 Capsid Protein Residues 2-472 Antigen, Human Papillomavirus Type 6 L1 Capsid 
Protein Antigen, Human Rabies Virus Immune Globulin, Human Rho(D) Immune 
Globulin, Hydralazine Hydrochloride, Hydrochlorothiazide, Hydrocodone Bitartrate, 
Hydrocortisone, Hydrocortisone Acetate, Hydrocortisone Cypionate, Hydrocortisone 
Sodium Succinate, Hydroflumethiazide, Hydromorphone Hydrochloride, 
Hydroxyprogesterone Caproate, Ibritumomab Tiuxetan, Ibuprofen, Ifosfamide, 
Iloprost, Imatinib Mesylate, Imiglucerase, Imipenem, Indapamide, Indinavir Sulfate, 
Indomethacin, Infliximab, Interferon Alfa-2A, Interferon Alfa-2B, Interferon 
Alfacon-1, Interferon Beta-1A, Interferon Beta-1B, Interferon Gamma-1B, 
Ipilimumab, Irbesartan, Irinotecan Hydrochloride, Isocarboxazid, Isoflurane, 
Isometheptene Mucate, Isoniazid, Isosorbide Dinitrate, Isosorbide Mononitrate, 
Isotretinoin, Itraconazole, Ivermectin, Japanese Encephalitis Virus Strain Nakayama-
Nih Antigen (Formaldehyde Inactivated), Ketoconazole, Ketoprofen, Ketorolac 
Tromethamine, Khuskia Oryzae, Labetalol Hydrochloride, Lacosamide, Lamivudine, 
Lamotrigine, Lansoprazole, Leflunomide, Lenalidomide, Lepirudin, Letrozole, 
Leuprolide Acetate, Levetiracetam, Levocetirizine Dihydrochloride, Levodopa, 
Levofloxacin, Levonorgestrel, Levothyroxine, Levothyroxine Sodium, Lincomycin 
Hydrochloride, Lindane, Liothyronine, Liothyronine Sodium, Lisdexamfetamine 
Dimesylate, Lisinopril, Lomefloxacin Hydrochloride, Lomitapide Mesylate, 
Lopinavir, Losartan Potassium, Lovastatin, Loxapine Succinate, Lumefantrine, Lysine 
Hydrochloride, Magnesium Salicylate, Maraviroc, Measles Virus Strain Enders' 
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Attenuated Edmonston Live Antigen, Mebendazole, Mebrofenin, Meclofenamate 
Sodium, Medroxyprogesterone Acetate, Mefenamic Acid, Megestrol Acetate, 
Melopsittacus Undulatus Feather, Meloxicam, Melphalan Hydrochloride, Memantine 
Hydrochloride, Menthol, Meperidine Hydrochloride, Mephenytoin, Meprobamate, 
Mercaptopurine, Meropenem, Mesalamine, Mesna, Metformin Hydrochloride, 
Methadone Hydrochloride, Methazolamide, Methenamine, Methimazole, 
Methocarbamol, Methotrexate Sodium, Methyclothiazide, Methyl Aminolevulinate 
Hydrochloride, Methyl Salicylate, Methyldopa, Methyldopate Hydrochloride, 
Methylergonovine Maleate, Methylprednisolone, Methylprednisolone Acetate, 
Methylprednisolone Sodium Succinate, Methyltestosterone, Metoclopramide 
Hydrochloride, Metolazone, Metoprolol Succinate, Metoprolol Tartrate, Mexiletine 
Hydrochloride, Micafungin Sodium, Midazolam Hydrochloride, Mifepristone, 
Milnacipran Hydrochloride, Minocycline Hydrochloride, Mipomersen Sodium, 
Mirtazapine, Misoprostol, Mitoxantrone Hydrochloride, Mivacurium Chloride, 
Modafinil, Moexipril Hydrochloride, Montelukast Sodium, Morella Cerifera Pollen, 
Moricizine Hydrochloride, Morphine, Morphine Sulfate, Moxifloxacin 
Hydrochloride, Mumps Virus Strain B Level Jeryl Lynn Live Antigen, Muromonab-
Cd3, Mycophenolate Mofetil, Mycophenolate Sodium, Nabumetone, Nadolol, 
Nafcillin Sodium, Nalmefene Hydrochloride, Naloxone, Naloxone Hydrochloride, 
Naloxone Hydrochloride Dihydrate, Naltrexone, Naltrexone Hydrochloride, 
Nandrolone Decanoate, Naproxen, Naproxen Sodium, Nateglinide, Nefazodone 
Hydrochloride, Neisseria Meningitidis Group A Capsular Polysaccharide Diphtheria 
Toxoid Conjugate Antigen, Neisseria Meningitidis Group C Capsular Polysaccharide 
Diphtheria Toxoid Conjugate Antigen, Neisseria Meningitidis Group W-135 Capsular 
Polysaccharide Diphtheria Toxoid Conjugate Antigen, Neisseria Meningitidis Group 
Y Capsular Polysaccharide Diphtheria Toxoid Conjugate Antigen, Nelfinavir 
Mesylate, Nevirapine, Niacin, Niacinamide, Nicardipine Hydrochloride, Nifedipine, 
Nilotinib, Nilutamide, Nimodipine, Nisoldipine, Nitrofurantoin, Nitrofurantoin 
Monohydrate, Nizatidine, Norelgestromin, Norethindrone, Norethindrone Acetate, 
Norfloxacin, Nortriptyline Hydrochloride, Octreotide Acetate, Ofatumumab, 
Ofloxacin, Olanzapine, Olanzapine Pamoate, Olmesartan Medoxomil, Olsalazine 
Sodium, Omeprazole, Omeprazole Magnesium, Orlistat, Ormetoprim, Oseltamivir 
Phosphate, Oxaliplatin, Oxandrolone, Oxaprozin, Oxazepam, Oxcarbazepine, 
Oxycodone Hydrochloride, Oxycodone Terephthalate, Oxymetholone, Oxymorphone 
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Hydrochloride, Oxytetracycline Hydrochloride, Oxytocin, Paclitaxel, Palivizumab, 
Pamabrom, Pancuronium Bromide, Pantoprazole Sodium, Papaverine Hydrochloride, 
Paroxetine Hydrochloride Anhydrous, Paroxetine Hydrochloride Hemihydrate, 
Paroxetine Mesylate, Peginterferon Alfa-2A, Peginterferon Alfa-2B, Pegvisomant, 
Penicillamine, Penicillin G Potassium, Penicillin G Sodium, Pentamidine Isethionate, 
Pentazocine Hydrochloride, Pentoxifylline, Pergolide, Perindopril Erbumine, 
Periplaneta Americana, Perphenazine, Phenazopyridine Hydrochloride, Phenol, 
Phentermine Hydrochloride, Phenylephrine Bitartrate, Phenylephrine Hydrochloride, 
Phenyltoloxamine Citrate, Phenytoin, Phenytoin Sodium, Phytonadione, Pilocarpine 
Hydrochloride, Pindolol, Pinus Banksiana Pollen, Pioglitazone Hydrochloride, 
Piperacillin Sodium, Piroxicam, Pitavastatin Calcium, Poliovirus Type 1 Antigen 
(Formaldehyde Inactivated), Poliovirus Type 2 Antigen (Formaldehyde Inactivated), 
Poliovirus Type 3 Antigen (Formaldehyde Inactivated), Polythiazide, Ponatinib 
Hydrochloride, Posaconazole, Potassium Bicarbonate, Potassium Chloride, Potassium 
Phosphate, Monobasic, Povidone-Iodine, Pravastatin Sodium, Prazosin 
Hydrochloride, Prednisolone, Prednisolone Acetate, Prednisolone Sodium Phosphate, 
Prednisone, Probenecid, Prochlorperazine, Prochlorperazine Edisylate, 
Prochlorperazine Maleate, Progesterone, Proguanil Hydrochloride, Promethazine 
Hydrochloride, Propafenone, Propafenone Hydrochloride, Propofol, Propoxyphene 
Hydrochloride, Propoxyphene Napsylate, Propranolol Hydrochloride, 
Propylthiouracil, Protein C, Prothrombin, Pseudoephedrine Hydrochloride, 
Pseudoephedrine Sulfate, Pyrazinamide, Quinapril Hydrochloride, Quinidine 
Gluconate, Quinidine Sulfate, Quinine Sulfate, Quinupristin, Rabeprazole Sodium, 
Raltegravir Potassium, Ramelteon, Ramipril, Ranitidine Hydrochloride, Ranolazine, 
Regorafenib Monohydrate, Repaglinide, Reserpine, Ribavirin, Rifabutin, Rifampin, 
Rifapentine, Rilonacept, Rilpivirine Hydrochloride, Riluzole, Ritonavir, Rituximab, 
Rivaroxaban, Rivastigmine, Rivastigmine Tartrate, Ranolazine, Regorafenib 
Monohydrate, Repaglinide, Reserpine, Ribavirin, Rifabutin, Rifampin, Rifapentine, 
Rilonacept, Rilpivirine Hydrochloride, Riluzole, Ritonavir, Rituximab, Rivaroxaban, 
Rivastigmine, Rivastigmine Tartrate, Rizatriptan Benzoate, Rocuronium Bromide, 
Ropinirole Hydrochloride, Rosiglitazone Maleate, Rosuvastatin Calcium, Rubella 
Virus Strain Wistar Ra 27/3 Live Antigen, Rufinamide, Safflower Oil, Salicylamide, 
Salmonella Typhi Ty2 Vi Polysaccharide Antigen, Salsalate, Saquinavir Mesylate, 
Selegiline Hydrochloride, Sequoia Sempervirens Pollen, Sertraline Hydrochloride, 
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Sevoflurane, Sildenafil Citrate, Silver Sulfadiazine, Simvastatin, Sirolimus, Sitagliptin 
Phosphate, Sitotroga Cerealella, Sodium Acetate, Sodium Chloride, Sodium 
Phosphate, Dibasic, Anhydrous, Sodium Phosphate, Monobasic, Monohydrate, 
Sodium Salicylate, Sorafenib, Soybean Oil, Spinosad, Spironolactone, Stavudine, 
Sulfacetamide Sodium, Sulfadiazine, Sulfadimethoxine, Sulfamethizole, 
Sulfamethoxazole, Sulfasalazine, Sulfisoxazole Acetyl, Sulfur, Sulindac, Sumatriptan 
Succinate, Tacrolimus, Tacrolimus Anhydrous, Tadalafil, Tamoxifen Citrate, 
Tapentadol Hydrochloride, Tazobactam Sodium, Telaprevir, Telbivudine, 
Telithromycin, Telmisartan, Temozolomide, Tenofovir Disoproxil Fumarate, 
Terbinafine Hydrochloride, Teriflunomide, Testosterone, Testosterone Cypionate, 
Testosterone Enanthate, Thalidomide, Theophylline, Theophylline Anhydrous, 
Thioguanine, Thrombin Human, Thyroid, Unspecified, Tiagabine Hydrochloride, 
Ticarcillin Disodium, Ticlopidine Hydrochloride, Timolol Maleate, Tinzaparin 
Sodium, Tipranavir, Tizanidine, Tizanidine Hydrochloride, Tocilizumab, Tofacitinib 
Citrate, Tolazamide, Tolbutamide, Tolcapone, Tolmetin Sodium, Tolvaptan, 
Topiramate, Toremifene Citrate, Torsemide, Tramadol Hydrochloride, Trandolapril, 
Tranylcypromine Sulfate, Trazodone Hydrochloride, Tretinoin, Triamcinolone 
Acetonide, Triamcinolone Diacetate, Triamcinolone Hexacetonide, Triamterene, 
Trichophyton Mentagrophytes, Trichophyton Rubrum, Trientine Hydrochloride, 
Trifluoperazine Hydrochloride, Trimethadione, Trimethoprim, Tromethamine, 
Trovafloxacin Mesylate, Tuberculin Purified Protein Derivative, Tyrosine, Urochloa 
Mutica Pollen, Urokinase, Ursodiol, Valacyclovir Hydrochloride, Valdecoxib, 
Valganciclovir Hydrochloride, Valproate Sodium, Valproic Acid, Valsartan, 
Varicella-Zoster Virus Strain Oka/Merck Live Antigen, Vecuronium Bromide, 
Venlafaxine Hydrochloride, Verapamil Hydrochloride, Vitamin A Palmitate, Von 
Willebrand Factor Human, Voriconazole, Warfarin Sodium, Wine Grape, Zafirlukast, 
Zidovudine, Zileuton, Zinc Acetate, Zinc Oxide, Ziprasidone Hydrochloride, 
Zonisamide. 
3.7.4 Drugs from FDALabel (extraliver side effects) 
Abacavir Sulfate, Abiraterone Acetate, Acamprosate Calcium, Acetaminophen, 
Acitretin, Adalimumab, Adefovir Dipivoxil, Ado-Trastuzumab Emtansine, Agalsidase 
Beta, Albumin Human, Aldesleukin, Alemtuzumab, Alglucosidase Alfa, Aliskiren 
Hemifumarate, Allopurinol, Allopurinol Sodium, Almotriptan Malate, Alogliptin 
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Benzoate, Alteplase, Altretamine, Amiloride Hydrochloride, Aminocaproic Acid, 
Aminophylline, Amiodarone Hydrochloride, Amitriptyline, Amitriptyline 
Hydrochloride, Amlodipine Besylate, Amoxapine, Amphetamine Aspartate, 
Amphetamine Sulfate, Amphotericin B, Anagrelide Hydrochloride, Anhydrous Citric 
Acid, Antimony Potassium Tartrate, Aprepitant, Aripiprazole, Arsenic Trioxide, 
Asenapine Maleate, Asparaginase Erwinia Chrysanthemi, Aspirin, Atazanavir Sulfate, 
Atenolol, Atomoxetine Hydrochloride, Atorvastatin Calcium Trihydrate, Atovaquone, 
Atropine Sulfate, Auranofin, Azacitidine, Azathioprine, Azathioprine Sodium, 
Azithromycin Dihydrate, Azithromycin Monohydrate, Azithromycin, Unspecified 
Form, Bacillus Anthracis Strain V770-Np1-R Antigens, Baclofen, Balsalazide 
Disodium, Bedaquiline Fumarate, Benazepril Hydrochloride, Bendroflumethiazide, 
Benzphetamine Hydrochloride, Betamethasone, Betamethasone Acetate, 
Betamethasone Sodium Phosphate, Bexarotene, Bismuth Subcitrate Potassium, 
Bismuth Subsalicylate, Bisoprolol Fumarate, Boceprevir, Bortezomib, Bosutinib 
Monohydrate, Botulinum Toxin Type A, Brentuximab Vedotin, Brompheniramine 
Maleate, Buprenorphine, Bupropion Hydrobromide, Bupropion Hydrochloride, 
Buspirone Hydrochloride, Busulfan, Cabazitaxel, Cabozantinib S-Malate, Caffeine, 
Calcitriol, Calcium Chloride, Canagliflozin, Candesartan Cilexetil, Capecitabine, 
Captopril, Carbamazepine, Carbidopa, Carfilzomib, Carprofen, Caspofungin Acetate, 
Cefdinir, Ceftriaxone Sodium, Celecoxib, Certolizumab Pegol, Chenodiol, 
Chlorambucil, Chloroquine Phosphate, Chlorothiazide, Chlorothiazide Sodium, 
Chlorpheniramine Maleate, Chlorthalidone, Cholestyramine, Choline Fenofibrate, 
Chromic Chloride, Cidofovir, Cimetidine, Cimetidine Hydrochloride, Ciprofloxacin, 
Ciprofloxacin Hydrochloride, Cisatracurium Besylate, Cisplatin, Citalopram 
Hydrobromide, Clarithromycin, Clevidipine, Clofarabine, Clomiphene Citrate, 
Clomipramine Hydrochloride, Clonidine Hydrochloride, Clopidogrel Bisulfate, 
Clozapine, Cobicistat, Codeine Phosphate, Codeine Sulfate, Colchicine, Colesevelam 
Hydrochloride, Conivaptan Hydrochloride, Corticotropin, Cortisone Acetate, 
Crizotinib, Crofelemer, Cyclobenzaprine Hydrochloride, Cyclophosphamide, 
Cyclosporine, Cytarabine, Dabrafenib Mesylate, Dalfopristin, Danazol, Dapsone, 
Daptomycin, Darunavir Ethanolate, Dasatinib, Daunorubicin, Daunorubicin Citrate, 
Daunorubicin Hydrochloride, Decitabine, Deferasirox, Deferiprone, Delavirdine 
Mesylate, Demeclocycline Hydrochloride, Denosumab, Desflurane, Desipramine 
Hydrochloride, Desogestrel, Desvenlafaxine, Desvenlafaxine Succinate, 
 99 
Dexamethasone, Dexamethasone Phosphate, Dexamethasone Sodium Phosphate, 
Dexlansoprazole, Dexmethylphenidate Hydrochloride, Dexrazoxane, 
Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Dextrose Monohydrate, 
Diatrizoate Meglumine, Diatrizoate Sodium, Diazoxide, Diclofenac Potassium, 
Diclofenac Sodium, Didanosine, Difenoxin Hydrochloride, Digoxin, Dihydrocodeine 
Bitartrate, Diltiazem Hydrochloride, Dimyristoylphosphatidylcholine, Dl-, 
Dimyristoylphosphatidylglycerol, Dl-, Diphenhydramine Hydrochloride, 
Diphenoxylate Hydrochloride, Dipyridamole, Disopyramide Phosphate, Disulfiram, 
Divalproex Sodium, Docetaxel, Docetaxel Anhydrous, Dolasetron Mesylate, 
Donepezil Hydrochloride, Doxercalciferol, Doxorubicin Hydrochloride, Doxylamine 
Succinate, Drospirenone, Duloxetine Hydrochloride, Efavirenz, Egg Phospholipids, 
Eletriptan Hydrobromide, Elvitegravir, Emtricitabine, Enalapril Maleate, Enalaprilat, 
Enfuvirtide, Entacapone, Entecavir, Epirubicin Hydrochloride, Eprosartan Mesylate, 
Eribulin Mesylate, Erlotinib Hydrochloride, Ertapenem Sodium, Erythromycin, 
Erythromycin Ethylsuccinate, Erythromycin Stearate, Escitalopram Oxalate, 
Esomeprazole Magnesium, Esomeprazole Sodium, Esomeprazole Strontium, 
Estradiol, Estradiol Acetate, Estradiol Cypionate, Estradiol Hemihydrate, Estradiol 
Valerate, Estrogens, Conjugated, Estrogens, Conjugated Synthetic A, Estrogens, 
Conjugated Synthetic B, Estrogens, Esterified, Estropipate, Eszopiclone, Ethacrynate 
Sodium, Ethacrynic Acid, Ethambutol Hydrochloride, Ethinyl Estradiol, Ethiodized 
Oil, Etidronate Disodium, Etodolac, Etonogestrel, Etravirine, Everolimus, Exenatide, 
Ezetimibe, Febuxostat, Felbamate, Felodipine, Fenofibrate, Fenofibric Acid, 
Fenoprofen Calcium, Fentanyl, Fentanyl Citrate, Firocoxib, Flecainide Acetate, 
Fluconazole, Flucytosine, Fludarabine Phosphate, Fludrocortisone Acetate, Fluoxetine 
Hydrochloride, Flurbiprofen, Fluvastatin Sodium, Fluvoxamine Maleate, 
Fosamprenavir Calcium, Foscarnet Sodium, Fosinopril Sodium, Fosphenytoin 
Sodium, Furosemide, Gabapentin, Gadobenate Dimeglumine, Ganciclovir Sodium, 
Gefitinib, Gemfibrozil, Gemifloxacin Mesylate, Gentamicin Sulfate, Glatiramer 
Acetate, Glimepiride, Glipizide, Glutamine, Glyburide, Glycerin, Glycerol 
Phenylbutyrate, Glycopyrrolate, Gold Sodium Thiomalate, Griseofulvin, Guaifenesin, 
Haloperidol, Haloperidol Decanoate, Haloperidol Lactate, Hepatitis B Virus Subtype 
Adw Hbsag Surface Protein Antigen, Hetastarch, Human Albumin Microspheres, 
Human Papillomavirus Type 11 L1 Capsid Protein Antigen, Human Papillomavirus 
Type 16 L1 Capsid Protein Antigen, Human Papillomavirus Type 18 L1 Capsid 
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Protein Antigen, Human Papillomavirus Type 6 L1 Capsid Protein Antigen, 
Hydralazine Hydrochloride, Hydrochlorothiazide, Hydrocodone Bitartrate, 
Hydrocortisone, Hydrocortisone Acetate, Hydrocortisone Cypionate, Hydrocortisone 
Sodium Succinate, Hydroflumethiazide, Hydromorphone Hydrochloride, 
Hydroxychloroquine Sulfate, Hydroxyethyl Starch 130/0.4, Hydroxyurea, 
Hyoscyamine Sulfate, Ibuprofen, Icosapent Ethyl, Idarubicin Hydrochloride, 
Ifosfamide, Iloperidone, Imatinib Mesylate, Imipramine Hydrochloride, Imipramine 
Pamoate, Imiquimod, Indapamide, Indinavir Sulfate, Indomethacin, Insulin Aspart, 
Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Human, Insulin Lispro, 
Insulin Pork, Interferon Alfa-2A, Interferon Alfa-2B, Interferon Alfacon-1, Interferon 
Beta-1A, Interferon Beta-1B, Interferon Gamma-1B, Iodipamide Meglumine, 
Iodixanol, Iohexol, Iopamidol, Iopromide, Iothalamate Meglumine, Ioversol, 
Ioxaglate Meglumine, Ioxaglate Sodium, Ioxilan, Ipilimumab, Irbesartan, Irinotecan 
Hydrochloride, Isoniazid, Isosorbide Dinitrate, Isosorbide Mononitrate, Isotretinoin, 
Itraconazole, Ixabepilone, Ketoconazole, Ketoprofen, Ketorolac Tromethamine, 
Labetalol Hydrochloride, Lamivudine, Lamotrigine, Lanreotide Acetate, 
Lansoprazole, Leflunomide, Lenalidomide, Leuprolide Acetate, Levetiracetam, 
Levocarnitine, Levodopa, Levofloxacin, Levonorgestrel, Linagliptin, Linezolid, 
Liothyronine Sodium, Liraglutide, Lisdexamfetamine Dimesylate, Lisinopril, 
Lomefloxacin Hydrochloride, Lomitapide Mesylate, Lopinavir, Lorazepam, Losartan 
Potassium, Lovastatin, Loxapine, Lurasidone Hydrochloride, Magnesium Hydroxide, 
Magnesium Oxide, Magnesium Sulfate, Mannitol, Maprotiline Hydrochloride, 
Maraviroc, Maropitant Citrate, Mebrofenin, Mecasermin, Medroxyprogesterone 
Acetate, Mefenamic Acid, Megestrol Acetate, Melarsomine Dihydrochloride, 
Meloxicam, Memantine Hydrochloride, Meprobamate, Mesalamine, Metformin 
Hydrochloride, Methadone Hydrochloride, Methamphetamine Hydrochloride, 
Methotrexate Sodium, Methyclothiazide, Methyldopa, Methyldopate Hydrochloride, 
Methylphenidate, Methylphenidate Hydrochloride, Methylprednisolone, 
Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, 
Methyltestosterone, Metolazone, Metoprolol Succinate, Metoprolol Tartrate, 
Metronidazole, Mexiletine Hydrochloride, Mifepristone, Miglustat, Milnacipran 
Hydrochloride, Minocycline Hydrochloride, Mirtazapine, Misoprostol, Mitoxantrone 
Hydrochloride, Moexipril Hydrochloride, Montelukast Sodium, Morphine Sulfate, 
Moxifloxacin Hydrochloride, Mycophenolate Mofetil, Mycophenolate Sodium, 
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Nabumetone, Nadolol, Naloxone Hydrochloride, Naltrexone, Naltrexone 
Hydrochloride, Naproxen, Naproxen Sodium, Nefazodone Hydrochloride, 
Nelarabine, Nelfinavir Mesylate, Nesiritide, Nevirapine, Niacin, Nilotinib, 
Nitrofurantoin, Nitrofurantoin Monohydrate, Nitroglycerin, Norelgestromin, 
Norepinephrine Bitartrate, Norethindrone Acetate, Norfloxacin, Nortriptyline 
Hydrochloride, Octreotide Acetate, Ofloxacin, Olanzapine, Olanzapine Pamoate, 
Olmesartan Medoxomil, Olsalazine Sodium, Omega-3-Acid Ethyl Esters, 
Omeprazole, Omeprazole Magnesium, Oprelvekin, Orlistat, Oxaliplatin, Oxaprozin, 
Oxcarbazepine, Oxycodone Hydrochloride, Oxymorphone Hydrochloride, 
Oxytetracycline Hydrochloride, Paclitaxel, Paliperidone, Paliperidone Palmitate, 
Pancrelipase, Pancrelipase Amylase, Pancrelipase Lipase, Pancrelipase Protease, 
Pantoprazole Sodium, Paroxetine Hydrochloride Anhydrous, Paroxetine 
Hydrochloride Hemihydrate, Paroxetine Mesylate, Pasireotide, Pazopanib 
Hydrochloride, Pegaspargase, Peginterferon Alfa-2A, Peginterferon Alfa-2B, 
Pemetrexed Disodium, Penicillamine, Penicillin G Benzathine, Penicillin G Procaine, 
Pentamidine Isethionate, Pentazocine Hydrochloride, Pergolide, Perindopril 
Erbumine, Perphenazine, Pertuzumab, Phentermine Hydrochloride, Phenylephrine 
Hydrochloride, Pilocarpine Hydrochloride, Pimobendan, Pimozide, Pioglitazone 
Hydrochloride, Piperacillin Sodium, Piroxicam, Pitavastatin Calcium, Podofilox, 
Polythiazide, Pomalidomide, Ponatinib Hydrochloride, Posaconazole, Potassium 
Bromide, Potassium Chloride, Potassium Phosphate, Monobasic, Potassium Sulfate, 
Pramipexole Dihydrochloride, Pravastatin Sodium, Prazosin Hydrochloride, 
Prednisolone, Prednisolone Acetate, Prednisolone Sodium Phosphate, Prednisone, 
Pregabalin, Procainamide Hydrochloride, Progesterone, Propafenone, Propafenone 
Hydrochloride, Propofol, Propoxyphene Hydrochloride, Propoxyphene Napsylate, 
Propranolol Hydrochloride, Protriptyline Hydrochloride, Pseudoephedrine 
Hydrochloride, Pyrazinamide, Pyridoxine Hydrochloride, Pyrilamine Maleate, 
Quetiapine Fumarate, Quinapril Hydrochloride, Quinine Sulfate, Quinupristin, 
Rabeprazole Sodium, Raltegravir Potassium, Ramipril, Ranitidine Hydrochloride, 
Regadenoson, Repaglinide, Reserpine, Reteplase, Ribavirin, Rifampin, Rifapentine, 
Rilpivirine Hydrochloride, Riluzole, Risperidone, Ritonavir, Rivastigmine, 
Rivastigmine Tartrate, Rocuronium Bromide, Roflumilast, Ropinirole Hydrochloride, 
Rosiglitazone Maleate, Rosuvastatin Calcium, Rotigotine, Safflower Oil, Saquinavir 
Mesylate, Saxagliptin Hydrochloride, Secretin Human, Selegiline Hydrochloride, 
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Sertraline Hydrochloride, Sevoflurane, Sildenafil Citrate, Simvastatin, Sipuleucel-T, 
Sirolimus, Sitagliptin Phosphate, Sodium Benzoate, Sodium Bicarbonate, Sodium 
Chloride, Sodium Lactate, Sodium Nitroprusside, Sodium Phenylacetate, Sodium 
Phenylbutyrate, Sodium Phosphate, Dibasic, Anhydrous, Sodium Phosphate, 
Monobasic, Monohydrate, Sodium Picosulfate, Sodium Sulfate, Somatropin, 
Sorafenib, Sorbitol, Sotalol, Sotalol Hydrochloride, Soybean Oil, Spironolactone, 
Stavudine, Succinylcholine Chloride, Sulfadiazine, Sulfamethizole, 
Sulfamethoxazole, Sulfasalazine, Sulfisoxazole Acetyl, Sulindac, Sumatriptan, 
Sumatriptan Succinate, Sunitinib Malate, Tacrolimus, Tacrolimus Anhydrous, 
Tadalafil, Tamoxifen Citrate, Tapentadol Hydrochloride, Tazobactam Sodium, 
Teduglutide, Telaprevir, Telbivudine, Telithromycin, Telmisartan, Temsirolimus, 
Tenecteplase, Tenofovir Disoproxil Fumarate, Terbinafine Hydrochloride, 
Teriflunomide, Tetrabenazine, Tetracycline Hydrochloride, Thalidomide, 
Theophylline, Theophylline Anhydrous, Thiotepa, Ticlopidine Hydrochloride, 
Tigecycline, Tipranavir, Toceranib Phosphate, Tolcapone, Tolmetin Sodium, 
Tolvaptan, Topiramate, Torsemide, Tramadol Hydrochloride, Trametinib Dimethyl 
Sulfoxide, Trandolapril, Tretinoin, Triamcinolone Acetonide, Triamcinolone 
Diacetate, Triamcinolone Hexacetonide, Triamterene, Trientine Hydrochloride, 
Trilostane, Trimethoprim, Trimipramine Maleate, Trospium Chloride, Trovafloxacin 
Mesylate, Urokinase, Ursodiol, Valdecoxib, Valganciclovir Hydrochloride, Valproate 
Sodium, Valproic Acid, Valsartan, Vandetanib, Vardenafil Hydrochloride Trihydrate, 
Varenicline Tartrate, Venlafaxine Hydrochloride, Verapamil Hydrochloride, 
Vigabatrin, Vincristine Sulfate, Vinorelbine Tartrate, Voriconazole, Warfarin Sodium, 
Ziconotide Acetate, Zidovudine, Zinc Acetate, Ziprasidone Hydrochloride, 








4 Characterisation of complex I within drug-
induced mitochondrial dysfunction: the Enzo 
Library 
4.1 Introduction and aims 
The knowledge and methods developed in chapter 3 provided a basis for screening a 
much bigger set of drugs. The “Enzo SCREEN-WELL FDA approved drug library 
V2” was chosen for drug screening: the library includes 786 drugs that belong to 44 
different classes and well represents the universe of (FDA-approved) pharmaceuticals. 
By combining the ability of an assay to detect inhibition of complexes I-III-IV 
(NADH:O2 oxidoreduction) with another assay that detects inhibition of complexes 
II-III-IV (succinate:O2 oxidoreduction) it is possible to identify specific inhibitors of 
complex I (and II). Furthermore, the availability of assays that assess the activity of 
isolated complex I at the flavin-site and at the Q-site allows identification of the drug 
binding site within the complex. SMPs and isolated mitochondria may then be used to 
further characterize the role of drugs in complex I inhibition. Finally, a proposal for 
the described methods to be applied to other enzymes that are similar to complex I, in 
terms of mechanism and location in crossing metabolic pathways, has been laid out. 
4.1.1 Aims 
The aims of this work are to 
1) Obtain a pharmacological characterization of the effect of FDA approved drugs on 
complex I, both within the ETC and in isolation. 
2) Present a method that combines results from two assays that measure activity from 
converging metabolic pathways (I-III-IV and II-III-IV) to pinpoint target specificity 
within the ETC. 
3) Present a method that combines results from assays that measure two different 
aspects of complex I activity (NADH:dQ or Q10 and NADH:APAD or FeCN) to 
determine the binding location of a drug within the complex (Q-site or flavin-site). 
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4) Investigate the determinants of complex I inhibition within specific therapeutic 
classes. 
4.1.2 Choice of the appropriate library 
Several libraries of approved drugs are commercially available so it was necessary to 
develop criteria for selecting the most appropriate one: the libraries with a number of 
drugs close to 1000 (the chosen order of magnitude for the number of drugs to be 
tested) were the Prestwick, the Pharmakon and the Screen-Well Enzo V2. The most 
important criterion adopted for the library selection was that it must include the 
highest number of drugs known to cause drug-induced mitochondrial dysfunction: it 
was therefore decided to build up a “virtual library” of drugs in exactly the same way 
as it was obtained in chapter 3, this time including drug-induced side effects related to 
brain and nervous system (apathy, ataxia, muscular weakness, polymyoneuropathy, 
facial and peripheral paresthesia, neuromuscular blockade317, schwannopathy318), 
kidney (Fanconi syndrome, proximal tubular dysfunction, acute tubular necrosis319, 
glucosuria, aminoaciduria, phosphaturia, bicarbonaturia 320 ) and heart 
(myopericarditis, sinus tachycardia, reversible arrhythmias, prolonged QT interval, 
flattening of T wave321), not just liver and extraliverg. 
Once the drugs associated with those side effects were collected, redundancies were 
removed according to generic drug names and, subsequently, according to UNII codes 
(many drugs include several UNII codes each). The final number of UNII codes 
unique to each set is presented in Table 4.1, which illustrates the filtering process. 
 Database hits according to organ-based side effects 
 Brain Extraliver Heart Kidney Liver 
Initial entries 12702 23354 9025 935 24518 
Drugs without redundancies 841 1376 734 105 1315 
UNII EXPANSION 
Unique UNIIs to each set 798 991 595 92 1454 
Table 4.1. Database filtering process during the choice of the library. The FDALabel 
database search returned many redundancies (both within the initial list of drugs and the 
subsequent UNII expansion) that were eliminated in order to obtain the final list of UNII 
codes unique to each set. 
                                               
g The FDALabel database was accessed on 23rd October 2014 
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At this point the UNII codes were converted to their associated items and narrowed 
down to only include drugs (differences in covalently attached species such as 
carboxylic acids and esters were kept): items discarded included roots, pollens, 
different counterions for the same molecules (e.g. HCl, besylate, phosphates,…), 
insects (e.g. acheta domesticus), bacteria, herbs, viruses, proteases inhibitors and 
proteins. After this filtering process, 1185 unique compounds were left and those 
formed the “virtual library” to which the three commercial libraries were compared.  
Other criteria for the selection process included price, number of times the library was 
used in recent scientific papers (after 2012), number of drugs in common with the 
DrugBank databaseh (approved drugs and nutraceuticals, bioactive molecules derived 
from food that provide physiological benefits beyond nutrition322) and number of 
drugs that possess at least one dimethoxybenzene moiety, a feature of interest 
inasmuch as it is possessed by the canonical inhibitors of complex I rotenone and 
piericidin (see chapter 3). The overall results are summarized in Table 4.2. 
Eventually, the Screen-Well library was chosen, also because the drugs that constitute 
it are all FDA-approved, differently than the other two (the Prestwick library contains 
drugs approved by different agencies, not just FDA, and the Pharmakon also includes 
compounds that have reached clinical trial, not necessarily approved drugs). 
 PRESTWICK SCREEN-WELL PHARMAKON Number of drugs included 1280 786 1600 
Drugs in common with “virtual” 
drug-induced mitochondrial 
dysfunction library 
466 533 540 
Literature references after 2012 10 13 5 
Price € 10,600 £ 5800 $ 9800 
Dimethoxybenzene moiety drugs 25 31 27 
DrugBank Approved Drugs 643 613 698 
DrugBank Nutraceuticals 9 3 14 
Table 4.2. Comparison of the three commercially available drug libraries considered for 
purchase. Several criteria were considered, but the most important one was how many drugs 
each library has with the “virtual” library generated with the method described in chapter 3.  
 
                                               
h The DrugBank database was accessed on 26th October 2014 
 106 
4.1.3 Introduction to the method 
The characterization of complex I was based on the assays used in chapter 3 and is 
summarised in Figure 4.1. The NADH:O2 oxidoreduction assay in membranes was 
the first experiment to filter out weak ETC inhibitors and isolate compounds that 
interact strongly with complex I: the 200 drugs with the highest inhibitory potency 
were chosen. In addition, the minor degree of coupling present in membranes allowed 
to identify 19 compounds that caused a limited degree of stimulation of the rate of 
NADH:O2 oxidoreduction, and as such they could be potential uncouplers (7 of those 
belong to the drug class of bisphosphonates, the other 12 exhibited the highest 
residual activity in the NADH:O2 initial screening). While the potential uncouplers 
are tested with SMPs (which possess a higher degree of coupling), the 200 most 
potent inhibitors are then tested with the succinate:O2 oxidoreduction assay: by 
combining the results of the two oxidoreduction assays it is possible to identify 
specific inhibitors of complex I and II. While the most potent complex I-specific 
inhibitors are tested against isolated mitochondria, specificity towards the other ETC 
complexes is assessed with succinate:dQ, succinate:cyt c and (red.) cytochrome c:O2 
oxidoreduction assays. The same 200 drugs are then tested on isolated complex I and 
arranged in order to highlight Q-site inhibitors as opposed to flavin-site inhibitors. 
Since the ROS assay requires a conspicuous amount of isolated enzyme, the drugs 
tested for their effect on ROS formation are the ones that exhibited the highest 
inhibition in isolated enzyme assays. Finally, the overall results of the database search 
to identify the drugs featured in chapter 3 were validated in this chapter thanks to the 
availability of the library. 
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Figure 4.1. Pharmacological characterisation of complex I. The Enzo library drugs were 
tested in different systems (membranes, isolated complex I, mitochondria and SMPs) to 
assess target specificity and to validate the FDALabel search featured in chapter 3. 
4.2 Mitochondrial membrane-based assays  
Membranes for short are the main experimental system adopted in this chapter to 
assess ETC-based drug-induced mitochondrial dysfunction, since they contain all of 
the respiratory chain enzymes (see chapter 3 for more information on this system). 
4.2.1 NADH:O2 oxidoreduction in membranes: initial screening 
NADH:O2 oxidoreduction covers the electron flow from complex I to IV and it was 
the first experiment to be conducted on the whole library in order to filter out drugs 
whose inhibitory power was not deemed interesting: the results are shown in Figure 
4.2. It would have been overly cumbersome to perform IC50 determinations on all of 
the drugs in the library: it was therefore decided to obtain one-point percentage 
activity determinations instead at 50 µM for each drug. The average specific activity 
for control (drug-free) experiments was 1.24 ± 0.09 µmol min-1 mg-1 (standard 
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Figure 4.2. Initial classification of drugs according to their inhibitory potency towards 
the NADH:O2 pathway. The 200 compounds with the lowest residual activity were selected 
for follow-up experiments. Also, given the (limited) coupling capability of mitochondrial 
membranes it was possible to isolate potential uncouplers. Each drug is presented with SEM 
of duplicates. 
The 200 most potent compounds (Daunorubicin and Tamoxifen exhibited the highest 
and lowest residual activity in this set of drugs, 68% and 0% residual activity 
respectively) were identified as the most promising complex I-specific inhibitors and 
chosen for the next stage of characterisation, the succinate:O2 and isolated complex I 
assays. On the other hand, potential uncouplers were tested in SMPs because this 
system is much more coupled than membranes and, as such, should be more sensitive 
towards uncoupling conditions. 
In order to detect artefacts that could lead to false positives, general chemical 
reactivity of the drugs to experimental conditions was addressed by running the 
NADH:O2 assay without the protein and only Nisoldipine was found to exhibit a 
chemically-driven loss of absorbance at 340-380 nm in NADH:O2 buffer. Follow-up 
experiments with Nisoldipine and structurally similar calcium channel blockers 
Nifedipine and Amlodipine confirmed that the former is the only compound that 
exhibited significant loss of absorbance over time in aqueous buffer (340-380 nm 
absorbance dropped by 15% after 2 minutes), as opposed to the other two which were 
stable in aqueous solution (Nisoldipine is also stable in DMSO). Nisoldipine and, in 
general, 1,4-dihydropyridines derivatives, are known to undergo considerable 
hydrolytic323 and photochemical324 degradation.  
Solubility issues were addressed by quantifying the difference in pathlength between 
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threshold for insoluble drugs when their pathlength was more than 10% lower than 
the control (pathlengths of the control, drug-free, experiments were never 5% lower 
than their average). The following drugs were identified: Amiodarone in both 
NADH:O2 and succinate:O2, Clofazimine and Nilotinib in NADH:O2, Tazarotene in 
succinate:O2, Nepafenac, Medroxyprogesterone, Mitoxantrone and Danazol in 
isolated complex I assays. 
The data from the drugs featured in chapter 3 (Hill parameters of NADH:O2 IC50 
measurements) were used to obtain their expected residual activity at the same drug 
concentration used in the NADH:O2 first screening assay (50 µM). Such expected 
values were then compared with their actual residual activity in the experiments 
performed on the Enzo library: the correlation coefficient between the two series is 
0.97, indicating a high agreement between the two sets of data. Figure 4.3 shows 
where the drugs featured in chapter 3 can be found along the NADH:O2 trace 
displayed in Figure 4.2 and their expected inhibitory power at 50 µM according to 
data presented in chapter 3. 
 
Figure 4.3. Drugs featured in chapter 3 within the initial NADH:O2 screening. All the 
drugs featured in chapter 3 were highlighted in the NADH:O2 trace displayed in Figure 4.2, 
plus their expected inhibitory potency at 50 µM according to the data presented in chapter 3. 
4.2.2 Therapeutic plasma concentration of drugs in the Enzo 
library 
The therapeutic plasma concentrations for 195 out of the 200 drugs were obtained 
from the literature (references for five drugs were not available, see appendix 4.9) and 
it was found that the vast majority of them (176) are lower than 5 µM. An IC50 value 
was estimated for each drug (using the Hill equation) in order to compare it with the 










































































Compounds with less than 100% residual NADH:O2 activity 
Drugs from database search 














literature plasma level range was considered in the plot for each drug, when 
available). Top and bottom Hill parameters were assumed to be 100 and 0, 
respectively, and the Hill coefficient was set at -1.2. The latter value was chosen in 
line with the other experimental IC50 values determined in this thesis with 
membranes; however the estimates do not change significantly when the Hill 
coefficient is set at -1 or -1.5. By plugging the three parameters into the standard Hill 
equation it is possible to work backwards and estimate the IC50 value. 
 
Figure 4.4. Estimated IC50 values and plasma therapeutic concentrations for the drugs 
with the lowest residual activity in the NADH:O2 plot. Values are in logarithmic form for 
better visual representation. Four drugs have undetectable plasma concentrations and were not 
included in the plot. The red dashed line indicates where the two variables assume the same 
value. 
There are 23 drugs (out of 191) whose estimated IC50 is lower than their 
corresponding therapeutic concentrations (data point on the right of the 1:1 red line in 
Figure 4.4): for these compounds, therapeutic blood levels are likely to cause a 
significant effect on complex I. Interestingly, 7 of these 23 drugs are antineoplastic 
agents and 6 are antifungals (Clotrimazole, Sulconazole, Miconazole, Terbinafine, 
Oxiconazole, and Ketoconazole, see section 4.2.7 for details of antifungal drugs 
featured in this work). 
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1) The plasma concentration of the drug can be different from the concentration in 
target cells (e.g. some drugs in the library come in the form of antifungal creams, so 
the epidermal concentrations would be a more appropriate indicator). The property of 
kinetic homogeneity (i.e. the drug concentration in plasma is directly related to its 
concentration at the receptor site where it produces its therapeutic effects) is the main 
assumption in this regard325.  
2) Intracellular accumulation mechanisms (not captured by plasma drug concentration 
measurements) may be central to the drug mechanism of action169. 
3) Drug metabolites produced by drug-metabolising enzymes are often important in 
determining the biological response to a pharmaceutical. This is particularly true in 
the case of drugs that undergo first-pass effect (i.e. reaching the liver for metabolism 
before systemic diffusion in the body)264: drug concentration measurements are, in 
fact, taken after this stage. 
4) Therapeutic plasma concentrations are based on the assumption that drugs are 
administered accurately, according to the prescribed dosage: this does not take into 
account the important phenomenon of overdose (whether it be accidental or suicidal). 
Almost 40,000 people died of pharmaceutical overdose in 2010 in the US alone326, 
while the DILI-related deaths are estimated to be in the US, by extension, about 
100,000327, so in the same order of magnitude than pharmaceutical overdose-related 
deaths. 
4.2.3 Succinate:O2 oxidoreduction and determination of drug 
specificity towards complex I 
The succinate:O2 oxidoreduction assay is based on coupled enzyme reactions: it is, 
therefore, crucial to check whether a drug inhibits the coupled enzyme system or not 
to avoid artefacts. Not only was testing the drugs against the coupled enzyme system 
of this assay (fumarase and malic enzyme) a requirement for its validity, it was also 
required to rule out potential aggregation-based inhibition (the phenomenon whereby 
protein targets can be inhibited by drug-like organic molecules through colloid-like 
aggregation in aqueous media at micromolar or submicromolar concentrations328,329). 
This can be tested by checking the activity of the drug towards different and unrelated 
enzymes330, and the coupled enzyme system of the succinate:O2 assay may serve this 
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purpose. Only four drugs were found to inhibit the enzyme coupled system enough to 
compromise the results, Nisoldipine, Raloxifene, Hexachlorophene and Pazopanib, 
pointing to the possibility of aggregation-based inhibition: therefore, it appears that 
the succinate:O2 assay is robust since just 2% of the tested drugs interfere with iti. 
The inhibition of any of the ETC enzymes from complex I or II down the chain will 
result in a lower specific activity detected (depending on how rate-limiting the 
inhibited enzyme is within the chain). As NADH:O2 oxidoreduction relies on 
complexes I, III and IV and succinate:O2 oxidoreduction relies on complexes II, III 
and IV, comparison of the inhibition of the two pathways allows the compounds to be 
classified into 4 groups conveniently: specific inhibitors of complex I (60 drugs), 
specific inhibitors of complex II (12 drugs), non-specific inhibitors (the drug could 
inhibit both complex I and complex II, or complex III and/or complex IV, hence it 
could be a Q-site-type inhibitor, 46 drugs) and relatively weak inhibitors of both 
pathways  (82 drugs) (Figure 4.5)j. Importantly, the boundaries that define the four 
regions are arbitrary, so, for the purposes of this thesis, it was decided to set both of 
them to the average level of residual activities for each pathway (78.5% for 
succinate:O2 and 29.7% for NADH:O2). The drugs that are classified as relatively 
good inhibitors of at least one of the two pathways (as opposed to poor inhibitors) are, 
therefore, 118 (out of 786 overall in the library) and these fit into one of three 
categories according to their target(s) within the respiratory chain. The average 
specific activity for (control) drug-free experiments in the succinate:O2 assay was 





                                               
i The Enzo Life Science tech team stated that there has never been any incidence of aggregation-based inhibition 
happening or being reported by customers as in February 2016. 
j The class “non-specific” could be misleading because, for instance, a specific inhibitor of complex IV, beyond a 
certain concentration, would fall into this category (as it will be seen in section 4.2.5). Even though this 
terminology will be maintained throughout the thesis, the meaning of “non-specific” inhibition is more akin to 
“unresolved” inhibition.  
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Figure 4.5. Drug specificity towards OXHPOS enzymes. The NADH:O2 and succinate:O2 assays results can be conveniently combined to isolate four different regions and 
identify specific inhibitors of complex I and II. The drugs in the bottom-left corner could inhibit both complex I or II (the only enzymes that the two pathways do not have in 
common) but also complex III or IV (the enzymes in common between the two pathways): these compounds were also tested for complex IV activity with the reduced 
cytochrome c:O2 assay but only 6 of them appear to be potent inhibitors of such enzyme. The plot also shows where the hits from the FDALabel search are distributed, with 13 
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4.2.4 Validation of the results obtained in chapter 3  
The drugs tested in chapter 3 were the result of a database search (FDALabel) 
combined with a set of drugs known to be complex I inhibitors from the literature: of 
the 52 overall hits (violet points in Figure 4.5), 8 are not included in the Enzo library. 
The availability of a commercial library of approved drugs allowed to test the validity 
of the method employed in chapter 3 by analysing the results of the 44 drugs in 
common between the two libraries. 17 drugs were not tested for succinate:O2 activity 
since their NADH:O2 residual activity is greater than the chosen threshold. Of the 
remaining 27 drugs, 13 are specific inhibitors of complex I, 6 are non-specific 
inhibitors, 7 are poor inhibitors and one is a complex II specific inhibitor.  
Figure 4.6 shows the drugs analysed (and colour-coded according to the result 
presented) in chapter 3, mapped in the same position as Figure 4.5 for comparisonk. 
Drugs which inhibited the succinate:O2 pathway more than 15% at 3x NADH:O2 IC50 
are highlighted in orange and drugs whose NADH:O2 IC50 was found to be less than 
20 µM are highlighted in green (the NADH:O2 IC50 values for the drugs in the first 
group are lower than 20 µM too). 
 
Figure 4.6. Inhibition specificity of the drugs tested in chapter 3. The drugs featured in 
chapter 3 are mapped in the same positions as Figure 4.5 and coloured according to the results 
presented in chapter 3. Orange drugs exhibited the highest inhibition in the succinate:O2 
assay, the NADH:O2 IC50 of the green (and orange) drugs is less than 20 µM. 
                                               
k Three drugs are missing from the set of drugs in chapter 3: Papaverine is not included in the Enzo library, 
Bupivacaine and Doxorubicin exhibited NADH:O2 residual activity higher than the chosen threshold for the 
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4.2.5 Confirmation using ETC canonical inhibitors and 
cytochrome c 
Canonical inhibitors of the ETC (rotenone for complex I, atpenin for complex II, 
myxothiazol and antimycin for complex III and NaCN for complex IV) and 
cytochrome c were used to validate the succinate:O2 against NADH:O2 plot shown in 
Figure 4.5. The results are shown in Figure 4.7.  
 
Figure 4.7. Canonical inhibitors ETC map. Specific ETC inhibitors were tested in 
membranes to obtain their location in the succinate:O2 vs NADH:O2 plot. NaCN was also 
tested with the IC50 concentration of rotenone (9 nM) against complex I and cytochrome c 
was included in the analysis. Selected concentrations are shown. Bars are SEM of triplicates. 
Complex I and II specific inhibitors should not inhibit the succinate:O2 and NADH:O2 
pathways, respectively, hence the corresponding areas in the plot should run parallel 



















































































c, the substrate needed for both pathways, was found to fall within the 1:1 line of the 
plot as its concentration lowers: this is equivalent to following the substrate saturation 
curves for both NADH:O2 and succinate:O2 (see chapter 3) pathways as cytochrome c 
concentration decreases. Specific complex III inhibitors like antimycin and 
myxothiazol were found to fall in a diagonal area running through the 1:1 line of the 
plot (turquoise to azure area in Figure 4.7): complex I and II seem to be similarly rate-
limiting towards complex III in their corresponding pathways. Complex IV specific 
inhibitors like NaCN fall in the yellow area of the plot in Figure 4.7: they first exhibit 
a stronger inhibition in the NADH:O2 pathway than in the succinate:O2 one, so it 
seems that complex I is more rate-limiting for the NADH:O2 than complex II is for 
the succinate:O2 pathway. This can be explained by the different specific activities of 
the two assays and by the relative capacity of complexes III and IV to catalyse 
electron transfer (i.e. whether it is the former or the latter that is more rate-limiting 
within the chain). In the NADH:O2 assay, the rate is about 1.3-1.7 µmol min-1 mg-1, 
compared to a rate of 0.5-0.7 µmol min-1 mg-1 for succinate:O2 (see chapter 3 for the 
corresponding substrates saturation curves). If complex IV is more rate-limiting, at 
first its inhibition will mostly affect the NADH:O2 pathway (the one with the highest 
rate) and by the time the NADH:O2 rate will equal the succinate:O2 rate the 
percentage inhibition of the two pathways will also be equal (i.e. the NaCN inhibition 
line in Figure 4.7 will tend to approach the 1:1 line in the plot). In agreement with this 
interpretation, lowering the rate of the NADH:O2 experiment by selective inhibition 
of complex I with rotenone (9 nM, rate decreased by about 50%) brings the NaCN 
line in Figure 4.7 inside the complex III corridor (i.e. close to the 1:1 line). 
Additionally, antimycin and myxothiazol exhibit sigmoidal inhibitor titration curves 
in both NADH:O2 and succinate:O2: these are indicative of complex I and II being 
more rate-limiting within their corresponding pathways with respect to complex III331. 
Briefly, the capacity to oxidise ubiquinol by complex III is in excess compared to the 
capacity to reduce it by complex I or II, hence significant inhibition of complex III 
will occur only when the inhibitor concentration will render quinol oxidation more 
rate-limiting. This can be seen in Figure 4.8 (bottom panel), where sigmoidal titration 
curves for antimycin are shown for both NADH:O2 and succinate:O2: such sigmoidal 
pattern is also present when complex IV is cut out from the chain (NADH:cytochrome 
c and succinate:cytochrome c assays). In contrast, non-saturating concentrations of 
NaCN generate a hyperbolic inhibition curve for NADH:O2, but increasing 
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concentrations of rotenone lower the rate of electron transfer along the chain and, as a 
result, the titration curves shift from hyperbolic to sigmoidal (see Figure 4.8 top 
panel). Overall, the data illustrated in Figure 4.8 suggest that a small percentage of 
inhibition of complex III generates a smaller inhibition of the overall respiratory flux 
than the same percentage of inhibition on complex IV, therefore complex III possess 
an higher capacity for transferring electrons than complex IV in mitochondrial 
membranes.  
 
Figure 4.8. Titration curves for different experiments with NaCN and antimycin. Top 
panel, NaCN titration curves for NADH:O2 with different rotenone concentrations 
(succinate:O2 curve shown for comparison). Bottom panel, Antimycin titration curves for four 
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Examples of cyanide respiratory inhibition of both hyperbolic and sigmoidal nature 
have been reported (the former in rat liver SMPs332, the latter in permeabilised human 
muscle fibers where the sigmoidal character become less pronounced when succinate 
was added to glutamate/malate respiration333): this indicates that the capacity to 
transfer electron in the respiratory chain by complex IV can vary significantly 
between different systems. It must be pointed out that both NADH:O2 and 
succinate:O2 experiments always exhibit perfectly straight (absorbance) traces up 
until they run out of substrate, and this is diagnostic of steady-state conditions being 
reached almost immediately after the reaction started. Furthermore, the OXPHOS 
complexes and substrates are not in a 1:1 stoichiometric ratio in the mitochondrial 
IMM with respect to one another: in bovine heart, mean molar ratios are about 1 x 
complex I, 2 x complex II, 4 x complex III, 8 x complex IV, 74 x ubiquinone and 10 x 
cytochrome c334. This means that it is not complex I and II that are rate-limiting 
towards complex III per se but, rather, they are rate-limiting within the mitochondrial 
membrane system. 
4.2.6 Investigating cytochrome c (reduced):O2 oxidoreduction in 
membranes for non-specific inhibitors: determining the 
role of complex IV 
Given that the full ETC is available for testing in mitochondrial membranes it was 
possible to perform the (reduced) cytochrome c:O2 oxidoreduction assay: by 
monitoring the complex IV-catalysed oxidation of (reduced) cytochrome c by O2, 
drugs for which complex IV is a biological target can be identified. It is important to 
note that the protein concentration was five times lower than the other membrane-
based assays discussed so far (6 as opposed to 30 µg mL-1) because the rate would 
have been too fast to detect, while the drug concentration was kept at 50 µM. The 
most potent complex IV inhibitors were found among the 46 non-specific inhibitors in 
Figure 4.5, since these compounds exhibit a high level of inhibition of both NADH:O2 
and succinate:O2 pathways (there was no significant inhibition detected among the 12 
complex II specific inhibitors). Just six out of 46 drugs inhibited complex IV by more 
than 50% at 50 µM concentration and two of these results are questionable: Silver 
Sulfadiazine is provided as a suspension in the library due to its very low solubility 
and Hexachlorophene inhibits the coupled enzyme system in the succinate:O2 assay, 
so both drugs could easily form aggregates. The other four are Fingolimod (14.9% 
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residual activity), Desogestrel (18.5%), Chlorhexidine (23.1%) and Trifluoperazine 
(48.4%).  
Evidently, complex IV does not appear to be a promising pharmacological target if, of 
almost 800 candidate inhibitors, only four demonstrably inhibit it, even at such a high 
drug to protein concentration ratio. The remaining 40 compounds in the non-specific 
inhibition area of Figure 4.5 (out of the overall 46 tested) are either complex III 
inhibitors or they inhibit more than one of the complexes I, II and III. Notably, all of 
these three enzymes use ubiquinone/ol as a substrate, and thus overlapping inhibition 
could indicate targeting of ubiquinone-binding sites. 
4.2.7 Structural filters and the role of antifungal agents 
The 200 drugs featured in Figure 4.5 were evaluated for similarities between them 
based on their molecular structures and their class. Although these drugs are 
structurally very diverse, three structural scaffolds occur in a substantial proportion of 
the set (Figure 4.9 upper panel). The three structural motifs are an ortho-dialkoxy 
benzene motif (14 drugs, 44 drugs in the whole library), a tricyclic antidepressant 
(TCA) moiety (16 drugs, 18 drugs in the whole library not including an anthraquinone 
core) and a meta-Cl benzene moiety (13 drugs, 16 drugs in the whole library). While 
the first two classes are mainly complex I inhibitors (except for Apomorphine, 
Fenoldopam, Thioridazine and Trifluoperazine that interact more strongly with the 
complex II pathway), drugs that belong to the third class cluster together in the non-
specific region: this functional group is common to many antifungal drugs, as it can 
be seen when the 200 drugs are classified according to clinical application (Figure 4.9 
lower panel). Several antifungal classes335-337 are present in the library (22 drugs in 




Figure 4.9. Structural filters and types of drugs. In the upper panel, drugs possessing 
particular moieties cluster together as mostly non-specific inhibitors (meta-Cl) or specific 
complex I inhibitors (ortho-dimethoxy and TCA). In the lower panel, many antifungal drugs, 
especially first generation azoles, are non-specific ETC inhibitors and most of them share a 
meta-Cl benzene ring. Common structural features of antidepressants and antipsychotics are 
indicated with colour-coded labels. 
Imidazoles of 14 α-Sterol demethylase and especially squalene epoxidase inhibitors 
are the most potent antifungals against the NADH:O2 pathway and they are all 
classified as non-specific inhibitors (except for Ketoconazole which is specific to 
complex I). Three of the 14 α-Sterol demethylase triazoles are complex I specific 
inhibitors. The other categories of antifungals do not appear to inhibit any of the 































































































































Antifungal type/class meta-Cl Drug Residual Activity % at 50 µM 
14 α-Sterol demethylase inhibitors   NADH:O2 Succ:O2 
 
Imidazole 
✓ Oxiconazole 2.2 50.7 
 ✓ Sertaconazole 4.2 51.5 
 ✓ Sulconazole 1.7 44.5 
 ✓ Econazole 2.1 40.3 
 ✓ Butoconazole 2.5 38.7 
 ✓ Miconazole 1.6 23.5 
 ✓ Ketoconazole 5.3 96.2 
  Clotrimazole 4.9 27.1 
 
Triazole 
✓ Terconazole 4.8 96.0 
  Posaconazole 23.2 103.5 
 ✓ Itraconazole 58.7 97.7 
  Voricozanole 96.8 / 
  Fluconazole 123.2 / 
Squalene epoxidase inhibitors     
 Allylamines 
 Terbinafine 2.0 23.9 
  Naftifine 0.9 26.2 
 Benzylamines  Butenafine 2.5 18.6 
Fungal mitosis inhibitors  Griseofulvin 99.1 / 
Polyene inhibitors of fungal 
membrane stability 
 Amphotericin B 95.8 / 
 Nystatin 75.6 / 
 Natamycin 95.3 / 
Fungal wall synthesis inhibitors 
(Echinocandins) 
 Micafungin 70.5 / 
Hydroxypyridones (Iron chelators)  Cyclopirox 99.0 / 
Table 4.3. Antifungal drugs for human use in the Enzo Library. The antifungal drugs in 
the library display a wide range of potencies, with 14 α-Sterol demethylase Imidazoles being 
the most potent category towards complex I and the Squalene Expoxidase being the most 
potent category towards complex II. 
Both antipsychotics and antidepressants tend to concentrate in the complex I region, 
with some antipsychotics like Thioridazine, Trifluoperazine and Fluphenazine 
exhibiting higher inhibition of the succinate:O2 pathway. None of the drugs included 
in these categories appears in the complex II specific inhibitor region. 
Benzisoxazoles-based antipsychotics (see lower panel in Figure 4.9) included in the 
library are Risperidone, Paliperidone and Iloperidone and they are all specific 
complex I inhibitors: they are very structurally similar to each other (Paliperidone is 
actually a metabolite of Risperidone and, interestingly, both affect the expression of 
the complex I accessory subunit NDUFS4 in rats338). Intriguingly, the only other 
benzisoxazole-containing drug in the library, Zonisamide (an anticonvulsant), does 
not inhibit the NADH:O2 pathway at all: this compound lacks both the fluorine atom 
 122 
in the benzisoxasole moiety and the whole piperidine-containing side compared to the 
other three. Figure 1.10 shows the structural differences among the four species. 
 
Figure 4.10. Drugs containing a benzisoxazole moiety in the Enzo library. Zonisamide is 
the only benzisoxazole-containing compound in the library that does not inhibit the 
NADH:O2 pathway. Differences with the other compounds are the fluorine atom in the 
benzisoxasole moiety and the whole piperidine-containing side. 
Since the TCA structural core is the main structural feature of TCA drugs, it is no 
surprise that several drugs appear in both plots in Figure 4.9: of particular importance 
are antidepressants in the complex I specific region that share either a 
dibenzosuberane (Amitriptyline, Nortriptyline and Protriptyline) or dibenzazepine 
(Clomipramine and borderline complex I-specific Desipramine and Imipramine) core 
(see lower panel in Figure 4.9). While other dibenzosuberanes (antihistamine 
Cyproheptadine and muscle relaxer Cyclobenzaprine) still retain NADH:O2 activity 
(51.0 and 15.8% respectively) but do not interact with the succinate:O2 pathway, 
dibenzazepine anticonvulsants Carbamazepine and Oxcarbazepine do not inhibit the 
NADH:O2 pathway at all. Intriguingly, the antidepressant Sertraline (the only 
antidepressant to exhibit non-specific inhibition) has been shown to possess 
antifungal activity339,340. 
4.3 Assays on isolated complex I and target resolution 
of non-specific OXPHOS inhibitors 
A set of standard assays158 was applied to the isolated complex to investigate whether 
the compounds are inhibitors that act at the flavin site or at the ubiquinone binding 
site, and whether they affect the production of reactive oxygen species. To test the 
effects on the overall rate of catalysis (including the activity of both active sites) the 
NADH:dQ oxidoreductase reaction was initially used but given its several drawbacks 






















pointed out, however, that a compound that inhibits the Q-site in complex I would be 
indistinguishable from a compound binding to (and inhibiting) a proton pump subunit, 
since ubiquinone reduction and proton pumping are coupled processes. Complex I-
specific assays were employed, alongside other assays in membranes, to identify other 
categories of OXPHOS inhibitors (complex III- and non-specific, see section 4.3.2). 
Finally, to test the effects on the flavin site within complex I, the FeCN, APAD and 
ROS reactions were used.  
4.3.1 The NADH:dQ and NADH:Q10 oxidoreduction assays: 
testing the Q-site and indirectly determining potential 
specific complex III inhibitors 
The NADH:dQ assay tests Q-site activity for the isolated complex (involving the 
entire catalytic cycle) but there are some drawbacks when comparing it to the 
NADH:O2 in membranes. The frequency distribution of drugs plotted according to 
residual activity shows that the drugs tested distribute differently within the two 
experiments: the NADH:dQ distribution is shifted further to the right (black and red 
bars in Figure 4.11), indicating that this assay is less susceptible to inhibition than the 
NADH:O2 assay. In order to overcome the limitations of the NADH:dQ assay 
unveiled in this work (listed later on in this paragraph) a NADH:Q10 assay in 
proteoliposomes was performed. In this assay the physiologically relevant ubiquinone 
Q10 is constantly recycled upon reduction by complex I via an excess of alternative 
oxidase (AOX) within a reconstituted proteoliposome environment341. AOX is a 
component of the mitochondrial respiratory chain in many plants and fungi and 
oxidises ubiquinol by concomitantly reducing oxygen, thus bypassing complexes III 
and IV, without pumping protons342. Collectochlorin (a specific and potent AOX 
inhibitor) was tested on Q10-free (complex I-containing) proteoliposomes with added 
dQ, and a sigmoidal titration curve was obtained, suggesting that AOX was not the 
rate-limiting enzyme (the NADH:dQ rate in proteoliposomes was about 50% lower 
than the NADH:Q10 rate). The 150 drugs that inhibited the NADH:O2 pathway the 
most (residual activity of less than 49%) were tested with the NADH:Q10 assay and 
the improvement on detection of complex I inhibition compared to the NADH:dQ 
assay was remarkable: the overall NADH:Q10 distribution is much closer to the 
NADH:O2 one than to NADH:dQ (blue bars in Figure 4.11). 
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Figure 4.11. Frequency distribution of drugs according to percentage residual activity in 
NADH:O2, NADH:dQ and NADH:Q10. The drugs affect the NADH:O2 and NADH:dQ 
oxidoreductions differently: while the O2 pathway distribution is centred on low residual 
activity, the dQ pathway distribution is shifted to higher residual activity. The NADH:Q10 
assay brings the overall data closer to the NADH:O2 distribution. 
The limitations of the NADH:dQ are even clearer when analysed in conjunction with 
other assays: several drugs in the library exhibit contradictory values of NADH:O2, 
succinate:O2 and NADH:dQ assays. Namely the low residual activity of the first and 
high residual activity of the second should point towards complex I inhibition which 
is not detected by the third, whose residual activity remains high (50% or more). For 
example, Paroxetine exhibits residual activities of 8.3, 100.6 and 82.8% for 
NADH:O2, succinate:O2 and NADH:dQ, respectively; similarly, for Nortriptyline the 
corresponding values are 9.7, 98.1 and 84.2 %.  Figure 4.12 (black and grey points) 
shows how the NADH:dQ assay does not detect complex I inhibition with 41 drugs 
previously determined as complex I specific inhibitors in membranes (their residual 
activity is higher than 50%). The area in the plot in Figure 4.12 includes 73 drugs 
overall (60 specific inhibitors of complex I as illustrated in section 4.2.3 plus other 13 
included by lowering the succinate:O2 threshold from 78.5 to 50%), hence 32 drugs 
out of 73 leave a residual activity in the NADH:dQ assay less than 50%. The 
NADH:Q10 assay is, again, better at detecting complex I inhibition than NADH:dQ, 
since only four drugs (highlighted in Figure 4.12, red and green points) within the 73 
in the area are not detected as inhibitors (as opposed to 41 with the NADH:dQ assay). 
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Figure 4.12. Comparison of NADH:dQ and NADH:Q10 inability to detect complex I 
inhibitors. 41 drugs in the complex I specific inhibitor category are not detected as such by 
the NADH:dQ assay. The NADH:Q10 assay, instead, is far more effective, lowering the 
number of undetected drugs to only four (highlighted in the plot). Dots refer to percentage 
residual activity as indicated in the legend. 
In addition, the correlation coefficient between the NADH:O2 and NADH:dQ results 
is 0.13 and the correlation coefficient between the NADH:O2 and NADH:Q10 results 
is 0.69: such an improvement is likely due to chemical incompatibilities of some 
drugs with the NADH:dQ assay environment that are mostly resolved by the 
NADH:Q10 assay. Since the NAHD:Q10 assay depends on Q10 being reoxidised by 
AOX, drugs needed testing on AOX too in order to rule out drug interference with the 
Q10 regeneration system: only Miconazole, Oxiconazole and Amiodarone were 
incompatible with the NADH:Q10 assayl. It is possible, however, that AOX activity 
may be affected by the (proteo)liposome environment in the NADH:Q10 assay and, as 




                                               
l All the drugs were tested on isolated AOX enzyme with Q1H2 as electron donor (the reaction catalysed is 
therefore Q1H2:O2) at a concentration of AOX 6x less than the actual NADH:Q10 assay (0.27 as opposed to 1.7 µg 
mL-1): Oxiconazole and Miconazole exhibited the lowest residual activity (less than 5%) and Amiodarone 
exhibited a descending (not ascending) absorbance trace in the assay. Also, 14 randomly selected drugs out of the 
overall 150 were tested at 0.34 µg mL-1 of isolated AOX in the Q1H2:O2 assay and their residual percentage 
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There are several reasons that can explain the shift in distribution from NADH:O2 to 
NADH:dQ 
1) The dQ assay contains asolectin and CHAPS, so drug diffusion in the medium 
is different than in NADH:O2 conditions. The hydrophobic phase is bigger by 
mass in the experimental conditions of the NADH:dQ assay (0.075% of 
asolectin or 750 µg mL-1) than in the NADH:O2 assay (30 µg mL-1 of 
membranes include about 10 µg mL-1 of lipid, assuming a protein-to-lipid 
ratio of about 3:1 commonly found in the IMM343). 
2) Q species are different (native Q10 vs dQ) and so is their reduction potential. 
3) In the NADH:O2 assay complex I is surrounded by its native membrane 
whereas in the dQ assay asolectin and CHAPS provide an artificial 
membranous environment, hence the enzyme activity can be affected by the 
different environment it resides in. 
4) The drugs in membranes may have more than one target, hence the collective 
response from the chain can be different from the isolated enzyme. 
5) The concentration of complex I in the two assays (isolated enzymes and 
membranes) is different, therefore the enzymatic response to the drugs will be 
different accordingly. 
Specificity towards OXPHOS enzymes can be addressed by plotting the NADH:O2 
against NADH:Q10 values for drugs, similarly to the IC50 ratio between NADH:O2 
and NADH:dQ described in chapter 3. In this plot (see Figure 4.13, where drug 
categories are colour-coded to correspond to the succinate:O2 against NADH:O2 plot 
in Figure 4.5), non-specific inhibitors (red dots) are concentrated below the 1-to-10 
line (i.e. their ratio of residual activity of NADH:Q10 over residual activity of 
NADH:O2 is higher than 10). A situation where the NADH:Q10 residual activity for a 
drug is much higher than the corresponding residual activity for NADH:O2 could be 
diagnostic of complex III specific inhibition. This, of course, implies that (as it was 
seen in paragraph 4.2.6) complex IV is very rarely a target for drugs in this library; 
also, the concentration of complex I in the two assays (isolated enzymes and 
membranes) is different, therefore the enzymatic response to the drugs will be 
different accordingly. Nonetheless, it is still possible to define areas of the plot in 
Figure 4.13 where complex III-specific inhibitors are most likely to be found: the 
three lines 1-to-2, 1-to-4 and 1-to-10 delimit the regions where the ratio of residual 
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activity of NADH:Q10 over NADH:O2 is greater than 2, 4 and 10 respectively (a 
complex III-specific inhibitor should be found progressively more likely on the right 
of these lines). As the area enlarges (going from 10 to 4), more complex I specific 
inhibitors (green dots) are progressively included. There are 17 drugs in the 1-to-4 
region, 15 of which are classified as non-specific inhibitors and two are classified as 
complex I specific inhibitors. Of the three drugs identified as complex-III specific 
inhibitors (see later section 4.3.2, underlined in Figure 4.13), two fall below the 1:4 
line (Meclizine and Atovaquone) and one is close to the 1:2 line (Fenoldopam). Other 
hits (highlighted but not underlined in Figure 4.13) include two of the drugs that the 
NADH:Q10 assay failed to identify as complex I-specific inhibitors (Ciclesonide and 
Mitoxantrone, see Figure 4.12) and Permethrin, which was reported to be a complex 
I-specific inhibitor and not to inhibit complex III by Gassner et al.344. It must be 
pointed out that, in such study, the authors tested complex I activity with duroquinone 
using freeze-thawed rat liver SMPs with a 70-80% of rotenone-sensitive activity 
(bovine membranes and SMPs have about 96% rotenone-sensitive activity or higher). 
In addition, complex III activity was tested with a duroquinol:cytochrome c assay 
that, similarly to the membrane-based complex III activity assay presented in this 
work (see section 4.6.3) is plagued by a substantial background activity (spontaneous 
ubiquinol oxidoreduction was reported at 38% of the total activity). Finally, the 
activity of complex III was monitored at 520 nm instead of 550 nm for cytochrome c 
reduction (the difference in absorbance between oxidised and reduced cytochrome c 
at the former wavelength is much lower than at the latter). 
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Figure 4.13. NADH:O2 and NADH:Q10 values for the most potent 150 drugs. The plot 
shows the values for the two assays for each drug in addition to their inhibition specificity 
according to Figure 4.5. Dots below the 1-to-2, 1-to-4 and 1-to-10 lines are drugs whose ratio 
of residual activity of NADH:Q10 over NADH:O2 is higher than 2, 4 and 10 respectively. 
Complex III specific inhibitors identified in section 4.3.2 are highlighted and underlined. 
Other drugs in the complex III areas close to the three specific inhibitors are highlighted but 
not underlined. 
4.3.2 Focus on a subset of Complex I- and III-specific and non-
specific inhibitors 
The results illustrated in section 4.3.1 allowed three drug categories to be defined, 
according to whether their residual activity in NADH:O2, succinate:O2 and 
NADH:Q10 assays fall within appropriate ranges: the compounds thus found could 
now be further characterized. Importantly, these categories reflect two critical aspects 
of ETC inhibition that this work encompasses, target specificity (complex I- and III-
specific inhibitors) and drug ability to interact with more than one ETC enzyme (non-
specific inhibitors). Figure 4.14 shows the three drug categories thus created and their 
activity level thresholds for the three assays. Succinate:dQ (complex II) and 
succinate:cyt c (complex II-III pathway) assays in mitochondrial membranes were 

























































precisely the involvement of complexes II and III. Also, IC50 values in NADH:O2 
were obtained for complex I specific inhibitors. The data is illustrated in Table 4.4 
and Table 4.5, with table header rows presented in the same colour codes for the three 
drug categories used in Figure 4.14. Data from other assays, therapeutic blood 
concentrations, pKa levels, charge at physiological pH and also whether the drugs 
caused mitochondrial side effects (based on the FDALabel search featured in chapter 
3) are presented for reference. Lastly, significant inhibition of succinate:dQ, 
succinate:cytochrome c and (red.) cytochochrome c:O2  were defined as residual 
activities less than 50% (pink), 20% (green) and 50% (teal) respectively (Table 4.4). 
 
Figure 4.14. Three important categories of drugs according to their ETC targets. Of all 
the drugs whose NADH:Q10 and NADH:O2 activities were both less than 10%, complex I-
specific (green) and non-specific (blue) inhibitors exhibited succinate:O2 activity higher than 
90% and lower than 50%, respectively. Complex III-specific (red) inhibitors exhibited the 
lowest succinate:O2 activity among drugs whose NADH:Q10 activity was higher than 60%. 
Header rows in Table 4.4 and Table 4.5 share the same colour code. 
Non-specific and complex I-specific inhibitors possess either a positive or neutral 
charge at physiological pH (Sulfadiazine and Hexachlorophene are the only two 
compounds with negative charge), and some of them have already been described in 
chapter 3 (Trifluoperazine, Fenofibrate and Tamoxifen in Table 4.4, Carvedilol, 
Nefazodone, Haloperidol and Capsaicin in Table 4.5). The three complex III-specific 

































NADH:Q10 < 10% 
NADH:Q10 < 10% 
NADH:Q10 > 60% 
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As for complex III specific inhibitors, Atovaquone is a known complex III inhibitor in 
different systems: Plasmodium falciparum, Pneumocystis jirovecii, FaDu345 (human 
hypopharyngeal carcinoma) and MCF-7346 (breast cancer) cells. Interestingly, Mootha 
and co-workers found that Meclizine induced an increase in OCR and a decrease in 
ECAR in STHdhQ7/7 (mouse striatal), human HEK293 (embryonic kidney) and HeLa 
cells, but had no effect on respiration of isolated mitochondria from mouse kidney 
(indistinguishable for the control experiment)347. They later ascribed this effect to 
Meclizine inhibiting CTP:phosphoethanolamine cytidylyltransferase, a cytosolic 
enzyme that participates in the Kennedy pathway of phosphatidylethanolamine 
biosynthesis348. 
Of note among the non-specific inhibitors (Table 4.4) is Fingolimod, a drug used to 
treat multiple sclerosis. Low residual activity in NADH:O2, succinate:cytochrome c 
and (red.) cytochrome c:O2 assays and high residual activity in the succinate:dQ assay 
suggest strong inhibition of complexes I, III and IV. One of the major side effects of 
Fingolimod is liver injury in the form of elevated blood liver enzymes several times 
the upper limit levels, which tend to return to normal levels once the dosage is 
reduced349. Some enzymes in hepatocytes (especially aminotransferases and alkaline 
phosphatases) but also in other tissues (especially muscle350) are markers of cellular 
injury: in normal conditions their serum concentrations is very low but events leading 
to necrosis or cell membrane injury (often but not exclusively associated with ROS 
overproduction351) cause leakage into the serum, thus increasing their concentrations 
therein352. The mechanism whereby Fingolimod leads to elevated liver enzymes 
remains unknown353 but it is possible that its substantial inhibition of OXPHOS 
enzymes is a contributing factor. In this regard, Fingolimod is extensively 
metabolised by humans, with only 23% of the parent drug left untouched354. 
Among the complex I specific inhibitors (Table 4.5), exposure of mouse 3T3-L1 
adipocytes to Nebivolol (the compound with the highest NADH:O2 and NADH:Q10 
inhibition) was interestingly found to increase expression levels of complex I, II and 
transcription factors involved in mitochondrial biogenesis355. These may be the result 
of Nebivolol interaction with organelles outside mitochondria, since it did not have an 
effect on respiration of isolated mitochondria (see section 4.5). 
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Drug NADH: Succinate: (Red.) cyt c:O2  % 
Therapeutic 
concentration µM pKa 
Charge at 
physiological pH 
Mito side effects 
Q10 % O2 % O2 % dQ % cyt c % Liver Extraliver 
 COMPLEX III-SPECIFIC INHIBITORS 
 > 60%  
Meclizine 64.1 7.2 1.4 80.1 1.7 102.7 0.28 6.2 Neutral   
Atovaquone 87.1 16.1 21.4 102.0 10.0 105.7 56.7 5.0 N ✓ ✓ 
Fenoldopam 74.2 40.3 16.3 105.2 7.9 91.4 0.15 8.0 P   
 NON-SPECIFIC INHIBITORS 
 < 10% < 10% < 50% < 50% < 20% < 50%  
Fingolimod 1.3 1.5 22.3 68.6 8.1 14.9 0.1 7.8 P/Neutral   
Cinacalcet 4.4 1.3 31.8 71.7 5.9 70.0 0.1 10.3 P   
Econazole 4.8 2.1 40.3 66.4 28.5 97.8 1.4 nM 6.6 Neutral   
Ag·Sulfadiazine 5.1 0.8 0.0 96.0 44.5 4.7 56.0 6.5 N ✓  
Clotrimazole 5.3 4.9 27.1 44.5 33.3 95.7 5.0 4.7 Neutral   
Butoconazole 5.7 2.5 38.7 64.1 30.2 112.6 0.04 6.8 P/Neutral   
Trifluoperazine 6.4 3.2 23.9 80.8 70.0 48.4 0.02 9.0 P ✓  
Miconazole 7.2 1.6 23.5 72.5 16.9 107.5 155.6 6.7 P/Neutral   
Terbinafine 7.3 2.0 23.9 80.0 14.1 86.7 4.1 7.1 P/Neutral ✓ ✓ 
Sulconazole 7.9 1.7 44.5 69.7 36.0 104.2 80.0 6.7 P/Neutral   
Fenofibrate 7.9 2.2 30.0 83.8 19.7 112.8 13.9 / Neutral ✓ ✓ 
Sorafenib 8.1 8.2 15.1 86.5 14.3 91.9 97.6 12.9 Neutral ✓ ✓ 
Butenafine 8.5 2.5 18.6 86.7 16.1 85.4 17 nM 7.9 P/Neutral   
Hexachlorophene 8.7 0.9 0.3 7.2 1.3 8.2 1.6 3.9 N   
Tamoxifen 9.4 0.1 10.8 59.0 3.0 51.8 0.15 10.8 P ✓ ✓ 
Table 4.4. Characterization of complex III-specific and non-specific inhibitors. Complex III-specific and non-specific inhibitors have the same colour codes of Figure 4.14 
(red and blue, respectively), with thresholds for specific assays highlighted in the same colours. Thresholds for succinate:dQ, succinate:cytochrome c and (red.) cytochrome 
c:O2 to identify significant inhibition in pink, green and teal, respectively. Therapeutic concentrations, pKa values and charge at physiological pH are reported for comparison. 
FDALabel database search results (from chapter 3) in terms of mitochondrial-associated liver and extraliver side effects are also presented. 
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concentration µM pKa 
Charge at 
physiological pH 
Mito side effects 
O2 % Q10 % Liver Extraliver 
 COMPLEX I-SPECIFIC INHIBITORS 
 < 10% < 10% > 90%  
Nebivolol 1.1 3.9 93.4 1.2 0.05 8.4 P   
Salmeterol 1.3 4.0 90.7 2.0 0.02 10.2 P   
Carvedilol 2.0 4.6 99.2 6.7 0.40 7.8 P/Neutral ✓  
Fluoxetine 1.9 5.3 100.9 6.6 1.45 8.8 P ✓ ✓ 
Duloxetine 1.9 6.2 96.7 8.6 0.36 9.3 P ✓ ✓ 
Iloperidone 2.6 6.3 90.9 12.0 0.02 7.7 P/Neutral  ✓ 
Calcipotriene 4.0 6.7 90.9 12.7 0.1 nM / Neutral   
Propafenone 3.4 7.4 98.2 9.6 5.3 9.3 P ✓ ✓ 
Ketoconazole 5.3 7.8 96.2 11.5 11.3 6.5 Neutral ✓ ✓ 
Nefazodone 2.5 8.7 98.0 0.8 4.0 6.5 Neutral ✓ ✓ 
Haloperidol 3.8 9.0 104.0 2.4 0.1 8.65 P  ✓ 
Capsaicin 9.1 9.1 94.6 25.8 8.1 nM 10.1 Neutral ✓  
Aripiprazole 1.6 9.3 98.9 1.7 1.12 7.6 P/Neutral ✓ ✓ 
Oxybutynin 5.7 9.4 98.5 17.0 0.04 8.0 P/Neutral   
Ethinyl Estradiol 9.6 9.7 91.2 12.2 1 nM 10.0 Neutral ✓ ✓ 
Table 4.5. Characterization of complex I-specific inhibitors. Complex I-specific inhibitors have the same colour code of Figure 4.14, green, with 
thresholds for specific assays highlighted in the same colours. NADH:O2 IC50s for each drug are presented. Therapeutic concentrations, pKa values and 
charge at physiological pH are reported for comparison. FDALabel database search results (from chapter 3) in terms of mitochondrial-associated liver and 





4.3.3 Flavin site assays: NADH:FeCN and NADH:APAD 
By plotting the results of a flavin-site assay (carried out with isolated enzyme) against 
the results of a Q-site assay (similarly to what was done for membranes with 
NADH:O2 and succinate:O2 assays, see Figure 4.5), four different areas can be 
isolated: flavin-site inhibitor and Q-site inhibitor regions are on the left hand-side of 
the plot (see Figure 4.15 and Figure 4.16). Given the sequential nature of the electron 
transfer mechanism from NADH (first) to ubiquinone (last) through complex I, no 
drug should appear in the bottom-right corner: in fact, if a drug inhibits the flavin site 
the electron transfer should be affected throughout complex I and hence detected by 
the NADH:dQ assay too. Hence, a drug should appear in this region because it is 
incompatible with the assay system. It is possible, however, that a compound could 
selectively bind to the reduced flavin-site and block access to FeCN. 
The first attempt at this methodology was made with NADH:FeCN oxidoreduction to 
assess flavin-site reactivity but it turned out to be very prone to artefacts (Figure 
4.15): 18 drugs exhibit substantial protein-free FeCN activitym. The NADH:APAD 
assay was chosen instead: it fails to identify as many hits compared to NADH:FeCN 
(on account of its much narrower vertical variability) but only 10 drugs exhibited very 
erratic tracesn (labelled as “Dubious APAD activity” in Figure 4.16). This assay gives 
a more conservative response for both drug interaction with complex I and for 
identification of drugs that belong to the bottom right region: likely this is due to the 
hydride transfer on which the assay is based that avoids side reactions that single-
electron artificial acceptors are prone to. 
The horizontal and vertical lines are, again, arbitrary and were set equal to the average 
inhibition percentages, 28.4% for NADH:Q10, 99.3% for NADH:FeCN and 98.5% for 
NADH:APAD: the very high mean residual activities for both APAD and FeCN 
indicate a poor overall reactivity of the flavin site of complex I towards drugs. This 
can also be gathered by the very few drugs that appear to exhibit significant flavin-site 
activity: these are compounds that were tested for ROS activity (see section 4.3.4). 
                                               
m Protein-free activity in the FeCN assay is defined substantial if the raw rate is higher than 15% the normal raw 
rate. 
n The APAD reaction always gives very straight traces with a R2 value of at least 0.995. The drugs were 
considered to have an erratic trace when they exhibited an average R2 of less than 0.96. 
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Figure 4.15. Drug binding site determination on complex I with FeCN assay. The NADH:Q10 and NADH:FeCN results can be conveniently combined to isolate regions 
where Q-site and flavin-site inhibitors should fall into. This assay, though, is very prone to artefacts: 18 drugs exhibit a very high complex I-free activity (orange points). The 
average residual activity in the FeCN assay is 100.2%, hence the FeCN-related flavin site reactivity is generally not affected by these drugs. Error bars are SEM of duplicates. 























































Figure 4.16. Drug binding site determination on complex I with APAD assay. The average residual activity in the NADH:APAD assay is 98.8%, thus confirming the general 
lack of reactivity of the drugs towards the flavin site. The artefacts detected in this assay are different than the one encountered in the FeCN one: a very erratic trace was found in 






















































4.3.4 ROS assay 
The compounds that showed the highest flavin-site inhibition (both in APAD and 
FeCN assays) were chosen for a ROS assay follow-up (Table 4.6). This experiment 
detects H2O2 production via peroxidase-catalysed conversion of Amplex Red to 
Resorufin. Any superoxide is quickly converted into H2O2, either chemically or 
enzymatically via superoxide dismutase. All of the drugs were tested for interaction 
with HRP to rule out artefact detection, similarly to what was done in the succinate:O2 
assay (see paragraph 4.2.3). Fenoldopam and Apomorphine are the most potent HRP 
inhibitors, followed by Promethazine and Liothyronine. It is assumed that the extent 
of HRP inhibition of the other drugs is not enough to hamper the H2O2 detection 
system. Hexachlorophene is the strongest hit but its mild HRP inhibition combined 
with its promiscuous activity in membranes cast serious doubts on its being a genuine 
inhibitor of complex I flavin-site activity, including ROS. The remaining three drugs 
tested are Levothyronine, Zafirlukast (both seem to be mild ROS inhibitors) and 
Sulfadiazine, which does not inhibit ROS production at all. It appears that these drugs 
prevent complex I-driven ROS formation very poorly. 
DRUGS ROS ACTIVITY HRP ACTIVITY X% ROS/HRP residual activity at Y drug concentration (µM) 
Apomorphine / 2.0 ± 0.1% 2 
Hexachlorophene 9.2 ± 0.1% 150 67.8 ± 0.9% 50 
Fenoldopam / 2.0 ± 0.0% 0.5 
Levothyroxine 85.4 ± 0.8% 100 47.8 ± 3.9% 50 
Liothyronine 76.9 ± 3.0% 100 62.3 ± 1.2% 0.5 
Promethazine 42.8 ± 0.7% 200 73.7 ± 1.7% 1 
Sulfadiazine 101.9 ± 0.2% 280 101.3 ± 0.8% 100 
Zafirlukast 61.6 ± 0.0% 100 52.1 ± 1.6% 50 
Table 4.6. ROS assay results with the most powerful flavin-site inhibitors in the library.  
This small set of drugs did not exhibit a strong potency against complex I-driven ROS 
formation and also some of the compound inhibited HRP which the ROS assay is based on. 





4.4 SMPs: accounting for potential uncouplers 
The majority of the compounds in the library do not inhibit the NADH:O2 pathway 
and the above-mentioned mild coupling of mitochondrial membranes could be used to 
detect uncouplers: these drugs should therefore stimulate activity in the NADH:O2 
assay to a higher level than that of the control. The NADH:O2 assay performed with 
SMPs (also in uncoupled conditions with gramicidin to rule out direct complex I 
activation) to better capture uncoupling properties of the drugs were unsuccessful: the 
12 compounds that exhibited the highest residual activity in the NADH:O2 initial 
screening (see Figure 4.2) did not produce the same results with SMPs. Similarly, the 
compounds that belong to the class of bisphosphonates (discussed in detail in 
paragraph 4.5) all share a very high NADH:O2 activity in membranes that is not 
reflected in a corresponding high activity in SMPs. Figure 4.17 shows the results of 
the NADH:O2 assay in SMPs and in membranes for comparison.  
It is possible that these results may be explained by experimental error in the 
NADH:O2 assay that is measured as overactivation of the complex I-IV pathway. An 
alternative explanation invokes the strong sonication process needed to make SMPs 
that does not happen in the preparation of mitochondrial membranes. The resulting 
structural differences between the two systems (e.g. different parts of the membrane 
phospholipid bilayer may be exposed to the drugs) could bring about more favourable 
interactions between the drug and mitochondrial membranes than with SMPs, hence 
explaining the different uncoupling features of the compounds in different systems. 
Lastly, while membranes are prepared with just one centrifugation step, SMPs require 
six (see chapter 2): the lack of membrane elements lost during SMP purification could 
play a role in the different reactivity of these compounds towards the two systems. 
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Figure 4.17. Potential uncouplers tested with SMPs. Drugs that exhibited the highest 
NADH:O2 residual activity were tested in this system: none of them was capable of raising 
the residual activity higher than with membranes. Error bars are SEM of duplicates.   
4.5 Inhibition of respiration in isolated mitochondria 
The effects of complex I-specific inhibitors (see section 4.3.2) on respiration of 
isolated rat liver mitochondria (measured by Seahorse XF 96) were studied in order to 
extend the scope and pharmacological relevance of this work. The drugs were tested 
at 60 µM each (their IC50 in membranes is around 10 µM, see Table 4.5): after 
addition of glutamate/malate and a waiting time of 14 minutes, drugs were injected. 
30 minutes later ADP was injected to stimulate respiration, followed 3 minutes later 
by rotenone. Figure 4.18 shows some representative OCR traces for the experiment. 
The results are shown in Figure 4.19 and presented as percentage of inhibition 
compared to control, including statistical significance (Papaverine was included in the 
experiment because of the data presented in chapter 3, even though it does not belong 












































































































































Figure 4.18. Representative OCR traces of Seahorse experiments on isolated 
mitochondria. The OCR percentages are normalised with respect to the last measured OCR 
prior to drug addition. Data show means ± SEM (n=6 for control, n=4 for Salmeterol, n=3 for 
Carvedilol). 
Salmeterol and Papaverine are the drugs that inhibit mitochondrial respiration the 
most, followed by Propafenone, Ketoconazole and Nefazodone. Propafenone and 
Papaverine also exhibited the highest difference between inhibition of basal state and 
that of ADP-stimulated respiration. Remarkably, Capsaicin did not inhibit 
mitochondrial function in this assay but inhibited OCR and increased ECAR in HeLa 
cells at 75 µM; conversely, Papaverine also inhibited OCR and increased ECAR in 
HeLa cells at 6 µM, but it did inhibit OCR in rat liver mitochondria (see chapter 3 
where both Papaverine and Capsaicin were labelled as OXPHOS inhibitors in cells). 
The other drugs, however, do not lower, to an appreciable degree, oxygen 
consumption in isolated mitochondria. It is possible that transport inside mitochondria 
is paramount to exert their inhibitory power and for some drugs such transport is 
hindered. Alternatively, accumulation processes inside mitochondria could explain 
their contradictory pharmacological properties. In this regard, Sgobbo et al.356 found 
that Carvedilol caused a mild decrease of the respiration rate in H9C2 (embryonic rat 
heart) cells in addition to a significant complex I inhibition in cell lysates (the same 





































concentration of 20 µM was used for both experiments and the cells in the former 
experiment were incubated with Carvedilol for 24 hours before measurements were 
taken). A slow accumulation in mitochondria could, thus, explain why Carvedilol 
failed to curtail respiration in isolated liver mitochondria (see Figure 4.19): the 
incubation time may not have been long enough. 
 
Figure 4.19. Drug inhibition of rotenone-sensitive respiration in isolated mitochondria. 
Complex I-specific inhibitors at 60 µM were left to interact with rat liver mitochondria 
(respiring on glutamate and malate) for 30 minutes (basal respiration % inhibition) before 
ADP was added (ADP-stimulated % inhibition). Rotenone-insensitive rates were subtracted. 
Statistical significance expressed as ****, p ≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 
0.05. Error bars are SEM (n=6 for control, n=5 for Fluoxetine, Iloperidone, Haloperidol, 
Aripiprazole, Oxybutynin and Papaverine, n=4 for Salmeterol, Calcipotriene, n=3 for the 
other drugs). 
4.6 Discussion 
The 789 drugs that constitute the Enzo library were screened for complex I-mediated 
toxicity following the methodology applied in chapter 3 and illustrated in Figure 4.1. 
118 ETC inhibitors were identified from the first screening (60 specific to complex I, 
12 to complex II and 46 non-specific). The former results were used in conjunction 



















































inhibitors (15, 3 and 15 respectively). The site of action within complex I was 
examined and very few compounds (if any) were found to target the flavin site. While 
complex I-specific inhibitors were also tested in isolated mitochondria, complex-III 
specific and non-specific inhibitors were assayed to further characterise their main 
targets within OXPHOS. Lastly, experiments with SMPs failed to identify uncouplers. 
4.6.1 In-silico methods 
The selection process that led to the choice of the Enzo drug library culminated with 
the generation of a “virtual” library of 1185 compounds that came from a database 
search according to an organ-based mitochondrially-linked side effects (see section 
4.1.2). There are 25 drugs in common between the five different categories (brain, 
extraliver, heart, kidney and liver), 18 of which are included in the library: 
interestingly, only two of those inhibited the NADH:O2 pathway enough to warrant a 
follow-up succinate:O2 assay, Tretinoin (32.8% and 78.1% of residual activity in 
NADH:O2 and succinate:O2, respectively) and Amoxapine (51.3% and 98.9% of 
residual activity in NADH:O2 and succinate:O2, respectively). The other 16 drugs did 
not affect the NADH:O2 pathway: this indicates that drug-induced mitochondrial 
dysfunction is a complex condition that cannot just be detected by assays aimed at the 
ETC but requires a more extensive and comprehensive treatment. On the other hand, 
the in silico method for specific complex I inhibitors determination featured in chapter 
3 was validated and proved to be rather successful, considering its ease and free 
availability of the database source. 
4.6.2 Bisphosphonates as potential uncouplers 
The experiments performed with SMPs failed to validate the drugs with the highest 
NADH:O2 activation as uncouplers (see section 4.4). Nonetheless, an interesting 
pattern emerged, concerning drugs that treat osteoporosis and similar skeletal 
disorders. The drug class of bisphosphonates (replacing a phosphoric acid anhydride 
moiety with a central P-C-P in lieu of a P-O-P which make the drugs resistant to 
enzymatic hydrolysis and heat357), all accelerate the NADH:O2 rate to a significant 
degree (see heading row of Table 4.7). Interestingly, the other two drugs in the whole 
library that treat similar skeletal disorders (Calcitriol and Raloxifene) contain no 
phosphorous atoms and are both classified as complex I-specific inhibitors.  
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The pharmacology of bisphosphonates is based on the cluster of negative charges 
around the P-C-P core at physiological pH: this causes a remarkable affinity and 
prolonged binding to the positively charged surface of bone mineral358. The intensity 
of the negative charge depends on whether an amino group is present or not (the pKa 
values of nitrogen-containing groups, especially the pyridinyl group in Risedronate, 
can be very close to physiological pH 359 ): five pKa values or four can be 
experimentally determined, with an overall negative charge of -2 or -3 respectively360. 
The residual activity in the NADH:O2 assay, along with substituents and pKa values 
associated with the previously mentioned overall charge (pKa,3), are presented in 
Table 4.7 for every bisphosphonate tested. 
These drugs are the only ones in the library with a P-C-P core and they all activate the 
NADH:O2 pathway to a significant degree: intriguingly, the only compound in the 
series that does not possess a OH group as central substituent, Tiludronate, is the one 
that activates the pathway the least. These drugs possess at least a double negative 
charge at physiological pH and it is interesting that they could actually exhibit 
uncoupling properties not detected by SMPs: since this system is positively charged 
on the inside of the lumen the drugs might shuttle protons across the (inverted) IMM. 
 




361 115.4 ± 0.4 
Ibandronate 
 
6.37361 118.7 ± 0.5 
Pamidronate  6.01
362 115.5 ± 0.8 
Etidronate CH3 7.03363 118.5 ± 0.3 
Risedronate 
 
6.10359 115.6 ± 0.1 
Zolendronate 
 
6.63364 113.0 ± 1.2 
Tiludronate H 
 
6.90365 107.3 ± 0.0 
Table 4.7. The bisphosphonate drugs in the Enzo library. All drugs exhibit a significant 
activation of the NADH:O2 pathway but their negative charge makes it unlikely to be caused 

















Several antifungal drugs significantly inhibit the complex I pathway (with the 
exception of Echinocandins, Hydroxipiridones and inhibitors of fungal membrane 
stability and fungal mitosis, see Table 4.3) while exhibiting a heterogeneous response 
towards complexes II-IV. They are mostly first generation azole compounds366, 
classified as imidazoles in Table 4.3. Since fungi are eukaryotic organisms and their 
mitochondrial respiration is basically identical to their human counterparts, it is 
possible that complex I inhibition contribute to the antifungal nature of imidazoles 
along with their primary target, lanosterol 14 α-demethylase (a key enzyme in 
ergosterol biosynthesis)367. 
On the other hand, the antifungals squalene epoxidase inhibitors Butenafine, Naftifine 
and Terbinafine, displayed in Table 4.8, share a naphthylmethylamine structural core 
and the ratio of their residual activity towards the NADH:dQ assay over the 
NADH:O2 assay is higher than 3: this is a feature that complex III specific inhibitors 
should possess (see paragraph 4.3.1). Remarkably, Cinacalcet (a calcimimetic) is the 
only other drug in the whole Enzo library that is structurally very similar to the three 
antifungals and exhibits the same response towards relevant assays: high ratio of 
residual activity towards NADH:dQ over NADH:O2 assays and no significant 
inhibition towards either complex I flavin-site or complex IV activities. Furthermore, 
all of these drugs are categorised as non-specific ETC inhibitors (bottom left area of 
Figure 4.5) and are all located below the 1:2 line in Figure 4.13: it is, therefore, likely 
that these compounds be specific inhibitors of complex III. A dQH2: cytochrome c 
assay was, therefore, carried out in membranes with these 4 drugs to test their 
inhibitory potency towards complex III: remarkably, no inhibition was detected. Since 
the electron donor is dQH2 in this assay (rather than Q10H2), it is possible that these 
drugs could block Q10 access to complex III and dQ, being smaller, is not affected and 
could gain entrance without interferenceo. It was recently found that the mechanism of 
squalene epoxidase inhibition by Terbinafine involves the tert-butyl group being 
buried in the catalytic pocket: the naphthylmethylamine moiety then blocks one of the 
two entrances to the catalytic site directly while the other is blocked by 
conformational change upon inhibitor binding368. Since the other three drugs possess a 
                                               
o It must be pointed out that the dQH2:cytochrome c assay is the least reliable of the membrane-based assays 
presented in this thesis, mainly because of its very high signal-to-noise ratio (the rate of the chemical reaction 
between the two substrates is substantial) and artefacts due to reduced dQ. 
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similar long hydrophobic “handle” the inhibitory mechanism towards complex III 
could occur in a similar fashion. Additionally, the NADH:Q10 assay reveals a stronger 
inhibition of complex I than the NADH:dQ assay: this means that the compounds 
should be more correctly classified as non-specific inhibitors. 
 
 
Electron donor Electron acceptor 
Residual % Activity in assay 
Succinate Red. Cyt c NADH 
R1 R2 R3 Name Ox. Cyt c O2 dQ (Q10) FeCN APAD 
 
Me H Butenafine 17.4 18.6 85.4 2.5 72.2 (8.5) 103.8 90.9 
 
Me H Naftifine 15.0 26.2 106.3 0.87 73.3 (21.2) 88.3 93.1 
 
Me H Terbinafine 15.0 23.9 86.7 2.0 47.9 (7.3) 96.7 89.6 
 
H Me Cinacalcet 10.0 31.8 70.1 1.3 61.5 (4.4) 106.0 99.8 
Table 4.8. The four naphthylmethylamines in the Enzo library. The results of several 
assays in membranes and isolated enzyme are presented for Butenafine, Naftifine, Terbinafine 
(squalene epoxidase antifungals) and Cinacalcet (calcimimetic). Electron donors are in the 
green row and electron acceptors are in the red row below the green one. 
4.6.4 Complex II-specific and non-specific inhibitors 
Complex II specific inhibitors do not share many structural similarities at all, apart 
from a hexose core in Auranofin and Clindamycin, a 8 carbon-long conjugated tail in 








The drugs that deliver the highest degree of non-specific inhibition (yellow inset in 
Figure 4.5) are the most potent drugs of the library against ETC enzymes and some 
structural similarities are noteworthy. Three of those are selective estrogen receptor 
modulator or SERMs (Toremifene, Tamoxifen and Clomiphene) and since they are 
clustered very close together the minor structural differences between them should not 
affect their binding interactions. Also, it is possible that these drugs (especially 
Tamoxifen) exert a general non-specific action towards the OXPHOS enzymes that is 
not related to their binding sites at all but just linked to their diffusion in membranes. 
Testosterone Enanthate and Desogestrel share a steroideal core, yet the former (with a 
longer alkyl chain on the 5-membered ring as ester) exerts a more potent effect on the 
complex II pathway. Conversely, Desogestrel is the fourth most potent complex IV 
inhibitor in the library: Danazol shares the same steroideal structure but its potency is 
much lower (from 18.6 to 54.6% residual activity in the reduced cytochrome c:O2 
assay).  
Hexachlorophene was used as an antimicrobial agent in soaps, detergents and 
cosmetics during the 1960s and 1970s and it was then discontinued upon discovering 
its toxicity in animal models along with severe side effects in humans (e.g. dermal 
rashes, wounds, premature labour)369,370. Not surprisingly, Hexachlorophene is the 
drug that generated significant inhibition in all of the assays and enzymes it was tested 
on: NADH:O2, dQ and Q10, succinate:O2, dQ and cyt c, reduced cyt c:O2, 
fumarase/malic enzyme, HRP and ROS. 
4.6.5 Flavin-site and isolated mitochondria assays 
Overall, the flavin site of complex I seems a very poor target for inhibition by drugs: 
given the wide variety of compounds tested in this work with 3 different flavin-site 
assays it seems reasonable to conclude a structure-based drug design for lead 
discovery would likely not produce fruitful results when applied to the flavin-site of 
complex I (or indeed to complex IV, see section 4.2.6). The ROS assay did not reveal 
any potent complex I-mediated ROS inhibitor but, interestingly, identified at least 4 
major inhibitors of HRP (even though it must be pointed out that Apomorphine has 
been shown to be a potent antioxidant and free radical scavenger371): it is worthy of 
note that the almost identical Liothyronine and Levothyroxine exhibit a potency range 
that spans over 2 orders of magnitude towards inhibition of this enzyme. 
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The Seahorse experiment with isolated mitochondria identified Salmeterol (a long-
acting β2-adrenoceptor agonist used to treat asthma and chronic obstructive 
pulmonary disease) as a potent inhibitor of mitochondrial function. Its mechanism of 
action and long-lasting duration reside in its lipophilicity and a long side chain: the 
former allows the drug to remain in the lipid cell membrane and to resist tissue 
washing, the latter anchors at an exosite of the target in the cell membrane permitting 
its continuos activation372 (the shorter and structurally similar Salbutamol is cleared 
from tissues more rapidly because of its higher hydrophilicity373). It is, therefore, 
likely, that hydrophobicity could contribute to the inhibition of mitochondrial 
respiration by Salmeterol. 
4.7 Application of the methodologies to enzymes 
similar to complex I: pyruvate carboxylase 
Finally, it is proposed that the method followed in this work with complex I could be 
adapted to other enzymes that share both its position in converging metabolic 
pathways and its sequential mechanism of action: the enzyme pyruvate carboxylase 
(PC) is a potential candidate. This enzyme catalyses the first step in the 
gluconeogenetic pathway, is the major anaplerotic enzyme and resides in the 
mitochondrial matrix. The reactions catalysed by the enzyme are the following 
1) !"#$% + '() ⇄ (!"#$%)()#$-%) + '.) 
 (!"#$%)()#$-%) = ("#-%)(#)()#$-%) = ("#-%)()0) 
2) (123425)65789: + ("#-%)()0) ⇄ ("#-)(123425)65789: + )0 
3) ("#-)(123425)65789: + ;8<=>?4: ⇄ (123425)65789: + 3@?A3?B:4?4: 
The first two reactions use up one equivalent of ATP to load the biotin cofactor of PC 
with CO2 (one oxygen atom from bicarbonate ends up in the phosphate ion), hence 
carboxyphosphate formation followed by biotin activation. The last reaction, 
transcarboxylation, incorporates the biotin-activated CO2 group to pyruvate to form 
oxaloacetate374. This means that the enzyme activity can be broken down into 
different steps that could, in theory, be individually assayed. Furthermore, the product 
of the enzyme, oxaloacetate, is a metabolic crossroads between the major pathways of 
gluconeogenesis and TCA cycle (Figure 4.20). Such similarities with complex I thus 
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render PC a promising enzyme to be characterized with the methods proposed in this 
chapter. 
 
Figure 4.20 The enzyme pyruvate carboxylase in mitochondria. The enzyme location 
crosses, similarly to complex I, different metabolic pathways (TCA cycle and 
gluconeogenesis) and, as such, a similar methodology to the one applied in this chapter could 
be used to assess the specificity of a drug towards an enzyme. 
4.8 Conclusions 
Thanks to the availability of a library of approved drugs and novel methods to express 
the data from assays and experimental systems routinely used in our lab, key findings 
in the role of complex I-mediated drug-induced mitochondrial dysfunction have been 
revealed in this chapter. One of the main conclusions of this chapter is that many 
drugs included in the Enzo library affect complex I to different extents. The 
availability of several assays allowed to address the issue of identifying ETC drug 
targets and complex I appears to be the enzyme that is affected the most within 
OXPHOS, either in isolation or concomitantly with other respiratory chain enzymes. 
The drugs are structurally different between one another and this indicates how 
sensitive complex I is towards inhibition: this should emphasise the ubiquitous role of 
complex I in one of the recognised mechanisms of drug-induced mitochondrial 
dysfunction, impairment of mitochondrial respiration375. Out of 786 compounds that 
well reflect the variety of current approved drugs, experiments with membranes 
identified 118 ETC inhibitors, of which 60 are specific to complex I, 12 to complex II 
and 46 are non-specific. One of the major conclusions of this thesis is, therefore, that 
membranes are a biological system of easy preparation that could be applied to 
preliminary compound screening in HTS drug discovery protocols: that is why it was 
decided to adopt this system (and the facile NADH:O2 assay) to perform the very first 
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drug screening on the whole library. Additionally, complex IV was not found to be an 
important target for any of the drugs. Lastly, while Salmeterol and Papaverine were 
identified as inhibitors of mitochondrial respiration from a broader perspective than 
the other assays, the results obtained in chapter 3 were validated thanks to the 
methodologies followed in this chapter. 
Finally, results are not as clear-cut with isolated complex I assays as they are with 
membrane-based ones: it emerged nonetheless that the flavin site of complex I is a 
poor target for drugs and that the NADH:Q10 assay can be used in conjunction with 
membrane-based assays to identify complex I-, III-specific and non-specific ETC 
inhibitors.  
4.9 Appendix - Literature therapeutic concentration 
for drugs included in membrane-based assays 
References for 5 drugs (Halcinonide, Mestranol, Methylclothiazide, 
Phenoxybenzamine and Testosterone enanthate) were not available. 
Alitretinoin 376 , Alosetron 377 , Aprepitant 378 , Atomoxetine 379 , Auranofin 380 , 
Bexarotene 381 , Butenafine 382 , Butoconazole 383 , Calcipotriene 384 , Calcitriol 385 , 
Capsaicin257, Chlorhexidine 386 , Ciclesonide 387 , Cilostazol 388 , Cinacalcet 389 , 
Clindamycin Palmitate 390 , Clofazimine 391 , Clomiphene 392 , Clotrimazole 393 , 
Cyproheptadine 394 , Danazol 395 , Darifenacin 396 , Dasatinib 397 , Daunorubicin 398 , 
Desogestrel399, Desoximetasone400, Dexchlorpheniramine401, Dexmedetomidine402, 
Dicloxacillin 403 , Dicyclomine 404 , Dienogest 405 , Dobutamine 406 , Dofetilide 407 , 
Droperidol 408 , Drospirenone 409 , Dutasteride 410 , Econazole 411 , Efavirenz 412 , 
Epinastine 413 , Estradiol405, Estrone405, Ethinyl Estradiol 414 , Etonogestrel 415 , 
Exemestane 416 , Ezetimibe 417 , Fenofibrate235, Fingolimod354, Flavoxate 418 , 
Flunisolide 419 , Gefitinib 420 , Guanabenz Acetate 421 , Guanfacine 422 , Ibutilide423 , 
Idarubicin 424 , Imiquimod 425 , Ivermectin 426 , Lansoprazole 427 , Latanoprost 428 , 
Lindane429, Liothyronine430, Loperamide431, Lovastatin432, Malathion433, Meclizine434, 
Medroxyprogesterone Acetate 435 , Megestrol Acetate 436 , Miconazole 437 , 
Mifepristone 438 , Misoprostol 439 , Mitoxantrone 440 , Nabumetone 441 , Naftifine 442 , 
Nepafenac 443 , Nilutamide 444 , Norethindrone 445 , Orlistat 446 , Oxiconazole 447 , 
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Oxybutynin 448 , Palonosetron 449 , Pazopanib 450 , Permethrin 451 , Pioglitazone 452 , 
Posaconazole 453 , Prasugrel 454 , Progesterone 455 , Raloxifene 456 , Ranolazine 457 , 
Salmeterol 458 , Sertaconazole 459 , Silver Sulfadiazine 460 , Sorafenib Tosylate 461 , 
Sunitinib Malate462 , Tamoxifen247, Tamsulosin463 , Tazarotene464 , Terbinafine465 , 
Terconazole 466 , Tetrabenazine 467 , Tolterodine Tartrate 468 , Toremifene Base 469 , 
Travoprost470 , Tretinoin471 , Sulconazole330, Acitretin, Albendazole, Amiodarone, 
Amitriptyline, Amoxapine, Apomorphine, Aripiprazole, Asenapine Maleate, 
Atovaquone, Azelastine, Benztropine Mesylate, Betaxolol, Bicalutamide, Biperiden, 
Bisoprolol Fumarate, Brompheniramine Maleate, Buspirone, Carvedilol, Celecoxib, 
Chloroquine Diphosphate, Chlorpromazine, Clemastine Fumarate, Clomipramine, 
Clopidogrel Hydrogen Sulfate , Clozapine, Colistin Sulfate, Cyclobenzaprine, 
Desipramine, Desloratadine, Dimenhydrinate, Disulfiram, Donepezil, Doxazosin 
Mesylate, Doxepin, Duloxetine, Esmolol, Felodipine, Fenoldopam Mesylate, 
Fluoxetine, Fluphenazine· HCl, Flutamide, Fluvoxamine Maleate, Haloperidol, 
Hexachlorophene, Iloperidone, Imipramine, Isotretinoin (13-Cis-Retinoic Acid), 
Ketoconazole, Ketotifen Fumarate, Labetalol, Levothyroxine, Loratadine, Loxapine 
Succinate, Maprotiline, Mefloquine, Mitotane, Montelukast, Nicardipine, Nisoldipine, 
Nortriptyline, Orphenadrine Citrate, Paliperidone, Paroxetine, Pentamidine 
Isethionate, Perphenazine, Pimozide, Promethazine, Propafenone, Propranolol, 
Protriptyline, Pyrimethamine, Quetiapine Fumarate, Risperidone, Rosiglitazone, 
Saquinavir Mesylate, Sertraline, Simvastatin, Thioridazine, Ticlopidine, Trazodone, 
Trifluoperazine, Trimipramine Maleate, Verapamil, Zafirlukast, Ziprasidone255, 
Amlodipine, Cisplatin, Granisetron, Itraconazole, Mycophenolate Mofetil, Nebivolol, 
Nefazodone472. 
4.10 Appendix - Literature pKa values for drugs 
included in the membrane-based assays 
Aripiprazole473 , Atovaquone474 , Butenafine475 , Butoconazole476 , Calcipotriene477 , 
Capsaicin478, Carvedilol473, Cinacalcet479, Clotrimazole, Duloxetine473, Econazole480, 
Ethinyl Estradiol481, Fenofibrate482, Fenoldopam483, Fingolimod484, Fluoxetine485, 
Haloperidol251, Hexachlorophene481, Iloperidone 486 , Ketoconazole, Meclizine, 
Miconazole473, Nebivolol 487 , Nefazodone244, Oxybutynin 488 , Papaverine 489 , 
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Propafenone481, Salmeterol490, Silver Sulfadiazine481, Sorafenib491, Sulconazole492, 
Tamoxifen248, Terbinafine481, Trifluoperazine229. 
4.11 Appendix - Literature charge at physiological pH 
Aripiprazole473, Atovaquone 493 , Butenafine475, Butoconazole476, Calcipotriene477, 
Capsaicin478, Carvedilol246, Cinacalcet479, Clotrimazole473, Duloxetine473, Ethynyl 
Estradiol481, Fenoldopam483, Fingolimod484, Fluoxetine485, Haloperidol252, 
Hexachlorophene481, Iloperidone486, Ketoconazole473, Meclizine473, Miconazole473, 
Nebivolol494, Nefazodone244, Oxybutynin488, Propafenone481, Salmeterol490, Silver 

















5 SAR studies on derivatives of Rotenone and 
Deguelin as potential anticancer agents 
5.1 Introduction 
Rotenone is an isoflavonoid natural compound extracted with organic solvents from 
plants of the Leguminosae family (e.g. Lonchocarpus, Derris, Tephrosia) in the form 
of cubé resin495. It is a canonical inhibitor of complex I that is routinely used as an 
experimental tool to selectively block electron transfer within the respiratory chain in 
cells and isolated systems from numerous different species; it has also been reported 
to induce cellular metabolic dysfunction, resulting in symptoms that resemble 
Parkinson’s disease (PD), Leber's hereditary optic neuropathy (LHON) and metabolic 
retinal dysfunction in mice and rats496 . Rotenone was used as an agricultural 
insecticide to control acari, trips and aphids for many years, due to its short 
persistence in the environment and safety towards nontarget organisms497; today it is 
mostly used in fish management strategies to eliminate undesirable populations498. 
Rotenone is classified as moderately hazardous by the WHO, but there are only a few 
reports on toxicity in humans499: its toxicity is associated with augmented ROS 
production, decline in intracellular ATP levels and (given its high lipophilicity and 
subsequent ability to cross the blood brain barrier) accumulation in the brain, 
ultimately inducing neuronal cell death500. Recently, rotenone has also been used in 
pigs towards the development of an in vivo large animal model for mimicking 
complex I-driven metabolic crisis and evaluating pharmaceutical interventions501. 
However, in-depth SAR studies on rotenone and its analogues (rotenoids) are scarce. 
This chapter describes a collaboration with the Chemistry Department at Cambridge 
University to bridge this gap: a library of 66 rotenoids was synthesised by Dr. David 
Russell and the analysis of their potency on mammalian complex I is presented here. 
5.1.1 Aims 
The aims of this work are to  
• improve understanding of how rotenone analogs bind to complex I 
• identify structural determinants of binding within the rotenone core 
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• identify bioactive hydroxylated rotenoids that are less neurotoxic than their 
lipophilic counterparts due to their inability to cross the blood brain barrier, 
but that still retain their potency on complex I, for development as anticancer 
compounds. 
5.1.2 The rotenone family  
The major ingredients of cubé resin are rotenone, deguelin, rotenolone and tephrosin, 
the four rotenone natural products495,502. Structurally, rotenoids are characterised by a 
chromano-chromanone unit (a fused four-ring system, rings A-D) in addition to a fifth 
ring (E-) whose size differentiates rotenone (5-membered) from deguelin (6-
membered)503. Figure 5.1 shows the above-mentioned four major rotenoids and their 
usual ring labelling system504.  
A commonly underappreciated aspect of rotenoids is their three-dimensional 
structure: two-dimensional representations of rotenone fail to effectively convey its 
wedge-like shape, shown in the X-ray crystal structure505 in Figure 5.1. In this regard, 
an important structural aspect of rotenoids is that their B-C rings collectively form a 
cis-decalin system, whereby one 6-membered ring joins another one so that it is axial 
at one point of attachment and equatorial at the other506. Even though cis-decalin 
systems can undergo ring inversion, steric hindrance may prevent it in many 
rotenoids. 
  
X-Ray crystal structure of Rotenone 
Figure 5.1. 2D and 3D features of the rotenoid skeleton. The conventional 2D 
representations of rotenone and deguelin (with their ring labelling system) do not effectively 
convey their three-dimensional shape. Focussing on the B-C ring junction (a cis-decalin) 









































5.1.3 Rotenoids as anticancer agents 
Several studies have described the different biochemical mechanisms underlying the 
in vitro anticancer activity of rotenone and deguelin. Casida507,508 recognised that the 
in vitro activity of rotenoids against complex I correlates with, and is followed by, a 
decrease in activity of ornithine decarboxylase, an enzyme involved in polyamine 
biosynthesis that is upregulated in neoplastic transformation 509 . A study by 
Chiaradonna and co-workers showed that specific complex I inhibitors, such as 
rotenone, piericidin A and capsaicin (used at low concentrations not harmful to 
normal cells), induced cell death in hyperglycolytic cancer cells whose respiration 
was raised via glucose depletion510. This study is an example of how mitochondrial 
reactivation could be a strategy in cancer therapeutics511.  
In addition to the effects of rotenone on complex I, deguelin and two of its analogues, 
SH-1242 and L80, have been found to bind to the ATP-binding pocket of heat shock 
protein Hsp90, a molecular chaperone that contributes to the maturation of several 
oncogenic proteins, thus disrupting its function512,513. Deguelin was also shown to be 
effective at reducing proliferation in two prostate cancer cell lines in vitro514; it also 
appeared to be more strongly active against the more malignant cells tested in the 
study (possibly due to their increased proliferation rates), thus making rotenoids a 
particularly promising family of compounds towards this type of cancer515.  
5.1.4 Rotenone as a complex I inhibitor and its putative binding 
site 
Rotenone is used experimentally to selectively inhibit complex I in many different 
systems, but some species are known to possess an affinity for rotenone much lower 
than that of the mammalian enzyme. For example, complex I from Trypanosoma 
brucei516, Solanum tuberosum (potato tuber) and Escherichia coli517  exhibit IC50 
values for rotenone of about 10 µM, while the IC50 for the bovine enzyme is about 8 
nM (see section 5.3.1). 
The binding site of rotenone in complex I is yet to be identified, but several lines of 
evidence point to its approximate location. Experiments by Earley used tritiated 
radiolabelled rotenoid-based probes to covalently bind rotenone to its binding site in 
bovine complex I by incubation in the dark followed by photolysis: it was recognised 
that rotenoids could photolabel their binding site easily on account of their 
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benzoketone moiety in rings C and D becoming a ketyl radical upon UV irradiation. 
In the first experiment518 a tritiated arylazidoamorphigenin probe (an analogue of 
rotenone in which the azido moiety becomes a reactive nitrene upon UV irradiation, 
see Figure 5.2, left) was found to react non-specifically to several complex I subunits 
in the membrane domain. The non-specificity was ascribed to the hydrophobicity of 
the probes, and so tritiated dihydrorotenone was tested (see Figure 5.2, right): this 
turned out to be a superior probe because of its greater affinity for complex I519. The 
hydrophobic domain subunit ND1 was identified in both experiments as the major site 
of labelling. 
 
Figure 5.2. The radiolabelled probes used by Early and co-workers. The 
arylazidoamorphigenin probe (left) was replaced with a dihydrorotenone probe (right) 
because of its stronger binding to complex I. Tritiated hydrogens are shown in red. 
Later, Brandt’s group studied the relationships between the binding sites of several 
canonical inhibitors of complex I: rotenone, piericidin A and capsaicin. Direct 
competition binding assays suggested the existence of a common binding domain 
with partially overlapping sites for all the inhibitors, and the idea of a large 
ubiquinone binding pocket that could include such a domain was put forward520. The 
idea of a large ubiquinone catalytic site spacious enough for rotenoids to bind was 
also put forward by Miyoshi and co-workers, even though it was also concluded that 
the binding sites of ubiquinone and rotenone are different within the cavity521. Site-
directed mutagenesis studies then indicated that the inhibitor binding site is formed by 
the 49-kDa and PSST subunits, and identified key residues lining the site that, when 
mutated, may lead to rotenone resistance522. Interestingly, the affinity of rotenone to 
























S192T mutation in the 49-kDa subunit of complex I from the former species (to make 
the residue the same as the bovine enzyme) led to a dramatic rise in sensitivity to 
rotenone (the IC50 values were about 160, 260 and 540 nM for bovine heart 
mitochondria, S192T mutation and parental strain, respectively), in addition to a slight 
reduction (about 20%) in ubiquinone reductase activity523. Figure 5.3 shows that this 
residue is located close to the ubiquinone binding site and proximal to the ND1 
subunit in the bovine enzyme.  
 
Figure 5.3. Complex I quinone binding sites in the mammalian enzyme. Complex I from 
Bos taurus, colour code 49 kDa (blue), PSST (magenta) and ND1 (orange), T156 residue 
(corresponding to S192 in Yarrowia) highlighted in yellow; Y144 and H59, key residues for 
ubiquinone binding highlighted in red, are adjacent to the binding site of the ubiquinone head 
group. Original structure from Hirst86. 
Casida and co-workers also showed that the binding site for a photoaffinity ligand 
based on pyridaben, a specific complex I inhibitor, involved the PSST subunit in 
different systems (bovine and bacterial) and that rotenone binds to the same (or to a 
closely coupled) site524. Their work was later used as accessory evidence by Dupuis 
and co-workers, who localised the rotenone binding site to the interface between the 
49 kDa and PSST subunits via mutations on the 49 kDa subunit C-terminus in 
Rhodobacter capsulatus525.  
Since the main contact area of the 49-kDa and PSST subunits is the matrix surface of 
ND1526, the results of Earley’s, Brandt’s, Casida’s and Dupuis’ above-mentioned 
experiments are consistent and combining them indicates that the rotenone binding 
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site in mitochondrial complex I is probably located at the junction between the 49-
kDa, PSST and ND1 subunits. 
5.1.5 SAR analyses of rotenoids in the literature 
Several SAR studies have shed light on some of the relationships between structural 
features of rotenone and deguelin and their effect on complex I. The SAR studies on 
rotenoids by Ueno and Miyoshi focussed on two isomers of epi-rotenone521 and 17 
rotenoids517, respectively (see Figure 5.4, left). The former study found that epi-
rotenone was tenfold less active than rotenone (see section 5.3.1 for epi-rotenone 
results in this work); the latter study included the striking finding that the rotenoid 
obtained by replacing a benzyloxy group in lieu of the E-ring (in order to allow for 
nine subsequent convenient modifications of the A-ring) was equipotent with 
rotenone. Bovine heart SMPs was used in both studies but since the electron acceptor 
was pentylubiquinone the physiological relevance was limited. Another study by Fang 
and Casida 527  examined 29 rotenoids (19 of which were variants of deguelin) 
extracted from cubé resin, and ranked them by their potency against bovine complex I 
and by their anticancer activity as reflected by inhibition of ornithine decarboxylase 
(see section 5.1.3) and cytotoxicity in mouse and human cancer cells: the four major 
constituents of cubé resin (see Figure 5.1) were found to account for most of the 
biological activity reported in the study. A later work by Nicolaou and Casida528 
featured a combinatorial library of over 100 benzopyran-based compounds 
(equivalent to the E- and D-ring core of deguelin) tested in bovine heart SMPs and 6 
different cancer cell lines: the 3D lowest energy conformation of the two leads 
(obtained via molecular modelling) resembled the configuration of deguelin and thus 
explained their potency (see Figure 5.4, right). They also found that introduction of 
polar groups in the corresponding E-ring of deguelin was not well tolerated. 
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Figure 5.4. The structures of key rotenoids in SAR studies. For Ueno and Miyoshi 
structural changes (left) involved the E-ring of rotenone. For Nicolaou and Casida (right) 
extension of a benzopyran core was similar to deguelin. 
5.2 The rotenoids SAR analysis 
5.2.1 Description of the library 
The therapeutic relevance behind the synthesis of the rotenone analogues described 
here was to obtain hydroxylated species that, whilst keeping their potency towards 
complex I, were less neurotoxic (i.e. less capable of crossing the blood brain barrier). 
The rotenoids that constitute the library used here thus possess hydroxyl groups 
installed at different locations across the rotenone skeleton, alterations of the E-ring 
(e.g. different stereochemistry at the junction carbon and ring opening), 
deoxygenations and stereochemical flattening. Lastly, a few halogenated rotenoids 
were included in the analysis for their potential use in structural studies. Figure 5.5 












































R = CH2, OCH2






Figure 5.5. Overview of the rotenoids library. The types of modifications and their 
locations across the rotenone molecule are shown to summarise the library. 
Some of the rotenone derivatives were tested as a mixture of diastereomers because it 
was not possible to separate them (every structure that includes a wavy bond in Table 
5.2, Figure 5.11 and Figure 5.20, see later). 
5.2.2 Measurement of complex I IC50 values for the rotenoid 
library 
Membranes were used for testing the potency of rotenoids. Since the IC50 of rotenone 
is about 8 nM, it was decided to only provide an IC50 estimation of rotenoids whose 
IC50 values were over 2 µM: at that point their potency is so low compared to the 
original rotenone core that any SAR conclusions are of minor importance. For the 
same reason, any rotenoid whose IC50 is higher than 20 µM is considered inactive. 
Figure 5.6 shows examples of data from weak-binding rotenoids (µM-range and 
hundreds of µM-range IC50 values, second and third rows, respectively) and strong-
binding rotenoids (first and last rows, nM-range IC50 values), for both specific activity 






















5- and 6-membered ring
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Figure 5.6. Typical procedure for IC50 determination. The NADH:O2 specific activity plot 
(central panel) and the corresponding logarithmic dose-response curve (right) are shown for 
selected rotenoids. Error bars are SEM of triplicates. 
5.2.3 Summary of IC50 results 
IC50 values (with 95% confidence intervals), Hill coefficients and clogP values 
(calculated using MarvinSketch Version 16.5.2.0 Consensus Model by ChemAxon, 
MA529) are presented in Table 5.1 for all the rotenoids studied. Rotenoids that share 
common structural features will be described in the sections indicated in Table 5.1 in 























































































































































































































Structure IC50 nM 95% C.I. HILL clogP Structure 
IC50 nM 
95% C.I. HILL clogP Paragraph 
 
7.57 
6.8-8.43 1.24 3.32 
 
20.5 
17.8-23.7 1.12 3.32 5.3.1 
 
8.78 
7.57-10.2 1.11 3.59 
 
16.4 
14.1-19 1.16 3.59 5.3.1 
 
1024 
956-1097 1.26 3.83 
 
Inactive / 2.55 5.3.2 
 
678 
551-835 1.06 3.89 
 
Inactive / 2.18 5.3.2 
 
11.5 
10.3-12.9 1.18 3.3 
 
~4 µM / 1.69 5.3.3 
 
22.3 
17.8-28 1.04 3.43 
 
68.4 
60.2-77.8 1.18 2.56 5.3.3 
 
91.7 





5.23-6.43 1.33 4.4 
 
12.7 
11.5-14 1.07 3.21 5.3.4 
 
5.04 
4.44-5.72 1.62 4.13 
 
10.6 
8.57-13 1.03 2.94 5.3.4 
 
12.2 
11.4-13.2 1.24 2.93 
 
7.71 
7.03-8.47 1.14 4.11 5.3.4 
 
66.2 
58.9-74.2 0.94 3.05 
 
30.0 






















































































































































Structure IC50 nM 95% C.I. HILL clogP Structure 
IC50 nM 
95% C.I. HILL clogP Paragraph 
 
~19 µM 
 / 4.29 
 
Inactive / 3.45 5.3.5 
 
~4 µM / 4.02 
 
Inactive / 3.21 5.3.5 
 
30.5 
28.1-33.2 0.93 3.44 
 
202 
175-232 1.14 3.3 5.3.6 
 
156 
138-177 1.24 2.84 
 
125 
109-143 1.05 2.27 5.3.7 
 
83.5 
71.7-97.4 1.00 2.71 
 
446 
286-695 0.78 2.39 5.3.7 
 
132 
116-150 1.44 2.73 
 
84.9 
81.5-88.5 1.20 2.56 5.3.7 
 
152 
136-171 1.40 3 
 
135 
111-163 1.18 2.29 5.3.7 
 
131 
119-144 1.37 2.04 
 
237 
206-273 1.35 2.19 5.3.8 
 
~2 µM 1.25 2.9 
 
626 
476-822 1.35 2.35 5.3.8 
 
58.1 
53-63.7 1.11 2.47 
 
486 
422-559 1.19 1.66 5.3.8 
 
~4 µM / 1.31 
 
503 
391-648 1.04 1.82 5.3.8 
 
~2 µM / 1.31 
 
Inactive / -0.87 5.3.8 

































































































































































Structure IC50 nM 95% C.I. HILL clogP Structure 
IC50 nM 
95% C.I. HILL clogP Paragraph 
 
853 
647-1130 0.94 1.97 
 
~6 µM / 1.45 5.3.8 
 
~5 µM / 0.93 
 
Inactive / 2.31 5.3.8 
 
~3 µM / 1.6 
 
~6 µM / 1.88 5.3.8 
 
~16 µM / 1.76 
 
Inactive / 0.71 5.3.8 
 
Inactive / 0.27 
 
209 
185-237 1.03 3.06 5.3.8 
 
8.94 
8.34-9.57 1.41 3.65 
 
783 
660-928 1.09 2.35 5.3.8 
 
172 
148-200 1.21 2.38 
 
~8 µM / 1.31 5.3.8 
 
739 
691-791 1.15 3.67 
 
406 
346-476 1.49 3.08 5.3.8 
 





3.86-4.45 1.47 3.58 
 
6.00 
4.86-7.41 1.07 3.39 5.3.9 
 
48.5 
39.9-59.1 1.54 3.89 
 
18.9 
15.1-23.8 1.05 3.71 5.3.9 
Table 5.1. Results of the SAR study on the rotenoid library. IC50 values (in nM unless 
otherwise specified) with 95% confidence intervals, Hill coefficients and clogP values are 
presented, as well as the paragraphs (alternating grey and white colours) where the 
























































































































































The class of rotenoids that exhibits the tightest binding is the halogenated class, with 
the lowest IC50 in the series of 4.1 nM (see penultimate row in Table 5.1 and section 
5.3.9). Even though the IC50 value is very low (and associated with an apparent Hill 
coefficient of 1.47) it is not near the stoichiometric inhibition threshold that would be 
detected by a very high Hill coefficient. In mitochondrial membranes approximately 
10% of the protein present is complex I159, so its concentration in the NADH:O2 assay 
was about 1.5 nM. As a comparison, two species with a lower IC50 detected with the 
same assay are fenazaquin (1.69 nM, apparent Hill coefficient of 1.41) and pyridaben 
(1.73 nM, apparent Hill coefficient of 1.58). 
The IC50 values reported in Table 5.1 were calculated with no constraints on the Hill 
coefficient: when this parameter deviates from (an ideal value of) unity, it can be 
diagnostic of some specific physical properties. High values (above 1.5, indicating a 
steep dose-response curve), may represent multisite binding or cooperativity, phase 
transitions (e.g. colloid formation or inhibitor precipitation) or (as noted above) very 
tight, stoichiometric inhibition207. The magnitude of the Hill coefficient is not an issue 
in this work, for the following reasons: 
• It is assumed that any inhibition observed comes exclusively from complex I 
and not from complex III and IV, since the rotenoid core is maintained 
throughout the compound series and rotenone is a specific complex I inhibitor.  
• The Hill coefficients (shown in Table 5.1) ranged from 0.78 to 1.62 so they do 
not consistently indicate a substantial cooperative behaviour.  
• Solubility issues were not encountered at any rotenoid concentration used in 
the assays (no turbidity was observed nor were the well pathlength readings 
abnormally low). 
Finally, to make sure that the different Hill slopes did not affect the reliability of the 
IC50 values, the latter were also calculated by constraining the Hill slope to -1 and the 
correlation coefficient between the two sets of IC50 values (unconstrained vs 
constrained Hill slope) was 0.99: the correlation between the same sets of data in 
logarithmic form is 1, as shown in Figure 5.7. 
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Figure 5.7. Effect of constraining the Hill coefficient to 1 on determined IC50 values. The 
plot shows that when IC50 values from the rotenoid library are calculated by constraining the 
Hill coefficient to -1 the change is negligible. A linear fit of the data with related equation and 
R2 values are shown. 
5.2.4 Correlation between IC50 and hydrophobicity 
The rotenoids in the library exhibit a wide hydrophobicity range (quantified by their 
clogP values) and can be classified according to the number and location of additional 
hydroxyl groups compared to rotenone. Figure 5.8 shows how these hydroxylations 
correlate with inhibitory potency. The most lipophilic species are the C-ring 
deoxygenated rotenoids (see section 5.3.4 and 5.3.5): their clogP values are all above 




Figure 5.8. Relationship between hydrophobicity and inhibitory potency for rotenoids. 
The number indicates how many hydroxyl groups are included in each rotenoids of that class, 
the letter indicates which ring(s) the hydroxyl is attached to (the category of two or three 
hydroxylations at the E-ring includes 4 rotenoids hydroxylated at the C ring too). The plot 
shows how the hydrophobicity of rotenoids (expressed by their clogP values) correlates with 
the number and location (rotenoid ring attached to it) of additional OH groups and with their 
inhibitory potency (expressed by their IC50 in nM in logarithmic scale). Crosses indicate the 
mean clogP value for each category. 
The correlation coefficient between clogP and IC50 values is -0.49 (-0.62 when 
considering logarithmic IC50). The negative sign implies that the most lipophilic 
rotenoids (higher clogP) are most potent against complex I (lower IC50), and this 
suggests that the rotenone binding site is located inside a hydrophobic region of the 
protein, such as the Q site. 
The next section evaluates the structure activity relationships for different aspects of 
the rotenoid structure: modifications of the E-ring (change of stereochemistry, ring-
opening and other alterations, sections 5.3.1-5.3.3), reduction and deoxygenation of 
the C-ring (section 5.3.4), flattening of the rotenone core (section 5.3.5), 
hydroxylation of the A-ring (section 5.3.6), hydroxylation at the B-C ring junction 
(section 5.3.7), D- and E-ring hydroxylations (section 5.3.8) and, lastly, chlorination 
and bromination of the E-ring (section 5.3.9).  
 166 
5.3 Structural determinants of inhibitory potency 
5.3.1 Stereochemistry at the E-ring 
The importance of the alkene and the stereochemistry at the junction carbon in the E-
ring were investigated by comparing rotenone with epi-rotenone and their 
corresponding hydrogenated products (Figure 5.9, IC50 in nM). Reversing the 
stereochemistry (from the R to the S configuration at the chiral outermost carbon) 
leads to a two to threefold increase in IC50, perhaps indicating that the cavity is 
spatially restricted. Hydrogenation of the double bond in epi-rotenone generates a 
mild increase in potency, different from rotenone where such a transformation elicits 
little effect. Ueno and Miyoshi concluded in their above-mentioned rotenoids SAR 
study that the π-electron system of the isopropenyl group attached to the E-ring does 
not confer inhibitory potency517 and these results support the same conclusion. The E-
ring overall appears to be important for binding, though, and this will also be seen in 
later sections 5.3.2 and 5.3.8. 
 
Figure 5.9. Rotenone and epi-rotenone. The relevance of the stereochemistry at the E-ring 
was investigated with rotenone and epi-rotenone (R and S configuration, respectively), in 
addition to their corresponding hydrogenated E-ring tail counterparts. IC50 values in nM. 
5.3.2 Loss of the E-ring: formation of the prenyl unit 
The general importance of the E-ring was evaluated by opening the ether junction, 
with subsequent formation of a prenyl unit (Figure 5.10). This causes the molecule to 
elongate, and a major loss of activity follows (the IC50 increases into the hundreds of 
nM range). The different potencies of the isomers, 1024 and 679 nM, may be caused 






































units as opposed to one where bond rotation can occur) and therefore mimicking more 
closely the binding arrangement of the original rotenone. This suggests the existence 
of steric restriction around the E-ring in the binding pocket (as was already suggested 
in section 5.3.1). Consistent with this idea, hydroxylation of the prenyl moiety and 
loss of the double bond to a brominated 1,2-diol render the molecule inactive. 
However, the last two transformations also make the molecule more hydrophilic (by 
at least one clogP unit, see Table 5.1) and this could mean that the E-ring binding 











Figure 5.10. E-ring opening and modifications of the prenyl unit. The four rotenoids 
obtained by opening the E-ring are either poor inhibitors of (or completely inert towards) 
complex I. IC50 values in nM. 
5.3.3 Alterations of the E-ring: Deguelin and Elliptone 
Further insights into the importance of the E-ring in complex I inhibition came from 
its expansion to a 6-membered ring (Deguelin) and removal of its isopropenyl tail 
(Elliptone), plus their hydrogenated counterparts (Figure 5.11). Deguelin is almost as 
effective as rotenone but it does not tolerate hydrogenation of its E-ring as well since 
its IC50 doubles from 11 to 22 nM (see Figure 5.9). On the other hand, Elliptone 
possesses a flat E-ring with no alkyl groups protruding from the E-ring plane 
(differently to rotenone and deguelin). Hydrogenation of the double bond also leads to 
lower potency, and a further hydroxylation brings the IC50 into the µM range. The E-
ring can therefore tolerate a minor isomerisation that keeps the same number of 



































~4 µM  
Figure 5.11. Alterations to the E-ring. The E-ring in rotenone was expanded (deguelin) or 
removed (Elliptone) to further investigate its importance in complex I binding. IC50 values in 
nM. 
5.3.4 The C-ring carbonyl 
A major structural handle within the library is the carbonyl oxygen in the C-ring: the 
effects of its reduction and removal were investigated as shown in Figure 5.12. 
 
   
 
10.6 5 7.6 
E-Ring hydrogenation 12.7 5.8 8.8 
 
12.2 7.7 11.5 
E-Ring hydrogenation 66.2 30 22.3 
Figure 5.12. Modifications at the carbonyl (C-ring). Reduction of the C-ring carbonyl 
(brown), dexoygenation (orange) and related IC50 values. Values for rotenone and deguelin 























































While the reduction of the C-ring carbonyl (hydroxy- variant) leaves the activity of 
rotenone and deguelin almost intact, deoxygenation (deoxo- variant) surprisingly 
improves the potency. This suggests that rotenone binding interactions with complex I 
do not strongly depend on the carbonyl group. Saturation of the E-ring double bond 
causes the IC50 to drop more in hydroxy- and deoxo-deguelin than in the 
corresponding rotenoids, in line with previous findings (see sections 5.3.1 and 5.3.3). 
Importantly, the cis-decalin ring system (B-C) ring inversion is probably more 
energetically challenging in rotenone due to steric hindrance between the junction 
decalin hydrogens and the carbonyl group in the C-ring, so removing the carbonyl 
moiety via deoxygenation may improve the flexibility of the rotenoid and make the 
inverted cis-decalin conformation energetically accessible. Such improved flexibility 
could allow the deoxygenated rotenoids to accommodate better within the binding 
site, hence their slightly lower IC50.  
5.3.5 Flattening of the rotenone core 
Ueno and Miyoshi521 proposed that a rigid bend at the junction of the B/C rings is 
paramount for inhibition: inversion of the stereochemistry at the junction (i.e. with the 
decalin hydrogens of rotenone pointing down instead of up in Figure 5.9) led to a 
drastic decrease in inhibitory potency compared to rotenone. On the other hand, it was 
recently found by Echeverri and co-workers530 that rotenone flattened in the C-ring 
opposite the ether oxygen is 10 times more potent than rotenone itself against the 
human protozoan parasite Leishmania panamensis (Leishmania mitochondria contain 
complex I531,532), suggesting that in some species the requirement for a bent geometry 
in rotenoids is not absolute. 
The rotenoid library used here includes four species with a C-C double bond that 
renders them flatter than rotenone, either at the B/C ring junction (resulting from the 
dehydrogenation of the cis-decalin hydrogens) or in the C-ring opposite the ether 
oxygen (resulting from dehydration of the carbonyl C-ring). Figure 5.13 shows how 











Figure 5.13. The flattening effect of C-C double bond formation. The cis-decalin core of 
rotenone (left) becomes flatter upon dehydrogenation at the B/C ring junction (upper-right 
corner) or upon dehydration at the C-ring opposite the ether oxygen (lower-right corner). 3D 
rendering of the molecules was obtained with MarvinSpace, ChemAxon, 16.5.2.0. 
Figure 5.14 (teal) shows that the wedge-like geometry of rotenone is indispensable for 
retaining inhibitory activity: evidently the binding site is not capable of 
accommodating the more planar, open and extended structure that results from 
generation of a double bond, indicating that it recognises the shape of the molecule. 
The dehydrated products also include the effect on saturation of the isoproprenyl tail 
(upper portion of Figure 5.14, yellow) and the dehydrogenated products also include 



































Figure 5.14. The effect of flattening of the rotenoid core. Formation of double bonds in the 
C-ring (teal) causes loss of flexibility and three-dimensional character. Further 
transformations (orange) erode the inhibitory potency even more. Estimated IC50 values in 
nM. 
5.3.6 Modifications of the A-ring 
The role of the ortho-dimethyl ether portion of the A-ring was tested by successive 
demethylations according to Figure 5.15 (IC50 in nM); the double bond in the E-ring 
tail was not retained because it interfered with the chemical synthesis: the progressive 
drop in potency from single to double hydroxylation (4x and 23x compared to the 
starting rotenoid) suggests the presence of hydrophobic pockets in complex I that 
respond favourably to alkyl groups (at least methyl). In this regard, Miyoshi 
concluded that while the two methoxy hydrogen-bond acceptor moieties in the A-ring 
are required for tight fitting into the binding site, replacing one of them with a longer 
ethoxy group retains the activity, suggesting the existence of a relatively spacious (or 






































Figure 5.15. The 3,4-dimethoxy moiety in the A-ring. Progressive demethylation in the A-
ring causes a drop in potency. IC50 values in nM. 
5.3.7 Hydroxylation at the B-C junction 
Figure 5.16 shows a comparison of X-ray crystal structures of rotenone and 
dihydroxy-rotenolone (courtesy of Dr. David Russell), two more highly hydroxylated 
rotenone analogues than the ones encountered so far and, as such, more hydrophilic 
(the same applies to the deguelin related tephrosin). The dihedral angle between rings 
A- and D- of the former is 91˚ and the same angle of the latter is 76˚ (for comparison, 
the same angle for deoxo-rotenone is 98˚, see section 5.3.4). Addition of an hydroxyl 
group to the carbon junction in the B-C ring does not effect any conformational 
change but reduction of the nearby carbonyl contributes towards a more pronounced 
wedge-like conformation, possibly by intramolecular hydrogen bonding between two 
contiguous OH in the trans-1,2-diol motif515.  
   
Figure 5.16 The wedge-like geometry of rotenone is more pronounced when the C-ring 
carbonyl is reduced. The X-ray crystal structures of rotenone (left) and dihydroxy-rotenolone 
(right) show that two hydroxy groups at the B-C junction generate a smaller dihedral angle 
between the A- and D-rings. The angle is similar to rotenone with only one hydroxyl group 
















The effects of such transformation are summarised in Figure 5.17. 
 
   
 
132 135 7.6 
E-Ring hydrogenation 152 85 8.8 
 
84 157 11.5 
E-Ring hydrogenation 125 447 22.3 
Figure 5.17. Rotenolone, Tephrosin and dihydroxy-rotenoids. Hydroxylation at the B-C 
ring junction generates rotenolone and tephrosin from rotenone and deguelin, respectively 
(brown), and further reduction of the C-ring carbonyl generates their dihydroxy counterparts 
(cyan). Values for rotenone and deguelin are shown for comparison (magenta). IC50 values in 
nM.  
Addition of the hydroxyl group at the B-C ring junction (Rotenolone and Tephrosin, 
brown in Figure 5.17) renders, for the first time, the rotenone derivative less potent 
than the deguelin one (IC50 132 and 84 nM, respectively), and E-ring saturation is 
detrimental to both. On the other hand, in the related dihydroxylated derivatives (cyan 
in Figure 5.17) the rotenone variant is more potent than the deguelin one (IC50 135 
and 157 nM, respectively) and, intriguingly, E-ring saturation leads to a dramatic 
improvement in potency (from 135 to 85 nM): it appears that the addition of OH 
group prevents optimal binding but a further OH group (hence a more pronounced 
wedge-like conformation) is tolerated.  
A tentative explanation for this behaviour is that the different conformation must push 
the E-ring tail towards a more hydrophobic region, where more favourable binding 
interactions are obtained, since loss of a double bond in the tail region leads to an 


































Figure 5.18. A tentative explanation of the effects of E-ring saturation upon B/C ring 
hydroxylation(s). E-ring saturation in rotenolone is mildly detrimental to the activity, 
perhaps because some hydrophobic interactions are lost in the hydrophobic pocket dedicated 
to the E-ring; conversely, E-ring saturation in the dihydroxy- derivative leads to a marked 
improvement in potency, possibly because the tail can reach out to a more favourable binding 
site thanks to newly formed H-bond interactions (magenta). IC50 values in nM. 
When the same set of structural modifications is applied to deguelin (Figure 5.17, 
tephrosin), the effects are reversed compared to rotenone: hydroxylation of the B-C 
junction still lowers the potency (from 11.5 to 84 nM), but now the dihydroxy- 
arrangement drops it even more (from 84 to 157 nM), particularly if the double bond 
in the 6-membered E-ring is hydrogenated (125 and 447 nM). This could be explained 
by the bigger E-ring of deguelin causing different overall binding interactions than 
rotenone, where a more compact structure is no longer tolerated.  
Fang and Casida527 found inhibitory potencies (in bovine heart electron transport 
particles) for rotenolone and tephrosin similar to the ones found in this work but, 














































side (i.e. trans-decalin as opposed to cis-decalin) the result is much more detrimental 







Figure 5.19. Inhibitory potencies in the Fang and Casida SAR study. Fang and Casida 
showed inhibitory potencies for rotenone and tephrosin similar to the ones in this work and 
showed the detrimental effect of reversing the stereochemistry at the B-C junction hydroxyl 
group. IC50 values in nM.    
5.3.8 E- and D-ring hydroxylations 
A wide array of oxidative alterations at the E-ring (combined with different oxygen 
patterns at the B-C rings) are presented in Table 5.2 (IC50 values in nM). 
Hydroxylation of the E-ring destabilises the binding overall, and this is always 
substantially worsened by additional hydroxylations and oxygen addition at the B-C 
rings (going across the table from left to right), just as if the OH groups pushed the 
molecule further away from the binding site (this could be diagnostic of a 
hydrophobic binding site): with such a high loss of binding affinity, the binding mode 
could also be very different than for the original rotenone. Substantial potency losses 
derived from E-ring based oxidations are encountered with endocyclic hydroxylations 
(when the OH is directly attached to the E-ring, third row in Table 5.2) and with 
multiple oxidative modifications (seventh row in Table 5.2). Amorphigenin (Table 
5.2, third row from the bottom, first column) exhibits an IC50 over 16x higher than 
rotenone, but it was recently found that it is more potent than rotenone against 
complex I isolated from the chinese mosquito Culex pipiens pallens533. The only 
glycosylated rotenoid tested (the disaccharide D-glucose-L-arabinose was attached to 
the E-ring) confirmed the importance of the E-ring for binding, since such a bulky 
substituent generated the biggest potency loss in the whole rotenoid library. The only 

























challenging ones to synthesise (the D-ring is the most unreactive portion of the 
rotenoid skeleton515) and are not very potent inhibitors at all. 
A smaller set of similar structural modifications were incorporated in the E-ring of 
deguelin with similar results: while exocyclic alcohols (at least one carbon away from 
the E-ring) are still relatively well tolerated, endocyclic and multiple hydroxylations 
thoroughly disrupt binding (Figure 5.20). This finding is in agreement with the work 
of Nicolaou and Casida528: polar groups in the E-ring of a similar variant to deguelin 
were not well tolerated. Interestingly, it was found that a doubly hydroxylated 
deguelin (red and green handles in Figure 5.20) loses completely its potency 
(compared to deguelin) against Hsp90, one of the major targets that make deguelin an 
anticancer agent 534 (see section 5.1.3). 
 
     
11.5 172 783 ~8 µM ~6 µM 
 
Figure 5.20. Hydroxylations at the E-ring of deguelin. The same conclusions drawn for 
rotenone apply to deguelin: endocyclic and double addition of OH lowers the potency more 





























         B-C 
 
    E-     
R 
 
7.6 10.6 132 135 H 
739  406  OH 
 
~3 µM   Inactive   H 
 
626  853  ~16 µM  H 
 
58   ~6 µM   H 
 




~5 µM Inactive Inactive  
H 
Data refer to mixture of enatiomers 
 
131  486  ~6 µM   H 
 
8.9  209  H 
 
Inactive    H 
Table 5.2. Two-dimensional oxidative SAR on rotenoids: the B-C ring against the E-
ring. Addition of oxygen atoms in various forms (both in the E-ring and, more importantly, at 
the B-C rings) causes a dramatic fall in potency (going left to right across the table). Red and 
blue, IC50 values for different diastereomers. The grey row shows values encountered in 






































5.3.9 Halogenated rotenoids 
Figure 5.21 illustrates the set of halogenated rotenoids investigated, with the IC50 
values for the corresponding hydroxylated rotenoids also presented for comparison 
(all values in nM). 
 
   
X=H 7.6 8.8 
X=OH 131 626 
X=Cl 6 19 
X=Br 4.1 49 
   
Figure 5.21. Halogenation of the E-ring. Chlorine and bromine were added to the E-ring in 
two different locations (blue and green colours). The IC50 values for species encountered in 
previous sections are shown for comparison in grey. IC50 values in nM. 
Chlorine and bromine were added to the E-ring tail and the additions that keep the 
double bond intact (blue colour) render the rotenoids even more powerful than 
rotenone itself (blue in grey background, X=H). When the halogen addition is across 
the double bond (green colour), the potency loss is noticeable but much less 
pronounced than the effect of hydroxylation. Since the corresponding oxygenations 
are more detrimental, and the spatial requirements of OH, Cl and Br groups are 
similar to each other (and bigger than rotenone with X=H)535, the main factor 
involved in adverse binding interactions (at least around the E-ring) may not be steric 
hindrance but hydrogen bonding. An alternative explanation for such tight binding 
could involve halogen bonding with nucleophilic residues within the binding 
chamber536,537. The fact that some halogenated rotenoids are potent inhibitors of 
complex I is advantageous for structural studies: the large electron density on halogen 
atoms may make structural determination easier in the future. 
5.4 Discussion 
The determinants of rotenoid potency towards complex I inhibition were analysed 
with IC50 measurements in bovine mitochondrial membranes as described in section 














modification retain the same potency as rotenone or increase it (e.g. dihydro- and 
halogenated rotenoids in sections 5.3.1 and 5.3.9 respectively). This suggests that the 
rotenone binding site strictly recognises the E-ring and the room for improving 
potency through this handle is narrow. On the other hand, structural requirements in 
the C- and A-ring regions are less strict and some alterations even improve the 
potency compared to rotenone. 
When the rotenone structure is flattened along the B/C rings, the inhibitory potency 
drops substantially, therefore the three-dimensional wedge-like conformation is 
paramount for optimal binding. The cis-decalin core in rotenoids is probably 
motionally challenged but not energetically prohibited, and some degree of 
conformational flexibility may contribute towards the binding affinity (e.g. deoxo-
rotenone, section 5.3.4). In this regard, the possibility of intramolecular hydrogen 
bonding brought about by adding hydroxyl groups could explain, along with steric 
hindrance, the potency loss of some rotenoids: such intramolecular interaction would 
lock the rotenoid species to a specific conformation incompatible with tight binding. 
The putative ubiquinone-binding channel in mammalian complex I is characterised by 
a very distinctive bottleneck: while the channel (shown in Figure 5.22, left) is mainly 
uncharged and hydrophobic, the bottleneck is formed by polar and charged residues, 
especially arginine86.  
  
Figure 5.22. The ubiquinone-binding site in mammalian complex I. The picture on the left 
(from Hirst86) shows the main residues forming the ubiquinone-channel in bovine complex I 
plus the bottleneck region highlighted by the arrows. The picture on the right illustrates how 
rotenone would fit inside the bottleneck region in the same structure. 
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Given the approximate location of the rotenone biding site, it is tempting to speculate 
that rotenoids may access their binding site through the ubiquinone-channel (more 
hydrophobic rotenoids tend to be stronger inhibitors, see Figure 5.8). The bottleneck 
region of the ubiquinone-site actually resembles the wedge-like geometry of the 
rotenone core, and binding in this region could be favourable in terms of both 
stabilising interactions (e.g. hydrogen bonding with the above-mentioned polar 
residues) and forcing a stable wedge conformation (shown in Figure 5.22, right). 
The rotenoids in the library span both a wide hydrophobicity and potency range (see 
Figure 5.8), hence there are opportunities to find a compound suitable for therapeutic 
use with limited neurotoxicity. The most promising anticancer therapeutics within the 
library are Rotenolone, Tephrosin and their dihydroxy-counterparts (see section 
5.3.7): their low hydrophobicity and high potency makes them the best candidates for 
further biological evaluation.  
There are numerous examples of rotenoids less hydrophilic than rotenone that possess 
anticancer activity: some of them shown in Figure 5.23 along with their clogP value. 
 
Figure 5.23. Hydrophilic rotenoids that exert anticancer activity. These hydrophilic 
rotenoids (their clogP values are lower than rotenone, shown for comparison) have shown 
promising anticancer activity in several cancer cell lines through various mechanisms. clogP 



















































In two recent studies by the Kinghorn group538,539, Rotenolone was found to inhibit 
growth and K-Ras activity (a protein expressed by the KRAS gene required for tumor 
maintenance540) in HT-29 human colon cancer, 697 human acute lymphoblastic 
leukemia and Raji human Burkitt’s lymphoma cells; it was also found to inhibit NF-
kB signalling (crucial in KRAS mutant tumors for cell survival541) in HeLa cells. 
Rotenolone was also not cytotoxic towards CCD-112CoN human normal colon cells. 
An hydroxylated rotenoid (bottom-left corner in Figure 5.23) was shown to possess 
inhibitory activity of adipocyte differentiation in 3T3-L1 cells542 and this could 
signify a potential anticancer treatment, given the several mechanisms of metabolic 
symbiosis between adipocytes and cancer cells, especially in breast cancer cells543,544. 
Finally, 6-Deoxyclitoriacetal (bottom-right corner in Figure 5.23) was found to exert 
growth inhibition activity against human oral carcinoma KB, breast cancer MCF-7 
and human small lung cancer NCI-H187 cell lines, along with inhibition of 
topoisomerase II activity545, a class of enzymes ubiquitous within most nucleic acid 
processes and targets for treating many human malignancies546.  
5.5 Summary 
The rotenoids analysed thus far provide many insights into the binding interactions of 
rotenone towards complex I: a conformationally rigid E-ring is required for optimal 
binding, the reduction/deoxygenation of the C-ring carbonyl does not cause high loss 
of inhibitory activity (hence an hydroxyl group does not provide hydrogen bonds to 
the C-ring binding target) while reaching an extended and flatter conformation 
completely disrupts binding; finally, the methyl ethers in the A-ring point towards the 
presence of a hydrophobic pocket. Hydroxylation of the B-C ring junction leads to 
slight loss of activity, and conversion of the nearby carbonyl to hydroxyl is well 
tolerated: particularly rotenoids possessing the anti-diol motif are the most promising 
for follow-up experiments in more sophisticated systems (cell-based assays and 
mouse models of cancer), on account of their high hydrophilicity combined with 
relatively high potency. Oxidative modifications at the E-ring lead to far more varied 
results, depending on the hydroxylation site, so it appears that the rotenone binding 
site is more temperamental towards changes in the E-ring milieu. The results on the 
halogenated series suggest that disruption of inhibitory potency is due to hydrogen 
bonding interactions rather than mere steric hindrance. 
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6 SAR studies of complex I on-target and off-
target drugs: IACS-10759 and Mubritinib 
6.1 Introduction and aims 
During the safety assessment process of lead compounds, toxicology studies are 
indispensable to predict risks for human use. Adverse toxicologic effects can be 
chemical-based, on-target and off-target: the former relates to the side effects linked 
to the physicochemical characteristics of a compound (e.g. cationic amphiphilic drugs 
incorporated into phospholipid bilayers of plasma membrane547), the latter two are 
connected with unwanted pharmacological effects at the target of interest (on-target or 
exaggerated pharmacology, e.g. bleeding events with antithrombotics548) or at other 
targets549. Collaborations were established with the Texas MD Anderson Cancer 
Center and the Leicester MRC Toxicology Unit to test two libraries of candidate 
drugs (and their variants) that interact with complex I in an on-target (IACS-10759) 
and off-target (Mubritinib) fashion: these drugs are structurally similar to each other, 
since they share two phenyl rings on either side and a central oxa(di)azole ring 
(Figure 6.1 shows representative examples of both libraries). 
 
Figure 6.1. Comparison between Anderson Centre drugs and Mubritinib. There are some 
structural similarities between the Anderson Centre drugs (2713 is shown) and Mubritinib: 
two phenyl rings on either side and a central oxa(di)azole ring. 
The aims of this work are to 
• improve understanding of inhibition and drug binding to complex I 
















6.2 The Anderson Cancer Centre drugs 
The collaboration with the Texas MD Anderson Cancer Center was developed in two 
stages. Firstly, a set of drugs (8 compounds, Library A), which had already been 
extensively characterised in cell based assays and xenograft models for cancer and 
identified as a complex I inhibitor, was tested with different assays to determine their 
potency and selectivity against complex I. Secondly, a bigger set of 30 related 
compounds (Library B), hitherto uncharacterised in terms of their biological 
antitumorigenic effect, was analysed to complete a SAR study on complex I. This 
family of molecules is considered to exert its anticancer properties via complex I 
inhibition. The compounds share a common structural motif that was originally 
explored by Bayer AG in 2013 for one of their lead candidate anticancer drugs. 
6.2.1 The pyrazolyl oxadiazole scaffold: HIF suppression, 
energy depletion and reduced aspartate production  
The pharmaceutical company Bayer AG was the first to report that pyrazolyl 
oxadiazoles derivatives can suppress the expression of HIF target genes under 
hypoxic conditions and their work culminated in the anticancer drug 87-2243 (see 
Figure 6.2). The most important drug in the libraries tested in this work (10759, see 
section 6.3.4) shares an almost identical scaffold with 87-2243 (1,3,4 triazolyl 
oxadiazole) but, interestingly, the Anderson Centre proposed a different mechanism 
of action for its antiproliferative activity than Bayer AG. While 87-2243 was mainly 
tested in HIF target gene expression, 10759 was primarily assessed in cancer 








Figure 6.2. Representative structures of confirmed hit cluster from initial screening by 
Bayer AG. The figure illustrates the steps that Bayer took to improve potency, aqueous and 
metabolic stability from the original cluster 1 to lead compounds 2 and 3. It was 87-2243 that 
was ultimately chosen for extensive follow-up experiments. 10759 is shown for comparison. 
6.2.1.1 87-2243 by Bayer AG and the role of ROS in tumorigenesis 
The stepwise development of 87-2243 is shown in Figure 6.2550. The key point was 
the introduction of the oxadiazole ring to address the lack of stability in aqueous 
solution. Further refinements on either side of the core led to compounds 2 and 3 that 
showed remarkable specificity for suppression of hypoxia-induced expression of HIF-
targeted genes, as well as very favourable pharmacokinetic properties. Bayer AG 
discovered the pharmacologic potential of the pyrazolyl oxadiazole class in this work 
and this subsequently led to the development of 87-2243. 
In a further paper by the same group, 87-2243 was extensively characterized with 
respect to its activity towards HIF-1, mitochondria and complex I551. It was found that 
87-2243 decreased both expression of hypoxia-targeted genes and HIF protein 
accumulation in H460 (human lung cancer) cells. More specifically to mitochondria, 
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The carboxymide unit is 
unstable in aqueous buffer
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cultured in glucose but it did when the cells were cultured in galactose (when cells are 
more dependent on OXPHOS); additionally it decreased mitochondrial oxygen 
consumption (measured with the LUX-MitoXpress dye) with an IC50 of 10 nM. 
Specificity to complex I was addressed by succinate- or NDI1-rescue experiments 
involving H1299 lung cancer cells expressing firefly luciferase with rotenone and 
antimycin A (a specific complex III inhibitor), the same techniques used by the 
Anderson Centre, see section 6.2.1.2. 
The authors of the paper erroneously concluded that the antitumorigenic effect of 87-
2243 was to be ascribed to the HIF-activating role of mitochondrial ROS during 
hypoxia (no ROS assays were carried out in the study on 87-2243 although they did 
test a class of alkyliminophenylacetate inhibitors of hypoxia-induced HIF-1 activation 
for ROS generation mentioned in section 1.6.3). They referred to ROS generated from 
complex III which can form and direct superoxide ion in the intermembrane space for 
cytosolic signaling as well as in the matrix (as opposed to complex I and II which can 
only direct superoxide ion in the matrix, see chapter 1 for a review of mitochondrial 
ROS and the hypoxia response)552. The Schumacker group indeed found that hypoxia 
in wild type mouse and rat pulmonary arterial smooth muscle cells elevated cytosolic 
but not mitochondrial H2O2 levels553. In theory, however, reduced electron flow 
caused by inhibition upstream of complex III (for example at complex I) should 
disrupt electron transport, generating lower cytosolic ROS emission from this 
enzyme554 and, as a result, should partially restore PHD2 activity in cancer cells 
(recall from chapter 1 that ROS inactivates PHD2 via disulphide bond-mediated 
dimerization). Within this logic, the Bayer group linked inhibition of mitochondrial 
complex I to lower cytosolic ROS levels that would otherwise inhibit PHD2, thus 
preventing accumulation of HIF-1α. It must be pointed out, however, that while a 
decrease in mitochondrial ROS emission in the cytosol from complex III generated by 
complex I inhibition may initially happen, at some point increased matrix ROS will 
cross the IMM and reach the cytosol in the form of H2O2. Forkink et al.555 recently 
reported that a 24 hour inhibition by rotenone in HEK293 (human embryonic kidney) 
cells elevated cytosolic H2O2 levels, but not enough to cause oxidative stress or cell 
death. The authors did not account for the role of drug metabolising enzymes that 
could have mitigated the effects of rotenone inhibition (see chapter 3 for experiments 
with CYP450 and rotenone). The lack of ROS assays to back up the conclusions by 
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the Bayer group was remedied by another group within Bayer AG556 where ROS 
production was addressed in melanoma cell lines. They found that 87-2243 inhibited 
tumorigenesis by generating high levels of both mitochondrial and cytosolic ROS that 
resulted in oxidative damage and, eventually, cell death. ROS scavengers were 
successfully used to establish the causative role of ROS in 87-2243-induced cell 
death. They also found that 87-2243 was more effective in conditions of limited 
glucose availability. Ultimately, Bayer concluded that the antitumorigenic activity of 
87-2243 occurs through complex-I generated ROS oxidative stress and ATP depletion 
in conditions where glucose is limited (e.g. in the centre of a tumour).  
Further characterization by Bayer AG included xenograft models indicating that 87-
2243 improves the outcome of tumour control concomitant with fractionated 
irradiation557, as well as the use of compatible PET tracers to better monitor its 
therapeutic efficacy558. 
A recent study by the Ihnat group559 showed that the carbazole-based compound 
AG311 induced necrosis in two breast cancer mouse models via mitochondrial 
depolarization, oxidative stress and loss of membrane integrity. A later study by the 
same group560 identified complex I as the molecular target responsible for the drug 
mode of action and, interestingly, it was also found that AG311, by lowering oxygen 
consumption through complex I inhibition, mediated a localized increase in oxygen 
tension (hence higher PHD2 activity) within the tumour milieu (detected with 
pimonidazole, an hypoxia marker), thus preventing HIF-1α stabilization. 
6.2.1.2 10759 by the Anderson Cancer Centre 
10759 (shown in Figure 6.2) was identified with a SAR study that included 
compounds similar to 87-2243. 10759 was very active (IC50 in units of nM) in 
lowering OCR in several human, mouse, rat and monkey cancer cell lines grown in 
galactose. The biological target was proposed to be complex I on account of 
succinate- or NDI1-driven electron-flow rescue experiments in permeabilised H460 
cells and NADH:dQ assay on isolated mouse complex I (this last aspect will be 
described in the results section)561. A concentration-dependent degradation of HIF-1α 
was also observed. By generating clones of H292 (human lung cancer) cells resistant 
to 10759, a common L55F mutation was found in the ND1 subunit of complex I, 
close to the entrance of the Q-channel, suggestive of the binding site of the drug. 
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10759 was then tested in two different tumour contexts: glycolytic-deficient human 
brain cancer cell lines and acute myeloid leukemia (AML) cells heavily reliant on 
OXPHOS. In both cases, inhibition of proliferation and apoptosis induction were 
accomplished at well tolerated doses in mice. The first tumour type was present in 
about 9% of a sample of tumours from the Anderson Centre patients and the 
consistent anti-leukemia response generated by 10759 in the second tumour context 
granted the beginning of a phase 1 trial for AML patients. 
The mechanism of action of 10759 was further elucidated with isotope tracing 
experiments in AML cell lines for carbon and amino acid metabolism, and as noted 
below, energy depletion and reduced aspartate synthesis were concluded to account 
for the antiproliferative effects of the drug towards cancer cells. It was found that 
NADH and nucleotide monophosphate (NMP) levels were higher and nucleotide 
triphosphate (NTP) levels lower than in control cells, consistent with complex I 
inhibition and low energy charge (NTPs are generated with two equivalents of ATP 
via nucleoside kinases). Further metabolic changes occurring upon treatment with 
10759 included higher levels of lactate and alanine and lower levels of several TCA 
cycle intermediates: this is consistent with the diversion of glucose to lactate 
(following glycolysis) and energetic distress that causes branched-chain amino acid to 
be used as a source of fuel562. Of note, the only amino acid whose biosynthesis was 
inhibited by 10759 was aspartate: it has been shown that this species is paramount in 
proliferating cells (for amino acid in proteins and de novo purine and pyrimidine 
synthesis) where respiration feeds electron acceptors towards its synthesis563. 
6.3 Anderson Cancer Center drugs: specific and 
powerful complex I inhibitors 
6.3.1 Compounds features and libraries description 
All of the compounds tested in the same family as 10759 belong to two different 
libraries, labelled A and B, and can be considered in 6 sections, according to their 
different functional groups. Figure 6.3 shows a representative compound of the whole 
series and the most common handles in each group: groups B and E are constant 
throughout the series, A and F are the most variable. 35 drugs possess a 2-pyridone 
moiety in C, the remaining 3 drugs a triazolyl moiety (e.g. 10759). Notably, these 
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molecules are endowed with substantial conformational flexibility and can become 
very flat overall (see top of Figure 6.3 for a three-dimensional rendering). It was 
decided to illustrate the compounds in terms of relative orientation (from left to right, 
A to F based on the bottom panel of Figure 6.3), rather than standard chemical 
nomenclature, for easier referencep. 
 
 
Figure 6.3. Representative scaffold for the Anderson drugs. The 38 compounds that form 
the two libraries can be split into 6 portions, according to the molecular handles that were 
modified for SAR purposes. A three-dimensional view of the the representative compound is 
also shown on top (3D rendering was obtained with MarvinSpace, ChemAxon, 16.5.2.0). 
As for Library B, a set of 30 compounds was designed according to the left- and right-
hand side groups relative to two specific orientations of the central oxadiazole core: 
while the former group possesses a OCF3 handle at the right far end with the 
oxadiazole ring oxygen pointing towards (and different side attachments on) the left, 
                                               
p Standard chemical nomenclature would include the segments “3-(4-(trifluoromethoxy)phenyl)-5-(2-pyridone)” 




























B C D E F
 189 
the latter group possesses a methoxyethoxy handle on the left, with the oxadiazole 
ring oxygen pointing towards (and different side attachments on) the right. Figure 6.4 
shows the main features that distinguish the two categories from one another. Despite 
the orientation of the oxadiazole ring towards the left, 2430 was included in the right-
hand side library for better comparison purposes (see Table 6.3 and Figure 6.8, panel 
C). 
 
Figure 6.4. Structural elements that specifies the two categories of Library B. Orientation 
of the oxadiazole oxygen atom and different side attachments define the two categories of 
drugs in Library B. 
The compounds included in Library A possess less functional groups in common with 
each other (and they were also delivered one year earlier) than Library B but they 
were tested with further experiments and systems than just the NADH:O2 assay in 
order to fully elucidate their role and specificity towards complex I inhibition (Dr. 
Febin Varghese kindly provided the Yarrowia and Paracoccus membranes, Ahmed-
















Moiety changes through the series
Oxadiazole ring oxygen
points towards the left
Oxadiazole ring oxygen
points towards the right
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6.3.2 Main experimental details and NADH:O2 results 
Mitochondrial membranes from bovine (and other species for Library A, see section 
6.3.5 for details) enriched with exogenous cytochrome c were used for testing the 
potency of the drugs in this SAR study. All of the drugs were tested with the 
NADH:O2 oxidoreduction assay and, rarely, erratic 340-380 nm absorbance traces 
(the R2 was close to 0.9) were encountered at the highest drug concentrations within 
the titration series (drugs 2708, 2720 and 10573, see section 6.3.6.2). No turbidity was 
observed nor were the pathlengths readings abnormally low compared to the expected 
value. clogP values were also determined for all the drugs (calculated using 
MarvinSketch Version 16.5.2.0, Consensus Model, ChemAxon, MA529). The 
NADH:O2 (and also NADH:dQ for Library A) IC50 determination process was 
exactly the same as the one used in the other chapters (4-parameters Hill equation). It 
was also decided to provide an IC50 estimation for compounds whose IC50 values 
were over 2 µM and to consider inactive the compounds whose IC50 was higher than 
20 µM. The best-fit Hill coefficients ranged from 0.64 to 1.77 and do not consistently 
indicate a substantial cooperative behaviour. 
IC50 values for the NADH:O2 and NADH:dQ assays (with 95% confidence intervals), 
Hill coefficients and clogP values are presented in Table 6.1 (Library A), Table 6.2 
(Library B left-hand side handle) and Table 6.3 (Library B right-hand side handle) 
where the compounds that make up the libraries are shown. Three representative 





































IC50 139 nM 
Figure 6.5. Representative dose-response curves for Anderson centre compounds. The 
plots show NADH:O2 assay plots for tight (1225), moderate (10759) and poor (10576) 


























  NADH:O2 NADH:dQ  
STRUCTURE DRUG IC50 nM (95% C.I.) HILL IC50 nM (95% C.I.) HILL clogP 
 
10759 139 (124-155) 1.28 478 (382-599) 0.91 5.24 
 
4101 3.79 (3.28-4.39) 1.30 23.1 (20.2-26.3) 1.10 4.18 
 
4872 41.7 (33.2-52.4) 1.08 170 (128-226) 0.83 4.67 
 
5416 35.5 (30.5-41.3) 0.81 244 (201-297) 0.97 6.71 
 
2858 4.64 (4.39-4.90) 1.77 10.0 (8.69-11.5) 1.13 5.12 
 
1131 46.7 (43.1-50.6) 1.46 405 (332-492) 0.99 5.42 
 
4871 252 (232-273) 1.12 532 (450-627) 1.04 3.66 
 
5417 187 (96.6-363) 0.64 685 (527-891) 0.94 5.52 
Table 6.1. Results of SAR study on the Library A. NADH:O2 and NADH:dQ IC50 values (in nM unless otherwise specified) with 95% confidence 


































































STRUCTURE DRUG IC50 nM (95% C.I.) HILL clogP 
 
1919 1277 (569-2870) 1.00 5.01 
 
2490 20.5 (16.3-25.7) 1.05 7 
 
10747 16.8 (13.5-21.0) 1.01 5.54 
 
1240 840 (597-1180) 0.90 4.67 
 
2438 Inactive / 4.86 
 
2834 82.3 (66.9-101) 1.30 5.80 
 
1921 806 (592-1100) 1.20 6.92 
 
1920 404 (330-496) 1.20 5.25 
 
2414 83.4 (71.2-97.6) 1.01 5.91 
 
1225 13.1 (11.9-14.4) 1.15 6.03 
 
2997 14.8 (13.3-16.6) 1.09 4.65 
 
2716 13.7 (10.9-17.1) 0.95 4.81 
 
1239 666 (542-818) 1.19 4.86 
 
2398 821 (664-1020) 1.26 6.77 
Table 6.2. Results of SAR study on the Library B – Left-hand side handles. NADH:O2 IC50 values (in nM 






















































































STRUCTURE DRUG IC50 nM (95% C.I.) HILL clogP 
 
2544 1023 (372-2810) 1.07 5.13 
 
2708 395 (257-606) 1.44 4.86 
 
2720 262 (207-331) 1.12 5.33 
 
2711 674 (517-877) 1.42 3.91 
 
3145 ~3 µM / 4.44 
 
10507 ~15 µM / 3.36 
 
10575 ~4 µM / 3.71 
 
2718 299 (179-499) 0.87 5.68 
 
2713 639 (528-774) 1.50 4.98 
 
2712 1145 (935-1400) 1.48 4.61 
 
10573 1.68 (1.24-2.28) µM 0.98 5.11 
 
2719 ~2 µM / 3.96 
 
3152 912 (542-1530) 1.11 5.01 
 
3004 660 (456-956) 1.3 4.02 
 
10576 701 (597-822) 1.23 3.79 
 
2430 72.1 (60.4-86.0) 1.46 5.68 
Table 6.3. Results of SAR study on the Library B – Right-hand side handles. NADH:O2 IC50 values (in nM 


































































































6.3.3 Complex I specificity of drugs, binding site and 
hydrophobicity 
Drugs from library A were tested to determine their specificity, binding site on 
complex I and level of ROS production (all assays were performed at 3x their IC50 in 
NADH:O2 in membranes). Specificity to complex I was checked with the 
succinate:O2 assay: no compounds affected the rates, indicating specificity towards 
complex I. The reactivity at the flavin site was tested with the NADH:FeCN and 
NADH:HAR assays, and no compound was found to affect these reactions. The mild 
stimulation of NADH:FeCN for some drugs is likely chemical in nature (this assay 
was found to be very prone to artefacts, see chapters 3 and 4). Lastly, ROS production 
(Amplex Red assay) was unaffected by all species. The overall results are summarised 
in Figure 6.6. 
 
Figure 6.6. Flavin-site and succinate:O2 reactivity of Library A. The drugs in Library A 
were tested at 3x their IC50 in the NADH:O2 assay (see Table 6.1) to check their reactivity 
towards the flavin site of complex I and towards the succinate:O2 pathway. Error bars are 
SEM of triplicates. 
Figure 6.7 shows how lipophilicity (expressed by clogP values) correlates with 
inhibitory potency. The drugs are fairly hydrophobic: the average (± SEM) of clogP is 
5.63 ± 0.23, 4.60 ± 0.18 and 5.07 ± 0.31 for the left-hand and the right-hand sides of 
Library B and Library A respectively. Similarly to the rotenoids library, a negative 
correlation between hydrophobicity and potency implies that the more lipophilic a 

































Surprisingly, the clogP and NADH:O2 IC50 values (presented in Table 6.1, Table 6.2 
and Table 6.3) correlate with each other much more in the right-hand side group than 
the left-hand side group (correlation coefficients of -0.563 and -0.057 respectively), 
and expressing the IC50 in logarithmic scale does not change the overall trends (-0.717 
and 0.004 respectively). This suggests that hydrophobic interactions are more relevant 
for binding in the right-hand side of the compounds. Drugs from Library A exhibit a 
small correlation coefficient of -0.32 that becomes 0.01 upon logarithmic IC50 
transformation, indicating a lack of substantial correlation. 
 
Figure 6.7. Relationship between hydrophobicity and inhibitory potency for the 
Anderson centre compounds. The drugs that belong to the right-hand side library are the 
only ones that exhibit a substantial correlation between potency and hydrophobicity. Lines are 
linear fits for the two variables. 
6.3.4 SAR on Library A 
Library A includes the only three drugs that do not possess a central oxadiazole ring 
and 1131 is the only species where the benzyl moiety is replaced with pyridine (see 
Table 6.4). Incorporation of basic nitrogen-containing aromatics to replace phenyl 
rings is usually performed to improve metabolic stability564  and enhance water 
solubility (especially by increasing the chances of salt formation)565 but in this case 
the nearby piperazine N-atom attached in ortho position can also play a role in both 
stability and solubility, given its electron withdrawing inductive effect that influences 
the lone pair at the pyridine nitrogen (similarly, the ammonium ion of pyridine 

























clogP mean values 
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to the N atom in o-position566). 4101 and 2858 possess a sulfonyl group (but see also 
panel B in Figure 6.8): this moiety (compared to its bioisostere amide) is much more 
electron-withdrawing, provides a different substituent directionality (due to the sp3 
hybridisation compared to sp2) and gives more opportunities for hydrogen bonding 
interactions567. 
The IC50 values in bovine mitochondrial membranes are summarised in Table 6.4: 
even though it is still possible to draw some SAR conclusions, those are more limited 
than the ones related to the bigger group of drugs because of the limited extent of the 
structural modifications that Library A encompasses. The IC50 for the isolated enzyme 
NADH:dQ are listed too: the values are well correlated with the corresponding ones 
for membranes, with a correlation coefficient of 0.89. 
DRUG  
IC50 NADH:O2 (nM)  
IC50 NADH:dQ (nM) 
 
 A B 
10759 139 478   
 5416 35 244 
 5417 187 685  
 
 
 C X D E 





4872 42 170 
 
4101 3.8 23 
 
 
2858 4.6 10 
 1131 76 405 
 
N 
Table 6.4. Summary of SAR analysis on Library A. The 8 species can be divided into two 
categories depending on the different structural variables. The upper group maintains the 

































4101 and 2858 are the most potent drugs and they only differ by the orientation and 
type of core 5-membered heterocycle (similarly to 2430 and 2718 in Figure 6.8, panel 
C) that does not affect their inhibitory power: the IC50 of 1131 is 15x higher and this 
is more likely due to the sulfonyl group than to the pyridine nitrogen. This is further 
confirmed by replacing the sulfonyl with a long-chain alkyl amide in 4872 which 
leads to a tenfold loss in potency (IC50 from 4.6 to 42 nM). Further loss in potency 
occurs when replacing the right-hand side OCF3 with an azide in 4871 (IC50 252 nM), 
which can act as a hydrogen bond acceptor568 but in this case it only appears to 
provide an unfavourable binding option, just as it happens for 5416 in comparison to 
5417 (from 35 to 187 nM IC50): the longer left-hand side alkyl chain could reach out 
to a hydrophobic pocket, whereas the shorter methyl group in 10759 cannot, hence its 
lower potency compared to 5416. 
6.3.5 Mitochondrial membranes from different species and lead 
compound 10759 
The Anderson Centre has turned the spotlight on drug 10759 for over 2 years now, 
after a medicinal chemistry campaign that included their collaboration with our 
group569. In addition to all of the above-mentioned assays (aimed at addressing 
specificity and potency towards complex I), a screening of how the drug interacts with 
mitochondrial membranes obtained from different species was performed. Drugs 4101 
and 1131 were included in such screening for comparison. Table 6.5 summarises the 
results, with IC50 in nM. There are two major conclusions: firstly, these drugs have a 
very weak effect on bacterial and yeast complex I (the IC50 was only estimated given 
the very high drug concentration required to cause any inhibition), whereas they are 
very potent in mammalian tissues. Secondly, in mouse and rat systems, all the drugs 
display similar inhibition to each other, whereas in bovine membranes 4101 is the 
most potent and 10759 the weakest, with a range encompassing single to triple 
nanomolar digits. It appears, therefore, that bovine mitochondrial complex I possesses 
additional features (compared to its mouse and rat counterpart) that prevent optimal 
binding of 10759. This interesting capacity of 10759 to elicit significantly different 
responses in complex I from different mammalian species makes it a candidate probe 
for identifying structural differences in different mammalian enzymes. Such a 
different inhibition across mammalian species has not been observed yet. 
 199 
Bacterial and yeast complex I are less sensitive towards rotenone and piericidin than 
their corresponding bovine counterparts. The IC50 for Paracoccus denitrificans was 
reported to be 170 nM for rotenone and 100 nM for piericidin in the isolated enzyme 
for NADH:dQ570  and between 500 and 600 nM for rotenone in mitochondrial 
membranes from Yarrowia lipolytica571,572. In bovine membranes IC50 values for 
rotenone and piericidin are about 8 and 5 nM respectively. Furthermore, affinities 
measured for rotenone in Paracoccus denitrificans and Rhodobacter capsulatus 
vesicles were 500 and 150 times lower (higher Ki) than bovine heart SMPs573.  
 IC50 nM 
 
10759 4101 1131 
NADH:dQ isolated enzyme 
Heart Bovine 
478 23 405 
NADH:O2 membranes 
Heart Bovine 
139 3.8 46.7 
Mouse 
Kidney 
10.8 3.9 6.3 
Heart 
9.3 2.8 4.7 
 
Brain 
 2.9 Liver 
3.4 
Rat Heart 
6.5 4.3  
Yarrowia 
> 10 µM > 1 µM  
Paracoccus 
> 10 µM > 10 µM  
Table 6.5. Mitochondrial membranes interspecies screening. Three drugs were tested on 
mitochondrial membranes from different bacterial and mammalian species. While bacterial 
membranes are not affected by the drugs, rat and mouse membranes from different tissues are 
equally sensitive to them. In bovine membranes the compounds cause a different response. 
IC50 in nM unless otherwise stated. 
There are several examples of enzymes that respond differently to inhibitors 
depending on the species expressing them. Winkler et al.574 recently found that 
Kynurenine 3-monooxygenase (KMO) isolated from liver tolerates the inhibitor Ro-
61-8048 over a 25-fold range among species, from rat to human all the way to 


























the substrate L-kynurenine was similar among the six mammalian species tested (13.7 
± 0.9 µM). Chang et al.575 recently showed that the monoacylglycerol lipase (MAGL) 
inhibitor O-aryl carbamate JZL184 possesses single digit IC50 potency towards mouse 
brain and human kidney enzymes whereas O-hexafluoroisopropyl carbamate JW618, 
while still maintaining its potency towards the human enzyme, is over ten times 
weaker towards the mouse enzyme (both inhibitors exhibit three digit IC50 towards the 
corresponding rat enzymes). 
6.3.6 SAR on Library B: 30 compounds and left- vs right-hand 
side handles 
23 drugs possess an OCF3 moiety which is generally adopted as a methyl 
replacement: the fluorine atoms achieve better metabolic stability and higher 
electronegativity 576 . Also, deshielded fluorine atoms (i.e. those with decreased 
electron density) are known to engage as lone pair donors in unconventional 
F⋅⋅⋅C=O intermolecular interactions577. The central oxadiazole ring is common to 
35 out of 38 drugs and, as a functional group in medicinal chemistry, it is of 
considerable importance: interestingly, a 1,2,4-ring system was chosen for most of the 
drugs in both libraries, even though a 1,3,4-isomer usually imparts superior 
pharmacological properties, such as less lipophilicity, improved aqueous stability, 
reduced inhibition of hERG potassium ion channel (a typical unwanted side effect of 
lipophilic species) and improved metabolic (especially CYP-mediated) stability, on 
account of  the more favourable nitrogen-based hydrogen bond acceptors and stronger 
dipole moment578 . Indeed, doubly-substituted (3,5) 1,2,4-oxadiazoles sytems are 
known for their anti-proliferative effect against several cancer cell lines579,580. The 
floppy methoxyethoxy extension (the constant moiety in the right-hand side), 
included in 15 drugs, is commonly employed as a water solubilising agent, notably in 
the case of the anticancer agent Erlotinib581 but it can also provide strategic hydrogen 
bond acceptor capabilities582. 
6.3.6.1 The left-hand side drugs 
The left-hand side compounds are depicted in Figure 6.8, split into 4 different panels 
according to structural similarities (2718 will also be included in Figure 6.9, panel G, 
for comparison purposes).  Directionality of the core oxadiazole ring has an effect on 
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complex I inhibition: in panel C, changing the orientation of the oxygen from left 
(2430) to right (2718) is detrimental to the potency, from 72.1 to 299 nM.  
6-membered saturated heterocycles, depicted in panel A, exhibited excellent 
inhibitory activity. The most marked difference occurs when oxygen belongs to the 
ring in 2414 (83 nM) as opposed to when it sticks out in para position as an hydroxyl 
group in 10747 (16.8 nM): there appears to be unfavourable binding interactions with 
the ring oxygen, given that the hydroxyl species has a very similar IC50 to the other 
two nitrogen-containing heterocycles 2490 and 1225. 
In panel B, different flavours of sulfonyl groups are presented, and the most notable 
finding is the major difference in potency between sulfonyl-containing substituents 
1239 and 1240 compared to 2716, a cyclic sulphonamide or sultam: sultams are 
usually installed in order to reduce the number of rotatable bonds and, therefore, to 
increase their oral bioavailability583. The shift of the methyl sulfonyl group further 
away with a 3-carbon long linker in 2997 (the same length as 2716) makes little 
difference in activity (about 14 nM for both): these results suggest that the sulfonyl 
group is involved in a key binding interaction which is favoured by another 
hydrophobic interaction linked to the alkyl chain in 2716 (2997 could obtain the same 
conformation as 2716 on account of its flexible chain). 
Compounds in panel D display a wide range of moderate activity: addition of a 
methyl group to the amide (from 1919 to 1920) improves the IC50 threefold, 
suggesting a favourable hydrophobic interaction, whereas the iPrOH handle 2834 
allows to improve the inhibitory activity a further fivefold compared to 1920. Lastly, 
the halogenated aryl 2398 seems to be a poor substituent and even though 
fluorobenzyl moieties could engage in C-H π interactions 584 , the potency 
improvement following the addition of fluorine in para- position obtaining 1921 (to 
the bromine already present in meta- position in 2398) is so minor that could well be 
within experimental error. 
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Figure 6.8. The left-hand side group of Library B. 16 compounds are divided into 4 groups 
according to similarities between the moieties attached to the far left side of the scaffold. 
Panel A includes the most powerful species, 6-membered saturated heterocycles; Panel B 
includes sulfonyl containing groups; Panel C shows the effect of a different alignment of the 
central oxadiazole core; Panel D includes amides, a halogen and a hydroxy groups. IC50 in 
nM (unless otherwise stated) in underlined red. 
6.3.6.2 The right-hand side drugs 
All of the species in this group (depicted in Figure 6.9 and split into 4 different 
panels) exhibit only hundreds of nanomolar potency at best: it appears, therefore, that 
the methoxyethoxy handle is a poor choice for a substituent overall and the OCF3 
handle is better. In addition, some solubility issues were encountered in the NADH:O2 
assay, particularly with compounds containing aliphatic side chain substituents 2708, 
2720 and 10573: when the drug concentration was higher than midrange in the 
titration series the 340-380 nm absorbance descending traces were very erratic (the R2 
was close to 0.9). This may be because of precipitation, however the data obtained are 













































* when in para- position (2438), IC50 becomes inactive
HO Br
2834 82.3 2398 821**
** 806 when fluorine is added in para position together






In panel G, three different ways of arranging the CF3 group are presented: the oxygen 
atom introduced in 2713 to yield 2718 leads to a two fold improvement (from 639 to 
299 nM), perhaps due to the more extended range of circular motion of the fluorines 
which could be partially prevented by the oxygens of the sulfonyl in 2544 (hence 
explaining the higher IC50 of 1023 nM). The electron withdrawing capability of 2544 
might not be relevant to explain its low activity, unless the disturbance of the nearby 
phenyl π-cloud by the sulfonyl disrupt a key π-π interaction with aryl-containing 
residues in the pocket. 
Panel H includes relatively heterogeneous handles, the most effective of which are 
3004 and 2711, both slightly higher than 650 nM: since they do not bear structural 
similarity with each other it could be concluded that the other 4 species disrupt 
binding interactions that morpholine and methyl ether do not otherwise affect. The 
amide in 10507 is absolutely detrimental to the potency (about 15 µM IC50), possibly 
due to a steric clash of the two methyl groups. The slightly longer chain in 3152 than 
3145 could reach an enzyme cavity which could provide some sort of binding relief 
(2947 and 912 nM respectively). 
In panel E the methylenedioxy substituent renders 10576 over 5x more active than the 
corresponding 3,4-dimethoxy 10575, possibily because the suitable configuration for 
proper binding is held in place585: interestingly, this moiety is common to a number of 
recreational drugs, e.g. MDMA, Ethylone and MDPV586. In some cases, it does not 
matter whether the ring possesses a methylenedioxy (closed) or dimethoxy (open) 
configuration, because the relevant hydrophobic interactions occur exclusively at the 
benzene moiety587. 
Panel F includes species with different aliphatic side chains attached to a benzene 
scaffold, and the ones where such tail extends two carbons away (2720 and 2708) are 
more potent than the ones where it extends less further in space (2712 and 10573): 




Figure 6.9. The right-hand side group of the Library B. 15 compounds are divided into 4 
groups according to similarities between the moieties attached to the far right side of the 
scaffold. Panel E includes two different types of methoxy attachement to a benzene ring; 
Panel F aliphatic side chains; Panel G different CF3 extensions; Panel H diverse O- and N- 
containing groups. IC50 in nM in underlined red. 
Figure 6.10 summarises the main findings for library B. 
 
Figure 6.10. Effects of different substituents in the main structural variants in library B. 
Different substituents on either side plus directionality of the oxygen in the central oxadiazole 

















10575 ~4 µM 10576 700
2720 262 2708 395
2712 1145 10573 1.68 µM







































6.4 A collaboration with the Leicester MRC 
Toxicology Unit: Mubritinib 
The collaboration with the Leicester MRC Toxicology Unit involved testing 
Mubritinib, an anti-cancer agent under development by the Japanese pharmaceutical 
company Takeda. At the moment the major drawback to Mubritinib transitioning to a 
Phase II clinical trial is its toxicity encountered in Phase I and this work aimed to 
confirm complex I inhibition as its off-target effect resulting in toxicity, as suggested 
by Seahorse assays in permeabilised cells performed by the Toxicology Unit. In 
addition, 12 structural variants were tested in bovine mitochondrial membranes for 
complex I inhibition to gain insight into the SAR of Mubritinib binding to complex I. 
This information could allow the development of a compound with reduced toxicity. 
6.4.1 Mubritinib and its biological target HER2 
The HER (human epidermal growth factor receptor or ErbB) family of proteins 
consists of four receptor tyrosine kinases (HER 1-4) that possess an extracellular 
domain, a small transmembrane region and an intracellular domain. Binding of 
growth factors in the extracellular region (apart from HER 2 which does not bind 
ligands) initiates downstream signalling pathways and also homo- and hetero-dimeric 
interactions between family members588. Activation of HER signalling leads to a wide 
range of cellular effects, including cell proliferation and survival, angiogenesis, cell 
adhesion, cell motility, development and organogenesis589. HER2 in particular has a 
strong oncogenic potential, since it is overexpressed across a remarkably large subset 
of cancers (especially gastric, breast, bladder and ovarian); its pro-tumorigenic 
signalling cascade makes HER2 an attractive therapeutic target590. 
Mubritinib (or TAK-165) is being developed by the pharmaceutical company Takeda 
and a phase I clinical trial study was completed in 2004591. It is structurally similar to 
the Anderson Centre drugs: two phenyl ring on either side of a relatively long scaffold 
and a central 5-membered heterocyclic ring (see Figure 6.1). Pre-clinical studies 
found it inhibits HER 2 specifically (greater than 4000-fold selectivity compared to 
other 6 tyrosine kinases) and also possesses antiproliferative effects on four different 
cancer cell lines (IC50 referred to growth of cell numbers in tens of nM) and in 
xenograft tumor models using two different cell lines in mice592. Furthermore, in a 
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recent paper, Mubritinib was successfully used in combination with all-trans retinoic 
acid in differentiation therapy against acute myeloid leukemia593. 
6.4.2 Main experimental details and overall results 
Inhibition of the NADH:O2 oxidoreduction reaction in membranes was performed 
with the library of variants and IC50 values (with 95% confidence interval), Hill 
coefficients and clogP values were obtained (reported in Table 6.6). clogP values 
were determined with MarvinSketch Version 16.5.2.0 (Consensus Model, 
ChemAxon, MA529). The IC50 determination process was exactly the same as the one 
used in the rotenoids SAR chapter. Also, species whose IC50 was higher than 20 µM 
were considered inactive. It was not possible to obtain IC50 values for all variants 
because some had high (minimum reachable) levels of residual activity even at the 
highest concentrations tested and such minimum levels were reached very early along 
the titration series (differently than the inactive species where a minimum level of 
residual activity could not be reached because the compound concentration needed 
would have been too high). Table 6.6 therefore includes the background NADH 
oxidation activity at the highest concentration tested for all the variants and highlights 
in red the variants whose lowest attainable residual activity was so high as to preclude 
an IC50 determination. NADH:O2 inhibition traces for Mubritinib and variant C are 
shown in Figure 6.11 and the substantial background rate can be seen for the latter 
(this is similar to variants D and K): such rate can be abolished by rotenone or 
piericidin. 
A residual percentage rate in the succinate:O2 assay of 97.3 ± 1.0 % and in the 
NADH:dQ assay of 7.3 ± 0.2 % were observed upon addition of 500 nM of 
Mubritinib, indicating specificity towards complex I (data refers to SEM of 
triplicates). The same concentration of Mubritinib left a residual activity of 96.2 ± 0.6 
% and 101.0 ± 4.5 % in the NADH:APAD and NADH:FeCN assays, respectively, 
confirming that the location of binding is outside the flavin site (data refers to SEM of 
triplicates). 
The inhibitory potency of the drugs does not correlate with hydrophobicity, as it can 
be seen in the (log) IC50 against clogP plot (Figure 6.11, lower panel). The correlation 




Figure 6.11. Representative NADH:O2 inhibition traces for Mubritinib variants and 
relationship between hydrophobicity and inhibitory potency. While Mubritinib (upper 
panel) exhibits a typical descending trace to a low residual activity at high drug concentration, 
variant C (middle panel) maintains a very high NADH oxidation background rate regardless 
of the concentration used: such background rate is rotenone and piericidin sensitive. Error 
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STRUCTURE IC50 nM 95% C.I. HILL 
Lowest Res. 
Act. (%, nM) clogP STRUCTURE 
IC50 nM 
95% C.I. HILL 
Lowest Res. 




11.2 ± 0.1%  
500 nM 5.96 
 




8.3 ± 0.2%  




10.7 ± 0.2%  




9.2 ± 0.3%  
400 nM 6.01 
 




13.9 ± 0.1%  
500 nM 5.08 
 
/ / 60.0 ± 0.2%  20 µM 4.78 
 
/ / 25.7 ± 0.3%  1 µM 5.59 
 




17.2 ± 0.3%  
3 µM 4.92 
 
Inactive / 71.8 ± 0.7%  50 µM 4.63 
 
Inactive / 97.0 ± 0.2%  15 µM 5.52    
 
 
Table 6.6. Results of SAR study for Mubritinib variants. IC50 values (in nM unless otherwise specified) with 95% confidence intervals, Hill coefficients, lowest 
residual activity attainable with associated concentration and clogP values are presented for the NADH:O2 assay. Compounds highlighted in red possess the lowest residual 






























































































6.4.3 SAR on Mubritinib library 
The three different handles that vary across the Mubritinib series are displayed in 
Table 6.7. Most of this series is based on modification or substitution of the triazole 
group: this moiety has been employed towards a plethora of different biological 
targets (e.g. ß-lactamase, fatty acid synthase, cyclooxygenase) and properties (e.g. 
antibacterial, antifungal, antiviral, anticonvulsants, anticaspase-3)594. In addition, they 
are commonly employed as bioisosteres of amide groups (they join similar hydrogen 
bond patterns) and possess good resistance to metabolic degradation, high aromatic 
stabilisation and a high dipole moment595. Figure 6.12 shows the different types of H-
bond interactions that 1H-1,2,3-triazole (attached at the peripheral nitrogen, 
Mubritinib) and 2H-1,2,3-triazole (attached at the central nitrogen, B) can undergo 
plus the similarities with an amide group (however, technically a H-bond donor group 







 F 582 nM N 247 nM 
 
 
 C 60% J 116 nM 
  D 80% K 30% 
  E Inactive L 135 nM 







 H Inactive G 85 nM A Inactive 
Table 6.7. Summary of SAR study on Mubritinib variants. The three structural handles 
that vary across the series are highlighted with different colours in the table. IC50 in nM unless 




























Figure 6.12. Hydrogen bond interactions of the main rings within the Mubritinib series. 
The hydrogen bond pattern of the heterocycles used as right-hand side handles within the 
Mubritinib series is similar to the one in an amide. These interactions seem to be responsible 
for the vast majority of Mubritinib binding to complex I. 
The main finding is that a different point of attachment of the triazole moiety 
significantly alters the binding affinity of the variant: triazole is attached to 
Mubritinib as 1H-, and the shift from 1H- to 2H- in B generates an impressive loss of 
potency (IC50 from 19 nM to inactive) which also occurs throughout the series (upper 
part of Table 6.7), most of the variants on the left column possess a much poorer 
binding affinity compared to the variants on the right). Mubritinib binding appears to 
be based on the hydrogen bond interaction generated by the side nitrogen atom in the 
ring: the modest loss of potency upon rendering the triazole into an imidazole in G 
(from 19 nM to 85 nM) and the dramatic loss in potency upon eliminating the side 
nitrogen in H confirm this interpretation. It must be highlighted, however, that while 
the pKa of 1,2,3-triazoles is about 1.17 (hence the molecule is present in non-ionised 
form in aqueous solution), the pKa of imidazole is 7.00, so in physiological conditions 
the latter is present in ionised form in significant amount596: a still favourable 
electrostatic interaction with the ionised form of imidazole (that could be directed at a 
different part of the binding site than the non-ionised H-bond interaction, given their 



















































Mubritinib to G (or, more simply, the pH dependent equilibrium favours the non-
ionised side). 
The loss of the central double bond is also important for binding and, more 
remarkably, the decreased potency from 1H- to 2H-triazole is not as substantial as 
with the double bond (N and F, 247 and 582 nM IC50 respectively): the hydrogenation 
of the C=C double bond, present in Mubritinib, allows rotational motion around it 
and, consequently, extended binding opportunities. Mubritinib is less sensitive 
towards modifications in the CF3 group, causing only a 10-fold loss of potency when 
such group is exchanged for methoxy or just hydrogen (L and J). Finally, it is 
noteworthy how complex I activity is retained with some variants (C, D and K) 
regardless of the concentration used: it is possible that a concentration-independent 
enzymatic conformational rearrangement upon binding of C, D and K to complex I 
partially impedes ubiquinone access to the ubiquinone binding site. 
6.5 Discussion 
6.5.1 Molecular flexibility as rationale for binding?    
It is difficult to accurately predict the precise binding interactions for drugs in 
complex enzymes: this is particularly true for compounds in Libraries A and B which 
can be thought of as a string of individual units that possess the ability to rotate about 
each other and, as such, are very flexible overall (see Figure 6.3). For other complex I 
specific inhibitors, addressing binding interactions within the binding site may turn 
out to be easier. For instance, amino quinazolines are powerful complex I specific 
inhibitors520,597 and their binding site was located between the 49 kDa and ND1 
subunits 598 . There are several examples of amino quinazolines whose major 
enzymatic binding interaction is hydrogen bonding with the amino acid backbone of 
methionine residues: inhibitors of tyrosine kinases EGFR 599 , 600  and Trk 601 . 
Remarkably, a quinazoline inhibitor was resolved close to Met60 of PSST and the 49 
kDa subunit of complex I from Yarrowia lipolytica86. Since the kind of molecular 
flexibility of the Anderson drugs is not dissimilar from coenzyme Q10 (which also can 
be thought of as a string of individual units), this common structural feature between 
substrate and drugs could extend to their mode of binding inside or in the proximity of 
the Q chamber (recall that evidence suggested ND1 as the 10759 binding site, see 
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section 6.2.1.2). These species could, in fact, be capable of interacting with adjacent 
residues through the consecutive units that constitute them.   
6.5.2 Putative binding location of 10759 
The difference in potency across different mammalian species that the three 
compounds shown in Table 6.5 exert can be explained by the 2-pyridone core moiety: 
10759 does not possess this functional group but a triazole instead (see Figure 6.13), 
and its potency is significantly lower than the other two drugs in bovine (but not 
mouse and rat) complex I. 2-pyridones are known to be very versatile, as they can 
assume several binding poses within binding sites: van der Waals interactions with 
the ring core602, hydrogen bonding with C=O on its own603 and in association with the 
adjacent nitrogen604. An inhibitor of factor Xa, a trypsin-like serine protease, was 
found to engage in binding with a peculiar arrangement where its 2-pyridone moiety 
was enveloped within an aromatic pocket of the enzyme (sandwiched between 
tyrosine and phenylalanine and forming an edge-to-face interaction with 
tryptophan)605. Since the 2-pyridone core of compounds 4101 and 1131 (Table 6.5) is 
flanked by aromatic rings (and replaced by another aromatic ring in 10759) it was 
thought that an aromatic nest (akin to the one mentioned above) could be the key to 
understanding the binding differences found for complex I across different 
mammalian species. One tentative location could be I49 in bovine ND1, F49 in rat, 
mouse and human complex I (see Figure 6.13, sequence identities for ND1 are 78.3% 
in bovine-mouse, 92.7% in rat-mouse and 75.5% in bovine-rat-mouse, sequence and 
identity calculations obtained from UniProt database606). So, the 2-pyridone moiety 
(and its nearby benzene ring) in mouse and rat complex I could preferentially bind in 
this area of ND1 on account of the aromatic nest provided by F49 and F19 (the latter 
conserved in bovine, mouse and rat) via noncovalent aromatic interactions, which can 
be decisive in biochemical systems607. Replacing 2-pyridone with triazole (4101 vs 
10759) and benzene with pyridine (4101 vs 1131) does not elicit major losses in 
potency in mouse and rat tissues (see Table 6.5 and Figure 6.13). On the other hand, 
in bovine complex I such aromatic nest is disrupted (I49 instead of F49) and the same 
drug transformations (replacing 2-pyridone with triazole and benzene with pyridine) 
lead to significant potency losses: a replacement of a carbon with nitrogen in benzene 
leads to reduced polarizability and spatial extent of the π-electron cloud that have 
major consequences in terms of binding strengths and modes608. There are other 
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aromatic residues in the vicinity of F19 and F(I)49 (all conserved in bovine, mouse, 
rat and human complex I) that could be a part of the above-mentioned aromatic nest: 
Y43, F224 and Y228. The close proximity of this area to the membrane portion of the 
ubiquinone binding channel (see Figure 6.13) raises the possibility that the drug could 
compete for the Q-site and makes it a good candidate for cryo-EM studies. 
 
Figure 6.13. Tentative location of 10759 binding site in complex I. Complex I from Bos 
taurus, colour code 49 kDa (blue), PSST (magenta) and ND1 (orange). F19 residue in red, 
Y43, F224 and Y228 in yellow (all of these residues are present in human, bovine, mouse and 
rat complex I). I49 residue (bovine, F49 in human, mouse and rat) highlighted in green. Some 
of the helix F19 belongs to was hidden for clarity. Relevant aromatic centres of drugs 10759, 
4101 and 1131 (bottom right corner) and ubiquinone binding channel (bottom left corner) are 
highlighted. Original structure from Hirst86. 
6.5.3 Cancer pharmacology of 10759 and Mubritinib families of 
drugs 
A recent SAR study by Sheng et al. on the in vitro and in vivo inhibition of HIF-1-
mediated transcription in human colon carcinoma cell line HCT-116 and of tumor cell 
invasion in ovarian cancer cells SKOV3 reached similar conclusions to Library B in 
this work and Bayer’s library609: long handles in the left-hand and replacement of CF3 
with OCF3 moiety in the right-hand side generated the highest potencies (similarly to 
2713 and 2718). The compounds in the study were 3-aryl-5-indazole-1,2,4-oxadiazole 
derivatives, with indazole replacing 2-pyridone within the oxadiazole core: Figure 
6.14 shows the main features of the strongest inhibitors found in the study. 
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Figure 6.14. Main structural features of Sheng’s HIF-1 inhibitors. Long left-hand side 
handles and a OCF3 right-hand side handle were found to confer the highest potency within 
the oxadiazole-indazole core compounds. 
A recent study by Baccelli et al. identified Mubritinib as a potential treatment for 
AML610. Since this disease is characterized by a high genetic complexity, the group 
tested a library of about 5000 compounds across 20 different AML specimens 
(representative of the vast array of genetic mutations involved with AML): 
compounds that gave a characteristic response pattern in the specimens were clustered 
together as to reveal promising therapeutic pathways in the form of synergistic pairs 
of drugs. Interestingly, one such combination was found to be Mubritinib and 
Deguelin: the two species were found to possess highly correlated EC50 values as well 
as similar synergistic patterns with other drugs in the library with AML cells. It is of 
note that 10759 gave promising results against AML cells and it is now under Phase I 
trial for AML patients (see section 6.2.1.2): the structural similarities between 10759 
and Mubritinib corroborate the pharmacological potential to treat this particular type 
of cancer. Remarkably, one of the agents of proven clinical activity against AML 
(especially in association with intensive chemotherapy) is Sorafenib, a multi-kinase 
inhibitor that is structurally similar to both Mubritinib and 10759 (see Figure 6.15)611. 
In this regard, when comparing 10759 with Sorafenib, a sulfonyl group is a 
bioisostere for an amide (see section 6.3.4) and oxadiazole is a bioisostere for urea612; 
when comparing Mubritinib with Sorafenib, a triazole is a bioisostere for an amide 
(see section 6.4.3). Sorafenib was classified in this thesis as an unspecific OXPHOS 
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Figure 6.15. Structural similarities between 10759, Sorafenib and Mubritinib. Sorafenib 
possesses common features to 10759 and Mubritinib, particularly in light of bioisosterism 
between urea and oxadiazole on one hand and sulfonyl, amide and triazole on the other 
(highlighted in blue). 
6.6 Summary 
Mitochondrial complex I has recently emerged as a target for anticancer drugs and 
compounds with a pyra(tria)zolyl oxadiazole scaffold developed by the Anderson 
Cancer Centre and Bayer AG act through three of the several recognised modes of 
action (namely reduction of aspartate synthesis, HIF1α pathway and ROS damage). 
Other modes involve AMPK activation and angiogenesis inhibition via disruption of 
cellular hypoxic signalling613. The work presented in this chapter has shed light on 
some important aspects of complex I linked to its mechanism towards anticancer 
activity.  
The collaboration with the Anderson Cancer Center was fruitful, inasmuch as it 
allowed us to successfully test the hypothesis, originally put forward by Bayer AG, 
that pyrazolyl oxadiazoles (see Figure 6.2) have a strong inhibitory power towards 
complex I. Almost all drugs in the libraries, though, possess a 2-pyridone oxadiazole 
core, with a wide range of biological activity expressed throughout the series. SAR 





























potent (right-hand side saturated heterocycles) and least potent (left-hand side 
methoxyethoxy moiety) side extensions of the series. A wider variety of assays was 
performed on the Library A which include 10759, the compound put forward by the 
Anderson Center for Phase I clinical trials: these species exhibit a total specificity 
towards complex I and two of them (4101 and 2858) are even more powerful than 
rotenone.  
The SAR analysis of Mubritinib was instrumental in discovering a remarkable 
structural feature to which complex I appears to be very sensitive, the point of 
attachment of 1,2,3-triazole: shifting from 1H- (peripheral nitrogen) to 2H- (central 
nitrogen) causes a large potency drop. Also important is the rotational flexibility 
around the central C-C bond of Mubritinib that makes the 1H- to 2H- potency 
decrease much less significant. It is noteworthy that Mubritinib and 10759 have 
shown promising results against AML and they are structurally similar to Sorafenib, a 
kinase inhibitor with clinical efficacy against this disease and classified in this thesis 















Mitochondrial complex I (NADH:ubiquinone oxidoreductase) has essential roles in 
metabolism: it keeps the [NADH]/[NAD+] ratio low in both the matrix and 
intermembrane space and contributes towards the protonmotive force by pumping 
protons across the IMM. The consequences of its inhibition are, therefore, major, and 
while this could be desirable for pharmaceuticals whose target is complex I, adverse 
toxic effects can lead to severe physiological damage. The pharmacologic 
characterisation of this multisubunit enzyme is, thus, the primary aim of this thesis, to 
pinpoint its role in drug-induced mitochondrial dysfunction. In parallel, SAR studies 
were performed to gain knowledge of binding mechanisms of important classes of 
compounds: variants of rotenoids, species with a pyrazolyl oxadiazole core and 
Mubritinib were thoroughly tested in order to improve potency, limit toxicity and 
extend their therapeutic potentials. 
Chapter 3 was dedicated to generating a library of complex I specific inhibitors 
selected among a set of compounds that cause side effects linked to drug-induced 
mitochondrial dysfunction. This was carried out with an extensive literature search 
and the use of FDALabel, a freely accessible database. After filtering out compounds 
for various reasons (e.g. weak potency, cost, similarity to other drugs), eventually 21 
drugs were selected. Several routine assays were performed on the isolated enzyme, 
on the whole respiratory chain and on cells to classify the compounds in terms of 
potency and specificity towards complex I or other OXPHOS enzymes. It emerged 
that the majority of the drugs specifically target complex I while the others inhibited 
OXPHOS with various degrees of specificity. Of note, Tamoxifen was found to be a 
complex III-specific inhibitor and, together with the data presented in chapter 4, its 
established role in drug-induced liver injury was validated. On the other hand, the 
flavin site of complex I was found to be relatively inert to drugs, and no significant 
results were obtained, not even with follow-up experiments carried out on a separate 
library of dibenzoheterocyclics. Microsomes were employed to mimic drug 
metabolism and to obtain more physiologically relevant data: the results indicated that 
drug-metabolising enzymes detoxified the effects of some drugs (including rotenone) 
towards the complex I-IV pathway. The positive outcome of this experiment has 
determined a future direction to take, especially by implementing mass spectrometry 
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to better identify the major metabolites. Cellular assays with the Seahorse XF analyser 
further extended the physiological relevance of the chapter, and five classes of 
cellular effects were identified within the library.  
The methodology introduced in chapter 3 constituted a proof of principle that was 
subsequently applied to a much bigger commercial drug library in chapter 4. Drugs 
were initially screened to filter out compounds not potent enough and then complex I 
specificity was initially assessed by combining two assays affecting the I-IV pathway 
and the II-IV pathway, respectively. This method was validated with canonical 
OXPHOS inhibitors and implemented with data from a novel isolated enzyme assay 
in proteoliposomes that allowed the identification of non-specific, complex III- and I-
specific inhibitors. Compounds that belong to the latter category were tested with a 
Seahorse assay on isolated mitochondria, and it was found that most compounds did 
not elicit a major effect on mitochondrial respiration, indicating an important role for 
transport and/or accumulation processes. Experiments with SMPs failed to 
characterise uncouplers selected from the initial screening and flavin-site assays 
confirmed the general lack of reactivity of the flavin site towards drugs found in 
chapter 3. Lastly, mitochondrial membranes were shown to be a convenient system to 
test compounds for OXPHOS-related mitochondrial dysfunction. 
Chapter 5 was dedicated to a SAR study on rotenoids and crucial determinants to 
binding to complex I were found to be molecular flattening and hydroxylation of the 
E-ring. Hydroxylations at the B-C ring junction led to minor losses of potency and 
since those species are more hydrophilic than rotenone they are promising as 
anticancer agents (they would be less able to cross the blood brain barrier than their 
more lipophilic counterparts). Halogenation of the E-ring brought about the tightest 
binding in the rotenoids series, enlarging the scope of this work for future structural 
studies on account of the large electron density of halogens. 
Further SAR studies on complex I were described in Chapter 6, where the role of 
complex I as a target for anticancer therapy was further developed. The libraries 
provided by the Anderson Cancer Centre gave many insights into binding interactions 
with complex I, including a hitherto undescribed inhibition across different 
mammalian species that spanned three orders of magnitude in potency. The 
Mubritinib variants provided by the Leicester Toxicology Unit revealed that complex 
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I responded significantly to the point of attachment of the 1,2,3-triazole moiety. The 
fact that the most promising anticancer drug from the Anderson Centre and 
Mubritinib have both been reported to be effective against AML and that they are 
structurally similar to Sorafenib, another agent with proven clinical activity against 
the disease, reveals a pharmacologic potential of the two species. 
In conclusion, mitochondrial complex I appears to be a pharmacological target (away 
from its flavin site) for a myriad of structurally unrelated compounds: given its pivotal 
role in human metabolism, the results illustrated in this thesis should elevate its 
importance during toxicity screenings during drug development. At the same time, 
given the number of very potent complex I inhibitors analysed in this work, a parallel 
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